{"344b6e439bfdc57aba56cfadd092639e6d6a5420": [["IntroductionSince December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID- 19) , has caused a pandemic.", [["acute respiratory syndrome coronavirus", "DISEASE", 40, 78], ["coronavirus disease", "DISEASE", 120, 139], ["COVID- 19", "CHEMICAL", 146, 155], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 33, 80], ["SARS-CoV-2", "ORGANISM", 82, 92], ["coronavirus", "ORGANISM", 120, 131], ["severe acute respiratory syndrome coronavirus", "SPECIES", 33, 78], ["SARS-CoV-2", "SPECIES", 82, 92], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 33, 78], ["SARS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["coronavirus disease", "PROBLEM", 120, 139], ["COVID", "TEST", 146, 151], ["a pandemic", "PROBLEM", 170, 180], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory syndrome", "OBSERVATION", 46, 66], ["coronavirus disease", "OBSERVATION", 120, 139], ["pandemic", "OBSERVATION", 172, 180]]], ["As of April 13, 2020, 1,855,587 COVID-19 cases were recorded worldwide, and 114,232 patients died.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["COVID", "TEST", 32, 37]]], ["This respiratory disease quickly attracted attention given its high rate of transmission 1 , and significant health and economic burden.IntroductionCoronaviruses are single, plus-stranded RNA viruses that infect different animal species, including humans, and cause respiratory, neurological, and hepatic diseases 2 .", [["respiratory", "ANATOMY", 5, 16], ["respiratory", "ANATOMY", 266, 277], ["neurological", "ANATOMY", 279, 291], ["hepatic", "ANATOMY", 297, 304], ["respiratory disease", "DISEASE", 5, 24], ["respiratory, neurological, and hepatic diseases", "DISEASE", 266, 313], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 148, 161], ["humans", "ORGANISM", 248, 254], ["humans", "SPECIES", 248, 254], ["humans", "SPECIES", 248, 254], ["This respiratory disease", "PROBLEM", 0, 24], ["significant health and economic burden", "PROBLEM", 97, 135], ["IntroductionCoronaviruses", "PROBLEM", 136, 161], ["stranded RNA viruses", "PROBLEM", 179, 199], ["respiratory, neurological, and hepatic diseases 2", "PROBLEM", 266, 315], ["respiratory", "ANATOMY", 5, 16], ["disease", "OBSERVATION", 17, 24], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["economic", "OBSERVATION_MODIFIER", 120, 128], ["burden", "OBSERVATION", 129, 135], ["RNA viruses", "OBSERVATION", 188, 199], ["hepatic", "ANATOMY", 297, 304], ["diseases", "OBSERVATION", 305, 313]]], ["Previous studies have indicated that seven coronaviruses infect humans: 229E, OC43, NL63, HKU1, MERS-CoV, SARS-CoV, and SARS-CoV-2 3, 4 .", [["coronaviruses", "ORGANISM", 43, 56], ["humans", "ORGANISM", 64, 70], ["229E", "GENE_OR_GENE_PRODUCT", 72, 76], ["OC43", "GENE_OR_GENE_PRODUCT", 78, 82], ["NL63", "GENE_OR_GENE_PRODUCT", 84, 88], ["HKU1", "GENE_OR_GENE_PRODUCT", 90, 94], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 96, 104], ["SARS-CoV", "ORGANISM", 106, 114], ["SARS-CoV-2", "ORGANISM", 120, 130], ["humans", "SPECIES", 64, 70], ["humans", "SPECIES", 64, 70], ["MERS-CoV", "SPECIES", 96, 104], ["SARS-CoV", "SPECIES", 106, 114], ["SARS-CoV", "SPECIES", 120, 128], ["Previous studies", "TEST", 0, 16], ["OC43", "TEST", 78, 82], ["NL63", "TEST", 84, 88], ["HKU1", "TEST", 90, 94], ["MERS", "TEST", 96, 100], ["CoV", "TEST", 101, 104], ["SARS", "TEST", 106, 110], ["CoV", "TEST", 111, 114], ["SARS", "TEST", 120, 124], ["CoV", "TEST", 125, 128]]], ["Of these, the latter three viruses cause acute respiratory syndrome 5, 6, 7 .IntroductionSARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptors to enter host cells.", [["cells", "ANATOMY", 168, 173], ["acute respiratory syndrome", "DISEASE", 41, 67], ["angiotensin", "CHEMICAL", 105, 116], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 77, 99], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 105, 136], ["ACE2", "GENE_OR_GENE_PRODUCT", 138, 142], ["host cells", "CELL", 163, 173], ["angiotensin-converting enzyme 2 (ACE2) receptors", "PROTEIN", 105, 153], ["host cells", "CELL_TYPE", 163, 173], ["acute respiratory syndrome", "PROBLEM", 41, 67], ["IntroductionSARS", "TEST", 77, 93], ["angiotensin", "TREATMENT", 105, 116], ["converting enzyme 2 (ACE2) receptors", "TREATMENT", 117, 153], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["respiratory syndrome", "OBSERVATION", 47, 67], ["host cells", "OBSERVATION", 163, 173]]], ["ACE2 is highly expressed in alveolar type II cells of the lung 8 and gastrointestinal (GI) epithelial cells 9, 10 .", [["alveolar type II cells", "ANATOMY", 28, 50], ["lung 8", "ANATOMY", 58, 64], ["gastrointestinal (GI) epithelial cells", "ANATOMY", 69, 107], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["alveolar type II cells", "CELL", 28, 50], ["lung 8", "CELL", 58, 64], ["gastrointestinal (GI) epithelial cells", "CELL", 69, 107], ["ACE2", "PROTEIN", 0, 4], ["alveolar type II cells", "CELL_TYPE", 28, 50], ["lung 8 and gastrointestinal (GI) epithelial cells", "CELL_TYPE", 58, 107], ["ACE2", "TEST", 0, 4], ["gastrointestinal (GI) epithelial cells", "TEST", 69, 107], ["alveolar type II cells", "OBSERVATION", 28, 50], ["lung", "ANATOMY", 58, 62], ["gastrointestinal", "ANATOMY", 69, 85], ["GI", "ANATOMY", 87, 89], ["epithelial cells", "ANATOMY", 91, 107]]], ["Recent studies have shown that GI symptoms are common in patients with COVID-19 7, [11] [12] [13] , and a small proportion of infected patients have GI symptoms, but not other symptoms, at disease onset 14 .", [["GI", "ANATOMY", 31, 33], ["GI", "ANATOMY", 149, 151], ["GI symptoms", "DISEASE", 31, 42], ["GI symptoms", "DISEASE", 149, 160], ["COVID-19", "CHEMICAL", 71, 79], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 135, 143], ["GI", "ORGANISM_SUBDIVISION", 149, 151], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 135, 143], ["Recent studies", "TEST", 0, 14], ["GI symptoms", "PROBLEM", 31, 42], ["COVID", "TEST", 71, 76], ["GI symptoms", "PROBLEM", 149, 160], ["other symptoms", "PROBLEM", 170, 184], ["small", "OBSERVATION_MODIFIER", 106, 111], ["infected", "OBSERVATION", 126, 134]]], ["In addition, SARS-CoV-2 nucleic acid was detected not only in nasopharyngeal swabs and saliva samples, but also in stool samples 15, 16 .", [["nasopharyngeal swabs", "ANATOMY", 62, 82], ["saliva samples", "ANATOMY", 87, 101], ["stool samples", "ANATOMY", 115, 128], ["SARS-CoV-2 nucleic acid", "CHEMICAL", 13, 36], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 62, 82], ["saliva samples", "ORGANISM_SUBSTANCE", 87, 101], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "TEST", 13, 17], ["CoV", "TEST", 18, 21], ["nucleic acid", "TEST", 24, 36], ["nasopharyngeal swabs", "TEST", 62, 82], ["saliva samples", "TEST", 87, 101], ["stool samples", "TEST", 115, 128], ["nasopharyngeal", "ANATOMY", 62, 76]]], ["There was evidence that patients with COVID-19 may This article is protected by copyright.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["COVID", "TEST", 38, 43]]], ["All rights reserved.Accepted Articletransmit the virus through the fecal-oral route 17, 18 .", [["oral", "ANATOMY", 73, 77], ["oral", "ORGANISM_SUBDIVISION", 73, 77], ["Articletransmit the virus", "PROBLEM", 29, 54], ["virus", "OBSERVATION", 49, 54], ["fecal", "ANATOMY", 67, 72]]], ["However, few studies evaluated the clinical features and prognosis of COVID-19 patients with GI symptoms.", [["GI", "ANATOMY", 93, 95], ["patients", "ORGANISM", 79, 87], ["GI", "ORGANISM_SUBDIVISION", 93, 95], ["patients", "SPECIES", 79, 87], ["few studies", "TEST", 9, 20], ["COVID", "TEST", 70, 75], ["GI symptoms", "PROBLEM", 93, 104]]], ["This large sample study analyzed the clinical characteristics and prognosis of these patients and independent risk factors for clinical deterioration.Study design and participantsFrom February 5, 2020, to March 9, 2020, 1848 patients aged 18 to 65 years were diagnosed with COVID-19 at the Jianghan Fangcang Shelter Hospital.", [["patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 85, 93], ["participants", "SPECIES", 167, 179], ["patients", "SPECIES", 225, 233], ["This large sample study", "TEST", 0, 23], ["clinical deterioration", "PROBLEM", 127, 149], ["COVID", "TEST", 274, 279], ["large", "OBSERVATION_MODIFIER", 5, 10]]], ["A total of 1320 COVID-19 patients with mild or common type were enrolled after excluding cases with missing data (Figure 1 ).", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["COVID", "TEST", 16, 21], ["mild or common type", "PROBLEM", 39, 58], ["mild", "OBSERVATION_MODIFIER", 39, 43]]], ["Jianghan Fangcang Shelter Hospital is responsible for isolating patients and providing medical care, monitoring disease progression, promote social activities, and cater for basic needs, including food and shelter 19 .", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["medical care", "TREATMENT", 87, 99], ["monitoring disease progression", "PROBLEM", 101, 131]]], ["Patients whose clinical condition worsened were transferred to tertiary hospitals.Study design and participantsClinical worsening was defined as progression from mild or common to severe type based on one of the following criteria: 1) respiratory rate >30 breaths per minute; 2) oxygen saturation <93%; 3) arterial partial pressure of oxygen/fraction of inspired oxygen <300 mmHg.", [["respiratory", "ANATOMY", 235, 246], ["arterial", "ANATOMY", 306, 314], ["oxygen", "CHEMICAL", 279, 285], ["oxygen", "CHEMICAL", 335, 341], ["oxygen", "CHEMICAL", 363, 369], ["oxygen", "CHEMICAL", 279, 285], ["oxygen", "CHEMICAL", 335, 341], ["oxygen", "CHEMICAL", 363, 369], ["Patients", "ORGANISM", 0, 8], ["participants", "ORGANISM", 99, 111], ["oxygen", "SIMPLE_CHEMICAL", 279, 285], ["arterial", "MULTI-TISSUE_STRUCTURE", 306, 314], ["oxygen", "SIMPLE_CHEMICAL", 335, 341], ["oxygen", "SIMPLE_CHEMICAL", 363, 369], ["Patients", "SPECIES", 0, 8], ["participants", "SPECIES", 99, 111], ["Clinical worsening", "PROBLEM", 111, 129], ["respiratory rate", "TEST", 235, 251], ["oxygen saturation", "TEST", 279, 296], ["arterial partial pressure", "TEST", 306, 331], ["inspired oxygen", "TEST", 354, 369], ["mild", "OBSERVATION_MODIFIER", 162, 166], ["pressure", "OBSERVATION_MODIFIER", 323, 331]]], ["Disease severity was defined according to the Chinese management guidelines for COVID-19 20 .Study design and participantsAll study participants were diagnosed based on the Chinese National Diagnosis and Treatment Guidelines for COVID-19 20 .", [["participants", "ORGANISM", 110, 122], ["participants", "ORGANISM", 132, 144], ["participants", "SPECIES", 110, 122], ["participants", "SPECIES", 132, 144], ["Disease severity", "PROBLEM", 0, 16], ["COVID", "TEST", 80, 85], ["All study", "TEST", 122, 131], ["COVID", "TEST", 229, 234]]], ["GI symptoms included diarrhea, abdominal pain, nausea and vomiting, and anorexia.Study design and participantsBased on the presence of GI symptoms, patients were divided into a GI group and a non-GI group.", [["abdominal", "ANATOMY", 31, 40], ["GI", "ANATOMY", 135, 137], ["GI symptoms", "DISEASE", 0, 11], ["diarrhea", "DISEASE", 21, 29], ["abdominal pain", "DISEASE", 31, 45], ["nausea", "DISEASE", 47, 53], ["vomiting", "DISEASE", 58, 66], ["anorexia", "DISEASE", 72, 80], ["abdominal", "ORGANISM_SUBDIVISION", 31, 40], ["participants", "ORGANISM", 98, 110], ["GI", "ORGANISM_SUBDIVISION", 135, 137], ["patients", "ORGANISM", 148, 156], ["GI", "CANCER", 177, 179], ["non-GI", "CANCER", 192, 198], ["participants", "SPECIES", 98, 110], ["patients", "SPECIES", 148, 156], ["GI symptoms", "PROBLEM", 0, 11], ["diarrhea", "PROBLEM", 21, 29], ["abdominal pain", "PROBLEM", 31, 45], ["nausea", "PROBLEM", 47, 53], ["vomiting", "PROBLEM", 58, 66], ["anorexia", "PROBLEM", 72, 80], ["GI symptoms", "PROBLEM", 135, 146], ["diarrhea", "OBSERVATION", 21, 29], ["abdominal", "ANATOMY", 31, 40], ["pain", "OBSERVATION", 41, 45], ["nausea", "OBSERVATION", 47, 53], ["anorexia", "OBSERVATION", 72, 80]]], ["Clinical features, laboratory findings, treatment procedures, and clinical outcomes were compared between the two groups.", [["laboratory findings", "TEST", 19, 38], ["treatment procedures", "TREATMENT", 40, 60]]], ["This retrospective study was approved by the Medical Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology ([2020]0038).ProceduresData on demographic and clinical characteristics, radiological and laboratory findings, treatment procedures, and clinical outcomes were obtained from electronic medical records.", [["This retrospective study", "TEST", 0, 24], ["treatment procedures", "TREATMENT", 270, 290]]], ["Normal body temperature was defined as <37.3 \u00b0C without using antipyretic drugs.", [["body", "ANATOMY", 7, 11], ["body", "ORGANISM_SUBDIVISION", 7, 11], ["antipyretic drugs", "TREATMENT", 62, 79], ["body temperature", "OBSERVATION_MODIFIER", 7, 23]]], ["Nasopharyngeal swab samples were collected, and SARS-CoV-2 nucleic acid was detected by real-time reverse transcriptase-polymerase chain reaction (RT-PCR).", [["Nasopharyngeal swab samples", "ANATOMY", 0, 27], ["SARS-CoV-2 nucleic acid", "CHEMICAL", 48, 71], ["Nasopharyngeal swab samples", "ORGANISM_SUBSTANCE", 0, 27], ["reverse transcriptase", "PROTEIN", 98, 119], ["SARS-CoV", "SPECIES", 48, 56], ["Nasopharyngeal swab samples", "TEST", 0, 27], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["nucleic acid", "TEST", 59, 71], ["polymerase chain reaction", "PROBLEM", 120, 145], ["RT-PCR", "TEST", 147, 153]]], ["The re-examination of nucleic acid was performed every other day after meeting the following criteria: 1) clinical symptoms were improved; 2) the total course of the disease was longer than 1 week; 3) body temperature was normal for at least 3 days without using antipyretic drugs.", [["body", "ANATOMY", 201, 205], ["nucleic acid", "CHEMICAL", 22, 34], ["body", "ORGANISM_SUBDIVISION", 201, 205], ["The re-examination of nucleic acid", "TEST", 0, 34], ["clinical symptoms", "PROBLEM", 106, 123], ["the disease", "PROBLEM", 162, 173], ["body temperature", "TEST", 201, 217], ["antipyretic drugs", "TREATMENT", 263, 280]]], ["Viral clearance was defined as two consecutive negative results on RT-PCR for SARS-CoV-2 RNA samples collected at least 24 h apart, and the date of first negative result was considered as the date of viral clearance.", [["Viral", "ORGANISM", 0, 5], ["SARS-CoV", "SPECIES", 78, 86], ["Viral clearance", "TEST", 0, 15], ["RT", "TEST", 67, 69], ["PCR", "TEST", 70, 73], ["SARS", "PROBLEM", 78, 82], ["CoV", "TEST", 83, 86], ["RNA samples", "TEST", 89, 100], ["viral clearance", "PROBLEM", 200, 215]]], ["The criteria for hospital discharge were 1) maintenance of normal body temperature for at least 3 days; 2) notable improvement in chest CT scan and symptoms; 3) two consecutive negative results in samples collected at least 24 h apart.Statistical analysisCategorical variables were presented as frequency and percentages, and continuous variables were shown as interquartile range (IQR), median, or mean.", [["body", "ANATOMY", 66, 70], ["chest", "ANATOMY", 130, 135], ["samples", "ANATOMY", 197, 204], ["body", "ORGANISM_SUBDIVISION", 66, 70], ["chest CT scan", "TEST", 130, 143], ["symptoms", "PROBLEM", 148, 156], ["Statistical analysisCategorical variables", "PROBLEM", 235, 276], ["percentages", "TEST", 309, 320], ["chest", "ANATOMY", 130, 135]]], ["Statistical analyses were performed using the \u03c7 2 test, Mann-Accepted ArticleWhitney U test, or t-test to evaluate differences between the GI and non-GI group.", [["Statistical analyses", "TEST", 0, 20], ["the \u03c7 2 test", "TEST", 42, 54], ["ArticleWhitney U test", "TEST", 70, 91], ["t-test", "TEST", 96, 102], ["GI", "ANATOMY", 139, 141]]], ["Logistic regression analysis was carried out to identify risk factors for clinical deterioration.", [["Logistic regression analysis", "TEST", 0, 28], ["clinical deterioration", "PROBLEM", 74, 96]]], ["The time to viral clearance was assessed using the Kaplan-Meier method.", [["viral clearance", "TEST", 12, 27]]], ["Statistical analysis was performed using SPSS software version 23, and figures were prepared using GraphPad Prism version 8.0.", [["Statistical analysis", "TEST", 0, 20], ["SPSS software version", "TEST", 41, 62], ["GraphPad Prism version", "TEST", 99, 121]]], ["A two-sided p-value of less than 0.05 indicated a statistically significant difference.Demographic and clinical characteristicsThis retrospective study included 1320 patients with confirmed COVID-19 infection admitted to Jianghan Fangcang Shelter Hospital from February 5, 2020, to March 9, 2020.", [["COVID-19 infection", "DISEASE", 190, 208], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["A two-sided p-value", "TEST", 0, 19], ["a statistically significant difference", "PROBLEM", 48, 86], ["This retrospective study", "TEST", 127, 151], ["COVID-19 infection", "PROBLEM", 190, 208], ["sided", "ANATOMY_MODIFIER", 6, 11], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["difference", "OBSERVATION", 76, 86], ["infection", "OBSERVATION", 199, 208]]], ["Based on the presence of GI symptoms, the patients were assigned to a GI group (n=192) or a non-GI group (n=1128).Demographic and clinical characteristicsThe median age of the total sample was 50 years (IQR, 40-57 years), and 741 (56.1%) subjects were female.", [["GI", "ANATOMY", 25, 27], ["GI", "ORGANISM_SUBDIVISION", 25, 27], ["patients", "ORGANISM", 42, 50], ["subjects", "ORGANISM", 238, 246], ["patients", "SPECIES", 42, 50], ["GI symptoms", "PROBLEM", 25, 36]]], ["The three most common symptoms were fever (83.0%), cough (42.8%), and fatigue (23.5%) ( Table 1Accepted ArticleAmong the 1320 patients, 1080 patients received antiviral drugs, including Lianhuaqingwen capsules (1012, 76.7%), arbidol (987, 74.8%), or oseltamivir (569, 43.1%).", [["fever", "DISEASE", 36, 41], ["cough", "DISEASE", 51, 56], ["fatigue", "DISEASE", 70, 77], ["arbidol", "CHEMICAL", 225, 232], ["oseltamivir", "CHEMICAL", 250, 261], ["arbidol", "CHEMICAL", 225, 232], ["oseltamivir", "CHEMICAL", 250, 261], ["patients", "ORGANISM", 126, 134], ["patients", "ORGANISM", 141, 149], ["arbidol", "SIMPLE_CHEMICAL", 225, 232], ["oseltamivir", "SIMPLE_CHEMICAL", 250, 261], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 141, 149], ["common symptoms", "PROBLEM", 15, 30], ["fever", "PROBLEM", 36, 41], ["cough", "PROBLEM", 51, 56], ["fatigue", "PROBLEM", 70, 77], ["antiviral drugs", "TREATMENT", 159, 174], ["Lianhuaqingwen capsules", "TREATMENT", 186, 209], ["arbidol", "TREATMENT", 225, 232], ["oseltamivir", "TREATMENT", 250, 261]]], ["Moreover, the risk of clinical deterioration was significantly higher in the GI group than in the non-GI group (15.6% vs. 10 .1%, p=0.032).", [["GI", "ANATOMY", 77, 79], ["GI", "CANCER", 77, 79], ["non-GI", "CANCER", 98, 104], ["clinical deterioration", "PROBLEM", 22, 44], ["higher", "OBSERVATION_MODIFIER", 63, 69]]], ["The length of hospital stay was significantly longer in patients with GI symptoms than in patients without these symptoms (19.6 \u00b1 5.9 days vs.18.4 \u00b1 6.0 days, p=0.013).", [["GI", "ANATOMY", 70, 72], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 90, 98], ["GI symptoms", "PROBLEM", 70, 81], ["these symptoms", "PROBLEM", 107, 121], ["p", "TEST", 159, 160], ["length", "OBSERVATION_MODIFIER", 4, 10]]], ["The average time from symptoms onset to viral clearance was 26.2 \u00b1 9.0 days and 24.7 \u00b1 9.0 days in patients with and without GI symptoms, respectively (p=0.046) ( Table 1) .Laboratory and radiological findingsThe median lymphocyte count was significantly higher in the non-GI group 65.1%, p<0.001) ( Table 2) .Factors associated with clinical worseningTo identify risk factors related with poor prognosis in our cohort, we compared clinical and laboratory features between patients transferred to tertiary hospitals (n=144) and those discharged from hospitals (n=1176).Factors associated with clinical worseningUnivariate analysis showed that GI symptoms (p=0.025), male gender (p<0.001), and elevated CRP (p=0.006) were associated with clinical deterioration ( Table 3) .", [["GI", "ANATOMY", 125, 127], ["lymphocyte", "ANATOMY", 220, 230], ["patients", "ORGANISM", 99, 107], ["lymphocyte", "CELL", 220, 230], ["patients", "ORGANISM", 473, 481], ["CRP", "GENE_OR_GENE_PRODUCT", 702, 705], ["CRP", "PROTEIN", 702, 705], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 473, 481], ["symptoms", "PROBLEM", 22, 30], ["viral clearance", "TEST", 40, 55], ["GI symptoms", "PROBLEM", 125, 136], ["radiological findings", "TEST", 188, 209], ["The median lymphocyte count", "TEST", 209, 236], ["clinical worsening", "PROBLEM", 334, 352], ["Univariate analysis", "TEST", 611, 630], ["GI symptoms", "PROBLEM", 643, 654], ["elevated CRP", "PROBLEM", 693, 705], ["clinical deterioration", "PROBLEM", 737, 759], ["elevated", "OBSERVATION_MODIFIER", 693, 701], ["CRP", "OBSERVATION_MODIFIER", 702, 705]]], ["Multivariable logistic regression analysis showed Accepted Article that GI symptoms (p=0.045), male gender (p<0.001), and elevated CRP (p=0.008) were independent risk factors for patient transfer to a tertiary hospital ( Table 3) .Viral clearance in the upper respiratory routeDuring the follow-up period, SARS-CoV-2 was detected in nasopharyngeal swab samples from 1320 patients.", [["respiratory", "ANATOMY", 260, 271], ["nasopharyngeal swab samples", "ANATOMY", 333, 360], ["CRP", "GENE_OR_GENE_PRODUCT", 131, 134], ["patient", "ORGANISM", 179, 186], ["Viral", "ORGANISM", 231, 236], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 306, 316], ["nasopharyngeal swab samples", "CANCER", 333, 360], ["patients", "ORGANISM", 371, 379], ["CRP", "PROTEIN", 131, 134], ["patient", "SPECIES", 179, 186], ["patients", "SPECIES", 371, 379], ["SARS-CoV", "SPECIES", 306, 314], ["Multivariable logistic regression analysis", "TEST", 0, 42], ["GI symptoms", "PROBLEM", 72, 83], ["elevated CRP", "PROBLEM", 122, 134], ["Viral clearance", "TEST", 231, 246], ["SARS", "PROBLEM", 306, 310], ["CoV", "TEST", 311, 314], ["nasopharyngeal swab samples", "TEST", 333, 360], ["upper", "ANATOMY_MODIFIER", 254, 259], ["respiratory", "ANATOMY", 260, 271], ["nasopharyngeal", "ANATOMY", 333, 347]]], ["Viral clearance was defined as two consecutive negative results on RT-PCR.", [["Viral", "ORGANISM", 0, 5], ["Viral clearance", "TEST", 0, 15], ["RT", "TEST", 67, 69], ["PCR", "TEST", 70, 73]]], ["The estimated median time from symptoms onset to viral clearance was 24 days in the non-GI group.Viral clearance in the upper respiratory routeHowever, this period was significantly longer in the GI group (27days vs. 24days, p <0.05) (Figure 2 ).COVID-19 has attracted attention worldwide in light of its high infectivity.Research on this disease has accelerated because of its significant health and economic burden, and studies have investigated the epidemiology 21 , clinical characteristics 22 , and viral genome sequences 23 of this entity.COVID-19 has attracted attention worldwide in light of its high infectivity.Studies conducted at the early stage of the COVID-19 outbreak indicated that respiratory symptoms such as fever and cough, but not GI symptoms, were common at disease onset 7,24 .", [["GI", "ANATOMY", 196, 198], ["respiratory", "ANATOMY", 698, 709], ["GI", "ANATOMY", 752, 754], ["COVID-19", "CHEMICAL", 246, 254], ["COVID-19", "CHEMICAL", 545, 553], ["respiratory symptoms", "DISEASE", 698, 718], ["fever", "DISEASE", 727, 732], ["cough", "DISEASE", 737, 742], ["non-GI", "CANCER", 84, 90], ["Viral", "ORGANISM", 97, 102], ["GI", "PATHOLOGICAL_FORMATION", 196, 198], ["COVID-19", "DNA", 246, 254], ["viral genome sequences", "DNA", 504, 526], ["COVID-19", "DNA", 545, 553], ["symptoms", "PROBLEM", 31, 39], ["viral clearance", "PROBLEM", 49, 64], ["Viral clearance", "TEST", 97, 112], ["its high infectivity", "PROBLEM", 301, 321], ["this disease", "PROBLEM", 334, 346], ["economic burden", "PROBLEM", 401, 416], ["clinical characteristics", "TEST", 470, 494], ["viral genome sequences", "TEST", 504, 526], ["its high infectivity", "PROBLEM", 600, 620], ["Studies", "TEST", 621, 628], ["the COVID", "TEST", 661, 670], ["respiratory symptoms", "PROBLEM", 698, 718], ["fever", "PROBLEM", 727, 732], ["cough", "PROBLEM", 737, 742], ["GI symptoms", "PROBLEM", 752, 763], ["median", "OBSERVATION_MODIFIER", 14, 20], ["clearance", "OBSERVATION", 103, 112], ["upper", "ANATOMY_MODIFIER", 120, 125], ["respiratory", "ANATOMY", 126, 137], ["high infectivity", "OBSERVATION", 305, 321], ["disease", "OBSERVATION", 339, 346], ["significant", "OBSERVATION_MODIFIER", 378, 389], ["high infectivity", "OBSERVATION", 604, 620], ["cough", "OBSERVATION", 737, 742]]], ["However, later studies showed that the first clinical manifestations in some patients were diarrhea, abdominal discomfort, and nausea [25] [26] [27] .", [["abdominal", "ANATOMY", 101, 110], ["diarrhea", "DISEASE", 91, 99], ["abdominal discomfort", "DISEASE", 101, 121], ["nausea", "DISEASE", 127, 133], ["patients", "ORGANISM", 77, 85], ["abdominal", "ORGANISM_SUBDIVISION", 101, 110], ["patients", "SPECIES", 77, 85], ["later studies", "TEST", 9, 22], ["the first clinical manifestations", "PROBLEM", 35, 68], ["diarrhea", "PROBLEM", 91, 99], ["abdominal discomfort", "PROBLEM", 101, 121], ["nausea", "PROBLEM", 127, 133], ["abdominal", "ANATOMY", 101, 110], ["discomfort", "OBSERVATION", 111, 121]]], ["These patients contribute to the potential risk of infection for front-line clinicians and pose a greater challenge for early diagnosis of patients with COVID-19.", [["infection", "DISEASE", 51, 60], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 139, 147], ["infection", "PROBLEM", 51, 60], ["a greater challenge", "TREATMENT", 96, 115], ["COVID", "TEST", 153, 158], ["infection", "OBSERVATION", 51, 60]]], ["Therefore, patients with GI symptoms deserve special attention, and understanding differences in clinical characteristics and prognosis between patients with and without these symptoms is crucial.", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 144, 152], ["GI symptoms", "PROBLEM", 25, 36], ["these symptoms", "PROBLEM", 170, 184]]], ["All rights reserved.Accepted ArticleOur results indicated that the most common manifestations of SARS-CoV-2 infection were fever (83.0%), cough (42.8%), and fatigue (23.5%), which was consistent with a previous study 28 .", [["SARS-CoV-2 infection", "DISEASE", 97, 117], ["fever", "DISEASE", 123, 128], ["cough", "DISEASE", 138, 143], ["fatigue", "DISEASE", 157, 164], ["SARS-CoV-2", "ORGANISM", 97, 107], ["CoV-2", "SPECIES", 102, 107], ["SARS-CoV", "SPECIES", 97, 105], ["SARS", "PROBLEM", 97, 101], ["CoV", "TEST", 102, 105], ["2 infection", "PROBLEM", 106, 117], ["fever", "PROBLEM", 123, 128], ["cough", "TEST", 138, 143], ["fatigue", "PROBLEM", 157, 164], ["a previous study", "TEST", 200, 216], ["SARS", "OBSERVATION", 97, 101], ["consistent with", "UNCERTAINTY", 184, 199]]], ["Moreover, middle-aged and elderly people were more susceptible to SARS-CoV-2 infections, which may be the result of lower immunity in these populations.", [["SARS", "DISEASE", 66, 70], ["infections", "DISEASE", 77, 87], ["people", "ORGANISM", 34, 40], ["SARS-CoV-2", "ORGANISM", 66, 76], ["people", "SPECIES", 34, 40], ["SARS-CoV", "SPECIES", 66, 74], ["SARS", "PROBLEM", 66, 70], ["CoV-2 infections", "PROBLEM", 71, 87], ["lower immunity in these populations", "PROBLEM", 116, 151], ["middle", "ANATOMY_MODIFIER", 10, 16], ["infections", "OBSERVATION", 77, 87], ["lower", "OBSERVATION_MODIFIER", 116, 121], ["immunity", "OBSERVATION", 122, 130]]], ["The most common GI symptoms in our sample were diarrhea (8.1%) and anorexia (4.7%).", [["GI", "ANATOMY", 16, 18], ["diarrhea", "DISEASE", 47, 55], ["anorexia", "DISEASE", 67, 75], ["GI", "CANCER", 16, 18], ["The most common GI symptoms", "PROBLEM", 0, 27], ["diarrhea", "PROBLEM", 47, 55], ["anorexia", "PROBLEM", 67, 75]]], ["COVID-19 patients with GI symptoms were more likely to have symptoms of fatigue, myalgia, and headache, which may be due to electrolyte disturbances 29 .", [["GI", "ANATOMY", 23, 25], ["GI symptoms", "DISEASE", 23, 34], ["fatigue", "DISEASE", 72, 79], ["myalgia", "DISEASE", 81, 88], ["headache", "DISEASE", 94, 102], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["GI symptoms", "PROBLEM", 23, 34], ["symptoms", "PROBLEM", 60, 68], ["fatigue", "PROBLEM", 72, 79], ["myalgia", "PROBLEM", 81, 88], ["headache", "PROBLEM", 94, 102], ["electrolyte disturbances", "PROBLEM", 124, 148], ["fatigue", "OBSERVATION", 72, 79], ["myalgia", "OBSERVATION", 81, 88]]], ["Moreover, GI disturbances may lead to intestinal flora imbalance, potentially affecting the central nervous system through the gut-brain axis and causing symptoms such as headache and fatigue 30 .", [["GI", "ANATOMY", 10, 12], ["intestinal flora", "ANATOMY", 38, 54], ["central nervous system", "ANATOMY", 92, 114], ["gut", "ANATOMY", 127, 130], ["brain", "ANATOMY", 131, 136], ["GI disturbances", "DISEASE", 10, 25], ["headache", "DISEASE", 171, 179], ["fatigue", "DISEASE", 184, 191], ["intestinal flora", "PATHOLOGICAL_FORMATION", 38, 54], ["central nervous system", "ANATOMICAL_SYSTEM", 92, 114], ["gut", "ORGANISM_SUBDIVISION", 127, 130], ["brain", "ORGAN", 131, 136], ["GI disturbances", "PROBLEM", 10, 25], ["intestinal flora imbalance", "PROBLEM", 38, 64], ["symptoms", "PROBLEM", 154, 162], ["headache", "PROBLEM", 171, 179], ["fatigue", "PROBLEM", 184, 191], ["intestinal", "ANATOMY", 38, 48], ["flora", "OBSERVATION", 49, 54], ["central", "ANATOMY_MODIFIER", 92, 99], ["nervous system", "ANATOMY", 100, 114], ["gut", "ANATOMY", 127, 130], ["brain axis", "ANATOMY", 131, 141]]], ["GI disorders caused by SARS-CoV-2 infection may damage the intestinal barrier, which triggered bacterial translocation from the GI tract to internal compartments, aggravating infection and inflammation.", [["intestinal barrier", "ANATOMY", 59, 77], ["GI tract", "ANATOMY", 128, 136], ["internal compartments", "ANATOMY", 140, 161], ["GI disorders", "DISEASE", 0, 12], ["SARS", "DISEASE", 23, 27], ["infection", "DISEASE", 34, 43], ["infection", "DISEASE", 175, 184], ["inflammation", "DISEASE", 189, 201], ["SARS-CoV-2", "ORGANISM", 23, 33], ["intestinal barrier", "MULTI-TISSUE_STRUCTURE", 59, 77], ["GI tract", "ORGANISM_SUBDIVISION", 128, 136], ["SARS-CoV-2", "SPECIES", 23, 33], ["GI disorders", "PROBLEM", 0, 12], ["SARS", "PROBLEM", 23, 27], ["CoV", "PROBLEM", 28, 31], ["2 infection", "PROBLEM", 32, 43], ["the intestinal barrier", "PROBLEM", 55, 77], ["bacterial translocation from the GI tract", "PROBLEM", 95, 136], ["aggravating infection", "PROBLEM", 163, 184], ["inflammation", "PROBLEM", 189, 201], ["disorders", "OBSERVATION", 3, 12], ["SARS", "OBSERVATION", 23, 27], ["infection", "OBSERVATION", 34, 43], ["intestinal", "ANATOMY", 59, 69], ["bacterial translocation", "OBSERVATION", 95, 118], ["GI tract", "ANATOMY", 128, 136], ["internal compartments", "ANATOMY", 140, 161], ["aggravating", "OBSERVATION_MODIFIER", 163, 174], ["infection", "OBSERVATION", 175, 184], ["inflammation", "OBSERVATION", 189, 201]]], ["In our cohort, the proportion of patients transferred to tertiary hospitals was 10.9%, and there was a significant difference in the rate of clinical deterioration between the GI and non-GI group (15.6% vs. 10.1%).", [["GI", "ANATOMY", 176, 178], ["patients", "ORGANISM", 33, 41], ["non-GI", "CANCER", 183, 189], ["patients", "SPECIES", 33, 41], ["clinical deterioration", "PROBLEM", 141, 163], ["the GI", "TEST", 172, 178], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["difference", "OBSERVATION_MODIFIER", 115, 125], ["GI", "ANATOMY", 176, 178]]], ["Among discharged patients, the length of hospital stay was significantly longer in patients with GI symptoms than those without these symptoms (19.6 \u00b1 5.9 days vs. 18.4 \u00b1 6.0 days, p=0.013).", [["GI", "ANATOMY", 97, 99], ["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 83, 91], ["GI symptoms", "PROBLEM", 97, 108], ["these symptoms", "PROBLEM", 128, 142]]], ["Furthermore, a previous study showed that the need for mechanical ventilation and ICU care was significantly higher in patients with GI symptoms (p=0.034) 29 , indicating that prognosis was worse in this group.", [["GI", "ANATOMY", 133, 135], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["a previous study", "TEST", 13, 29], ["mechanical ventilation", "TREATMENT", 55, 77], ["ICU care", "TREATMENT", 82, 90], ["GI symptoms", "PROBLEM", 133, 144]]], ["The average time from symptoms onset to viral clearance was 26.2 \u00b1 9.0 days and 24.7 \u00b1 9.0 days in patients with and without GI symptoms, respectively (p=0.046).", [["GI", "ANATOMY", 125, 127], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["symptoms", "PROBLEM", 22, 30], ["viral clearance", "TEST", 40, 55], ["GI symptoms", "PROBLEM", 125, 136]]], ["Patients in the GI group were more likely to have bilateral lesions on chest CT, which might indicate higher viral load in the respiratory system.", [["GI", "ANATOMY", 16, 18], ["lesions", "ANATOMY", 60, 67], ["chest", "ANATOMY", 71, 76], ["respiratory system", "ANATOMY", 127, 145], ["Patients", "ORGANISM", 0, 8], ["GI", "CANCER", 16, 18], ["lesions", "PATHOLOGICAL_FORMATION", 60, 67], ["chest", "ORGAN", 71, 76], ["Patients", "SPECIES", 0, 8], ["bilateral lesions", "PROBLEM", 50, 67], ["chest CT", "TEST", 71, 79], ["higher viral load in the respiratory system", "PROBLEM", 102, 145], ["bilateral", "ANATOMY_MODIFIER", 50, 59], ["lesions", "OBSERVATION", 60, 67], ["chest", "ANATOMY", 71, 76], ["higher", "OBSERVATION_MODIFIER", 102, 108], ["viral load", "OBSERVATION", 109, 119], ["respiratory system", "ANATOMY", 127, 145]]], ["A large number of viruses This article is protected by copyright.", [["A large number of viruses", "PROBLEM", 0, 25], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["viruses", "OBSERVATION", 18, 25]]], ["All rights reserved.Accepted Articlepresent in the respiratory tract may have reached the GI tract through the blood, leading to GI infection, and higher viral load may prolong the time to viral clearance in the GI group.Accepted ArticleFindings on the relationship between GI symptoms and illness progression are inconsistent across studies.", [["respiratory tract", "ANATOMY", 51, 68], ["GI tract", "ANATOMY", 90, 98], ["blood", "ANATOMY", 111, 116], ["GI", "ANATOMY", 129, 131], ["GI", "ANATOMY", 212, 214], ["GI infection", "DISEASE", 129, 141], ["GI symptoms", "DISEASE", 274, 285], ["illness", "DISEASE", 290, 297], ["respiratory tract", "ORGANISM_SUBDIVISION", 51, 68], ["GI tract", "ORGANISM_SUBDIVISION", 90, 98], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["GI", "CANCER", 212, 214], ["Articlepresent in the respiratory tract", "PROBLEM", 29, 68], ["the GI tract", "PROBLEM", 86, 98], ["the blood", "PROBLEM", 107, 116], ["GI infection", "PROBLEM", 129, 141], ["higher viral load", "PROBLEM", 147, 164], ["viral clearance", "TEST", 189, 204], ["GI symptoms", "PROBLEM", 274, 285], ["illness progression", "PROBLEM", 290, 309], ["respiratory tract", "ANATOMY", 51, 68], ["GI tract", "ANATOMY", 90, 98], ["GI", "ANATOMY", 129, 131], ["infection", "OBSERVATION", 132, 141]]], ["In our cohort, GI symptoms, male gender, and elevated CRP were independent risk factors for clinical deterioration.", [["GI", "ANATOMY", 15, 17], ["GI", "ORGANISM_SUBDIVISION", 15, 17], ["CRP", "GENE_OR_GENE_PRODUCT", 54, 57], ["CRP", "PROTEIN", 54, 57], ["GI symptoms", "PROBLEM", 15, 26], ["elevated CRP", "PROBLEM", 45, 57], ["clinical deterioration", "PROBLEM", 92, 114]]], ["SARS-CoV-2 may infect GI epithelial cells in COVID-19 patients with GI symptoms, leading to inflammation.", [["GI epithelial cells", "ANATOMY", 22, 41], ["GI", "ANATOMY", 68, 70], ["SARS", "DISEASE", 0, 4], ["GI symptoms", "DISEASE", 68, 79], ["inflammation", "DISEASE", 92, 104], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["GI epithelial cells", "CELL", 22, 41], ["patients", "ORGANISM", 54, 62], ["GI", "ORGANISM_SUBDIVISION", 68, 70], ["GI epithelial cells", "CELL_TYPE", 22, 41], ["patients", "SPECIES", 54, 62], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["GI epithelial cells", "TEST", 22, 41], ["COVID", "TEST", 45, 50], ["GI symptoms", "PROBLEM", 68, 79], ["inflammation", "PROBLEM", 92, 104], ["epithelial cells", "OBSERVATION", 25, 41], ["inflammation", "OBSERVATION", 92, 104]]], ["Therefore, GI symptoms may be associated with higher viral load.", [["GI", "ANATOMY", 11, 13], ["GI symptoms", "PROBLEM", 11, 22], ["higher viral load", "PROBLEM", 46, 63], ["viral load", "OBSERVATION", 53, 63]]], ["In addition, the time from symptoms onset to admission was significantly longer in patients with GI symptoms, which might cause diagnostic delay and clinical worsening 26 .", [["GI", "ANATOMY", 97, 99], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["symptoms", "PROBLEM", 27, 35], ["GI symptoms", "PROBLEM", 97, 108], ["diagnostic delay", "PROBLEM", 128, 144], ["clinical worsening", "PROBLEM", 149, 167]]], ["The smoking rate is higher among men in China 31 .", [["men", "ORGANISM", 33, 36], ["men", "SPECIES", 33, 36], ["higher", "OBSERVATION_MODIFIER", 20, 26]]], ["Studies have proved that smoking can upregulate angiotensin-converting enzyme 2 (ACE2) receptors 31 , which may explain why male patients are at higher risk of clinical deterioration than female patients.", [["smoking", "CHEMICAL", 25, 32], ["angiotensin", "CHEMICAL", 48, 59], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 48, 79], ["ACE2", "GENE_OR_GENE_PRODUCT", 81, 85], ["patients", "ORGANISM", 129, 137], ["patients", "ORGANISM", 195, 203], ["angiotensin-converting enzyme 2 (ACE2) receptors 31", "PROTEIN", 48, 99], ["patients", "SPECIES", 129, 137], ["patients", "SPECIES", 195, 203], ["angiotensin", "TEST", 48, 59], ["converting enzyme", "TEST", 60, 77], ["clinical deterioration", "PROBLEM", 160, 182]]], ["The increase in CRP is an independent risk factor for clinical deterioration, which is consistent with current research.", [["CRP", "GENE_OR_GENE_PRODUCT", 16, 19], ["CRP", "PROTEIN", 16, 19], ["The increase in CRP", "PROBLEM", 0, 19], ["clinical deterioration", "PROBLEM", 54, 76], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["CRP", "OBSERVATION_MODIFIER", 16, 19], ["consistent with", "UNCERTAINTY", 87, 102]]], ["High CRP levels reflect a persistent inflammatory state 32 .Accepted ArticleIn summary, our study demonstrated that a higher proportion of COVID-19 patients with GI symptoms was transferred to tertiary hospitals than those without these symptoms.", [["GI", "ANATOMY", 162, 164], ["CRP", "GENE_OR_GENE_PRODUCT", 5, 8], ["patients", "ORGANISM", 148, 156], ["CRP", "PROTEIN", 5, 8], ["patients", "SPECIES", 148, 156], ["High CRP levels", "PROBLEM", 0, 15], ["a persistent inflammatory state", "PROBLEM", 24, 55], ["our study", "TEST", 88, 97], ["COVID", "TEST", 139, 144], ["GI symptoms", "PROBLEM", 162, 173], ["these symptoms", "PROBLEM", 231, 245], ["persistent", "OBSERVATION_MODIFIER", 26, 36], ["inflammatory", "OBSERVATION_MODIFIER", 37, 49]]], ["Potential risk factors for developing GI symptoms, male gender, and increased CRP may help clinicians predict clinical worsening in COVID-19 patients.Accepted ArticleThis study has limitations.", [["GI", "ANATOMY", 38, 40], ["GI symptoms", "DISEASE", 38, 49], ["GI", "ORGANISM_SUBDIVISION", 38, 40], ["CRP", "GENE_OR_GENE_PRODUCT", 78, 81], ["patients", "ORGANISM", 141, 149], ["CRP", "PROTEIN", 78, 81], ["patients", "SPECIES", 141, 149], ["Potential risk factors", "PROBLEM", 0, 22], ["developing GI symptoms", "PROBLEM", 27, 49], ["increased CRP", "PROBLEM", 68, 81], ["COVID", "TEST", 132, 137], ["ArticleThis study", "TEST", 159, 176]]], ["First, the study was single-center and retrospective; therefore, larger sample sizes are necessary to confirm our conclusions.", [["the study", "TEST", 7, 16], ["larger sample sizes", "TEST", 65, 84]]], ["Second, viral nucleic acid tests were not performed daily for each patient; there was a delay in the recorded time of viral clearance This article is protected by copyright.", [["nucleic acid", "CHEMICAL", 14, 26], ["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74], ["viral nucleic acid tests", "TEST", 8, 32], ["a delay", "PROBLEM", 86, 93], ["viral clearance", "TEST", 118, 133]]], ["All rights reserved.Accepted ArticleAccepted Article compared to actual time of viral clearance.", [["viral clearance", "PROBLEM", 80, 95]]], ["Last but not least, since our hospital was designated for to enroll the mild and common type patients with COVID-19, there was shortage of information about severe and critical type patients with COVID-19.Authors' contributionsAll authors made significant contributions to this study and approved the final manuscript.", [["COVID-19", "CHEMICAL", 196, 204], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 182, 190], ["COVID", "TEST", 107, 112], ["COVID", "TEST", 196, 201], ["this study", "TEST", 273, 283], ["mild", "OBSERVATION_MODIFIER", 72, 76], ["significant", "OBSERVATION_MODIFIER", 244, 255]]], ["Concept and design: TZ and CY; data acquisition, analysis, or interpretation: HW, XC, ZW, and LY; manuscript writing: TZ and CY; manuscript review and editing: HS; supervision: HS.Declaration of interestsWe declare no competing interests.", [["CY", "CHEMICAL", 27, 29], ["CY", "CHEMICAL", 125, 127], ["TZ", "SIMPLE_CHEMICAL", 20, 22], ["data acquisition", "TEST", 31, 47], ["analysis", "TEST", 49, 57]]]], "PMC5035928": [["Sample characterization ::: ResultsA total of 24 pools of 3\u20135 bat fecal samples were constituted, enriched for viral particles and sequenced.", [["fecal samples", "ANATOMY", 66, 79], ["bat", "ORGANISM", 62, 65], ["fecal samples", "ORGANISM_SUBSTANCE", 66, 79], ["Sample characterization", "TEST", 0, 23], ["bat fecal samples", "TEST", 62, 79], ["viral particles", "PROBLEM", 111, 126]]], ["Illumina sequencing yielded between 1.1 and 7.8 million reads per pool, and DIAMOND classification20 of the obtained contigs indicated that five pools contained a significant amount of RVA sequence reads.", [["DIAMOND classification20", "DNA", 76, 100], ["RVA sequence reads", "DNA", 185, 203], ["Illumina sequencing", "TEST", 0, 19]]], ["The percentage reads mapping to RVA in each pool ranged from 0.1\u20132.4% (Table 1).", [["RVA", "TEST", 32, 35]]], ["Partial segments were completed by regular PCR and Sanger sequencing, to obtain at least the entire ORF for each of the obtained variants.", [["ORF", "DNA", 100, 103], ["regular PCR", "TEST", 35, 46], ["Sanger sequencing", "TEST", 51, 68], ["segments", "ANATOMY_MODIFIER", 8, 16]]], ["Obtained sequences were used for phylogenetic comparison with a selection of representative members of each genotype.", [["Obtained sequences", "TEST", 0, 18]]], ["The RVA strains discovered in this study were named RVA/Bat-wt/CMR/BatLi08/2014/G31P[42], RVA/Bat-wt/CMR/BatLi09/2014/G30P[42], RVA/Bat-wt/CMR/BatLi10/2014/G30P[42], RVA/bat-wt/CMR/BatLy03/2014/G25P[43] and RVA/Bat-wt/CMR/BatLy17/2014/G30P[47] hereafter referred to as BatLi08, BatLi09, BatLi10, BatLy03 and BatLy17, respectively.", [["Bat", "GENE_OR_GENE_PRODUCT", 56, 59], ["BatLi08", "GENE_OR_GENE_PRODUCT", 67, 74], ["BatLi08", "GENE_OR_GENE_PRODUCT", 269, 276], ["BatLi09", "GENE_OR_GENE_PRODUCT", 278, 285], ["BatLi10", "GENE_OR_GENE_PRODUCT", 287, 294], ["BatLy03", "GENE_OR_GENE_PRODUCT", 296, 303], ["BatLy17", "GENE_OR_GENE_PRODUCT", 308, 315], ["BatLi08", "PROTEIN", 67, 74], ["BatLi09", "PROTEIN", 105, 112], ["CMR", "DNA", 177, 180], ["BatLy03", "DNA", 181, 188], ["CMR", "DNA", 218, 221], ["BatLy17", "DNA", 222, 229], ["BatLi08", "DNA", 269, 276], ["BatLi09", "DNA", 278, 285], ["BatLi10", "DNA", 287, 294], ["BatLy03", "DNA", 296, 303], ["BatLy17", "DNA", 308, 315], ["RVA/Bat-wt/CMR/BatLi08/2014/G31P", "SPECIES", 52, 84], ["RVA/Bat-wt/CMR/BatLi09/2014/G30P", "SPECIES", 90, 122], ["RVA/Bat-wt/CMR/BatLi10/2014/G30P", "SPECIES", 128, 160], ["RVA/bat-wt/CMR/BatLy03/2014/G25P", "SPECIES", 166, 198], ["RVA/Bat-wt/CMR/BatLy17/2014/G30P", "SPECIES", 207, 239], ["The RVA strains", "PROBLEM", 0, 15], ["this study", "TEST", 30, 40], ["RVA", "TEST", 52, 55], ["Bat", "TEST", 56, 59], ["wt", "TEST", 60, 62], ["CMR", "TEST", 63, 66], ["BatLi08", "TEST", 67, 74], ["G31P", "TEST", 80, 84], ["RVA", "TEST", 90, 93], ["Bat", "TEST", 94, 97], ["wt", "TEST", 98, 100], ["CMR", "TEST", 101, 104], ["BatLi09", "TEST", 105, 112], ["G30P", "TEST", 118, 122], ["RVA", "TEST", 128, 131], ["Bat", "TEST", 132, 135], ["wt", "TEST", 136, 138], ["CMR", "TEST", 139, 142], ["BatLi10", "TEST", 143, 150], ["G30P", "TEST", 156, 160], ["RVA", "TEST", 166, 169], ["bat", "TEST", 170, 173], ["wt", "TEST", 174, 176], ["CMR", "TEST", 177, 180], ["BatLy03", "TEST", 181, 188], ["G25P", "TEST", 194, 198], ["RVA", "TEST", 207, 210], ["Bat", "TEST", 211, 214], ["wt", "TEST", 215, 217], ["CMR", "TEST", 218, 221], ["BatLy17", "TEST", 222, 229], ["G30P", "TEST", 235, 239]]], ["All the obtained sequences were highly divergent from established genotypes and were therefore submitted to the Rotavirus Classification Working group (RCWG) for novel genotype assignments (see below) and to GenBank (accession numbers: KX268743\u2013KX268797).Phylogenetic analysis ::: ResultsThe VP7 gene of BatLy03 was 96% identical (on the nucleotide (nt) level, supplementary data S1) to the Kenyan bat RVA strain KE4852 counterpart, which had been previously classified as a G25 genotype (Fig. 2).", [["nucleotide", "CHEMICAL", 338, 348], ["VP7", "GENE_OR_GENE_PRODUCT", 292, 295], ["BatLy03", "GENE_OR_GENE_PRODUCT", 304, 311], ["VP7 gene", "DNA", 292, 300], ["BatLy03", "DNA", 304, 311], ["Kenyan bat RVA strain KE4852", "SPECIES", 391, 419], ["Phylogenetic analysis", "TEST", 255, 276], ["The VP7 gene", "TEST", 288, 300], ["BatLy03", "TEST", 304, 311], ["the nucleotide (nt) level", "TEST", 334, 359]]], ["BatLi10 and BatLi09 were 100% identical and also clustered closely with strain BatLy17 (92% similar).", [["BatLi10", "GENE_OR_GENE_PRODUCT", 0, 7], ["BatLi09", "GENE_OR_GENE_PRODUCT", 12, 19], ["BatLi10", "PROTEIN", 0, 7], ["BatLi09", "PROTEIN", 12, 19]]], ["This cluster was only distantly related to all other known VP7 RVA sequences as well as to strain BatLi08, which also formed a unique long branch in the phylogenetic tree.", [["VP7", "GENE_OR_GENE_PRODUCT", 59, 62], ["BatLi08", "GENE_OR_GENE_PRODUCT", 98, 105], ["VP7 RVA sequences", "DNA", 59, 76], ["all other known VP7 RVA sequences", "PROBLEM", 43, 76], ["unique", "OBSERVATION_MODIFIER", 127, 133], ["long", "OBSERVATION_MODIFIER", 134, 138], ["branch", "OBSERVATION_MODIFIER", 139, 145], ["phylogenetic tree", "OBSERVATION", 153, 170]]], ["The VP7 of these 4 strains (BatLi10, BatLi09, BatLy17 and BatLi08) did not belong to any of the established RVA G-genotypes, according to the established criteria6, and were assigned genotypes G30 (BatLi09, BatLi10 and BatLy17) and G31 (BatLi08) by the RCWG.", [["VP7", "GENE_OR_GENE_PRODUCT", 4, 7], ["BatLi10", "GENE_OR_GENE_PRODUCT", 28, 35], ["BatLi09", "GENE_OR_GENE_PRODUCT", 37, 44], ["BatLy17", "GENE_OR_GENE_PRODUCT", 46, 53], ["BatLi08", "GENE_OR_GENE_PRODUCT", 58, 65], ["VP7", "PROTEIN", 4, 7], ["BatLi09", "PROTEIN", 37, 44], ["BatLy17", "PROTEIN", 46, 53], ["BatLi08", "PROTEIN", 58, 65], ["G30", "PROTEIN", 193, 196], ["BatLi09", "PROTEIN", 198, 205], ["BatLi10", "PROTEIN", 207, 214], ["BatLy17", "PROTEIN", 219, 226], ["G31", "PROTEIN", 232, 235], ["BatLi08", "PROTEIN", 237, 244], ["The VP7", "TEST", 0, 7], ["BatLi10", "TEST", 28, 35]]], ["For VP4, VP1 and VP3, all five Cameroonian bat RVAs strains were distantly related to other known RVA strains, including the Kenyan and Chinese RVA strains and were therefore assigned to novel genotypes according to the RCWG classification criteria (Fig. 3).", [["VP4", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP1", "GENE_OR_GENE_PRODUCT", 9, 12], ["VP3", "GENE_OR_GENE_PRODUCT", 17, 20], ["RVAs", "GENE_OR_GENE_PRODUCT", 47, 51], ["VP4", "PROTEIN", 4, 7], ["VP1", "DNA", 9, 12], ["VP3", "PROTEIN", 17, 20], ["Cameroonian bat", "SPECIES", 31, 46], ["Chinese RVA strains", "SPECIES", 136, 155], ["VP4", "TEST", 4, 7], ["VP1", "TEST", 9, 12], ["VP3", "TEST", 17, 20], ["Cameroonian bat RVAs strains", "PROBLEM", 31, 59], ["known RVA strains", "PROBLEM", 92, 109], ["Chinese RVA strains", "PROBLEM", 136, 155], ["novel genotypes", "PROBLEM", 187, 202], ["VP3", "ANATOMY", 17, 20], ["RVA strains", "OBSERVATION", 98, 109]]], ["The VP4 gene of strains BatLi08, BatLi09 and BatLi10 (representatives of the novel genotype P[42]) were almost 99\u2013100% identical to each other and only 56\u201375% identical to any other P-genotype.", [["VP4", "GENE_OR_GENE_PRODUCT", 4, 7], ["BatLi08", "GENE_OR_GENE_PRODUCT", 24, 31], ["BatLi09", "GENE_OR_GENE_PRODUCT", 33, 40], ["BatLi10", "GENE_OR_GENE_PRODUCT", 45, 52], ["VP4 gene", "DNA", 4, 12], ["BatLi08", "DNA", 24, 31], ["BatLi09", "DNA", 33, 40], ["BatLi10", "DNA", 45, 52], ["P", "DNA", 182, 183]]], ["That of strains BatLy03 and BatLy17 had 29% nt dissimilarity to each other and their nt identity ranged from 60\u201376% with other P-genotypes and therefore were assigned the genotypes P[43] and P[47], respectively.", [["BatLy03", "GENE_OR_GENE_PRODUCT", 16, 23], ["BatLy17", "GENE_OR_GENE_PRODUCT", 28, 35], ["P", "DNA", 127, 128], ["strains BatLy03", "TEST", 8, 23], ["29% nt dissimilarity", "PROBLEM", 40, 60], ["their nt identity", "TEST", 79, 96], ["other P-genotypes", "PROBLEM", 121, 138]]], ["The VP1 and VP3 genes of BatLi08, BatLi09, BatLi10 and BatLy17 were nearly identical (nt identity range 99\u2013100%) and clustered together but distinct from other established R and M-genotypes, thereby representing the new genotypes R15 and M14, respectively (Fig. 3).", [["VP1", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP3", "GENE_OR_GENE_PRODUCT", 12, 15], ["BatLi08", "GENE_OR_GENE_PRODUCT", 25, 32], ["BatLi09", "GENE_OR_GENE_PRODUCT", 34, 41], ["BatLi10", "GENE_OR_GENE_PRODUCT", 43, 50], ["BatLy17", "GENE_OR_GENE_PRODUCT", 55, 62], ["R", "GENE_OR_GENE_PRODUCT", 172, 173], ["M14", "CELL", 238, 241], ["VP1 and VP3 genes", "DNA", 4, 21], ["BatLi08", "DNA", 25, 32], ["BatLi09", "DNA", 34, 41], ["BatLi10", "DNA", 43, 50], ["BatLy17", "DNA", 55, 62], ["The VP1", "TEST", 0, 7], ["BatLi08", "TEST", 25, 32], ["nt identity", "TEST", 86, 97], ["new", "OBSERVATION_MODIFIER", 216, 219]]], ["The VP1 and VP3 genes of BatLy03 were only distantly related to the other four Cameroonian bat RVAs (68\u201377% nt identity) and are the sole member of the newly assigned genotypes R16 and M15, respectively (Fig. 3).", [["VP1", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP3", "GENE_OR_GENE_PRODUCT", 12, 15], ["BatLy03", "GENE_OR_GENE_PRODUCT", 25, 32], ["M15", "CELL", 185, 188], ["VP1 and VP3 genes", "DNA", 4, 21], ["BatLy03", "DNA", 25, 32], ["Cameroonian bat RVAs", "DNA", 79, 99], ["Cameroonian bat RVAs", "SPECIES", 79, 99], ["The VP1", "TEST", 0, 7], ["VP3 genes", "OBSERVATION", 12, 21]]], ["The VP6, VP2, NSP2, NSP3 and NSP5 gene segments of 4 of our strains (BatLi08, BatLi09, BatLi10 and BatLy17) were distantly related to their counterparts of other mammalian and avian RVAs (Fig. 4).", [["VP6", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP2", "GENE_OR_GENE_PRODUCT", 9, 12], ["NSP2", "GENE_OR_GENE_PRODUCT", 14, 18], ["NSP3", "GENE_OR_GENE_PRODUCT", 20, 24], ["NSP5", "GENE_OR_GENE_PRODUCT", 29, 33], ["BatLi08", "GENE_OR_GENE_PRODUCT", 69, 76], ["BatLi09", "GENE_OR_GENE_PRODUCT", 78, 85], ["BatLi10", "GENE_OR_GENE_PRODUCT", 87, 94], ["BatLy17", "GENE_OR_GENE_PRODUCT", 99, 106], ["VP6, VP2, NSP2, NSP3 and NSP5 gene segments", "DNA", 4, 47], ["BatLi08", "DNA", 69, 76], ["BatLi09", "DNA", 78, 85], ["BatLi10", "DNA", 87, 94], ["BatLy17", "DNA", 99, 106], ["The VP6", "TEST", 0, 7], ["VP2", "TEST", 9, 12], ["NSP2", "TEST", 14, 18], ["NSP3", "TEST", 20, 24], ["our strains", "PROBLEM", 56, 67], ["BatLi08", "TEST", 69, 76], ["BatLi09", "TEST", 78, 85], ["BatLi10", "TEST", 87, 94], ["VP6", "ANATOMY_MODIFIER", 4, 7], ["VP2", "ANATOMY", 9, 12], ["segments", "OBSERVATION_MODIFIER", 39, 47]]], ["For all the 4 strains, these gene segments clustered together and were 99\u2013100% identical to each other and consequently they constitute new genotypes for the different gene segments (I22, C15 N15, T17 and H17, respectively).", [["T17", "DNA", 197, 200], ["H17", "DNA", 205, 208]]], ["The VP6, VP2, NSP2, NSP3 and NSP5 gene segments of BatLy03 phylogenetically clustered together with the Kenyan bat RVA strain KE4852 in the previously established I15, C8, N8, T11 and H10 genotypes, respectively (Fig. 4).", [["VP6", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP2", "GENE_OR_GENE_PRODUCT", 9, 12], ["NSP2", "GENE_OR_GENE_PRODUCT", 14, 18], ["NSP3", "GENE_OR_GENE_PRODUCT", 20, 24], ["NSP5", "GENE_OR_GENE_PRODUCT", 29, 33], ["BatLy03", "GENE_OR_GENE_PRODUCT", 51, 58], ["VP6, VP2, NSP2, NSP3 and NSP5 gene segments", "DNA", 4, 47], ["BatLy03", "DNA", 51, 58], ["Kenyan bat RVA strain KE4852", "SPECIES", 104, 132], ["The VP6", "TEST", 0, 7], ["VP2", "TEST", 9, 12], ["NSP2", "TEST", 14, 18], ["NSP3", "TEST", 20, 24], ["NSP5 gene segments of BatLy03 phylogenetically", "PROBLEM", 29, 75], ["VP6", "ANATOMY_MODIFIER", 4, 7], ["VP2", "ANATOMY", 9, 12], ["segments", "ANATOMY_MODIFIER", 39, 47], ["C8", "ANATOMY_MODIFIER", 168, 170], ["T11", "ANATOMY", 176, 179], ["H10", "ANATOMY_MODIFIER", 184, 187]]], ["For NSP1, the Cameroonian bat strains BatLi08, BatLi09, BatLi10 and BatLy17 clustered closely together (98\u2013100% nucleotide sequence identity) in the novel genotype A25, and showed only 67% nucleotide similarity to strain BatLy03 (A26).", [["nucleotide", "CHEMICAL", 112, 122], ["nucleotide", "CHEMICAL", 189, 199], ["nucleotide", "CHEMICAL", 112, 122], ["nucleotide", "CHEMICAL", 189, 199], ["NSP1", "GENE_OR_GENE_PRODUCT", 4, 8], ["BatLi08", "GENE_OR_GENE_PRODUCT", 38, 45], ["BatLi09", "GENE_OR_GENE_PRODUCT", 47, 54], ["BatLi10", "GENE_OR_GENE_PRODUCT", 56, 63], ["BatLy17", "GENE_OR_GENE_PRODUCT", 68, 75], ["NSP1", "PROTEIN", 4, 8], ["BatLi09", "PROTEIN", 47, 54], ["BatLi10", "PROTEIN", 56, 63], ["BatLy17", "PROTEIN", 68, 75], ["Cameroonian bat", "SPECIES", 14, 29], ["NSP1", "PROBLEM", 4, 8], ["BatLi10", "TREATMENT", 56, 63]]], ["These 5 new NSP1 gene segments were only 42\u201345% identical to that of the most closely related established NSP1 genotype A13 and A14 (from cow) (Fig. 5).", [["NSP1", "GENE_OR_GENE_PRODUCT", 12, 16], ["NSP1 genotype A13", "CELL", 106, 123], ["cow", "ORGANISM_SUBDIVISION", 138, 141], ["NSP1 gene segments", "DNA", 12, 30], ["cow", "SPECIES", 138, 141], ["cow", "SPECIES", 138, 141], ["segments", "ANATOMY_MODIFIER", 22, 30], ["NSP1 genotype", "OBSERVATION", 106, 119]]], ["The NSP4 gene segments of all the 5 RVAs discovered in this study were quite divergent to those of other known bat rotaviruses (at most 69% nucleotide sequence identity) and other RVAs (approximately 45\u201368% nucleotide similarity) forming two distinct clusters.", [["nucleotide", "CHEMICAL", 140, 150], ["nucleotide", "CHEMICAL", 207, 217], ["NSP4", "GENE_OR_GENE_PRODUCT", 4, 8], ["RVAs", "GENE_OR_GENE_PRODUCT", 36, 40], ["bat rotaviruses", "ORGANISM", 111, 126], ["RVAs", "PATHOLOGICAL_FORMATION", 180, 184], ["NSP4 gene segments", "DNA", 4, 22], ["RVAs", "DNA", 36, 40], ["RVAs", "DNA", 180, 184], ["this study", "TEST", 55, 65], ["other known bat rotaviruses", "PROBLEM", 99, 126], ["other RVAs", "PROBLEM", 174, 184], ["nucleotide similarity", "TEST", 207, 228], ["NSP4 gene", "OBSERVATION", 4, 13], ["segments", "ANATOMY_MODIFIER", 14, 22], ["bat", "ANATOMY", 111, 114], ["rotaviruses", "OBSERVATION", 115, 126], ["distinct", "OBSERVATION_MODIFIER", 242, 250], ["clusters", "OBSERVATION_MODIFIER", 251, 259]]], ["The NSP4 gene segments of strains BatLi08, BatLi09, BatLi10 and BatLy03 (genotype E22) were 100% identical but all were 37\u201338% divergent from that of BatLy03 (E23, Fig. 5).Bat rotaviruses in humans? ::: ResultsSeveral different primer pairs are currently being used to detect human RVA VP7 and VP4 gene segments, to determine the G- and P-genotypes using sequencing or multiplex PCR assays21222324.", [["NSP4", "GENE_OR_GENE_PRODUCT", 4, 8], ["BatLi08", "GENE_OR_GENE_PRODUCT", 34, 41], ["BatLi09", "GENE_OR_GENE_PRODUCT", 43, 50], ["BatLi10", "GENE_OR_GENE_PRODUCT", 52, 59], ["BatLy03", "GENE_OR_GENE_PRODUCT", 64, 71], ["BatLy03", "GENE_OR_GENE_PRODUCT", 150, 157], ["Bat rotaviruses", "ORGANISM", 172, 187], ["humans", "ORGANISM", 191, 197], ["human", "ORGANISM", 276, 281], ["RVA VP7", "GENE_OR_GENE_PRODUCT", 282, 289], ["VP4", "GENE_OR_GENE_PRODUCT", 294, 297], ["NSP4 gene segments", "DNA", 4, 22], ["BatLi09", "DNA", 43, 50], ["BatLi10", "DNA", 52, 59], ["BatLy03", "DNA", 64, 71], ["primer pairs", "DNA", 228, 240], ["human RVA VP7 and VP4 gene segments", "DNA", 276, 311], ["P", "DNA", 337, 338], ["rotaviruses", "SPECIES", 176, 187], ["humans", "SPECIES", 191, 197], ["human", "SPECIES", 276, 281], ["Bat rotaviruses", "SPECIES", 172, 187], ["humans", "SPECIES", 191, 197], ["human", "SPECIES", 276, 281], ["strains", "TEST", 26, 33], ["BatLi09", "TEST", 43, 50], ["BatLi10", "TREATMENT", 52, 59], ["genotype E22", "TEST", 73, 85], ["different primer pairs", "PROBLEM", 218, 240], ["the G", "TEST", 326, 331], ["sequencing", "TEST", 355, 365], ["multiplex PCR assays", "TEST", 369, 389], ["segments", "OBSERVATION_MODIFIER", 14, 22], ["rotaviruses", "OBSERVATION", 176, 187]]], ["In order to find out if the currently used human RVA screening primers would detect the bat RVA strain from this study in case of zoonosis, we compared these primers with their corresponding sequences in the respective gene segments (Table 2 and Supplementary data S2).", [["zoonosis", "DISEASE", 130, 138], ["human", "ORGANISM", 43, 48], ["human RVA screening primers", "DNA", 43, 70], ["gene segments", "DNA", 219, 232], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["human RVA screening primers", "TREATMENT", 43, 70], ["the bat RVA strain", "PROBLEM", 84, 102], ["this study", "TEST", 108, 118], ["zoonosis", "PROBLEM", 130, 138], ["these primers", "TEST", 152, 165]]], ["Overall, the similarity percentages for the VP7 forward and reverse primer between the bat RVA sequences and the human primers were 57.1\u2013100% and 63.2\u201395%, respectively.", [["VP7", "GENE_OR_GENE_PRODUCT", 44, 47], ["human", "ORGANISM", 113, 118], ["VP7 forward and reverse primer", "DNA", 44, 74], ["bat RVA sequences", "DNA", 87, 104], ["human primers", "DNA", 113, 126], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["the VP7 forward", "TEST", 40, 55], ["the bat RVA sequences", "TEST", 83, 104], ["the human primers", "TEST", 109, 126]]], ["For VP4, the percentage similarity ranged from 63.6\u201394.4% and 76.2\u201385.7% for the forward and reverse primers, respectively.", [["VP4", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP4", "PROTEIN", 4, 7], ["VP4", "TEST", 4, 7], ["the percentage similarity", "TEST", 9, 34], ["reverse primers", "OBSERVATION", 93, 108]]], ["VP7 forward primers Beg9, sBeg9 and 9Con1-L showed a (near) perfect match with BatLy03-G25, whereas strain BatLi08-G31 and BatLy17-G30 (first 6 nt are missing for this strain), showed up to 10 and 4 nucleotide mismatches at the 3\u2032end of the primers, respectively.", [["nucleotide", "CHEMICAL", 199, 209], ["VP7", "GENE_OR_GENE_PRODUCT", 0, 3], ["Beg9", "GENE_OR_GENE_PRODUCT", 20, 24], ["sBeg9", "GENE_OR_GENE_PRODUCT", 26, 31], ["9Con1-L", "GENE_OR_GENE_PRODUCT", 36, 43], ["BatLy03-G25", "GENE_OR_GENE_PRODUCT", 79, 90], ["BatLi08-G31", "GENE_OR_GENE_PRODUCT", 107, 118], ["BatLy17-G30", "GENE_OR_GENE_PRODUCT", 123, 134], ["VP7 forward primers", "DNA", 0, 19], ["Beg9", "DNA", 20, 24], ["sBeg9", "DNA", 26, 31], ["9Con1", "DNA", 36, 41], ["L", "DNA", 42, 43], ["BatLy03", "DNA", 79, 86], ["G25", "DNA", 87, 90], ["BatLi08", "DNA", 107, 114], ["G31", "DNA", 115, 118], ["BatLy17", "DNA", 123, 130], ["G30", "DNA", 131, 134], ["3\u2032end", "DNA", 228, 233], ["VP7 forward primers", "TEST", 0, 19], ["sBeg9", "TEST", 26, 31], ["BatLy03", "TEST", 79, 86], ["BatLi08", "TEST", 107, 114], ["BatLy17", "TEST", 123, 130], ["this strain", "TEST", 163, 174], ["4 nucleotide mismatches", "PROBLEM", 197, 220]]], ["VP7 forward primer 9con1-L showed a perfect match with all the genotypes (G25, G30 and G31).", [["9con1-L", "GENE_OR_GENE_PRODUCT", 19, 26], ["VP7 forward primer 9con1-L", "DNA", 0, 26], ["G25", "DNA", 74, 77], ["VP7 forward primer", "TEST", 0, 18], ["the genotypes", "TEST", 59, 72]]], ["Considering the VP7 reverse primers EndA, VP7-Rdeg, End9 and RVG9, BatLy03-G25 did not show a perfect match as there were 4, 1, 4 and 2 mutations, respectively.", [["VP7", "GENE_OR_GENE_PRODUCT", 16, 19], ["EndA", "GENE_OR_GENE_PRODUCT", 36, 40], ["VP7-Rdeg", "GENE_OR_GENE_PRODUCT", 42, 50], ["End9", "GENE_OR_GENE_PRODUCT", 52, 56], ["RVG9", "GENE_OR_GENE_PRODUCT", 61, 65], ["BatLy03", "GENE_OR_GENE_PRODUCT", 67, 74], ["VP7 reverse primers", "DNA", 16, 35], ["EndA", "DNA", 36, 40], ["VP7", "DNA", 42, 45], ["Rdeg", "DNA", 46, 50], ["End9", "DNA", 52, 56], ["RVG9", "DNA", 61, 65], ["BatLy03", "DNA", 67, 74], ["G25", "DNA", 75, 78], ["the VP7 reverse primers", "TEST", 12, 35], ["EndA", "TEST", 36, 40], ["VP7", "TEST", 42, 45], ["End9", "TEST", 52, 56], ["RVG9", "TEST", 61, 65], ["BatLy03", "TEST", 67, 74]]], ["The mismatches with EndA, VP7-Rdeg and RVG9 were near the middle or at the 5\u2032end of the primer, whereas 2 of those of End9 were close to the 3\u2032end.", [["EndA", "GENE_OR_GENE_PRODUCT", 20, 24], ["VP7-Rdeg", "GENE_OR_GENE_PRODUCT", 26, 34], ["RVG9", "GENE_OR_GENE_PRODUCT", 39, 43], ["End9", "GENE_OR_GENE_PRODUCT", 118, 122], ["EndA", "DNA", 20, 24], ["VP7", "DNA", 26, 29], ["Rdeg", "DNA", 30, 34], ["RVG9", "DNA", 39, 43], ["5\u2032end", "DNA", 75, 80], ["End9", "DNA", 118, 122], ["3\u2032end", "DNA", 141, 146], ["The mismatches", "PROBLEM", 0, 14], ["EndA", "TEST", 20, 24], ["VP7", "TEST", 26, 29], ["RVG9", "TREATMENT", 39, 43], ["mismatches", "OBSERVATION", 4, 14], ["middle", "ANATOMY_MODIFIER", 58, 64]]], ["Comparing the same VP7 reverse primers with strain BatLi08-G31 and BatLi09-G30 also showed mismatches.", [["VP7", "GENE_OR_GENE_PRODUCT", 19, 22], ["BatLi08-G31", "GENE_OR_GENE_PRODUCT", 51, 62], ["BatLi09-G30", "GENE_OR_GENE_PRODUCT", 67, 78], ["VP7 reverse primers", "DNA", 19, 38], ["BatLi08", "DNA", 51, 58], ["G31", "DNA", 59, 62], ["BatLi09", "DNA", 67, 74], ["G30", "DNA", 75, 78], ["strain BatLi08", "TEST", 44, 58], ["BatLi09", "TEST", 67, 74], ["mismatches", "PROBLEM", 91, 101], ["mismatches", "OBSERVATION", 91, 101]]], ["For EndA and VP7-Rdeg maximum 2 mismatches are located in the middle or near the 5\u2032-end, whereas for End9 and RVG, there were multiple mismatches of which 2 and 7 mismatches, respectively were right at the 3\u2032-end.", [["EndA", "GENE_OR_GENE_PRODUCT", 4, 8], ["VP7", "GENE_OR_GENE_PRODUCT", 13, 16], ["End9", "GENE_OR_GENE_PRODUCT", 101, 105], ["EndA and VP7-Rdeg maximum 2 mismatches", "DNA", 4, 42], ["middle or near the 5\u2032-end", "DNA", 62, 87], ["End9", "DNA", 101, 105], ["RVG", "DNA", 110, 113], ["3\u2032-end", "DNA", 206, 212], ["EndA", "TEST", 4, 8], ["VP7-Rdeg maximum 2 mismatches", "TREATMENT", 13, 42], ["End9", "TEST", 101, 105], ["RVG", "TEST", 110, 113], ["multiple mismatches", "PROBLEM", 126, 145], ["middle", "ANATOMY_MODIFIER", 62, 68], ["multiple", "OBSERVATION_MODIFIER", 126, 134], ["mismatches", "OBSERVATION", 135, 145], ["right", "ANATOMY_MODIFIER", 193, 198]]], ["For VP4 forward primer VP4-1-17F, BatLy03-P[43], BatLi08-P[42], BatLy17-P[47] and BatLi09-P[42] showed 2, 2, 1 and 2, mismatches, respectively, with at least a mutation at the first position from the 3\u2032end for all of them.", [["VP4", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP4-1-17F", "GENE_OR_GENE_PRODUCT", 23, 32], ["BatLy03-P", "GENE_OR_GENE_PRODUCT", 34, 43], ["VP4 forward primer VP4-1", "DNA", 4, 28], ["17F", "DNA", 29, 32], ["BatLy03", "DNA", 34, 41], ["P", "DNA", 42, 43], ["BatLi08", "DNA", 49, 56], ["P", "DNA", 57, 58], ["BatLy17", "DNA", 64, 71], ["P", "DNA", 72, 73], ["BatLi09", "DNA", 82, 89], ["P[42", "DNA", 90, 94], ["3\u2032end", "DNA", 200, 205], ["VP4 forward primer", "TEST", 4, 22], ["VP4", "TEST", 23, 26], ["BatLy03", "TEST", 34, 41], ["BatLi08", "TEST", 49, 56], ["BatLy17", "TEST", 64, 71], ["BatLi09", "TEST", 82, 89], ["mismatches", "TEST", 118, 128], ["a mutation", "PROBLEM", 158, 168], ["mutation", "OBSERVATION", 160, 168]]], ["For con3, there were 6, 7, 6 and 8 mismatches with BatLy03-P[43], BatLi08-P[42), BatLi09-P[42] and BatLy17-P[47], respectively.", [["BatLy03-P[43], BatLi08-P[42), BatLi09-P", "CHEMICAL", 51, 90], ["con3", "GENE_OR_GENE_PRODUCT", 4, 8], ["BatLi08-P[42)", "SIMPLE_CHEMICAL", 66, 79], ["BatLi09-P[42]", "SIMPLE_CHEMICAL", 81, 94], ["BatLy03", "PROTEIN", 51, 58], ["P", "DNA", 89, 90], ["BatLy17", "DNA", 99, 106], ["mismatches", "TEST", 35, 45], ["BatLy03", "TEST", 51, 58], ["BatLi08", "TEST", 66, 73], ["BatLi09", "TEST", 81, 88], ["BatLy17", "TEST", 99, 106]]], ["Considering the VP4 reverse primer con2, strains BatLy03-P[43], BatLi08-P[42], BatLi09-P[42], BatLy17-P[47] and BatLi10-P[42] showed 3\u20135 mismatches including one at the second position from the 3\u2032-end.Bat rotaviruses in humans? ::: ResultsAdditionally, to determine if any of these bat RVAs could cross species and infect humans, we designed primers (RVA-VP6_40F and RVA-VP6_1063R) from an alignment of both human and bat RVA VP6 segments to screen 25 diarrheic infant samples (infants living around the same region where the bat samples were collected).", [["samples", "ANATOMY", 469, 476], ["samples", "ANATOMY", 530, 537], ["VP4", "GENE_OR_GENE_PRODUCT", 16, 19], ["BatLi10-P[42]", "SIMPLE_CHEMICAL", 112, 125], ["Bat rotaviruses", "ORGANISM", 201, 216], ["humans", "ORGANISM", 220, 226], ["bat", "ORGANISM", 282, 285], ["RVAs", "GENE_OR_GENE_PRODUCT", 286, 290], ["humans", "ORGANISM", 322, 328], ["human", "ORGANISM", 408, 413], ["infants", "ORGANISM", 478, 485], ["bat", "ORGANISM", 526, 529], ["samples", "CANCER", 530, 537], ["VP4 reverse primer con2", "DNA", 16, 39], ["P", "DNA", 57, 58], ["BatLi08", "DNA", 64, 71], ["P", "DNA", 72, 73], ["BatLi09", "DNA", 79, 86], ["P", "DNA", 87, 88], ["BatLy17", "DNA", 94, 101], ["P", "DNA", 102, 103], ["BatLi10", "DNA", 112, 119], ["P[42]", "DNA", 120, 125], ["3\u20135 mismatches", "DNA", 133, 147], ["3\u2032-end", "DNA", 194, 200], ["VP6_40F", "DNA", 355, 362], ["RVA", "DNA", 367, 370], ["VP6_1063R", "DNA", 371, 380], ["human and bat RVA VP6 segments", "DNA", 408, 438], ["rotaviruses", "SPECIES", 205, 216], ["humans", "SPECIES", 220, 226], ["humans", "SPECIES", 322, 328], ["human", "SPECIES", 408, 413], ["infant", "SPECIES", 462, 468], ["infants", "SPECIES", 478, 485], ["Bat rotaviruses", "SPECIES", 201, 216], ["humans", "SPECIES", 220, 226], ["humans", "SPECIES", 322, 328], ["human", "SPECIES", 408, 413], ["the VP4 reverse primer con2", "TEST", 12, 39], ["BatLi08", "TEST", 64, 71], ["BatLi09", "TEST", 79, 86], ["BatLy17", "TEST", 94, 101], ["BatLi10", "TEST", 112, 119], ["mismatches", "TEST", 137, 147], ["RVA", "TEST", 351, 354], ["RVA", "TEST", 367, 370], ["VP6", "TEST", 371, 374], ["25 diarrheic infant samples", "PROBLEM", 449, 476], ["rotaviruses", "OBSERVATION", 205, 216]]], ["Thirty-six percent of human samples were positive for RVA, however, none of them was of bat RVA origin.", [["samples", "ANATOMY", 28, 35], ["human", "ORGANISM", 22, 27], ["samples", "CANCER", 28, 35], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["human samples", "TEST", 22, 35], ["RVA", "PROBLEM", 54, 57]]], ["They all possessed the typical human genotype I1 and were 99% identical to the Gambian, Senegalese, Belgian and Brazilian Wa-like G1P[8] strains BE00007 (HQ392029), MRC-DPRU3174 (KJ752288), MRC-DPRU2130-09 (KJ751561), rj1808-98 (KM027132), respectively (Supplementary data S3).Bat rotaviruses in humans? ::: ResultsIn summary, strain RVA/Bat-wt/CMR/BatLy03/2014/G25P[43] possessed the genotype constellation G25-P[43]-I15-R16-C8-M15-A26-N8-T11-E23-H10 (Table 3), which shared six genotypes with those of the Kenyan bat RVA strain KE4852.", [["KE4852", "CHEMICAL", 530, 536], ["human", "ORGANISM", 31, 36], ["Bat rotaviruses", "ORGANISM", 277, 292], ["humans", "ORGANISM", 296, 302], ["Bat-wt", "ORGANISM", 338, 344], ["BatLy03", "GENE_OR_GENE_PRODUCT", 349, 356], ["BatLy03", "PROTEIN", 349, 356], ["human", "SPECIES", 31, 36], ["rotaviruses", "SPECIES", 281, 292], ["humans", "SPECIES", 296, 302], ["human", "SPECIES", 31, 36], ["Bat rotaviruses", "SPECIES", 277, 292], ["humans", "SPECIES", 296, 302], ["RVA/Bat-wt/CMR/BatLy03/2014/G25P", "SPECIES", 334, 366], ["Kenyan bat RVA strain KE4852", "SPECIES", 508, 536], ["MRC", "TEST", 165, 168], ["MRC-DPRU2130-", "TEST", 190, 203], ["strain RVA", "TEST", 327, 337], ["CMR", "TEST", 345, 348], ["the genotype constellation", "TEST", 381, 407], ["M15-A26-N8-T11-E23", "TEST", 429, 447], ["rotaviruses", "OBSERVATION", 281, 292]]], ["For VP4 (P[6] vs P[43]), VP1 (R-unassigned vs R16) and NSP4 (E2 vs E23), different genotypes were observed, whereas for VP3 and NSP1 no sequence data were available for KE4852 for comparison.", [["E2", "CHEMICAL", 61, 63], ["KE4852", "CHEMICAL", 169, 175], ["KE4852", "CHEMICAL", 169, 175], ["VP4", "GENE_OR_GENE_PRODUCT", 4, 7], ["NSP4", "GENE_OR_GENE_PRODUCT", 55, 59], ["VP3", "GENE_OR_GENE_PRODUCT", 120, 123], ["KE4852", "SIMPLE_CHEMICAL", 169, 175], ["VP4", "PROTEIN", 4, 7], ["VP1", "PROTEIN", 25, 28], ["R-unassigned", "PROTEIN", 30, 42], ["R16", "PROTEIN", 46, 49], ["NSP4", "PROTEIN", 55, 59], ["E2", "PROTEIN", 61, 63], ["E23", "PROTEIN", 67, 70], ["VP3", "DNA", 120, 123], ["NSP1", "PROTEIN", 128, 132], ["VP4 (P", "TEST", 4, 10], ["P", "TEST", 17, 18], ["VP1", "TEST", 25, 28], ["R-unassigned", "TEST", 30, 42], ["R16", "TEST", 46, 49], ["NSP4", "TEST", 55, 59], ["E2", "TEST", 61, 63], ["E23", "TEST", 67, 70], ["different genotypes", "PROBLEM", 73, 92], ["VP3", "TEST", 120, 123], ["sequence data", "TEST", 136, 149]]], ["The 4 other strains were named BatLi08, BatLi09, BatLi10 and BatLy17 and possessed the genome constellations: Gx-P[x]-I22-R15-C15-M14-A25-N15-T17-E22-H17 with G31P[42] for BatLi08, G30P[47] for BatLy17, and G30P[42] for BatLi09 and BatLi10 (Table 3).", [["BatLi08", "GENE_OR_GENE_PRODUCT", 31, 38], ["BatLi09", "GENE_OR_GENE_PRODUCT", 40, 47], ["BatLi10", "GENE_OR_GENE_PRODUCT", 49, 56], ["BatLy17", "GENE_OR_GENE_PRODUCT", 61, 68], ["BatLi08", "GENE_OR_GENE_PRODUCT", 172, 179], ["BatLy17", "GENE_OR_GENE_PRODUCT", 194, 201], ["BatLi09", "GENE_OR_GENE_PRODUCT", 220, 227], ["BatLi08", "DNA", 31, 38], ["BatLi09", "DNA", 40, 47], ["BatLi10", "DNA", 49, 56], ["BatLy17", "DNA", 61, 68], ["E22", "DNA", 146, 149], ["H17", "DNA", 150, 153], ["E22", "TEST", 146, 149], ["G31P", "TEST", 159, 163], ["BatLi08", "TEST", 172, 179], ["BatLy17", "TEST", 194, 201], ["G30P", "TEST", 207, 211], ["BatLi09", "TEST", 220, 227]]], ["Screening human samples for these bat RVAs indicated no interspecies transmissions and primer comparison showed that not all the strains can be picked up with the currently used screening primers.DiscussionBats have been proven to harbor several human pathogenic viruses including SARS, MERS-related coronaviruses, as well as filoviruses, such as Marburgvirus, or Henipaviruses, such as Nipah and Hendra virus131415, but bat RVAs have only been sporadically reported.", [["samples", "ANATOMY", 16, 23], ["SARS", "DISEASE", 281, 285], ["filoviruses", "DISEASE", 326, 337], ["Nipah and Hendra virus131415", "CHEMICAL", 387, 415], ["human", "ORGANISM", 10, 15], ["human", "ORGANISM", 246, 251], ["MERS-related coronaviruses", "ORGANISM", 287, 313], ["filoviruses", "GENE_OR_GENE_PRODUCT", 326, 337], ["Nipah", "ORGANISM", 387, 392], ["Hendra virus131415", "ORGANISM", 397, 415], ["bat RVAs", "ORGANISM", 421, 429], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 246, 251], ["Nipah", "SPECIES", 387, 392], ["Hendra virus", "SPECIES", 397, 409], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 246, 251], ["Hendra virus131415", "SPECIES", 397, 415], ["Screening human samples", "TEST", 0, 23], ["these bat RVAs", "TEST", 28, 42], ["primer comparison", "TEST", 87, 104], ["all the strains", "PROBLEM", 121, 136], ["screening primers", "TREATMENT", 178, 195], ["several human pathogenic viruses", "PROBLEM", 238, 270], ["SARS", "PROBLEM", 281, 285], ["MERS", "PROBLEM", 287, 291], ["coronaviruses", "PROBLEM", 300, 313], ["filoviruses", "PROBLEM", 326, 337], ["Marburgvirus", "PROBLEM", 347, 359], ["Henipaviruses", "PROBLEM", 364, 377], ["Nipah", "PROBLEM", 387, 392], ["Hendra virus", "TREATMENT", 397, 409], ["pathogenic", "OBSERVATION_MODIFIER", 252, 262], ["viruses", "OBSERVATION", 263, 270]]], ["So far, only 3 bat RVA strains have been characterized and the first strain was reported in a straw-colored fruit bat in Kenya named RVA/Bat-wt/KEN/KE4852/2007/G25P[6]17; while the other two, named RVA/Bat-tc/CHN/MSLH14/2012/G3P[3] and RVA/Bat-tc/CHN/MYAS33/2013/G3P[10], were isolated from a lesser horseshoe bat, and a Stoliczka\u2019s trident bat in China, respectively1819.DiscussionTo better understand the spread and diversity of RVA in bats, we performed an RVA screening in Cameroonian bats, after trapping both male and female, young and adult bats close to human dwellings in Muyuka, Limbe and Lysoka localities of the South West region of Cameroon (Fig. 1).", [["G3P[10]", "SIMPLE_CHEMICAL", 263, 270], ["bats", "ORGANISM", 548, 552], ["human", "ORGANISM", 562, 567], ["CHN", "PROTEIN", 209, 212], ["MSLH14", "PROTEIN", 213, 219], ["tc", "PROTEIN", 244, 246], ["CHN", "PROTEIN", 247, 250], ["MYAS33", "PROTEIN", 251, 257], ["human", "SPECIES", 562, 567], ["RVA/Bat-wt/KEN/KE4852/2007/G25P", "SPECIES", 133, 164], ["RVA/Bat-tc/CHN/MYAS33/2013/G3P", "SPECIES", 236, 266], ["Stoliczka\u2019s trident bat", "SPECIES", 321, 344], ["Cameroonian bats", "SPECIES", 477, 493], ["human", "SPECIES", 562, 567], ["3 bat RVA strains", "PROBLEM", 13, 30], ["RVA", "TEST", 198, 201], ["Bat", "TEST", 202, 205], ["MSLH14", "TEST", 213, 219], ["RVA", "TEST", 236, 239], ["Bat", "TEST", 240, 243], ["MYAS33", "TEST", 251, 257], ["an RVA screening", "TEST", 457, 473]]], ["Using an unbiased viral metagenomics approach, we identified 5 divergent novel bat RVA strains, 4 of which were genetically similar to each other.", [["bat RVA strains", "ORGANISM", 79, 94], ["5 divergent novel bat RVA strains", "PROBLEM", 61, 94], ["viral metagenomics", "OBSERVATION", 18, 36]]], ["The fifth strain was related to the Kenyan bat strain.", [["bat", "ORGANISM", 43, 46], ["Kenyan bat", "SPECIES", 36, 46], ["The fifth strain", "PROBLEM", 0, 16], ["the Kenyan bat strain", "PROBLEM", 32, 53], ["fifth", "OBSERVATION_MODIFIER", 4, 9], ["strain", "OBSERVATION", 10, 16]]], ["Interestingly, all these RVAs were identified in adult (both female and male) straw-colored fruit bats (Eidolon helvum) which is in contrast to human and other animals whereby RVA (symptomatic) infections occur mostly in juveniles1.", [["RVA (symptomatic) infections", "DISEASE", 176, 204], ["RVAs", "GENE_OR_GENE_PRODUCT", 25, 29], ["fruit", "ORGANISM", 92, 97], ["bats", "ORGANISM", 98, 102], ["Eidolon helvum", "ORGANISM", 104, 118], ["human", "ORGANISM", 144, 149], ["RVAs", "PROTEIN", 25, 29], ["Eidolon helvum", "SPECIES", 104, 118], ["human", "SPECIES", 144, 149], ["Eidolon helvum", "SPECIES", 104, 118], ["human", "SPECIES", 144, 149], ["Eidolon helvum)", "TREATMENT", 104, 119], ["RVA (symptomatic) infections", "PROBLEM", 176, 204], ["fruit bats", "OBSERVATION", 92, 102], ["infections", "OBSERVATION", 194, 204]]], ["Also, diarrhea or other obvious signs of sickness were not noticed in these bats.", [["diarrhea", "DISEASE", 6, 14], ["sickness", "DISEASE", 41, 49], ["diarrhea", "PROBLEM", 6, 14], ["sickness", "PROBLEM", 41, 49], ["sickness", "OBSERVATION", 41, 49]]], ["This may suggest that bats may undergo active virus replication and shedding without obvious clinical signs25, which potentially could increase human exposure.DiscussionEven though there exists a considerable genetic divergence between bat RVA and human RVA, suggestions have been made about potential interspecies transmission of Chinese and Kenyan bat RVA strains.", [["bats", "ORGANISM", 22, 26], ["human", "ORGANISM", 144, 149], ["human", "ORGANISM", 248, 253], ["bat RVA strains", "ORGANISM", 350, 365], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 248, 253], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 248, 253], ["Kenyan bat RVA", "SPECIES", 343, 357], ["active virus replication", "TREATMENT", 39, 63], ["human RVA", "TREATMENT", 248, 257], ["Kenyan bat RVA strains", "PROBLEM", 343, 365], ["active", "OBSERVATION_MODIFIER", 39, 45], ["virus", "OBSERVATION", 46, 51]]], ["The two Chinese RVA strains are genetically quite conserved (all segments of both strains have the same genotype except for their VP4 gene).", [["VP4", "GENE_OR_GENE_PRODUCT", 130, 133], ["VP4 gene", "DNA", 130, 138], ["The two Chinese RVA strains", "PROBLEM", 0, 27]]], ["Based on genome comparisons of Chinese bat and partial human RVA strains from Thailand (CMH079 and CMH222) and India (69 M, 57 M and mcs60), Xia and colleagues speculated that Asian bat RVAs may have crossed the host species barrier to humans on a number of occasions19.", [["Chinese bat", "ORGANISM", 31, 42], ["human", "ORGANISM", 55, 60], ["RVAs", "GENE_OR_GENE_PRODUCT", 186, 190], ["humans", "ORGANISM", 236, 242], ["human", "SPECIES", 55, 60], ["humans", "SPECIES", 236, 242], ["Chinese bat", "SPECIES", 31, 42], ["human", "SPECIES", 55, 60], ["Asian bat", "SPECIES", 176, 185], ["humans", "SPECIES", 236, 242], ["Chinese bat", "PROBLEM", 31, 42], ["partial human RVA strains", "PROBLEM", 47, 72], ["host species", "OBSERVATION", 212, 224]]], ["In addition, the unusual equine strain E319826 shares the same genotype constellation with either MYAS33 and/or MSLH14 in all segments except VP6.", [["equine", "ORGANISM", 25, 31], ["MYAS33", "GENE_OR_GENE_PRODUCT", 98, 104], ["MSLH14", "GENE_OR_GENE_PRODUCT", 112, 118], ["VP6", "GENE_OR_GENE_PRODUCT", 142, 145], ["MYAS33", "DNA", 98, 104], ["MSLH14", "DNA", 112, 118], ["VP6", "PROTEIN", 142, 145], ["the unusual equine strain", "PROBLEM", 13, 38], ["all segments", "ANATOMY_MODIFIER", 122, 134]]], ["This data therefore suggests that this equine RVA strain most likely share a common ancestor with Asian bat RVAs.", [["equine RVA strain", "ORGANISM", 39, 56], ["Asian bat", "SPECIES", 98, 107], ["This data", "TEST", 0, 9], ["this equine RVA strain", "PROBLEM", 34, 56]]], ["Furthermore, the genotype constellations of these Asian bat RVA (Table 3) are reminiscent to the Au-1-like genotype backbone of feline/canine-like RVA strains, as well as to the genotype constellation of two unusual simian RVAs (RRV and TUCH)27, suggesting that interspecies transmissions might have also occurred in the distant past.", [["simian RVAs", "DISEASE", 216, 227], ["Table 3", "GENE_OR_GENE_PRODUCT", 65, 72], ["Au-1", "GENE_OR_GENE_PRODUCT", 97, 101], ["feline/", "ORGANISM", 128, 135], ["canine-like RVA strains", "ORGANISM", 135, 158], ["simian", "ORGANISM", 216, 222], ["RRV", "ORGANISM", 229, 232], ["Asian bat RVA", "SPECIES", 50, 63], ["RRV", "SPECIES", 229, 232], ["RVA strains", "PROBLEM", 147, 158]]], ["Moreover, an unusual Ecuadorean human RVA, Ecu53428 is closely related to bat sequences from Brazil recently submitted to GenBank.", [["human", "ORGANISM", 32, 37], ["Ecu53428", "GENE_OR_GENE_PRODUCT", 43, 51], ["Ecu53428", "DNA", 43, 51], ["bat sequences", "DNA", 74, 87], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["an unusual Ecuadorean human RVA", "PROBLEM", 10, 41]]], ["Similarly, possible interspecies transmission trends were also suggested by He and colleagues18 between bovine strain RVA/Cow-wt/IND/RUBV3/2005/G3P[3] and the bat strain MSLH14.DiscussionGiven the novelty of the bat RVA strains described here, it is questionable if the currently used human RVA screening primers (for VP7 and VP4) will pick up these divergent strains in case an interspecies transmission from bats to humans would occur.", [["bovine", "ORGANISM", 104, 110], ["Cow-wt/IND/RUBV3/2005", "ORGANISM", 122, 143], ["bat", "ORGANISM", 159, 162], ["bat", "ORGANISM", 212, 215], ["human", "ORGANISM", 285, 290], ["VP7", "GENE_OR_GENE_PRODUCT", 318, 321], ["VP4", "GENE_OR_GENE_PRODUCT", 326, 329], ["bats", "ORGANISM", 410, 414], ["humans", "ORGANISM", 418, 424], ["human RVA screening primers", "DNA", 285, 312], ["VP7", "PROTEIN", 318, 321], ["VP4", "PROTEIN", 326, 329], ["bovine", "SPECIES", 104, 110], ["human", "SPECIES", 285, 290], ["humans", "SPECIES", 418, 424], ["bovine strain RVA/Cow-wt/IND/RUBV3/2005/G3P", "SPECIES", 104, 147], ["human", "SPECIES", 285, 290], ["humans", "SPECIES", 418, 424], ["bovine strain RVA", "TEST", 104, 121], ["Cow", "TEST", 122, 125], ["RUBV3", "TEST", 133, 138], ["the bat strain MSLH14", "PROBLEM", 155, 176], ["the bat RVA strains", "PROBLEM", 208, 227], ["human RVA screening primers", "TREATMENT", 285, 312], ["VP7", "PROBLEM", 318, 321], ["these divergent strains", "PROBLEM", 344, 367], ["bat", "ANATOMY", 159, 162]]], ["Comparisons (Table 2 and Supplementary data S2) of these primers with the corresponding sequences showed that the primer combination 9Con1-L and VP7-Rdeg2122, would most likely detect both G25 and G31 RVA strains.", [["9Con1-L", "GENE_OR_GENE_PRODUCT", 133, 140], ["VP7-Rdeg2122", "GENE_OR_GENE_PRODUCT", 145, 157], ["primer combination 9Con1", "DNA", 114, 138], ["VP7", "DNA", 145, 148], ["Rdeg2122", "DNA", 149, 157], ["these primers", "TEST", 51, 64], ["the corresponding sequences", "TEST", 70, 97], ["the primer combination", "TEST", 110, 132], ["VP7", "TEST", 145, 148], ["G31 RVA strains", "PROBLEM", 197, 212]]], ["Also, the combination of either Beg9 or sBeg9 with End9 or RVG924 might be successful in amplifying G25, but the same combinations might not be able to pick up the novel G31 and G30 genotypes in PCR screening assays.", [["End9", "CHEMICAL", 51, 55], ["RVG924", "CHEMICAL", 59, 65], ["Beg9", "GENE_OR_GENE_PRODUCT", 32, 36], ["sBeg9", "GENE_OR_GENE_PRODUCT", 40, 45], ["End9", "GENE_OR_GENE_PRODUCT", 51, 55], ["RVG924", "GENE_OR_GENE_PRODUCT", 59, 65], ["G31", "GENE_OR_GENE_PRODUCT", 170, 173], ["G30", "GENE_OR_GENE_PRODUCT", 178, 181], ["Beg9", "PROTEIN", 32, 36], ["sBeg9", "PROTEIN", 40, 45], ["End9", "PROTEIN", 51, 55], ["RVG924", "DNA", 59, 65], ["G25", "DNA", 100, 103], ["G31 and G30 genotypes", "DNA", 170, 191], ["End9", "TREATMENT", 51, 55], ["PCR screening assays", "TEST", 195, 215]]], ["Furthermore, the primer combination Beg9/sBeg9 and EndA29 are likely to detect G25, but will be unsuccessful in case of G30 and G31 especially if the forward primer Beg9 is used.", [["Beg9", "GENE_OR_GENE_PRODUCT", 36, 40], ["sBeg9", "GENE_OR_GENE_PRODUCT", 41, 46], ["EndA29", "GENE_OR_GENE_PRODUCT", 51, 57], ["Beg9", "GENE_OR_GENE_PRODUCT", 165, 169], ["Beg9", "PROTEIN", 36, 40], ["sBeg9", "PROTEIN", 41, 46], ["EndA29", "PROTEIN", 51, 57], ["G25", "DNA", 79, 82], ["forward primer Beg9", "DNA", 150, 169], ["the primer combination Beg9/sBeg9", "TEST", 13, 46]]], ["Considering VP4, both forward primers, VP4-1-17F30 and Con323 in combination with the reverse primer Con2 will be sub-optimal in detecting any of the P genotypes.", [["Con323", "CHEMICAL", 55, 61], ["VP4", "GENE_OR_GENE_PRODUCT", 12, 15], ["VP4-1-17F30", "GENE_OR_GENE_PRODUCT", 39, 50], ["Con323", "GENE_OR_GENE_PRODUCT", 55, 61], ["Con2", "GENE_OR_GENE_PRODUCT", 101, 105], ["VP4", "DNA", 12, 15], ["forward primers", "DNA", 22, 37], ["VP4", "DNA", 39, 42], ["1-17F30", "DNA", 43, 50], ["Con323", "DNA", 55, 61], ["reverse primer Con2", "DNA", 86, 105], ["P genotypes", "DNA", 150, 161], ["VP4", "PROBLEM", 12, 15], ["VP4", "TEST", 39, 42], ["the P genotypes", "PROBLEM", 146, 161]]], ["Generally, with the exception of strain G25, detection of most of the bat strains will be sub-optimal or not successful at all for the different available primer combinations.", [["bat", "ORGANISM", 70, 73], ["the bat strains", "PROBLEM", 66, 81]]], ["Therefore, zoonotic events of bat RVA strains could easily be missed with the current screening primers depending on the primer combinations, PCR conditions and/or circulating zoonotic strains.DiscussionIn order to investigate the possibility of bat RVA infecting humans who are living in close contact with bats, we used novel primers (RVA-VP6_40F and RVA-VP6_1063R) designed from an alignment of both human and bat VP6 RVA segment to screen 25 infant samples from patients with gastroenteritis, living around the same region where the bat samples were collected.", [["samples", "ANATOMY", 453, 460], ["samples", "ANATOMY", 541, 548], ["gastroenteritis", "DISEASE", 480, 495], ["bat RVA", "ORGANISM", 30, 37], ["bat RVA", "ORGANISM", 246, 253], ["humans", "ORGANISM", 264, 270], ["human", "ORGANISM", 403, 408], ["patients", "ORGANISM", 466, 474], ["bat", "ORGANISM", 537, 540], ["samples", "CANCER", 541, 548], ["VP6_40F", "DNA", 341, 348], ["RVA", "DNA", 353, 356], ["VP6_1063R", "DNA", 357, 366], ["human and bat VP6 RVA segment", "DNA", 403, 432], ["humans", "SPECIES", 264, 270], ["human", "SPECIES", 403, 408], ["infant", "SPECIES", 446, 452], ["patients", "SPECIES", 466, 474], ["humans", "SPECIES", 264, 270], ["human", "SPECIES", 403, 408], ["bat RVA strains", "PROBLEM", 30, 45], ["the current screening primers", "TREATMENT", 74, 103], ["the primer combinations", "TEST", 117, 140], ["PCR conditions", "TEST", 142, 156], ["circulating zoonotic strains", "PROBLEM", 164, 192], ["novel primers", "TREATMENT", 322, 335], ["RVA", "TEST", 337, 340], ["RVA", "TEST", 353, 356], ["gastroenteritis", "PROBLEM", 480, 495], ["gastroenteritis", "OBSERVATION", 480, 495]]], ["Interestingly, 36% of human samples were positive, however, none of these were positive for bat RVAs.", [["samples", "ANATOMY", 28, 35], ["human", "ORGANISM", 22, 27], ["samples", "CANCER", 28, 35], ["bat", "ORGANISM", 92, 95], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["human samples", "TEST", 22, 35], ["bat RVAs", "PROBLEM", 92, 100]]], ["All were of the typical human RVA genotype I1 and therefore there is no evidence for interspecies transmissions of bat RVA to humans.", [["human", "ORGANISM", 24, 29], ["bat RVA", "ORGANISM", 115, 122], ["humans", "ORGANISM", 126, 132], ["human", "SPECIES", 24, 29], ["humans", "SPECIES", 126, 132], ["human", "SPECIES", 24, 29], ["humans", "SPECIES", 126, 132], ["no evidence for", "UNCERTAINTY", 69, 84]]], ["However, this result is not conclusive as only a small sample size was considered here.", [["a small sample size", "PROBLEM", 47, 66], ["not conclusive", "UNCERTAINTY", 24, 38], ["small", "OBSERVATION_MODIFIER", 49, 54], ["size", "OBSERVATION_MODIFIER", 62, 66]]], ["Sampling a larger number of subjects and from different localities around the region might result in more conclusive answers with respect to the zoonotic potential of these bat RVA strains.DiscussionThe genotype constellations of the two Chinese bat RVAs showed clear indication of recent reassortment event(s) because they possessed different P genotypes (P[10] for MYAS33 and P[3] for MSLH14), and some gene segments were nearly identical whereas others were not1819.", [["bat RVA strains", "ORGANISM", 173, 188], ["MSLH14", "GENE_OR_GENE_PRODUCT", 387, 393], ["P genotypes", "DNA", 344, 355], ["MSLH14", "DNA", 387, 393], ["Chinese bat", "SPECIES", 238, 249], ["these bat RVA strains", "PROBLEM", 167, 188], ["MYAS33", "TEST", 367, 373], ["MSLH14", "TEST", 387, 393], ["some gene segments", "PROBLEM", 400, 418], ["larger", "OBSERVATION_MODIFIER", 11, 17], ["number", "OBSERVATION_MODIFIER", 18, 24], ["segments", "ANATOMY_MODIFIER", 410, 418]]], ["Their genotype constellation differs markedly from the Kenyan straw-colored fruit bat strain (KE4852).", [["bat", "ORGANISM", 82, 85], ["Kenyan straw-colored fruit bat", "SPECIES", 55, 85]]], ["Although this strain showed a unique genotype backbone, some of its segments were similar to some human and other animal RVAs17.", [["human", "ORGANISM", 98, 103], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["this strain", "PROBLEM", 9, 20], ["a unique genotype backbone", "PROBLEM", 28, 54]]], ["Moreover, KE4852 share the same genotypes in several gene segments (VP2, VP6, VP7, NSP2, NSP3 and NSP5) with our bat RVA strain BatLy03 indicating possible reassortment events between different bat RVA strains, as well as a large geographical spread of this virus.", [["KE4852", "CHEMICAL", 10, 16], ["KE4852", "SIMPLE_CHEMICAL", 10, 16], ["VP2", "GENE_OR_GENE_PRODUCT", 68, 71], ["VP6", "GENE_OR_GENE_PRODUCT", 73, 76], ["VP7", "GENE_OR_GENE_PRODUCT", 78, 81], ["NSP2", "GENE_OR_GENE_PRODUCT", 83, 87], ["NSP3", "GENE_OR_GENE_PRODUCT", 89, 93], ["NSP5", "GENE_OR_GENE_PRODUCT", 98, 102], ["BatLy03", "GENE_OR_GENE_PRODUCT", 128, 135], ["bat RVA strains", "ORGANISM", 194, 209], ["KE4852", "PROTEIN", 10, 16], ["VP2", "DNA", 68, 71], ["VP6", "DNA", 73, 76], ["VP7", "DNA", 78, 81], ["NSP2", "DNA", 83, 87], ["NSP3", "DNA", 89, 93], ["NSP5", "DNA", 98, 102], ["VP2", "TEST", 68, 71], ["VP6", "TEST", 73, 76], ["VP7", "TEST", 78, 81], ["NSP2", "TEST", 83, 87], ["NSP3", "TEST", 89, 93], ["our bat RVA strain BatLy03", "PROBLEM", 109, 135], ["reassortment events", "PROBLEM", 156, 175], ["different bat RVA strains", "PROBLEM", 184, 209], ["this virus", "PROBLEM", 253, 263], ["segments", "ANATOMY_MODIFIER", 58, 66], ["possible", "UNCERTAINTY", 147, 155], ["reassortment", "OBSERVATION", 156, 168], ["large", "OBSERVATION_MODIFIER", 224, 229], ["geographical", "OBSERVATION_MODIFIER", 230, 242], ["spread", "OBSERVATION", 243, 249]]], ["Furthermore, BatLi08, BatLi09, BatLi10 and BatLy17 had conserved genotype constellations (in VP6, VP1\u2013VP3, NSP1\u2013NSP5) with 98\u2013100% nucleotide sequence similarity except for the VP7 of BatLi08 and VP4 of BatLy17, again confirming reassortment events within bat RVAs.DiscussionThe high genetic divergence and partial relatedness of most of the segments of the different bat RVA strains and the ones identified in this study indicate the frequent occurrence of reassortment events in the general bat population and those of Cameroon in particular.", [["nucleotide", "CHEMICAL", 131, 141], ["nucleotide", "CHEMICAL", 131, 141], ["BatLi08", "GENE_OR_GENE_PRODUCT", 13, 20], ["BatLi09", "GENE_OR_GENE_PRODUCT", 22, 29], ["BatLi10", "GENE_OR_GENE_PRODUCT", 31, 38], ["BatLy17", "GENE_OR_GENE_PRODUCT", 43, 50], ["VP6", "GENE_OR_GENE_PRODUCT", 93, 96], ["VP1", "GENE_OR_GENE_PRODUCT", 98, 101], ["VP3", "GENE_OR_GENE_PRODUCT", 102, 105], ["NSP1\u2013NSP5", "GENE_OR_GENE_PRODUCT", 107, 116], ["VP7", "GENE_OR_GENE_PRODUCT", 177, 180], ["BatLi08", "GENE_OR_GENE_PRODUCT", 184, 191], ["VP4", "GENE_OR_GENE_PRODUCT", 196, 199], ["BatLy17", "GENE_OR_GENE_PRODUCT", 203, 210], ["bat", "ORGANISM", 256, 259], ["RVAs", "PATHOLOGICAL_FORMATION", 260, 264], ["bat RVA strains", "ORGANISM", 368, 383], ["BatLi08", "PROTEIN", 13, 20], ["BatLi09", "PROTEIN", 22, 29], ["BatLi10", "PROTEIN", 31, 38], ["BatLy17", "PROTEIN", 43, 50], ["VP6", "PROTEIN", 93, 96], ["VP1", "PROTEIN", 98, 101], ["VP3", "DNA", 102, 105], ["NSP1", "DNA", 107, 111], ["NSP5", "DNA", 112, 116], ["VP7", "DNA", 177, 180], ["BatLi08", "DNA", 184, 191], ["VP4", "PROTEIN", 196, 199], ["BatLy17", "PROTEIN", 203, 210], ["conserved genotype constellations", "PROBLEM", 55, 88], ["VP6", "TEST", 93, 96], ["VP1", "TEST", 98, 101], ["VP3", "TEST", 102, 105], ["NSP1", "TEST", 107, 111], ["nucleotide sequence similarity", "TEST", 131, 161], ["the VP7", "TEST", 173, 180], ["VP4", "TEST", 196, 199], ["reassortment events", "PROBLEM", 229, 248], ["The high genetic divergence", "PROBLEM", 275, 302], ["the different bat RVA strains", "PROBLEM", 354, 383], ["this study", "TEST", 411, 421], ["reassortment events", "PROBLEM", 458, 477], ["reassortment", "OBSERVATION", 458, 470]]], ["Also, with the current knowledge of the genetic diversity, there seems to exist several true bat RVA genotype constellations, as has been previously described for humans, and cats/dogs1031.", [["humans", "ORGANISM", 163, 169], ["cats", "ORGANISM", 175, 179], ["dogs", "ORGANISM", 180, 184], ["humans", "SPECIES", 163, 169], ["cats", "SPECIES", 175, 179], ["dogs", "SPECIES", 180, 184], ["humans", "SPECIES", 163, 169], ["several true bat RVA genotype constellations", "PROBLEM", 80, 124]]], ["However, this needs to be further confirmed by identification of a larger number of RVAs from bats from different age groups and different geographical locations.Ethical authorization ::: MethodsEthical authorization for the use of human samples was obtained from the Cameroon National Ethics Committee, Yaound\u00e9.", [["samples", "ANATOMY", 238, 245], ["RVAs", "CANCER", 84, 88], ["human", "ORGANISM", 232, 237], ["samples", "CANCER", 238, 245], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 232, 237], ["a larger number of RVAs", "PROBLEM", 65, 88], ["larger", "OBSERVATION_MODIFIER", 67, 73], ["number", "OBSERVATION_MODIFIER", 74, 80], ["different", "OBSERVATION_MODIFIER", 129, 138], ["geographical locations", "OBSERVATION", 139, 161]]], ["All human experiments were performed in accordance with the Ministry\u2019s National Ethics Committee guidelines.", [["human", "ORGANISM", 4, 9], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9]]], ["Ethical authorization for the protocol and the use of animal samples was also obtained from the Cameroon National Ethics Committee, Yaound\u00e9.", [["the protocol", "TREATMENT", 26, 38]]], ["All animal experiments were performed in accordance with the Ministry\u2019s National Ethics Committee guidelines.", [["All animal experiments", "TEST", 0, 22]]], ["All experimental protocols used in this study were approved by Cameroon National Ethics Committee.", [["All experimental protocols", "TREATMENT", 0, 26], ["this study", "TEST", 35, 45]]], ["Informed consent was obtained from human subjects or their parents or guardians.Bat sample collection ::: MethodsBat samples were collected between December 2013 and May 2014 using a previously described method32.", [["samples", "ANATOMY", 117, 124], ["human", "ORGANISM", 35, 40], ["Bat samples", "CANCER", 113, 124], ["method32", "DNA", 204, 212], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40]]], ["Briefly, bats were captured in 3 different regions (Lysoka, Muyuka and Limbe) of the South West Region of Cameroon (Fig. 1) using mist nets around fruit trees and around human dwellings.", [["bats", "ORGANISM", 9, 13], ["human", "ORGANISM", 170, 175], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["Cameroon (Fig", "TREATMENT", 106, 119], ["fruit trees", "OBSERVATION", 147, 158]]], ["Captured bats were retrieved from the traps and held in paper sacks for 10\u201315 min, allowing enough time for the excretion of fresh fecal boluses.", [["fecal", "ANATOMY", 131, 136], ["bats", "ORGANISM", 9, 13], ["fecal", "ORGANISM_SUBSTANCE", 131, 136], ["the traps", "TREATMENT", 34, 43], ["fresh fecal boluses", "TREATMENT", 125, 144]]], ["Sterile disposable spatulas were used to retrieve feces from the paper sacks, and placed into tubes containing 1 ml of universal transport medium (UTM, Copan Diagnostics, Brescia, Italy).", [["feces", "ANATOMY", 50, 55], ["feces", "ORGANISM_SUBSTANCE", 50, 55], ["Sterile disposable spatulas", "TREATMENT", 0, 27], ["universal transport medium", "TREATMENT", 119, 145]]], ["Labeled samples were put on ice and then transferred to the Molecular and cell biology laboratory, Biotechnology Unit, University of Buea, Cameroon and stored at \u221220 \u00b0C, until they were shipped to the Laboratory of Viral Metagenomics, Leuven, Belgium where they were stored at \u221280 \u00b0C. Each captured bat was assessed to determine species, weight (g), forearm length (mm), sex, reproductive state, and age.", [["samples", "ANATOMY", 8, 15], ["cell", "ANATOMY", 74, 78], ["forearm", "ANATOMY", 350, 357], ["cell", "CELL", 74, 78], ["bat", "ORGANISM", 299, 302], ["forearm", "ORGANISM_SUBDIVISION", 350, 357], ["Labeled samples", "TEST", 0, 15], ["ice", "TREATMENT", 28, 31], ["weight", "TEST", 338, 344], ["forearm", "ANATOMY", 350, 357]]], ["All captured bats were then marked by hair clipping to facilitate identification of recaptures, and released afterwards.", [["hair", "ANATOMY", 38, 42], ["bats", "ORGANISM", 13, 17], ["hair", "ORGAN", 38, 42], ["hair clipping", "TREATMENT", 38, 51], ["clipping", "OBSERVATION", 43, 51]]], ["Trained zoologists used morphological characteristics to determine the species of the bats before they were released.", [["bats", "ORGANISM", 86, 90]]], ["No clinical signs of disease were noticed in any of these bats.Sample preparation for NGS ::: MethodsEighty-seven fecal samples were grouped into 25 pools each containing three to five samples and treated to enrich viral particles as follows: fecal suspensions were homogenized for 1 min at 3000 rpm with a MINILYS homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France) and filtered consecutively through 100 \u03bcm, 10 \u03bcm and 0.8 \u03bcm membrane filters (Merck Millipore, Massachusetts, USA) for 30 s at 1250 g.", [["fecal samples", "ANATOMY", 114, 127], ["samples", "ANATOMY", 185, 192], ["fecal suspensions", "ANATOMY", 243, 260], ["membrane", "ANATOMY", 441, 449], ["disease", "PROBLEM", 21, 28], ["MethodsEighty", "TREATMENT", 94, 107], ["seven fecal samples", "TEST", 108, 127], ["fecal suspensions", "TREATMENT", 243, 260], ["a MINILYS homogenizer", "TREATMENT", 305, 326], ["Montigny", "TEST", 349, 357], ["0.8 \u03bcm membrane filters", "TREATMENT", 434, 457], ["disease", "OBSERVATION", 21, 28], ["viral particles", "OBSERVATION", 215, 230], ["fecal", "ANATOMY", 243, 248]]], ["The filtrate was then treated with a cocktail of Benzonase (Novagen, Madison, USA) and Micrococcal Nuclease (New England Biolabs, Massachusetts, USA) at 37 \u00b0C for 2 h to digest free-floating nucleic acids.", [["Benzonase", "CHEMICAL", 49, 58], ["nucleic acids", "CHEMICAL", 191, 204], ["Benzonase", "SIMPLE_CHEMICAL", 49, 58], ["nucleic acids", "SIMPLE_CHEMICAL", 191, 204], ["The filtrate", "TREATMENT", 0, 12], ["Benzonase", "TREATMENT", 49, 58], ["Novagen", "TREATMENT", 60, 67], ["Micrococcal Nuclease", "TREATMENT", 87, 107], ["filtrate", "OBSERVATION", 4, 12], ["nucleic acids", "OBSERVATION", 191, 204]]], ["Nucleic acids were extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\u2019s instructions but without addition of carrier RNA to the lysis buffer.", [["Nucleic acids", "SIMPLE_CHEMICAL", 0, 13], ["carrier RNA", "RNA", 160, 171], ["Nucleic acids", "TEST", 0, 13], ["carrier RNA", "TREATMENT", 160, 171], ["the lysis buffer", "TREATMENT", 175, 191]]], ["First and second strand cDNA synthesis was performed and random PCR amplification for 17 cycles were performed using a Whole Transcriptome Amplification (WTA) Kit procedure (Sigma-Aldrich), with a denaturation temperature of 95 \u00b0C instead of 72 \u00b0C to allow the denaturation of dsDNA and dsRNA.", [["dsDNA", "CELLULAR_COMPONENT", 277, 282], ["second strand cDNA synthesis", "TEST", 10, 38], ["random PCR amplification", "TEST", 57, 81], ["a Whole Transcriptome Amplification", "TREATMENT", 117, 152], ["Kit procedure", "TREATMENT", 159, 172], ["a denaturation temperature", "TEST", 195, 221], ["the denaturation of dsDNA", "PROBLEM", 257, 282], ["dsRNA", "PROBLEM", 287, 292], ["dsDNA", "OBSERVATION", 277, 282], ["dsRNA", "ANATOMY", 287, 292]]], ["WTA products were purified with MSB Spin PCRapace spin columns (Stratec, Berlin, Germany) and the libraries were prepared for Illumina sequencing using the NexteraXT Library Preparation Kit (Illumina, San Diego, USA).", [["WTA products", "TREATMENT", 0, 12], ["MSB Spin PCRapace spin columns", "TREATMENT", 32, 62], ["the libraries", "TREATMENT", 94, 107], ["Illumina sequencing", "TEST", 126, 145]]], ["A cleanup after library synthesis was performed using a 1.8 ratio of Agencourt AMPure XP beads (Beckman Coulter, Inc., Nyon, Switzerland)33.", [["A cleanup", "TREATMENT", 0, 9], ["library synthesis", "TREATMENT", 16, 33], ["a 1.8 ratio of Agencourt AMPure XP beads", "TREATMENT", 54, 94]]], ["Sequencing of the samples was performed on a HiSeq 2500 platform (Illumina) for 300 cycles (2 \u00d7 150 bp paired ends).", [["samples", "ANATOMY", 18, 25], ["HiSeq 2500 platform", "DNA", 45, 64], ["the samples", "TEST", 14, 25], ["bp paired ends", "TREATMENT", 100, 114]]], ["Partial sequences were completed using RT-PCRs with specific primers (Supplementary S4).", [["Partial sequences", "TEST", 0, 17], ["RT-PCRs", "TREATMENT", 39, 46]]], ["For gene segments lacking the 5\u2032 and/or 3\u2032 ends of the ORF the single primer amplification method (Primers in Supplementary S4) was used as described previously34.", [["\u2032", "GENE_OR_GENE_PRODUCT", 31, 32], ["5\u2032 and/or 3\u2032 ends", "DNA", 30, 47], ["ORF", "DNA", 55, 58], ["the ORF", "TREATMENT", 51, 58], ["segments", "ANATOMY_MODIFIER", 9, 17]]], ["Sanger sequencing was done on an ABI Prism 3130 Genetic Analyzer (Applied Biosystems, Massachusetts, USA).Human fecal sample collection and Screening ::: MethodsHuman fecal samples were collected from patients in Lysoka local clinic and Kumba District Hospital of the South west Region of Cameroon (Fig. 1) after informed consent was obtained from patients or their parents or guardians.", [["fecal sample", "ANATOMY", 112, 124], ["fecal samples", "ANATOMY", 167, 180], ["Human", "ORGANISM", 106, 111], ["MethodsHuman fecal samples", "ORGANISM_SUBSTANCE", 154, 180], ["patients", "ORGANISM", 201, 209], ["patients", "ORGANISM", 348, 356], ["Human", "SPECIES", 106, 111], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 348, 356], ["Human", "SPECIES", 106, 111], ["Sanger sequencing", "TEST", 0, 17], ["an ABI Prism", "TEST", 30, 42], ["Genetic Analyzer", "TEST", 48, 64], ["MethodsHuman fecal samples", "TEST", 154, 180], ["fecal", "ANATOMY", 112, 117]]], ["The patients were either diarrheic or came into contact with bats directly (by eating, hunting or handling) or indirectly (if family member is directly exposed to bats).", [["diarrheic", "DISEASE", 25, 34], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["diarrheic", "PROBLEM", 25, 34]]], ["The samples were put in UTM containing tubes and stored the same way like the bat samples.", [["samples", "ANATOMY", 4, 11], ["samples", "ANATOMY", 82, 89], ["tubes", "ORGANISM_SUBSTANCE", 39, 44], ["bat", "ORGANISM", 78, 81], ["The samples", "TEST", 0, 11], ["UTM containing tubes", "TREATMENT", 24, 44], ["the bat samples", "TEST", 74, 89], ["tubes", "OBSERVATION", 39, 44]]], ["Screening primers (Supplementary data S4) were designed from a consensus sequences of human and bat VP6 RVAs and a total of 25 samples from infants (0\u20133 years) who had diarrhea were screened by reverse transcriptase polymerase chain reaction (RT-PCR) using the OneStep RT-PCR kit (Qiagen).", [["samples", "ANATOMY", 127, 134], ["diarrhea", "DISEASE", 168, 176], ["human", "ORGANISM", 86, 91], ["VP6", "ORGANISM", 100, 103], ["infants", "ORGANISM", 140, 147], ["consensus sequences", "DNA", 63, 82], ["reverse transcriptase", "PROTEIN", 194, 215], ["human", "SPECIES", 86, 91], ["infants", "SPECIES", 140, 147], ["human", "SPECIES", 86, 91], ["Screening primers", "TEST", 0, 17], ["a consensus sequences", "TEST", 61, 82], ["human and bat VP6 RVAs", "TREATMENT", 86, 108], ["diarrhea", "PROBLEM", 168, 176], ["RT-PCR", "TEST", 243, 249], ["the OneStep RT-PCR kit", "TREATMENT", 257, 279]]], ["The products of positive samples were sequenced using Sanger sequencing Method.Genomic and phylogenetic analysis ::: MethodsRaw Illumina reads were trimmed for quality and adapters using Trimmomatic35, and were de novo assembled into Scaffold using SPAdes36.", [["samples", "ANATOMY", 25, 32], ["Raw Illumina reads", "DNA", 124, 142], ["SPAdes36", "DNA", 249, 257], ["positive samples", "PROBLEM", 16, 32], ["Sanger sequencing Method", "TEST", 54, 78], ["Trimmomatic35", "TREATMENT", 187, 200]]], ["Scaffolds were classified using DIAMOND in sensitive mode20.", [["DIAMOND", "PROTEIN", 32, 39], ["Scaffolds", "TREATMENT", 0, 9]]], ["Contigs assigned to RVA were used to map the trimmed reads using the Burrows-Wheeler Alignment tool (BWA)37.", [["the Burrows", "TEST", 65, 76]]], ["Open reading frames (ORF) were identified with ORF Finder analysis tool (http://www.ncbi.nlm.nih.gov/gorf/Orfig.cgi) and the conserved motifs in the amino acid sequences were identified with HMMER38.", [["amino acid", "CHEMICAL", 149, 159], ["amino acid", "CHEMICAL", 149, 159], ["amino acid", "AMINO_ACID", 149, 159], ["Open reading frames", "DNA", 0, 19], ["ORF", "DNA", 21, 24], ["ORF", "DNA", 47, 50], ["HMMER38", "PROTEIN", 191, 198], ["ORF Finder analysis tool", "TEST", 47, 71], ["the amino acid sequences", "TEST", 145, 169]]], ["Amino acid alignments of the viral sequences and maximum likelihood phylogenetic trees were constructed in MEGA6.0639, using the GTR + G (VP1, VP6, NSP2 and NSP3), GTR + G + I (VP2\u2013VP4, VP7 and NSP1), HKY (NSP4) and T92 (NSP5) substitution models (after testing for the best DNA/protein model), with 500 bootstrap replicates.", [["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["GTR + G", "GENE_OR_GENE_PRODUCT", 129, 136], ["VP6", "GENE_OR_GENE_PRODUCT", 143, 146], ["NSP2", "GENE_OR_GENE_PRODUCT", 148, 152], ["NSP3", "GENE_OR_GENE_PRODUCT", 157, 161], ["GTR + G + I", "GENE_OR_GENE_PRODUCT", 164, 175], ["VP2\u2013VP4", "GENE_OR_GENE_PRODUCT", 177, 184], ["VP7", "GENE_OR_GENE_PRODUCT", 186, 189], ["NSP4", "GENE_OR_GENE_PRODUCT", 206, 210], ["DNA", "CELLULAR_COMPONENT", 275, 278], ["viral sequences", "DNA", 29, 44], ["VP6", "DNA", 143, 146], ["NSP2", "DNA", 148, 152], ["NSP3", "DNA", 157, 161], ["GTR", "DNA", 164, 167], ["VP2", "PROTEIN", 177, 180], ["VP4", "PROTEIN", 181, 184], ["VP7", "DNA", 186, 189], ["NSP1", "DNA", 194, 198], ["HKY", "DNA", 201, 204], ["NSP4", "PROTEIN", 206, 210], ["NSP5", "PROTEIN", 221, 225], ["Amino acid alignments", "TEST", 0, 21], ["the viral sequences", "TEST", 25, 44], ["the GTR", "TEST", 125, 132], ["VP1", "TEST", 138, 141], ["VP6", "TEST", 143, 146], ["NSP2", "TEST", 148, 152], ["NSP3", "TEST", 157, 161], ["GTR", "TEST", 164, 167], ["G", "TEST", 170, 171], ["VP2", "TEST", 177, 180], ["VP4", "TEST", 181, 184], ["VP7", "TEST", 186, 189], ["NSP1", "TEST", 194, 198], ["HKY", "TEST", 201, 204], ["NSP4", "TEST", 206, 210], ["T92", "TEST", 216, 219], ["substitution models", "TEST", 227, 246], ["testing", "TEST", 254, 261], ["the best DNA/protein model", "TEST", 266, 292], ["acid alignments", "OBSERVATION", 6, 21], ["phylogenetic trees", "OBSERVATION", 68, 86]]], ["Nucleotide similarities were also computed in MEGA by pairwise distance using p-distance model.", [["Nucleotide similarities", "TEST", 0, 23], ["p-distance model", "TREATMENT", 78, 94]]], ["Phylogenetic analyses were performed using appropriate reference strains in addition to the RVA discovered in this study.Additional InformationHow to cite this article: Yinda, C. K. et al. Novel highly divergent reassortant bat rotaviruses in Cameroon, without evidence of zoonosis.", [["zoonosis", "DISEASE", 273, 281], ["bat rotaviruses", "ORGANISM", 224, 239], ["Phylogenetic analyses", "TEST", 0, 21], ["the RVA", "TEST", 88, 95], ["this study", "TEST", 110, 120], ["Novel highly divergent reassortant bat rotaviruses", "PROBLEM", 189, 239], ["zoonosis", "PROBLEM", 273, 281], ["without evidence of", "UNCERTAINTY", 253, 272], ["zoonosis", "OBSERVATION", 273, 281]]], ["Rep.6, 34209; doi: 10.1038/srep34209 (2016).", [["Rep.6, 34209", "CHEMICAL", 0, 12]]]], "PMC7262154": [["IntroductionChina and the rest of the world are experiencing an outbreak of the 2019 novel coronavirus disease (COVID\u201019).", [["coronavirus disease", "DISEASE", 91, 110], ["coronavirus", "ORGANISM", 91, 102], ["coronavirus", "SPECIES", 91, 102], ["IntroductionChina", "TREATMENT", 0, 17], ["novel coronavirus disease", "PROBLEM", 85, 110], ["coronavirus disease", "OBSERVATION", 91, 110]]], ["By February 22, 2020, the rapid spread of the virus had caused 77,041 infections and 2,445 deaths in China, and emerging cases have been reported in more than 30 countries, including the U.S., Japan, and South Korea.", [["infections", "DISEASE", 70, 80], ["deaths", "DISEASE", 91, 97], ["the virus", "PROBLEM", 42, 51], ["infections", "PROBLEM", 70, 80]]], ["More than two thirds of cases and deaths from the infection occurred in Wuhan, China.", [["deaths", "DISEASE", 34, 40], ["infection", "DISEASE", 50, 59], ["the infection", "PROBLEM", 46, 59], ["infection", "OBSERVATION", 50, 59]]], ["On January 31, 2020, the World Health Organization declared COVID\u201019, caused by severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102), a public health emergency of international concern.IntroductionPatients with cancer are more susceptible to viral infection than healthy individuals because of their systemic immunosuppressive status caused by the malignancy and anticancer treatments, such as surgery or chemotherapy; therefore, these patients might be at increased risk for COVID\u201019 and have a poorer prognosis 1.IntroductionAs one of the largest medical centers in Wuhan, ground zero of the outbreak, our hospital encountered patients with COVID\u201019 with various medical conditions.", [["cancer", "ANATOMY", 219, 225], ["anticancer", "ANATOMY", 371, 381], ["acute respiratory syndrome coronavirus", "DISEASE", 87, 125], ["cancer", "DISEASE", 219, 225], ["viral infection", "DISEASE", 250, 265], ["malignancy", "DISEASE", 356, 366], ["cancer", "CANCER", 219, 225], ["anticancer", "CANCER", 371, 381], ["patients", "ORGANISM", 444, 452], ["patients", "ORGANISM", 637, 645], ["patients", "SPECIES", 444, 452], ["patients", "SPECIES", 637, 645], ["severe acute respiratory syndrome coronavirus", "SPECIES", 80, 125], ["SARS\u2010CoV", "SPECIES", 129, 137], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 80, 125], ["cancer", "PROBLEM", 219, 225], ["viral infection", "PROBLEM", 250, 265], ["their systemic immunosuppressive status", "PROBLEM", 302, 341], ["the malignancy", "PROBLEM", 352, 366], ["anticancer treatments", "TREATMENT", 371, 392], ["surgery", "TREATMENT", 402, 409], ["chemotherapy", "TREATMENT", 413, 425], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["acute", "OBSERVATION_MODIFIER", 87, 92], ["respiratory syndrome", "OBSERVATION", 93, 113], ["cancer", "OBSERVATION", 219, 225], ["viral", "OBSERVATION_MODIFIER", 250, 255], ["infection", "OBSERVATION", 256, 265], ["malignancy", "OBSERVATION", 356, 366], ["largest", "OBSERVATION_MODIFIER", 549, 556]]], ["Here, we report the results of a retrospective review of medical records from three women diagnosed with COVID\u201019 after gynecologic surgery in our Gynecologic Oncology ward in January 2020; each had met the diagnostic criteria of the New Coronavirus Pneumonia Prevention and Control Program (6th edition), published by the National Health Commission of China 2.ResultsFrom January 1, 2020, to January 31, 2020, three women were postoperatively diagnosed with COVID\u201019 in our Gynecologic Oncology ward (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology).", [["COVID", "DISEASE", 105, 110], ["Pneumonia", "DISEASE", 250, 259], ["women", "ORGANISM", 84, 89], ["women", "ORGANISM", 417, 422], ["women", "SPECIES", 84, 89], ["women", "SPECIES", 417, 422], ["gynecologic surgery", "TREATMENT", 120, 139], ["the New Coronavirus Pneumonia", "PROBLEM", 230, 259], ["New", "OBSERVATION_MODIFIER", 234, 237], ["Coronavirus", "OBSERVATION_MODIFIER", 238, 249], ["Pneumonia", "OBSERVATION", 250, 259]]], ["The incidence of COVID\u201019 was 0.77% (3 of 389) of the total hospitalizations and 1.59% (3 of 189) among the patients undergoing surgeries in the ward and hospitalized during the same time period.", [["COVID", "DISEASE", 17, 22], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["COVID", "TEST", 17, 22], ["surgeries", "TREATMENT", 128, 137]]], ["There were no COVID\u201019 diagnoses in the 200 patients without surgery.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["surgery", "TREATMENT", 61, 68], ["no", "UNCERTAINTY", 11, 13]]], ["Among the 189 patients with gynecologic tumors who had received surgery, COVID\u201019 occurred predominantly in those with malignant diseases, with comorbidities (hypertension, diabetes, and cardiovascular disease), aged >45 years, and with postoperative fever persisting for 3 days or longer (Table 1).ResultsThe detailed clinical features and disease courses of the three COVID\u201019 cases are summarized in Table 2.", [["gynecologic tumors", "ANATOMY", 28, 46], ["cardiovascular", "ANATOMY", 187, 201], ["gynecologic tumors", "DISEASE", 28, 46], ["malignant diseases", "DISEASE", 119, 137], ["hypertension", "DISEASE", 159, 171], ["diabetes", "DISEASE", 173, 181], ["cardiovascular disease", "DISEASE", 187, 209], ["postoperative fever", "DISEASE", 237, 256], ["patients", "ORGANISM", 14, 22], ["gynecologic tumors", "CANCER", 28, 46], ["patients", "SPECIES", 14, 22], ["gynecologic tumors", "PROBLEM", 28, 46], ["surgery", "TREATMENT", 64, 71], ["malignant diseases", "PROBLEM", 119, 137], ["comorbidities", "PROBLEM", 144, 157], ["hypertension", "PROBLEM", 159, 171], ["diabetes", "PROBLEM", 173, 181], ["cardiovascular disease)", "PROBLEM", 187, 210], ["postoperative fever", "PROBLEM", 237, 256], ["gynecologic", "ANATOMY", 28, 39], ["tumors", "OBSERVATION", 40, 46], ["malignant", "OBSERVATION_MODIFIER", 119, 128], ["diseases", "OBSERVATION", 129, 137], ["hypertension", "OBSERVATION", 159, 171], ["diabetes", "OBSERVATION", 173, 181], ["cardiovascular", "ANATOMY", 187, 201]]], ["The three patients did not report any direct contact with infected individuals, and their x\u2010rays and computed tomography (CT) scans of the chest did not show any abnormality preoperatively.", [["chest", "ANATOMY", 139, 144], ["patients", "ORGANISM", 10, 18], ["chest", "ORGAN", 139, 144], ["patients", "SPECIES", 10, 18], ["their x\u2010rays", "TEST", 84, 96], ["computed tomography", "TEST", 101, 120], ["CT) scans of the chest", "TEST", 122, 144], ["any abnormality", "PROBLEM", 158, 173], ["chest", "ANATOMY", 139, 144], ["abnormality", "OBSERVATION", 162, 173]]], ["The patients developed fever within 2 days after surgery, which persisted (highest temperatures of 38.7\u00b0C\u201339.4\u00b0C) despite the administration of anti\u2010inflammatory drugs (cephalosporin, meropenem, and moxifloxacin).", [["fever", "DISEASE", 23, 28], ["cephalosporin", "CHEMICAL", 169, 182], ["meropenem", "CHEMICAL", 184, 193], ["moxifloxacin", "CHEMICAL", 199, 211], ["cephalosporin", "CHEMICAL", 169, 182], ["meropenem", "CHEMICAL", 184, 193], ["moxifloxacin", "CHEMICAL", 199, 211], ["patients", "ORGANISM", 4, 12], ["cephalosporin", "SIMPLE_CHEMICAL", 169, 182], ["meropenem", "SIMPLE_CHEMICAL", 184, 193], ["moxifloxacin", "SIMPLE_CHEMICAL", 199, 211], ["patients", "SPECIES", 4, 12], ["fever", "PROBLEM", 23, 28], ["surgery", "TREATMENT", 49, 56], ["highest temperatures", "TEST", 75, 95], ["anti\u2010inflammatory drugs", "TREATMENT", 144, 167], ["cephalosporin", "TREATMENT", 169, 182], ["meropenem", "TREATMENT", 184, 193], ["moxifloxacin", "TREATMENT", 199, 211], ["fever", "OBSERVATION", 23, 28]]], ["One patient had a cough and significantly decreased blood oxygen.", [["blood", "ANATOMY", 52, 57], ["cough", "DISEASE", 18, 23], ["oxygen", "CHEMICAL", 58, 64], ["oxygen", "CHEMICAL", 58, 64], ["patient", "ORGANISM", 4, 11], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["oxygen", "SIMPLE_CHEMICAL", 58, 64], ["patient", "SPECIES", 4, 11], ["a cough", "PROBLEM", 16, 23], ["significantly decreased blood oxygen", "PROBLEM", 28, 64], ["cough", "OBSERVATION", 18, 23], ["decreased", "OBSERVATION_MODIFIER", 42, 51], ["blood oxygen", "OBSERVATION", 52, 64]]], ["Positive CT findings showed signs of a viral pneumonia approximately 10 days after surgery in all three patients (Fig. 1), whereas two of them had a negative chest x\u2010ray or CT on days 4\u20136 postoperatively.", [["chest", "ANATOMY", 158, 163], ["pneumonia", "DISEASE", 45, 54], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["CT findings", "TEST", 9, 20], ["a viral pneumonia", "PROBLEM", 37, 54], ["surgery", "TREATMENT", 83, 90], ["chest x\u2010ray", "TEST", 158, 169], ["CT", "TEST", 173, 175], ["viral", "OBSERVATION_MODIFIER", 39, 44], ["pneumonia", "OBSERVATION", 45, 54], ["chest", "ANATOMY", 158, 163]]], ["All patients had negative results from tests of blood and throat swab samples for seven common respiratory pathogens, including respiratory syncytial virus, adenovirus, mycoplasma pneumoniae, chlamydia pneumoniae, coxsackievirus group B, the influenza B virus, and the influenza A virus.", [["blood", "ANATOMY", 48, 53], ["throat swab samples", "ANATOMY", 58, 77], ["respiratory pathogens", "DISEASE", 95, 116], ["respiratory syncytial virus", "DISEASE", 128, 155], ["mycoplasma pneumoniae", "DISEASE", 169, 190], ["chlamydia pneumoniae", "DISEASE", 192, 212], ["coxsackievirus group B", "DISEASE", 214, 236], ["influenza B", "DISEASE", 242, 253], ["influenza A virus", "DISEASE", 269, 286], ["patients", "ORGANISM", 4, 12], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["throat swab samples", "ORGANISM_SUBSTANCE", 58, 77], ["respiratory syncytial virus", "ORGANISM", 128, 155], ["adenovirus", "ORGANISM", 157, 167], ["mycoplasma pneumoniae", "ORGANISM", 169, 190], ["chlamydia pneumoniae", "ORGANISM", 192, 212], ["coxsackievirus group B", "ORGANISM", 214, 236], ["influenza B virus", "ORGANISM", 242, 259], ["influenza A virus", "ORGANISM", 269, 286], ["patients", "SPECIES", 4, 12], ["respiratory syncytial virus", "SPECIES", 128, 155], ["mycoplasma pneumoniae", "SPECIES", 169, 190], ["chlamydia pneumoniae", "SPECIES", 192, 212], ["coxsackievirus group", "SPECIES", 214, 234], ["influenza B virus", "SPECIES", 242, 259], ["influenza A virus", "SPECIES", 269, 286], ["respiratory syncytial virus", "SPECIES", 128, 155], ["mycoplasma pneumoniae", "SPECIES", 169, 190], ["chlamydia pneumoniae", "SPECIES", 192, 212], ["coxsackievirus group B", "SPECIES", 214, 236], ["influenza B virus", "SPECIES", 242, 259], ["influenza A virus", "SPECIES", 269, 286], ["tests of blood", "TEST", 39, 53], ["throat swab samples", "TEST", 58, 77], ["seven common respiratory pathogens", "PROBLEM", 82, 116], ["respiratory syncytial virus", "PROBLEM", 128, 155], ["adenovirus", "PROBLEM", 157, 167], ["mycoplasma pneumoniae", "PROBLEM", 169, 190], ["chlamydia pneumoniae", "PROBLEM", 192, 212], ["coxsackievirus group B", "PROBLEM", 214, 236], ["the influenza B virus", "PROBLEM", 238, 259], ["the influenza A virus", "PROBLEM", 265, 286], ["throat", "ANATOMY", 58, 64], ["respiratory syncytial", "ANATOMY", 128, 149], ["mycoplasma pneumoniae", "OBSERVATION", 169, 190]]], ["Finally, the viral DNA of SARS\u2010CoV\u20102 was detected in the throat swab samples from the patients by using assays based on the real\u2010time reverse transcriptase polymerase chain reaction technique.ResultsThe patients were transferred to a quarantine hospital and treated with antiviral drugs (oseltamivir or umifenovir) combined with supportive care.", [["throat swab samples", "ANATOMY", 57, 76], ["SARS", "DISEASE", 26, 30], ["oseltamivir", "CHEMICAL", 288, 299], ["umifenovir", "CHEMICAL", 303, 313], ["oseltamivir", "CHEMICAL", 288, 299], ["umifenovir", "CHEMICAL", 303, 313], ["DNA", "CELLULAR_COMPONENT", 19, 22], ["SARS\u2010CoV\u20102", "ORGANISM", 26, 36], ["throat swab samples", "ORGANISM_SUBSTANCE", 57, 76], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 203, 211], ["oseltamivir", "SIMPLE_CHEMICAL", 288, 299], ["umifenovir", "SIMPLE_CHEMICAL", 303, 313], ["viral DNA", "DNA", 13, 22], ["SARS\u2010CoV\u20102", "DNA", 26, 36], ["reverse transcriptase", "PROTEIN", 134, 155], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 203, 211], ["SARS\u2010CoV", "SPECIES", 26, 34], ["the viral DNA", "TEST", 9, 22], ["SARS\u2010CoV\u20102", "PROBLEM", 26, 36], ["the throat swab samples", "TEST", 53, 76], ["assays", "TEST", 104, 110], ["the real\u2010time reverse transcriptase polymerase chain reaction technique", "TREATMENT", 120, 191], ["antiviral drugs", "TREATMENT", 271, 286], ["oseltamivir", "TREATMENT", 288, 299], ["umifenovir", "TREATMENT", 303, 313], ["supportive care", "TREATMENT", 329, 344], ["viral DNA", "OBSERVATION", 13, 22], ["throat", "ANATOMY", 57, 63]]], ["As of February 20, 2020, two of the three patients had been discharged from the hospital because they had met the discharge criteria (i.e., they had neither fever nor cough for at least 3 days, the lesions of lung had become much smaller according to chest CT imaging, and repeated negative results had been obtained in at least two consecutive viral DNA tests on different days 2); at this writing, the third patient was still being treated at the quarantine hospital.DiscussionIn previous studies, nearly half of patients with COVID\u201019 had underlying chronic diseases, such as diabetes, hypertension, and cardiovascular disease, and the common symptoms at onset of illness included fever, cough, shortness of breath, and fatigue.", [["lesions", "ANATOMY", 198, 205], ["lung", "ANATOMY", 209, 213], ["cardiovascular", "ANATOMY", 607, 621], ["fever", "DISEASE", 157, 162], ["cough", "DISEASE", 167, 172], ["COVID", "DISEASE", 529, 534], ["chronic diseases", "DISEASE", 553, 569], ["diabetes", "DISEASE", 579, 587], ["hypertension", "DISEASE", 589, 601], ["cardiovascular disease", "DISEASE", 607, 629], ["illness", "DISEASE", 667, 674], ["fever", "DISEASE", 684, 689], ["cough", "DISEASE", 691, 696], ["shortness of breath", "DISEASE", 698, 717], ["fatigue", "DISEASE", 723, 730], ["patients", "ORGANISM", 42, 50], ["lesions", "PATHOLOGICAL_FORMATION", 198, 205], ["lung", "ORGAN", 209, 213], ["DNA", "CELLULAR_COMPONENT", 351, 354], ["patient", "ORGANISM", 410, 417], ["patients", "ORGANISM", 515, 523], ["patients", "SPECIES", 42, 50], ["patient", "SPECIES", 410, 417], ["patients", "SPECIES", 515, 523], ["fever", "PROBLEM", 157, 162], ["cough", "PROBLEM", 167, 172], ["the lesions of lung", "PROBLEM", 194, 213], ["chest CT imaging", "TEST", 251, 267], ["viral DNA tests", "TEST", 345, 360], ["previous studies", "TEST", 482, 498], ["underlying chronic diseases", "PROBLEM", 542, 569], ["diabetes", "PROBLEM", 579, 587], ["hypertension", "PROBLEM", 589, 601], ["cardiovascular disease", "PROBLEM", 607, 629], ["the common symptoms", "PROBLEM", 635, 654], ["illness", "PROBLEM", 667, 674], ["fever", "PROBLEM", 684, 689], ["cough", "PROBLEM", 691, 696], ["shortness of breath", "PROBLEM", 698, 717], ["fatigue", "PROBLEM", 723, 730], ["lesions", "OBSERVATION", 198, 205], ["lung", "ANATOMY", 209, 213], ["chest", "ANATOMY", 251, 256], ["chronic", "OBSERVATION_MODIFIER", 553, 560], ["diseases", "OBSERVATION", 561, 569], ["hypertension", "OBSERVATION", 589, 601], ["cardiovascular", "ANATOMY", 607, 621], ["disease", "OBSERVATION", 622, 629], ["fatigue", "OBSERVATION", 723, 730]]], ["Most patients had lymphopenia, and nearly all patients had pneumonia with abnormal findings on chest CT.", [["chest", "ANATOMY", 95, 100], ["lymphopenia", "DISEASE", 18, 29], ["pneumonia", "DISEASE", 59, 68], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 46, 54], ["chest", "ORGANISM_SUBDIVISION", 95, 100], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 46, 54], ["lymphopenia", "PROBLEM", 18, 29], ["pneumonia", "PROBLEM", 59, 68], ["abnormal findings", "PROBLEM", 74, 91], ["chest CT", "TEST", 95, 103], ["lymphopenia", "OBSERVATION", 18, 29], ["pneumonia", "OBSERVATION", 59, 68], ["abnormal", "OBSERVATION_MODIFIER", 74, 82], ["chest", "ANATOMY", 95, 100]]], ["Some patients developed acute respiratory distress syndrome, and some of these patients worsened in a short period of time and died of multiple organ failure 3, 4.", [["respiratory", "ANATOMY", 30, 41], ["organ", "ANATOMY", 144, 149], ["acute respiratory distress syndrome", "DISEASE", 24, 59], ["organ failure", "DISEASE", 144, 157], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 79, 87], ["organ", "ORGAN", 144, 149], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 79, 87], ["acute respiratory distress syndrome", "PROBLEM", 24, 59], ["multiple organ failure", "PROBLEM", 135, 157], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["respiratory distress", "OBSERVATION", 30, 50], ["syndrome", "OBSERVATION", 51, 59], ["worsened", "OBSERVATION_MODIFIER", 88, 96], ["multiple", "OBSERVATION_MODIFIER", 135, 143], ["organ", "ANATOMY", 144, 149], ["failure", "OBSERVATION", 150, 157]]], ["Generally, the incubation period for COVID\u201019 can last 2 weeks, or longer 2, 5 considering that CT scan rather than x\u2010ray of the chest plays an essential role in the diagnosis of COVID\u201019 and that the viral detection assays are not always available or accurate 6.", [["chest", "ANATOMY", 129, 134], ["chest", "ORGAN", 129, 134], ["CT scan", "TEST", 96, 103], ["x\u2010ray of the chest", "TEST", 116, 134], ["COVID\u2010", "TEST", 179, 185], ["the viral detection assays", "TEST", 197, 223], ["chest", "ANATOMY", 129, 134]]], ["In the epidemic area, it would be helpful to use CT scans to screen patients preoperatively.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["CT scans", "TEST", 49, 57]]], ["For patients with persisting fever after surgery, a lung CT scan needs to be done in a timely manner.DiscussionData suggest that men are more susceptible than women, but in fact all populations are susceptible, including women 2, 3.", [["lung", "ANATOMY", 52, 56], ["fever", "DISEASE", 29, 34], ["patients", "ORGANISM", 4, 12], ["lung", "ORGAN", 52, 56], ["men", "ORGANISM", 129, 132], ["women", "ORGANISM", 159, 164], ["women", "ORGANISM", 221, 226], ["patients", "SPECIES", 4, 12], ["men", "SPECIES", 129, 132], ["women", "SPECIES", 159, 164], ["women", "SPECIES", 221, 226], ["persisting fever", "PROBLEM", 18, 34], ["surgery", "TREATMENT", 41, 48], ["a lung CT scan", "TEST", 50, 64], ["persisting", "OBSERVATION_MODIFIER", 18, 28], ["fever", "OBSERVATION", 29, 34], ["lung", "ANATOMY", 52, 56]]], ["Some studies reported that, with the rapid spread of the disease, many COVID\u201019 diagnoses were made in people who had not had direct contact with other individuals infected with SARS\u2010CoV\u201019 7.", [["SARS", "DISEASE", 178, 182], ["people", "ORGANISM", 103, 109], ["people", "SPECIES", 103, 109], ["Some studies", "TEST", 0, 12], ["the disease", "PROBLEM", 53, 64], ["disease", "OBSERVATION", 57, 64]]], ["In the current study, only one of three affected persons was from metropolitan Wuhan, and the others were from nearby.", [["persons", "ORGANISM", 49, 56], ["persons", "SPECIES", 49, 56], ["the current study", "TEST", 3, 20]]], ["In an epidemic area of COVID\u201019, more intensive surveillance for SARS\u2010CoV\u20102 should be done before surgery.", [["SARS", "DISEASE", 65, 69], ["SARS\u2010CoV", "SPECIES", 65, 73], ["SARS\u2010CoV\u20102", "TREATMENT", 65, 75], ["surgery", "TREATMENT", 98, 105], ["epidemic", "OBSERVATION_MODIFIER", 6, 14]]], ["After surgery, if a patient's fever lasts for more than 3 days or is accompanied by respiratory symptoms, then COVID\u201019 testing should be performed, even if the patient has had no contact with other verified cases.", [["respiratory", "ANATOMY", 84, 95], ["fever", "DISEASE", 30, 35], ["patient", "ORGANISM", 20, 27], ["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 20, 27], ["patient", "SPECIES", 161, 168], ["surgery", "TREATMENT", 6, 13], ["a patient's fever", "PROBLEM", 18, 35], ["respiratory symptoms", "PROBLEM", 84, 104], ["COVID\u201019 testing", "TEST", 111, 127], ["respiratory", "ANATOMY", 84, 95]]], ["In the present case report, the patients were older than the average age of the patients in the ward during the same time period, suggesting that age also may be a risk factor for COVID\u201019 after gynecologic tumor surgery.", [["gynecologic tumor", "ANATOMY", 195, 212], ["gynecologic tumor", "DISEASE", 195, 212], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 80, 88], ["tumor", "CANCER", 207, 212], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 80, 88], ["COVID\u2010", "TREATMENT", 180, 186], ["gynecologic tumor surgery", "TREATMENT", 195, 220], ["tumor", "OBSERVATION", 207, 212]]], ["It was also observed, in all three cases, that the white blood cell count was not high and the lymphocyte count was reduced.", [["white blood cell", "ANATOMY", 51, 67], ["lymphocyte", "ANATOMY", 95, 105], ["white blood cell", "CELL", 51, 67], ["lymphocyte", "CELL", 95, 105], ["the white blood cell count", "TEST", 47, 73], ["the lymphocyte count", "TEST", 91, 111], ["high", "OBSERVATION_MODIFIER", 82, 86], ["lymphocyte count", "OBSERVATION", 95, 111]]], ["It is suggested that only emergency gynecologic operations should be scheduled in an epidemic area.ConclusionWe found that patients undergoing gynecological surgery were at risk for clinical manifestations of COVID\u201019 after surgery in a gynecologic oncology ward.", [["gynecological", "ANATOMY", 143, 156], ["COVID", "DISEASE", 209, 214], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["emergency gynecologic operations", "TREATMENT", 26, 58], ["gynecological surgery", "TREATMENT", 143, 164], ["COVID\u2010", "TREATMENT", 209, 215], ["surgery", "TREATMENT", 224, 231]]], ["Postponement of scheduled gynecologic surgery for patients in the epidemic area is important and should be considered.", [["gynecologic", "ANATOMY", 26, 37], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["scheduled gynecologic surgery", "TREATMENT", 16, 45]]], ["More intensive surveillance for SARS\u2010CoV\u20102 should be considered for patients undergoing gynecologic surgery, especially for patients with fever for more than 3 days, older patients, and patients with comorbidities.DisclosuresThe authors indicated no financial relationships.", [["gynecologic", "ANATOMY", 88, 99], ["SARS", "DISEASE", 32, 36], ["fever", "DISEASE", 138, 143], ["CoV", "ORGANISM", 37, 40], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 124, 132], ["patients", "ORGANISM", 172, 180], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 124, 132], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 186, 194], ["SARS\u2010CoV", "SPECIES", 32, 40], ["SARS\u2010CoV\u20102", "TREATMENT", 32, 42], ["gynecologic surgery", "TREATMENT", 88, 107], ["fever", "PROBLEM", 138, 143], ["comorbidities", "PROBLEM", 200, 213]]]], "de452bf070bb2c100cab63901495507c492e6ada": [["Geminiviruses (family Geminiviridae) possess single-stranded circular DNA genomes that are replicated by cellular polymerases in plant host cell nuclei.", [["cellular", "ANATOMY", 105, 113], ["cell nuclei", "ANATOMY", 140, 151], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["cellular", "CELL", 105, 113], ["cell nuclei", "CELL", 140, 151], ["single-stranded circular DNA genomes", "DNA", 45, 81], ["cellular polymerases", "PROTEIN", 105, 125], ["Geminiviruses (family Geminiviridae)", "TREATMENT", 0, 36], ["single-stranded circular DNA genomes", "TREATMENT", 45, 81], ["stranded circular", "OBSERVATION_MODIFIER", 52, 69], ["DNA genomes", "OBSERVATION", 70, 81], ["cellular polymerases", "OBSERVATION", 105, 125], ["plant host cell nuclei", "OBSERVATION", 129, 151]]], ["In their hosts, geminivirus populations behave as ensembles of mutant and recombinant genomes, known as viral quasispecies.", [["geminivirus populations", "CELL", 16, 39], ["geminivirus populations", "CELL_TYPE", 16, 39], ["mutant and recombinant genomes", "DNA", 63, 93], ["geminivirus populations", "PROBLEM", 16, 39], ["mutant and recombinant genomes", "PROBLEM", 63, 93], ["viral quasispecies", "PROBLEM", 104, 122], ["viral quasispecies", "OBSERVATION", 104, 122]]], ["This favors the emergence of new geminiviruses with altered host range, facilitating new or more severe diseases or overcoming resistance traits.", [["geminiviruses", "CANCER", 33, 46], ["more severe diseases", "PROBLEM", 92, 112], ["overcoming resistance traits", "PROBLEM", 116, 144], ["new", "OBSERVATION_MODIFIER", 29, 32], ["geminiviruses", "OBSERVATION", 33, 46], ["host range", "OBSERVATION_MODIFIER", 60, 70], ["new", "OBSERVATION_MODIFIER", 85, 88], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["diseases", "OBSERVATION", 104, 112]]], ["In warm and temperate areas several whitefly-transmitted geminiviruses of the genus Begomovirus cause the tomato yellow leaf curl disease (TYLCD) with significant economic consequences.", [["Begomovirus", "CHEMICAL", 84, 95], ["tomato yellow leaf curl disease", "DISEASE", 106, 137], ["TYLCD", "DISEASE", 139, 144], ["Begomovirus", "GENE_OR_GENE_PRODUCT", 84, 95], ["tomato", "SPECIES", 106, 112], ["yellow leaf curl", "SPECIES", 113, 129], ["tomato yellow leaf curl disease (TYLCD", "SPECIES", 106, 144], ["the genus Begomovirus", "PROBLEM", 74, 95], ["the tomato yellow leaf curl disease", "PROBLEM", 102, 137], ["significant economic consequences", "PROBLEM", 151, 184], ["warm", "OBSERVATION", 3, 7], ["temperate", "OBSERVATION_MODIFIER", 12, 21], ["areas", "OBSERVATION_MODIFIER", 22, 27], ["genus Begomovirus", "OBSERVATION", 78, 95], ["yellow leaf", "OBSERVATION", 113, 124], ["curl disease", "OBSERVATION", 125, 137], ["significant", "OBSERVATION_MODIFIER", 151, 162], ["economic consequences", "OBSERVATION", 163, 184]]], ["TYLCD is frequently controlled in commercial tomatoes by using the dominant Ty-1 resistance gene.", [["TYLCD", "CHEMICAL", 0, 5], ["tomatoes", "ORGANISM_SUBDIVISION", 45, 53], ["Ty-1", "GENE_OR_GENE_PRODUCT", 76, 80], ["dominant Ty-1 resistance gene", "DNA", 67, 96], ["tomatoes", "SPECIES", 45, 53], ["TYLCD", "TREATMENT", 0, 5]]], ["Over a 45 day period we have studied the diversification of three begomoviruses causing TYLCD: tomato yellow leaf curl virus (TYLCV), tomato yellow leaf curl Sardinia virus (TYLCSV) and tomato yellow leaf curl Malaga virus (TYLCMaV, a natural recombinant between TYLCV and TYLCSV).", [["TYLCD", "CHEMICAL", 88, 93], ["TYLCD", "GENE_OR_GENE_PRODUCT", 88, 93], ["tomato yellow leaf curl virus", "ORGANISM", 95, 124], ["TYLCV", "ORGANISM", 126, 131], ["tomato yellow leaf curl Sardinia virus", "ORGANISM", 134, 172], ["TYLCSV", "ORGANISM", 174, 180], ["tomato yellow leaf curl Malaga virus", "ORGANISM", 186, 222], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 224, 231], ["TYLCV", "ORGANISM", 263, 268], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 273, 279], ["TYLCSV", "PROTEIN", 273, 279], ["tomato", "SPECIES", 95, 101], ["yellow leaf curl virus", "SPECIES", 102, 124], ["TYLCV", "SPECIES", 126, 131], ["tomato", "SPECIES", 134, 140], ["yellow leaf curl", "SPECIES", 141, 157], ["Sardinia virus", "SPECIES", 158, 172], ["tomato", "SPECIES", 186, 192], ["yellow leaf curl", "SPECIES", 193, 209], ["Malaga virus", "SPECIES", 210, 222], ["tomato yellow leaf curl virus", "SPECIES", 95, 124], ["TYLCV", "SPECIES", 126, 131], ["tomato yellow leaf curl Sardinia virus", "SPECIES", 134, 172], ["TYLCSV", "SPECIES", 174, 180], ["tomato yellow leaf curl Malaga virus", "SPECIES", 186, 222], ["TYLCV", "SPECIES", 263, 268], ["three begomoviruses", "PROBLEM", 60, 79], ["TYLCD", "PROBLEM", 88, 93], ["tomato yellow leaf curl virus", "PROBLEM", 95, 124], ["tomato yellow leaf curl Sardinia virus", "PROBLEM", 134, 172], ["(TYLCSV)", "TREATMENT", 173, 181], ["tomato yellow leaf curl Malaga virus (TYLCMaV", "TREATMENT", 186, 231], ["a natural recombinant between TYLCV and TYLCSV)", "TREATMENT", 233, 280], ["yellow leaf", "OBSERVATION", 102, 113], ["curl virus", "OBSERVATION", 114, 124], ["Sardinia virus", "OBSERVATION", 158, 172]]], ["Viral quasispecies resulting from inoculation of geminivirus infectious clones were examined in plants of susceptible tomato (ty-1/ty-1), heterozygous resistant tomato (Ty-1/ty-1), common bean, and the wild reservoir Solanum nigrum.", [["tomato", "ORGANISM", 118, 124], ["ty-1", "ORGANISM", 131, 135], ["tomato", "ORGANISM", 161, 167], ["ty-1", "ORGANISM", 174, 178], ["bean", "ORGANISM", 188, 192], ["Solanum nigrum", "ORGANISM", 217, 231], ["geminivirus infectious clones", "CELL_LINE", 49, 78], ["tomato", "SPECIES", 118, 124], ["tomato", "SPECIES", 161, 167], ["bean", "SPECIES", 188, 192], ["Solanum nigrum", "SPECIES", 217, 231], ["tomato", "SPECIES", 118, 124], ["tomato", "SPECIES", 161, 167], ["bean", "SPECIES", 188, 192], ["Solanum nigrum", "SPECIES", 217, 231], ["Viral quasispecies", "PROBLEM", 0, 18], ["inoculation of geminivirus infectious clones", "PROBLEM", 34, 78], ["heterozygous resistant tomato", "PROBLEM", 138, 167], ["common bean", "PROBLEM", 181, 192], ["quasispecies", "OBSERVATION", 6, 18], ["inoculation", "OBSERVATION_MODIFIER", 34, 45], ["geminivirus", "OBSERVATION_MODIFIER", 49, 60], ["infectious clones", "OBSERVATION", 61, 78], ["common bean", "ANATOMY", 181, 192], ["Solanum nigrum", "OBSERVATION", 217, 231]]], ["Differences in virus fitness across hosts were observed while viral consensus sequences remained invariant.", [["viral consensus sequences", "DNA", 62, 87], ["Differences in virus fitness across hosts", "PROBLEM", 0, 41], ["viral consensus sequences", "TEST", 62, 87], ["virus fitness", "OBSERVATION", 15, 28]]], ["However, the complexity and heterogeneity of the quasispecies were high, especially in common bean and the wild host.", [["bean", "ORGANISM_SUBDIVISION", 94, 98], ["bean", "SPECIES", 94, 98], ["bean", "SPECIES", 94, 98], ["the quasispecies", "PROBLEM", 45, 61], ["complexity", "OBSERVATION_MODIFIER", 13, 23], ["heterogeneity", "OBSERVATION_MODIFIER", 28, 41], ["quasispecies", "OBSERVATION", 49, 61], ["high", "OBSERVATION_MODIFIER", 67, 71]]], ["Interestingly, the presence or absence of the Ty-1 allele in tomato did not lead to differences in begomovirus mutant spectra.", [["Ty-1", "GENE_OR_GENE_PRODUCT", 46, 50], ["tomato", "ORGANISM", 61, 67], ["Ty-1 allele", "DNA", 46, 57], ["tomato", "SPECIES", 61, 67], ["tomato", "SPECIES", 61, 67], ["begomovirus mutant spectra", "PROBLEM", 99, 125]]], ["However, the fitness decrease of TYLCSV and TYLCV in tomato at 45 dpi might be related to an increase in CP (Coat protein) mutation frequency.", [["TYLCSV", "GENE_OR_GENE_PRODUCT", 33, 39], ["TYLCV", "ORGANISM", 44, 49], ["tomato", "ORGANISM", 53, 59], ["Coat protein", "GENE_OR_GENE_PRODUCT", 109, 121], ["TYLCSV", "PROTEIN", 33, 39], ["Coat protein", "PROTEIN", 109, 121], ["tomato", "SPECIES", 53, 59], ["TYLCV", "SPECIES", 44, 49], ["tomato", "SPECIES", 53, 59], ["TYLCSV", "TREATMENT", 33, 39], ["an increase in CP (Coat protein) mutation frequency", "PROBLEM", 90, 141], ["decrease", "OBSERVATION_MODIFIER", 21, 29], ["increase", "OBSERVATION_MODIFIER", 93, 101]]], ["In Solanum nigrum the recombinant TYLCMaV, which showed lower fitness than TYLCSV, at 45 dpi actively explored Rep (Replication associated protein) ORF but not the overlapping C4.", [["Solanum nigrum", "ORGANISM", 3, 17], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 34, 41], ["Rep", "GENE_OR_GENE_PRODUCT", 111, 114], ["recombinant TYLCMaV", "PROTEIN", 22, 41], ["Rep", "PROTEIN", 111, 114], ["Replication associated protein) ORF", "DNA", 116, 151], ["C4", "PROTEIN", 176, 178], ["Solanum nigrum", "SPECIES", 3, 17], ["Solanum nigrum", "SPECIES", 3, 17], ["lower fitness than TYLCSV", "PROBLEM", 56, 81], ["Replication associated protein) ORF", "PROBLEM", 116, 151], ["Solanum nigrum", "ANATOMY", 3, 17]]], ["Our results underline the importance of begomovirus mutant spectra during infections.", [["infections", "DISEASE", 74, 84], ["begomovirus mutant", "ORGANISM", 40, 58], ["begomovirus mutant spectra during infections", "PROBLEM", 40, 84], ["infections", "OBSERVATION", 74, 84]]], ["This is especially relevant in the wild reservoir of the viruses, which has the potential to maintain highly diverse mutant spectra without modifying their consensus sequences.INTRODUCTIONAnimal and plant RNA viruses exist as viral quasispecies that adapt to changing environments by evolving rapidly (Domingo et al., 2006 Roossinck and Schneider, 2006) .", [["consensus sequences", "DNA", 156, 175], ["plant RNA viruses", "PROBLEM", 199, 216], ["viral quasispecies", "PROBLEM", 226, 244], ["viruses", "OBSERVATION", 57, 64], ["RNA viruses", "OBSERVATION", 205, 216]]], ["Viral quasispecies are defined as distributions of nonidentical but related genomes subjected to a continuous process of genetic variation, competition, selection and genetic drift, and which act as a unit of selection .", [["Viral quasispecies", "PROBLEM", 0, 18], ["genetic drift", "PROBLEM", 167, 180], ["quasispecies", "OBSERVATION", 6, 18]]], ["Their high genetic diversity in host populations is partially explained by the low replication fidelity of viral RNA-dependent DNA (RdDp) or RNA polymerases (RdRp), which lack proofreading activity (Steinhauer et al., 1992; Domingo and Holland, 1997) .", [["RNA-dependent", "GENE_OR_GENE_PRODUCT", 113, 126], ["DNA", "CELLULAR_COMPONENT", 127, 130], ["(RdDp)", "GENE_OR_GENE_PRODUCT", 131, 137], ["RNA polymerases", "GENE_OR_GENE_PRODUCT", 141, 156], ["viral RNA-dependent DNA", "DNA", 107, 130], ["RdDp", "DNA", 132, 136], ["RNA polymerases", "PROTEIN", 141, 156], ["RdRp", "PROTEIN", 158, 162], ["viral RNA", "PROBLEM", 107, 116], ["dependent DNA", "PROBLEM", 117, 130], ["RNA polymerases (RdRp", "PROBLEM", 141, 162], ["high", "OBSERVATION_MODIFIER", 6, 10], ["genetic", "OBSERVATION_MODIFIER", 11, 18], ["diversity", "OBSERVATION_MODIFIER", 19, 28], ["host populations", "OBSERVATION_MODIFIER", 32, 48], ["low replication", "OBSERVATION_MODIFIER", 79, 94], ["viral RNA", "OBSERVATION", 107, 116]]], ["Eukaryotic single-stranded DNA (ssDNA) viruses do not encode DNA polymerases (Gutierrez, 2000; Hanley-Bowdoin et al., 2000) and replicate their genomes using unknown host cell polymerases.", [["cell", "ANATOMY", 171, 175], ["DNA", "CELLULAR_COMPONENT", 27, 30], ["ssDNA", "CELLULAR_COMPONENT", 32, 37], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["host cell", "CELL", 166, 175], ["DNA polymerases", "PROTEIN", 61, 76], ["host cell polymerases", "PROTEIN", 166, 187], ["Eukaryotic single-stranded DNA (ssDNA) viruses", "TREATMENT", 0, 46], ["unknown host cell polymerases", "TREATMENT", 158, 187], ["stranded DNA", "OBSERVATION_MODIFIER", 18, 30], ["host cell polymerases", "OBSERVATION", 166, 187]]], ["High mutation frequencies of approximately 10 \u22124 mutations per nucleotide as well as substitution rates similar or even higher than those observed for RNA viruses have been found in ssDNA viruses such as animal circoviruses (family Circoviridae) (Firth et al., 2009; Harkins et al., 2014; Sarker et al., 2014) and parvoviruses (family Parvoviridae) (L\u00f3pez-Bueno et al., 2006) , or plant geminiviruses (family Geminiviridae) (Isnard et al., 1998; Sanz et al., 1999; Ge et al., 2007; Holmes, 2008, 2009; Urbino et al., 2008; van der Walt et al., 2008; Harkins et al., 2009 ) and nanoviruses (family Nanoviridae) (Grigoras et al., 2010; Stainton et al., 2015) Observed genetic diversity within mutant spectra at a given time during viral evolution is the result of natural selection, genetic drift and migration over the continuous generation of viral variants.", [["nucleotide", "CHEMICAL", 63, 73], ["nucleotide", "CHEMICAL", 63, 73], ["animal circoviruses", "ORGANISM", 204, 223], ["parvoviruses", "ORGANISM", 314, 326], ["High mutation frequencies", "PROBLEM", 0, 25], ["nucleotide", "TREATMENT", 63, 73], ["substitution rates", "TEST", 85, 103], ["RNA viruses", "PROBLEM", 151, 162], ["ssDNA viruses", "PROBLEM", 182, 195], ["mutant spectra", "PROBLEM", 691, 705], ["natural selection", "PROBLEM", 762, 779], ["genetic drift", "PROBLEM", 781, 794], ["migration", "PROBLEM", 799, 808], ["viral variants", "PROBLEM", 843, 857], ["ssDNA viruses", "OBSERVATION", 182, 195], ["mutant spectra", "OBSERVATION", 691, 705], ["natural selection", "OBSERVATION", 762, 779], ["migration", "OBSERVATION_MODIFIER", 799, 808], ["viral variants", "OBSERVATION", 843, 857]]], ["The heterogeneous composition of the mutant ensemble enables viral emergence and pathogenesis (Coffin, 1996; Domingo et al., 2006 Domingo et al., , 2012 , thus complicating prevention and treatment of viral diseases .", [["viral diseases", "DISEASE", 201, 215], ["viral diseases", "PROBLEM", 201, 215], ["heterogeneous", "OBSERVATION_MODIFIER", 4, 17], ["composition", "OBSERVATION_MODIFIER", 18, 29], ["viral diseases", "OBSERVATION", 201, 215]]], ["Antiviral or immune-escape mutants present in small proportions of viral populations, for example in human immunodeficiency virus 1 (HIV-1) (Coffin, 1995; N\u00e1jera et al., 1995; Henn et al., 2012) , hepatitis B virus (HBV) or hepatitis C virus (HCV) Bittar et al., 2013) infections, may be selected and become dominant in quasispecies following antiviral treatment, thus making disease control more difficult (Perales et al., 2014) .", [["human immunodeficiency virus", "DISEASE", 101, 129], ["hepatitis B virus (HBV) or hepatitis C", "DISEASE", 197, 235], ["infections", "DISEASE", 269, 279], ["human immunodeficiency virus 1", "ORGANISM", 101, 131], ["HIV-1", "ORGANISM", 133, 138], ["hepatitis B virus", "ORGANISM", 197, 214], ["HBV", "ORGANISM", 216, 219], ["hepatitis C virus", "ORGANISM", 224, 241], ["HCV", "ORGANISM", 243, 246], ["human immunodeficiency virus 1", "SPECIES", 101, 131], ["HIV-1", "SPECIES", 133, 138], ["hepatitis B virus", "SPECIES", 197, 214], ["hepatitis C virus", "SPECIES", 224, 241], ["human immunodeficiency virus 1", "SPECIES", 101, 131], ["HIV-1", "SPECIES", 133, 138], ["hepatitis B virus", "SPECIES", 197, 214], ["HBV", "SPECIES", 216, 219], ["hepatitis C virus", "SPECIES", 224, 241], ["HCV", "SPECIES", 243, 246], ["Antiviral", "TREATMENT", 0, 9], ["escape mutants", "PROBLEM", 20, 34], ["viral populations", "PROBLEM", 67, 84], ["human immunodeficiency virus", "PROBLEM", 101, 129], ["HIV", "TEST", 133, 136], ["Henn et al.", "TEST", 176, 187], ["hepatitis B virus", "PROBLEM", 197, 214], ["HBV", "PROBLEM", 216, 219], ["hepatitis C virus", "PROBLEM", 224, 241], ["infections", "PROBLEM", 269, 279], ["antiviral treatment", "TREATMENT", 343, 362], ["escape mutants", "OBSERVATION", 20, 34], ["small proportions", "OBSERVATION_MODIFIER", 46, 63], ["viral populations", "OBSERVATION", 67, 84], ["dominant", "OBSERVATION", 308, 316], ["quasispecies", "OBSERVATION", 320, 332], ["antiviral treatment", "OBSERVATION", 343, 362]]], ["A widely employed strategy to control plant viruses is the use of host genetic resistance (Boiteux et al., 1993; Monci et al., 2005; Fuchs, 2008; Garc\u00eda-Cano et al., 2010) .", [["A widely employed strategy", "TREATMENT", 0, 26]]], ["However, given the dynamic nature of viral populations, resistant mutants can emerge and result in epidemics.INTRODUCTIONViral emergence requires a sufficient degree of genetic variation in the reservoir host to allow successful infection of the new host after transmission (Parrish et al., 2008; Holmes and Grenfell, 2009; Elena et al., 2011 Elena et al., , 2014 .", [["infection", "DISEASE", 229, 238], ["viral populations", "PROBLEM", 37, 54], ["resistant mutants", "PROBLEM", 56, 73], ["epidemics", "PROBLEM", 99, 108], ["the reservoir host", "TREATMENT", 190, 208], ["successful infection", "PROBLEM", 218, 238], ["viral populations", "OBSERVATION", 37, 54], ["infection", "OBSERVATION", 229, 238]]], ["Once the virus adapts to the new host, the emergent virus may spread and reach epidemic levels.", [["the virus adapts", "TREATMENT", 5, 21], ["the emergent virus", "PROBLEM", 39, 57]]], ["Thus, knowledge of the genetic structure of host viral populations, and the factors that determine their evolution and host adaptation, are essential for designing robust control strategies for plant viral diseases (Acosta-Leal et al., 2011) .", [["viral diseases", "DISEASE", 200, 214], ["host viral populations", "PROBLEM", 44, 66], ["designing robust control strategies", "TREATMENT", 154, 189], ["plant viral diseases", "PROBLEM", 194, 214], ["viral diseases", "OBSERVATION", 200, 214]]], ["The genetic diversity observed in several RNA plant virus quasispecies appears to be host dependent, indicating that virus-host interactions are responsible for the maintenance of variability in mutant spectra Roossinck, 2000, 2001) .", [["The genetic diversity", "PROBLEM", 0, 21], ["several RNA plant virus quasispecies", "PROBLEM", 34, 70], ["host dependent", "PROBLEM", 85, 99], ["virus", "PROBLEM", 117, 122], ["diversity", "OBSERVATION_MODIFIER", 12, 21], ["virus quasispecies", "OBSERVATION", 52, 70], ["virus", "OBSERVATION", 117, 122]]], ["It remains to be determined, however, to what extent hosts can play a similar role in shaping quasispecies genetic variability in ssDNA plant viruses.INTRODUCTIONBegomoviruses (genus Begomovirus, family Geminiviridae) are emerging pathogens transmitted by the whitefly Bemisia tabaci (Gennadius) (Hemiptera: Aleyrodidae).", [["Geminiviridae", "GENE_OR_GENE_PRODUCT", 203, 216], ["whitefly", "ORGANISM", 260, 268], ["Bemisia tabaci", "ORGANISM", 269, 283], ["Gennadius)", "ORGANISM", 285, 295], ["Hemiptera: Aleyrodidae", "ORGANISM", 297, 319], ["Bemisia tabaci", "SPECIES", 269, 283], ["Bemisia tabaci", "SPECIES", 269, 283], ["INTRODUCTIONBegomoviruses (genus Begomovirus, family Geminiviridae", "TREATMENT", 150, 216], ["emerging pathogens", "PROBLEM", 222, 240], ["ssDNA plant viruses", "OBSERVATION", 130, 149]]], ["They are responsible for severe losses of economically important crops such as tomato (Solanum lycopersicum), cotton (Gossypium spp.) or cassava (Manihot esculenta) in tropical, subtropical and temperate regions (Parrish et al., 2008; Rojas and Gilbertson, 2008; Hanssen et al., 2010; Navas-Castillo et al., 2011) .", [["tomato", "ORGANISM_SUBDIVISION", 79, 85], ["Solanum lycopersicum", "ORGANISM", 87, 107], ["cotton", "ORGANISM_SUBDIVISION", 110, 116], ["Gossypium spp.", "ORGANISM", 118, 132], ["cassava", "ORGANISM_SUBDIVISION", 137, 144], ["Manihot esculenta", "ORGANISM", 146, 163], ["tomato", "SPECIES", 79, 85], ["Solanum lycopersicum", "SPECIES", 87, 107], ["cotton", "SPECIES", 110, 116], ["Gossypium spp.", "SPECIES", 118, 132], ["cassava", "SPECIES", 137, 144], ["Manihot esculenta", "SPECIES", 146, 163], ["tomato", "SPECIES", 79, 85], ["Solanum lycopersicum", "SPECIES", 87, 107], ["cotton", "SPECIES", 110, 116], ["Gossypium spp.", "SPECIES", 118, 132], ["cassava", "SPECIES", 137, 144], ["Manihot esculenta", "SPECIES", 146, 163], ["severe losses of economically", "PROBLEM", 25, 54], ["tomato (Solanum lycopersicum)", "TREATMENT", 79, 108], ["cotton (Gossypium spp.", "TREATMENT", 110, 132]]], ["The tomato yellow leaf curl disease (TYLCD) is one of the most devastating diseases affecting tomato worldwide (Czosnek and Laterrot, 1997; D\u00edaz-Pend\u00f3n et al., 2010; Navas-Castillo et al., 2011) .", [["tomato yellow leaf curl disease", "DISEASE", 4, 35], ["TYLCD", "DISEASE", 37, 42], ["tomato yellow leaf curl", "ORGANISM", 4, 27], ["tomato", "ORGANISM", 94, 100], ["tomato", "SPECIES", 4, 10], ["yellow leaf curl", "SPECIES", 11, 27], ["tomato", "SPECIES", 94, 100], ["tomato yellow leaf curl disease (TYLCD)", "SPECIES", 4, 43], ["tomato", "SPECIES", 94, 100], ["The tomato yellow leaf curl disease", "PROBLEM", 0, 35], ["D\u00edaz", "TEST", 140, 144], ["Navas", "TEST", 166, 171], ["yellow leaf", "OBSERVATION", 11, 22], ["curl disease", "OBSERVATION", 23, 35], ["most", "OBSERVATION_MODIFIER", 58, 62], ["devastating", "OBSERVATION_MODIFIER", 63, 74], ["diseases", "OBSERVATION", 75, 83]]], ["TYLCD is caused by a complex of at least 11 different begomoviruses, which produce similar symptoms in infected tomato plants but can differ in host range (Czosnek and Laterrot, 1997; D\u00edaz-Pend\u00f3n et al., 2010; Navas-Castillo et al., 2011) .", [["TYLCD", "DISEASE", 0, 5], ["tomato plants", "ORGANISM", 112, 125], ["tomato", "SPECIES", 112, 118], ["tomato", "SPECIES", 112, 118], ["different begomoviruses", "PROBLEM", 44, 67], ["similar symptoms in infected tomato plants", "PROBLEM", 83, 125], ["begomoviruses", "OBSERVATION", 54, 67]]], ["Most TYLCD-associated viruses have a monopartite genome with coding regions present in both virion (V) and complementary (C) sense strands separated by an intergenic non-coding region (IR).", [["TYLCD", "GENE_OR_GENE_PRODUCT", 5, 10], ["monopartite genome", "DNA", 37, 55], ["virion (V) and complementary (C) sense strands", "RNA", 92, 138], ["intergenic non-coding region", "DNA", 155, 183], ["Most TYLCD-associated viruses", "PROBLEM", 0, 29], ["a monopartite genome", "PROBLEM", 35, 55], ["complementary (C) sense strands", "PROBLEM", 107, 138], ["viruses", "OBSERVATION", 22, 29], ["monopartite genome", "OBSERVATION", 37, 55], ["both", "ANATOMY_MODIFIER", 87, 91], ["virion", "ANATOMY", 92, 98], ["intergenic non-coding", "OBSERVATION", 155, 176]]], ["A total of six partially overlapping genes are encoded by monopartite TYLCD-associated virus genomes: CP (coat protein, open reading frame or ORF V1), V2 (movement-like protein, precoat protein), Rep (replication associated protein, C1), TrAP (transcriptional activator protein, C2), REn (replication enhancer protein, C3), and C4 (involved in systemic movement and a pathogenesis factor) (Czosnek, 2007) .", [["TYLCD", "GENE_OR_GENE_PRODUCT", 70, 75], ["CP (coat protein", "GENE_OR_GENE_PRODUCT", 102, 118], ["V2 (movement-like protein", "GENE_OR_GENE_PRODUCT", 151, 176], ["precoat protein", "GENE_OR_GENE_PRODUCT", 178, 193], ["Rep (replication associated protein, C1", "GENE_OR_GENE_PRODUCT", 196, 235], ["TrAP (transcriptional activator protein, C2", "GENE_OR_GENE_PRODUCT", 238, 281], ["REn (replication enhancer protein", "GENE_OR_GENE_PRODUCT", 284, 317], ["C3", "GENE_OR_GENE_PRODUCT", 319, 321], ["C4", "GENE_OR_GENE_PRODUCT", 328, 330], ["monopartite TYLCD-associated virus genomes", "DNA", 58, 100], ["coat protein", "PROTEIN", 106, 118], ["open reading frame", "DNA", 120, 138], ["ORF V1", "DNA", 142, 148], ["V2", "DNA", 151, 153], ["precoat protein", "PROTEIN", 178, 193], ["Rep", "PROTEIN", 196, 199], ["replication associated protein", "PROTEIN", 201, 231], ["C1", "PROTEIN", 233, 235], ["TrAP", "PROTEIN", 238, 242], ["transcriptional activator protein", "PROTEIN", 244, 277], ["C2", "PROTEIN", 279, 281], ["REn", "PROTEIN", 284, 287], ["replication enhancer protein", "PROTEIN", 289, 317], ["C3", "PROTEIN", 319, 321], ["C4", "PROTEIN", 328, 330], ["pathogenesis factor", "PROTEIN", 368, 387], ["CP", "PROBLEM", 102, 104], ["coat protein", "TEST", 106, 118], ["open reading frame", "TEST", 120, 138], ["protein", "TEST", 169, 176], ["precoat protein", "TEST", 178, 193], ["Rep (replication associated protein, C1)", "PROBLEM", 196, 236], ["TrAP (transcriptional activator protein, C2), REn (replication enhancer protein, C3), and C4 (involved in systemic movement", "PROBLEM", 238, 361], ["C4", "ANATOMY", 328, 330], ["systemic movement", "ANATOMY", 344, 361]]], ["TYLCD epidemics have occurred in the Mediterranean Basin since the late 1980s (Czosnek, 2007; Navas-Castillo et al., 2011) .", [["TYLCD", "DISEASE", 0, 5], ["TYLCD epidemics", "PROBLEM", 0, 15]]], ["In Spain, outbreaks of the disease in the early 1990s were associated with the Spanish (ES) strain of tomato yellow leaf curl Sardinia virus (TYLCSV) (Noris et al., 1994; Navas-Castillo et al., 2011) .", [["tomato yellow leaf curl Sardinia virus", "ORGANISM", 102, 140], ["tomato", "SPECIES", 102, 108], ["yellow leaf", "SPECIES", 109, 120], ["curl Sardinia virus", "SPECIES", 121, 140], ["tomato yellow leaf curl Sardinia virus", "SPECIES", 102, 140], ["TYLCSV", "SPECIES", 142, 148], ["the disease", "PROBLEM", 23, 34], ["tomato yellow leaf curl Sardinia virus", "PROBLEM", 102, 140], ["Navas", "TEST", 171, 176], ["Spain", "OBSERVATION_MODIFIER", 3, 8], ["outbreaks", "OBSERVATION_MODIFIER", 10, 19], ["disease", "OBSERVATION", 27, 34]]], ["The subsequent introduction in the late 1990s and early 2000s of the type (also known as Israel, IL) (currently accepted as type member) and Mild (Mld) strains of tomato yellow leaf curl virus (TYLCV) (Noris et al., 1994; Morilla et al., 2004) resulted in new sources of genetic variation, and the emergence of recombinant species such as tomato yellow leaf curl Malaga virus (TYLCMaV), derived from a genetic exchange between isolates of TYLCSV and TYLCV (Navas-Castillo et al., 1997) .", [["IL", "GENE_OR_GENE_PRODUCT", 97, 99], ["tomato yellow leaf curl virus", "ORGANISM", 163, 192], ["TYLCV", "ORGANISM", 194, 199], ["tomato yellow leaf curl Malaga virus", "ORGANISM", 339, 375], ["TYLCV", "ORGANISM", 450, 455], ["tomato", "SPECIES", 163, 169], ["yellow leaf curl virus", "SPECIES", 170, 192], ["tomato", "SPECIES", 339, 345], ["yellow leaf curl", "SPECIES", 346, 362], ["Malaga virus", "SPECIES", 363, 375], ["TYLCV", "SPECIES", 450, 455], ["tomato yellow leaf curl virus", "SPECIES", 163, 192], ["TYLCV", "SPECIES", 194, 199], ["tomato yellow leaf curl Malaga virus", "SPECIES", 339, 375], ["TYLCV", "SPECIES", 450, 455], ["Mild (Mld) strains of tomato yellow leaf curl virus", "PROBLEM", 141, 192], ["genetic variation", "PROBLEM", 271, 288], ["recombinant species", "PROBLEM", 311, 330], ["tomato yellow leaf curl Malaga virus", "PROBLEM", 339, 375], ["TYLCSV", "TREATMENT", 439, 445], ["Mild", "OBSERVATION_MODIFIER", 141, 145], ["genetic variation", "OBSERVATION", 271, 288]]], ["Although 99% of the TYLCMaV genome sequence is shared with its corresponding parental virus sequences, the virus significantly differs in host range (Morilla et al., 2004; Garc\u00eda-Andr\u00e9s et al., 2007) .", [["TYLCMaV", "GENE_OR_GENE_PRODUCT", 20, 27], ["TYLCMaV genome sequence", "DNA", 20, 43], ["the TYLCMaV genome sequence", "TEST", 16, 43], ["its corresponding parental virus sequences", "PROBLEM", 59, 101], ["the virus", "PROBLEM", 103, 112]]], ["Thus, TYLCMaV can infect common bean (Phaseolus vulgaris) and the wild host Solanum nigrum.", [["TYLCMaV", "CHEMICAL", 6, 13], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 6, 13], ["bean", "ORGANISM", 32, 36], ["Phaseolus vulgaris", "ORGANISM", 38, 56], ["Solanum nigrum", "ORGANISM", 76, 90], ["TYLCMaV", "PROTEIN", 6, 13], ["bean", "SPECIES", 32, 36], ["Phaseolus vulgaris", "SPECIES", 38, 56], ["Solanum nigrum", "SPECIES", 76, 90], ["common bean", "SPECIES", 25, 36], ["Phaseolus vulgaris", "SPECIES", 38, 56], ["Solanum nigrum", "SPECIES", 76, 90], ["TYLCMaV", "TREATMENT", 6, 13], ["common bean (Phaseolus vulgaris", "PROBLEM", 25, 56], ["Phaseolus vulgaris", "OBSERVATION", 38, 56], ["Solanum nigrum", "OBSERVATION", 76, 90]]], ["In contrast, TYLCSV cannot infect common bean and the accumulation of TYLCV is strongly impaired in S. nigrum , 2000 .", [["bean", "ANATOMY", 41, 45], ["TYLCSV", "CHEMICAL", 13, 19], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 13, 19], ["bean", "ORGANISM", 41, 45], ["TYLCV", "ORGANISM", 70, 75], ["S. nigrum", "ORGANISM", 100, 109], ["TYLCSV", "PROTEIN", 13, 19], ["bean", "SPECIES", 41, 45], ["S. nigrum", "SPECIES", 100, 109], ["TYLCSV", "SPECIES", 13, 19], ["bean", "SPECIES", 41, 45], ["TYLCV", "SPECIES", 70, 75], ["S. nigrum", "SPECIES", 100, 109], ["the accumulation of TYLCV", "PROBLEM", 50, 75], ["TYLCV", "OBSERVATION", 70, 75], ["impaired", "OBSERVATION_MODIFIER", 88, 96]]], ["None of the latter three viruses induce disease in tomato cultivars carrying the dominant Ty-1 resistance allele, which has been shown to limit the accumulation of TYLCV, TYLCSV and, to a lesser extent, TYLCMaV (Garc\u00eda-Andr\u00e9s et al., 2006 .INTRODUCTIONKnowing how hosts affect begomovirus diversity is important to understand the emergence of new begomovirus variants and to assist in designing more durable control strategies.", [["tomato", "ORGANISM", 51, 57], ["Ty-1", "GENE_OR_GENE_PRODUCT", 90, 94], ["TYLCV", "ORGANISM", 164, 169], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 171, 177], ["dominant Ty-1 resistance allele", "DNA", 81, 112], ["tomato", "SPECIES", 51, 57], ["tomato", "SPECIES", 51, 57], ["TYLCV", "SPECIES", 164, 169], ["disease in tomato cultivars", "PROBLEM", 40, 67], ["TYLCV", "PROBLEM", 164, 169], ["new begomovirus variants", "PROBLEM", 343, 367], ["durable control strategies", "TREATMENT", 400, 426], ["dominant", "OBSERVATION_MODIFIER", 81, 89], ["TYLCV", "OBSERVATION", 164, 169], ["lesser extent", "OBSERVATION_MODIFIER", 188, 201]]], ["To this end we have monitored the genetic variability of TYLCV, TYLCSV, and TYLCMaV begomovirus mutant spectra for 45 days after the inoculation of susceptible and Ty-1 resistant tomato, common bean and the wild reservoir S. nigrum with single sequence variants of each virus.", [["Ty-1", "CHEMICAL", 164, 168], ["TYLCV", "ORGANISM", 57, 62], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 64, 70], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 76, 83], ["Ty-1", "ORGANISM", 164, 168], ["tomato", "ORGANISM", 179, 185], ["bean", "ORGANISM_SUBDIVISION", 194, 198], ["S. nigrum", "ORGANISM", 222, 231], ["tomato", "SPECIES", 179, 185], ["bean", "SPECIES", 194, 198], ["S. nigrum", "SPECIES", 222, 231], ["TYLCV", "SPECIES", 57, 62], ["Ty-1", "SPECIES", 164, 168], ["tomato", "SPECIES", 179, 185], ["bean", "SPECIES", 194, 198], ["S. nigrum", "SPECIES", 222, 231], ["TYLCV", "PROBLEM", 57, 62], ["TYLCSV", "TREATMENT", 64, 70], ["TYLCMaV begomovirus mutant spectra", "TREATMENT", 76, 110], ["the inoculation", "TEST", 129, 144], ["common bean", "PROBLEM", 187, 198], ["the wild reservoir S. nigrum", "TREATMENT", 203, 231], ["each virus", "PROBLEM", 265, 275]]], ["Our results show that the host can have an important role in driving the fitness and diversity of begomovirus mutant spectra.", [["begomovirus mutant", "ORGANISM", 98, 116], ["begomovirus mutant spectra", "PROBLEM", 98, 124]]], ["Differences in absolute fitness of begomovirus in the different hosts existed without any modifications in their consensus sequences.", [["begomovirus", "GENE_OR_GENE_PRODUCT", 35, 46], ["consensus sequences", "DNA", 113, 132], ["begomovirus", "PROBLEM", 35, 46], ["absolute fitness", "OBSERVATION", 15, 31], ["begomovirus", "OBSERVATION", 35, 46]]], ["However, quasispecies with high complexity and heterogeneity existed in all four hosts, especially in common bean and the wild host.", [["bean", "ORGANISM_SUBDIVISION", 109, 113], ["bean", "SPECIES", 109, 113], ["bean", "SPECIES", 109, 113], ["quasispecies", "PROBLEM", 9, 21], ["high complexity", "PROBLEM", 27, 42], ["quasispecies", "OBSERVATION", 9, 21], ["high complexity", "OBSERVATION_MODIFIER", 27, 42], ["heterogeneity", "OBSERVATION_MODIFIER", 47, 60], ["all four hosts", "OBSERVATION_MODIFIER", 72, 86], ["common bean", "ANATOMY", 102, 113]]], ["Interestingly, the presence or absence of the Ty-1 resistance allele in tomato did not lead to differences in begomovirus mutant spectra.", [["Ty-1", "GENE_OR_GENE_PRODUCT", 46, 50], ["tomato", "ORGANISM", 72, 78], ["Ty-1 resistance allele", "DNA", 46, 68], ["tomato", "SPECIES", 72, 78], ["tomato", "SPECIES", 72, 78], ["the Ty-1 resistance allele in tomato", "PROBLEM", 42, 78], ["begomovirus mutant spectra", "PROBLEM", 110, 136]]], ["However, in tomato CP mutation frequency of TYLCSV and TYLCV increased at 45 dpi, which may be related to their fitness decrease in this host.", [["tomato CP", "ORGANISM", 12, 21], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 44, 50], ["TYLCV", "ORGANISM", 55, 60], ["tomato", "SPECIES", 12, 18], ["tomato", "SPECIES", 12, 18], ["TYLCV", "SPECIES", 55, 60], ["TYLCSV", "TREATMENT", 44, 50], ["TYLCV", "PROBLEM", 55, 60]]], ["In the wild host TYLCMaV displayed lower fitness than in the other hosts and actively explored Rep ORF but not the overlapping C4.", [["TYLCMaV", "GENE_OR_GENE_PRODUCT", 17, 24], ["Rep", "GENE_OR_GENE_PRODUCT", 95, 98], ["Rep ORF", "DNA", 95, 102], ["C4", "DNA", 127, 129], ["lower fitness", "PROBLEM", 35, 48], ["lower", "OBSERVATION_MODIFIER", 35, 40], ["fitness", "OBSERVATION", 41, 48]]], ["Our findings underline the great complexity and heterogeneity of begomovirus mutant spectra and that differences might exist between host plants.", [["begomovirus mutant", "ORGANISM", 65, 83], ["begomovirus mutant spectra", "PROBLEM", 65, 91], ["great complexity", "OBSERVATION_MODIFIER", 27, 43], ["heterogeneity", "OBSERVATION_MODIFIER", 48, 61], ["begomovirus mutant spectra", "OBSERVATION", 65, 91]]], ["This is particularly relevant for the wild reservoir, which hosts a highly diverse begomovirus population containing potentially emergent variants in spite of the stability of their quasispecies consensus sequences.Plants, Virus Source, and Viral InoculationHomozygous TYLCD susceptible (ty-1/ty-1) and heterozygous TYLCD resistant (Ty-1/ty-1) tomato quasi-isogenic lines (Navas-Castillo et al., 1999), and [ES:421:99] of TYLCMaV (AF271234) (Noris et al., 1994) .", [["Virus", "ORGANISM", 223, 228], ["ty-1/ty-1", "GENE_OR_GENE_PRODUCT", 288, 297], ["quasispecies consensus sequences", "DNA", 182, 214], ["tomato quasi-isogenic lines", "CELL_LINE", 344, 371], ["tomato", "SPECIES", 344, 350], ["tomato", "SPECIES", 344, 350], ["a highly diverse begomovirus population", "PROBLEM", 66, 105], ["Virus Source", "TEST", 223, 235], ["Viral InoculationHomozygous TYLCD", "TEST", 241, 274], ["heterozygous TYLCD resistant", "PROBLEM", 303, 331], ["Navas", "TEST", 373, 378], ["TYLCMaV", "TEST", 422, 429], ["reservoir", "OBSERVATION_MODIFIER", 43, 52], ["highly", "OBSERVATION_MODIFIER", 68, 74], ["diverse", "OBSERVATION_MODIFIER", 75, 82], ["begomovirus", "OBSERVATION", 83, 94], ["quasi-isogenic lines", "OBSERVATION", 351, 371]]], ["These isolates were derived from infected tomato plants except for TYLCMaV, which was derived from an infected common bean plant.", [["TYLCMaV", "CHEMICAL", 67, 74], ["tomato", "ORGANISM", 42, 48], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 67, 74], ["bean", "ORGANISM", 118, 122], ["tomato", "SPECIES", 42, 48], ["bean", "SPECIES", 118, 122], ["tomato", "SPECIES", 42, 48], ["bean", "SPECIES", 118, 122], ["These isolates", "TREATMENT", 0, 14], ["infected tomato plants", "TREATMENT", 33, 55], ["TYLCMaV", "TREATMENT", 67, 74], ["infected", "OBSERVATION_MODIFIER", 102, 110], ["common", "OBSERVATION_MODIFIER", 111, 117], ["bean plant", "OBSERVATION", 118, 128]]], ["TYLCMaV is the result of a genetic exchange between TYLCV-Mld and TYLCSV-ES, with recombinant genome sequences that share 99% nucleotide identity with that of the parental virus sequences.", [["nucleotide", "CHEMICAL", 126, 136], ["nucleotide", "CHEMICAL", 126, 136], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 0, 7], ["TYLCV", "ORGANISM", 52, 57], ["Mld", "GENE_OR_GENE_PRODUCT", 58, 61], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 66, 72], ["TYLCV-Mld and TYLCSV-ES", "DNA", 52, 75], ["recombinant genome sequences", "DNA", 82, 110], ["parental virus sequences", "DNA", 163, 187], ["the parental virus sequences", "TEST", 159, 187], ["Mld", "ANATOMY", 58, 61]]], ["As depicted in Figure 1 in TYLCMaV, the 3 \u2032 half of the IR and the virus sense V2 and the CP ORFs derive from TYLCSV, whereas the remainder 5 \u2032 half of the IR and the Rep, C4, TrAP and most of REn ORFs derive from TYLCV, with the 3 \u2032 terminal 40 nucleotides of the REn ORF derived from TYLCSV .", [["V2", "GENE_OR_GENE_PRODUCT", 79, 81], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 110, 116], ["Rep", "GENE_OR_GENE_PRODUCT", 167, 170], ["C4", "GENE_OR_GENE_PRODUCT", 172, 174], ["TrAP", "GENE_OR_GENE_PRODUCT", 176, 180], ["REn", "GENE_OR_GENE_PRODUCT", 193, 196], ["TYLCV", "ORGANISM", 214, 219], ["IR and the virus sense V2 and the CP ORFs", "DNA", 56, 97], ["TYLCSV", "DNA", 110, 116], ["IR", "DNA", 156, 158], ["Rep", "DNA", 167, 170], ["C4", "DNA", 172, 174], ["TrAP", "DNA", 176, 180], ["REn ORFs", "DNA", 193, 201], ["3 \u2032 terminal 40 nucleotides", "DNA", 230, 257], ["REn ORF", "DNA", 265, 272], ["TYLCSV", "DNA", 286, 292], ["TYLCV", "SPECIES", 214, 219], ["the IR", "TREATMENT", 52, 58], ["the virus sense V2", "PROBLEM", 63, 81], ["the CP ORFs", "PROBLEM", 86, 97], ["TrAP", "TREATMENT", 176, 180], ["REn ORFs", "PROBLEM", 193, 201], ["TYLCV", "PROBLEM", 214, 219], ["the 3 \u2032 terminal 40 nucleotides", "TREATMENT", 226, 257]]], ["Viral infectious clones of TYLCSV, TYLCV or TYLCMaV were used to inoculate three plants each of a TYLCD-susceptible tomato, a quasi-isogenic resistant tomato containing the Ty-1 allele in heterozygosis, common bean and S. nigrum (Figure 1) .", [["TYLCD", "CHEMICAL", 98, 103], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 27, 33], ["TYLCV", "ORGANISM", 35, 40], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 44, 51], ["TYLCD", "GENE_OR_GENE_PRODUCT", 98, 103], ["tomato", "ORGANISM", 116, 122], ["tomato", "ORGANISM", 151, 157], ["Ty-1", "GENE_OR_GENE_PRODUCT", 173, 177], ["bean", "ORGANISM_SUBDIVISION", 210, 214], ["S. nigrum", "ORGANISM", 219, 228], ["Ty-1 allele", "DNA", 173, 184], ["tomato", "SPECIES", 116, 122], ["tomato", "SPECIES", 151, 157], ["bean", "SPECIES", 210, 214], ["S. nigrum", "SPECIES", 219, 228], ["TYLCSV", "SPECIES", 27, 33], ["TYLCV", "SPECIES", 35, 40], ["TYLCMaV", "SPECIES", 44, 51], ["tomato", "SPECIES", 116, 122], ["tomato", "SPECIES", 151, 157], ["bean", "SPECIES", 210, 214], ["S. nigrum", "SPECIES", 219, 228], ["Viral infectious clones of TYLCSV", "PROBLEM", 0, 33], ["TYLCV", "PROBLEM", 35, 40], ["TYLCMaV", "TREATMENT", 44, 51], ["a quasi-isogenic resistant tomato", "PROBLEM", 124, 157], ["infectious", "OBSERVATION", 6, 16], ["common bean", "ANATOMY", 203, 214]]], ["Liquid cultures of A. tumefaciens were adjusted to an OD 600 of 1.00 and 20 \u00b5l were inoculated to each plant by the stempuncture method as described elsewhere .", [["Liquid cultures", "ANATOMY", 0, 15], ["A. tumefaciens", "ORGANISM", 19, 33], ["A. tumefaciens", "SPECIES", 19, 33], ["A. tumefaciens", "SPECIES", 19, 33], ["Liquid cultures", "TEST", 0, 15], ["A. tumefaciens", "PROBLEM", 19, 33]]], ["After agroinoculation, plants were maintained for 45 days in a growth chamber (26 \u2022 C during the day and 18 \u2022 C at night, 70% relative humidity, with a 16 h photoperiod at 250 \u00b5mol s \u22121 m \u22122 photosynthetically active radiation).", [["a growth chamber", "TREATMENT", 61, 77], ["a 16 h photoperiod", "TREATMENT", 150, 168], ["photosynthetically active radiation", "TREATMENT", 191, 226]]], ["Systemic virus infection of agroinoculated plants was confirmed on young noninoculated leaves by tissue-print hybridization using a mixture of digoxigenin (DIG)-labeled probes specific to TYLCV and TYLCSV that also recognizes TYLCMaV.DNA Extraction, Virus Amplification, Cloning, and SequencingTo monitor quasispecies in each infected plant, young apical leaves were harvested at 15, 30, and 45 dpi (Figure 1 ) and lyophilized.", [["leaves", "ANATOMY", 87, 93], ["tissue", "ANATOMY", 97, 103], ["apical leaves", "ANATOMY", 348, 361], ["Systemic virus infection", "DISEASE", 0, 24], ["digoxigenin", "CHEMICAL", 143, 154], ["DIG", "CHEMICAL", 156, 159], ["digoxigenin", "CHEMICAL", 143, 154], ["tissue", "TISSUE", 97, 103], ["digoxigenin", "SIMPLE_CHEMICAL", 143, 154], ["DIG", "SIMPLE_CHEMICAL", 156, 159], ["TYLCV", "ORGANISM", 188, 193], ["TYLCSV", "DNA", 198, 204], ["TYLCMaV.DNA", "PROTEIN", 226, 237], ["TYLCV", "SPECIES", 188, 193], ["TYLCSV", "SPECIES", 198, 204], ["Systemic virus infection of agroinoculated plants", "PROBLEM", 0, 49], ["digoxigenin (DIG)", "TREATMENT", 143, 160], ["TYLCV and TYLCSV", "TREATMENT", 188, 204], ["TYLCMaV.DNA Extraction", "TREATMENT", 226, 248], ["Virus Amplification", "TREATMENT", 250, 269], ["quasispecies", "PROBLEM", 305, 317], ["virus", "OBSERVATION", 9, 14], ["apical", "ANATOMY_MODIFIER", 348, 354], ["leaves", "ANATOMY", 355, 361]]], ["DNA was extracted following the Edwards' procedure (Edwards et al., 1991) with some modifications.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["the Edwards' procedure", "TREATMENT", 28, 50]]], ["From each sample, 8 mg of dried tissue were ground in a 1.5 ml Eppendorf tube with liquid nitrogen, and 400 \u00b5l of extraction buffer [200 mM Tris-HCl, 200 mM NaCl, 25 mM EDTA, SDS 0.5% (w/v), pH 7.5, 0.1% \u03b2-mercaptoethanol] added.", [["sample", "ANATOMY", 10, 16], ["tissue", "ANATOMY", 32, 38], ["Tris-HCl", "CHEMICAL", 140, 148], ["NaCl", "CHEMICAL", 157, 161], ["\u03b2-mercaptoethanol", "CHEMICAL", 204, 221], ["nitrogen", "CHEMICAL", 90, 98], ["Tris-HCl", "CHEMICAL", 140, 148], ["NaCl", "CHEMICAL", 157, 161], ["EDTA", "CHEMICAL", 169, 173], ["SDS", "CHEMICAL", 175, 178], ["\u03b2-mercaptoethanol", "CHEMICAL", 204, 221], ["tissue", "TISSUE", 32, 38], ["Tris-HCl", "SIMPLE_CHEMICAL", 140, 148], ["EDTA", "SIMPLE_CHEMICAL", 169, 173], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 204, 221], ["dried tissue", "PROBLEM", 26, 38], ["a 1.5 ml Eppendorf tube with liquid nitrogen", "TREATMENT", 54, 98], ["extraction buffer", "TREATMENT", 114, 131], ["Tris", "TEST", 140, 144], ["SDS", "TEST", 175, 178], ["pH", "TEST", 191, 193]]], ["After vortexing at 37 \u2022 C for 2 min extracts were centrifuged at 12,000 \u00d7 g at room temperature for 5 min.", [["extracts", "ANATOMY", 36, 44], ["extracts", "ORGANISM_SUBSTANCE", 36, 44]]], ["The supernatants were transferred to a new tube and mixed with 1 volume of phenol:chloroform (1:1).", [["supernatants", "ANATOMY", 4, 16], ["phenol:chloroform", "CHEMICAL", 75, 92], ["phenol", "CHEMICAL", 75, 81], ["chloroform", "CHEMICAL", 82, 92], ["tube", "TISSUE", 43, 47], ["phenol", "SIMPLE_CHEMICAL", 75, 81], ["chloroform", "SIMPLE_CHEMICAL", 82, 92], ["a new tube", "TREATMENT", 37, 47], ["1 volume of phenol:chloroform", "TREATMENT", 63, 92], ["tube", "OBSERVATION", 43, 47]]], ["The aqueous phase was transferred to a new tube and mixed with 1 volume of isopropanol.", [["isopropanol", "CHEMICAL", 75, 86], ["isopropanol", "CHEMICAL", 75, 86], ["tube", "TISSUE", 43, 47], ["isopropanol", "SIMPLE_CHEMICAL", 75, 86], ["a new tube", "TREATMENT", 37, 47], ["1 volume of isopropanol", "TREATMENT", 63, 86], ["aqueous", "OBSERVATION_MODIFIER", 4, 11], ["phase", "OBSERVATION_MODIFIER", 12, 17], ["tube", "OBSERVATION", 43, 47]]], ["After 2 min at room temperature, nucleic acids were recovered by centrifugation at 12,000 \u00d7 g at room temperature for 5 min.", [["nucleic acids", "CHEMICAL", 33, 46], ["nucleic acids", "SIMPLE_CHEMICAL", 33, 46], ["nucleic acids", "TEST", 33, 46]]], ["The pellet was washed with 70% ethanol, dried and resuspended in 200 \u00b5l of RTE buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA pH 8.0, 0.1% RNase A) by incubation at 65 \u2022 C for 10 min.", [["pellet", "ANATOMY", 4, 10], ["ethanol", "CHEMICAL", 31, 38], ["Tris-HCl", "CHEMICAL", 93, 101], ["ethanol", "CHEMICAL", 31, 38], ["Tris-HCl", "CHEMICAL", 93, 101], ["EDTA", "CHEMICAL", 116, 120], ["ethanol", "SIMPLE_CHEMICAL", 31, 38], ["The pellet", "TREATMENT", 0, 10], ["RTE buffer", "TREATMENT", 75, 85], ["Tris", "TEST", 93, 97], ["pH", "TEST", 102, 104], ["mM EDTA pH", "TEST", 113, 123], ["pellet", "OBSERVATION", 4, 10]]], ["Viral DNA from total DNA extracts was amplified by rollingcircle amplification (RCA) with \u03c6 29 DNA polymerase according to Inoue-Nagata et al. (Inoue-Nagata et al., 2004) using the TempliPhi DNA Amplification Kit (GE Healthcare).", [["extracts", "ANATOMY", 25, 33], ["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["extracts", "ORGANISM_SUBSTANCE", 25, 33], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["DNA", "CELLULAR_COMPONENT", 191, 194], ["Viral DNA", "DNA", 0, 9], ["\u03c6 29 DNA polymerase", "PROTEIN", 90, 109], ["Viral DNA", "PROBLEM", 0, 9], ["total DNA extracts", "TREATMENT", 15, 33], ["\u03c6 29 DNA polymerase", "TREATMENT", 90, 109], ["the TempliPhi DNA Amplification Kit (GE Healthcare", "TREATMENT", 177, 227], ["RCA", "ANATOMY", 80, 83]]], ["For all samples, 400 to 500 ng/\u00b5l of the amplification product measured by UV-spectrophotometry and gel electrophoresis were obtained.", [["samples", "ANATOMY", 8, 15], ["the amplification product", "TREATMENT", 37, 62], ["UV-spectrophotometry", "TEST", 75, 95], ["gel electrophoresis", "TEST", 100, 119]]], ["Full-lenght genomic consensus sequences were obtained by direct sequencing (Macrogen Inc., South Korea) of RCA products amplified from total DNA extractions.", [["DNA", "CELLULAR_COMPONENT", 141, 144], ["-lenght genomic consensus sequences", "DNA", 4, 39], ["RCA products", "DNA", 107, 119], ["RCA products", "TREATMENT", 107, 119], ["total DNA extractions", "TREATMENT", 135, 156], ["RCA", "ANATOMY", 107, 110]]], ["Primers used to sequence consensus sequences of TYLCSV, TYLCV, and TYLCMaV are indicated in Table 1 .", [["TYLCSV", "GENE_OR_GENE_PRODUCT", 48, 54], ["TYLCV", "ORGANISM", 56, 61], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 67, 74], ["TYLCSV", "DNA", 48, 54], ["TYLCV", "DNA", 56, 61], ["TYLCMaV", "DNA", 67, 74], ["TYLCV", "SPECIES", 56, 61], ["sequence consensus sequences", "TEST", 16, 44], ["TYLCSV", "TEST", 48, 54], ["TYLCV", "ANATOMY", 56, 61]]], ["Sanger sequencing was preferred over NGS due to the difficulty of the latter to discriminate between the error of the technology and the error rate of the viruses, which is paramount for quasispecies analysis.DNA Extraction, Virus Amplification, Cloning, and SequencingRCA products were digested with single cutter (in viral genome) restriction enzyme BamHI to obtain the linear fulllength DNA (c.", [["DNA", "CELLULAR_COMPONENT", 209, 212], ["BamHI", "GENE_OR_GENE_PRODUCT", 352, 357], ["DNA", "CELLULAR_COMPONENT", 390, 393], ["SequencingRCA products", "PROTEIN", 259, 281], ["single cutter (in viral genome", "DNA", 301, 331], ["restriction enzyme BamHI", "DNA", 333, 357], ["linear fulllength DNA", "DNA", 372, 393], ["Sanger sequencing", "TEST", 0, 17], ["NGS", "TEST", 37, 40], ["the viruses", "PROBLEM", 151, 162], ["quasispecies analysis", "TEST", 187, 208], ["DNA Extraction", "TREATMENT", 209, 223], ["Virus Amplification", "TREATMENT", 225, 244], ["Cloning, and SequencingRCA products", "TREATMENT", 246, 281], ["single cutter (in viral genome) restriction enzyme BamHI", "TREATMENT", 301, 357], ["the linear fulllength DNA", "PROBLEM", 368, 393], ["viruses", "OBSERVATION", 155, 162]]], ["2.7 kbp) that was subsequently cloned into pBluescript II SK (+) (Stratagene).", [["pBluescript II SK", "GENE_OR_GENE_PRODUCT", 43, 60], ["pBluescript II SK (+) (Stratagene", "DNA", 43, 76], ["kbp", "TEST", 4, 7]]], ["The product obtained was transformed into Escherichia coli DH5\u03b1 by electroporation.", [["Escherichia coli", "ORGANISM", 42, 58], ["DH5\u03b1", "GENE_OR_GENE_PRODUCT", 59, 63], ["Escherichia coli DH5\u03b1", "PROTEIN", 42, 63], ["Escherichia coli", "SPECIES", 42, 58], ["Escherichia coli", "SPECIES", 42, 58], ["Escherichia coli", "OBSERVATION", 42, 58]]], ["Transformed colonies were analyzed by PCR using the universal M13 primers (Table 1) .", [["colonies", "ANATOMY", 12, 20], ["Transformed colonies", "CELL", 0, 20], ["M13 primers", "DNA", 62, 73], ["PCR", "TEST", 38, 41], ["the universal M13 primers", "TREATMENT", 48, 73], ["colonies", "OBSERVATION", 12, 20]]], ["Only those clones containing inserts representing the 2.7 kbp full-length genome size were selected for the study.", [["2.7 kbp full-length genome", "DNA", 54, 80], ["the 2.7 kbp full-length genome size", "TREATMENT", 50, 85], ["the study", "TEST", 104, 113], ["clones", "OBSERVATION", 11, 17], ["size", "OBSERVATION_MODIFIER", 81, 85]]], ["Amplification of molecular clones was also performed FIGURE 1 | Time-course infections of tomato yellow leaf curl Sardinia virus (TYLCSV), tomato yellow leaf curl virus (TYLCV) and tomato yellow leaf curl Malaga virus (TYLCMaV) infectious clones in susceptible tomato, resistant tomato, common bean and the wild reservoir Solanum nigrum.", [["clones", "ANATOMY", 239, 245], ["infections", "DISEASE", 76, 86], ["tomato", "ORGANISM", 90, 96], ["yellow leaf curl Sardinia virus", "ORGANISM", 97, 128], ["TYLCSV", "ORGANISM", 130, 136], ["tomato yellow leaf curl virus", "ORGANISM", 139, 168], ["TYLCV", "ORGANISM", 170, 175], ["tomato yellow leaf curl Malaga virus", "ORGANISM", 181, 217], ["TYLCMaV", "ORGANISM", 219, 226], ["tomato", "ORGANISM", 261, 267], ["tomato", "ORGANISM_SUBDIVISION", 279, 285], ["bean", "ORGANISM_SUBDIVISION", 294, 298], ["Solanum nigrum", "ORGANISM", 322, 336], ["tomato", "SPECIES", 90, 96], ["yellow leaf", "SPECIES", 97, 108], ["curl Sardinia virus", "SPECIES", 109, 128], ["tomato", "SPECIES", 139, 145], ["yellow leaf curl virus", "SPECIES", 146, 168], ["TYLCV", "SPECIES", 170, 175], ["tomato", "SPECIES", 181, 187], ["yellow leaf curl", "SPECIES", 188, 204], ["Malaga virus", "SPECIES", 205, 217], ["tomato", "SPECIES", 261, 267], ["tomato", "SPECIES", 279, 285], ["bean", "SPECIES", 294, 298], ["Solanum nigrum", "SPECIES", 322, 336], ["tomato yellow leaf curl Sardinia virus", "SPECIES", 90, 128], ["TYLCSV", "SPECIES", 130, 136], ["tomato yellow leaf curl virus", "SPECIES", 139, 168], ["TYLCV", "SPECIES", 170, 175], ["tomato yellow leaf curl Malaga virus", "SPECIES", 181, 217], ["TYLCMaV", "SPECIES", 219, 226], ["tomato", "SPECIES", 261, 267], ["tomato", "SPECIES", 279, 285], ["bean", "SPECIES", 294, 298], ["Solanum nigrum", "SPECIES", 322, 336], ["tomato yellow leaf curl Sardinia virus (TYLCSV)", "PROBLEM", 90, 137], ["tomato yellow leaf curl virus", "PROBLEM", 139, 168], ["tomato yellow leaf curl Malaga virus (TYLCMaV) infectious clones", "PROBLEM", 181, 245], ["resistant tomato", "PROBLEM", 269, 285], ["common bean", "PROBLEM", 287, 298], ["molecular clones", "OBSERVATION", 17, 33], ["Solanum nigrum", "OBSERVATION", 322, 336]]], ["Genomic organization of the viruses showing the two open reading frames (ORFs), V2, and CP, on the sense strand, and four ORFs, Rep, TrAP, REn, and C4, on the complementary sense strand.", [["Rep", "GENE_OR_GENE_PRODUCT", 128, 131], ["TrAP", "GENE_OR_GENE_PRODUCT", 133, 137], ["REn", "GENE_OR_GENE_PRODUCT", 139, 142], ["open reading frames", "DNA", 52, 71], ["ORFs", "DNA", 73, 77], ["V2", "DNA", 80, 82], ["CP", "DNA", 88, 90], ["ORFs", "DNA", 122, 126], ["Rep", "DNA", 128, 131], ["TrAP", "DNA", 133, 137], ["REn", "DNA", 139, 142], ["C4", "DNA", 148, 150], ["complementary sense strand", "DNA", 159, 185], ["Genomic organization of the viruses", "PROBLEM", 0, 35], ["ORFs", "TEST", 73, 77], ["CP", "PROBLEM", 88, 90], ["the sense strand", "TEST", 95, 111], ["four ORFs", "TEST", 117, 126], ["TrAP, REn, and C4", "PROBLEM", 133, 150], ["viruses", "OBSERVATION", 28, 35], ["V2", "ANATOMY", 80, 82], ["CP", "OBSERVATION_MODIFIER", 88, 90], ["C4", "ANATOMY", 148, 150]]], ["They are separated by an intergenic non-coding region (IR) that contains the origin of replication in a region that adopts a stem-loop structure.", [["intergenic non-coding region", "DNA", 25, 53], ["IR", "DNA", 55, 57], ["intergenic", "OBSERVATION_MODIFIER", 25, 35], ["non-coding", "OBSERVATION_MODIFIER", 36, 46], ["region", "OBSERVATION_MODIFIER", 47, 53], ["origin", "OBSERVATION_MODIFIER", 77, 83], ["replication", "OBSERVATION", 87, 98], ["stem", "OBSERVATION_MODIFIER", 125, 129], ["loop structure", "OBSERVATION", 130, 144]]], ["Infectious clones and therefore single sequence variants of TYLCSV (black), TYLCV (gray) and recombinant TYLCMaV were used to inoculate three plants each of test hosts: susceptible (ST) and resistant (RT, carrying the Ty-1 resistance allele in heterozygosis) quasi-isogenic tomato plants, common bean (CB) and the wild reservoir S. nigrum (SN).", [["clones", "ANATOMY", 11, 17], ["SN", "ANATOMY", 340, 342], ["Infectious clones", "CELL", 0, 17], ["TYLCSV (black)", "ORGANISM", 60, 74], ["TYLCV (gray)", "ORGANISM", 76, 88], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 105, 112], ["Ty-1", "GENE_OR_GENE_PRODUCT", 218, 222], ["tomato", "ORGANISM", 274, 280], ["bean", "ORGANISM_SUBDIVISION", 296, 300], ["S. nigrum", "ORGANISM", 329, 338], ["SN", "CANCER", 340, 342], ["recombinant TYLCMaV", "PROTEIN", 93, 112], ["Ty-1 resistance allele", "DNA", 218, 240], ["TYLCV", "SPECIES", 76, 81], ["tomato", "SPECIES", 274, 280], ["bean", "SPECIES", 296, 300], ["S. nigrum", "SPECIES", 329, 338], ["TYLCV", "SPECIES", 76, 81], ["tomato", "SPECIES", 274, 280], ["bean", "SPECIES", 296, 300], ["S. nigrum", "SPECIES", 329, 338], ["Infectious clones", "PROBLEM", 0, 17], ["single sequence variants", "TEST", 32, 56], ["TYLCSV (black), TYLCV (gray)", "TREATMENT", 60, 88], ["recombinant TYLCMaV", "TREATMENT", 93, 112], ["susceptible (ST) and resistant (RT", "PROBLEM", 169, 203], ["quasi-isogenic tomato plants", "PROBLEM", 259, 287]]], ["Young apical non-inoculated leaves were collected at the indicated days post inoculation (dpi).DNA Extraction, Virus Amplification, Cloning, and Sequencingusing RCA before sequencing.", [["leaves", "ANATOMY", 28, 34], ["leaves", "ORGAN", 28, 34], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["Sequencingusing RCA", "DNA", 145, 164], ["Young apical non-inoculated leaves", "PROBLEM", 0, 34], ["DNA Extraction", "TREATMENT", 95, 109], ["Virus Amplification", "TREATMENT", 111, 130], ["apical", "ANATOMY_MODIFIER", 6, 12], ["non-inoculated leaves", "OBSERVATION", 13, 34]]], ["A total of 18-22 clones were sequenced per mutant spectrum from a single plant.", [["clones", "CELL", 17, 23], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Primers MA863 and M13 UNIV (-) were used for all virus isolates ( Table 1) to sequence the 5 \u2032 -end of Rep and C4 ORFs, and the intergenic region (IR) on the C strand.", [["MA863", "GENE_OR_GENE_PRODUCT", 8, 13], ["UNIV", "GENE_OR_GENE_PRODUCT", 22, 26], ["Rep", "GENE_OR_GENE_PRODUCT", 103, 106], ["C4 ORFs", "GENE_OR_GENE_PRODUCT", 111, 118], ["M13 UNIV", "DNA", 18, 26], ["5 \u2032 -end", "DNA", 91, 99], ["Rep and C4 ORFs", "DNA", 103, 118], ["intergenic region", "DNA", 128, 145], ["IR", "DNA", 147, 149], ["C strand", "DNA", 158, 166], ["Primers", "TEST", 0, 7], ["M13 UNIV", "TEST", 18, 26], ["all virus isolates", "PROBLEM", 45, 63], ["Rep and C4 ORFs", "TREATMENT", 103, 118], ["the C strand", "TREATMENT", 154, 166], ["C4 ORFs", "ANATOMY", 111, 118]]], ["On the virus sense strand the sequenced region comprises the 5 \u2032 -end of the V2 ORF and the complete CP ORF.", [["5 \u2032 -end", "DNA", 61, 69], ["V2 ORF", "DNA", 77, 83], ["CP ORF", "DNA", 101, 107], ["the V2 ORF", "PROBLEM", 73, 83], ["the complete CP ORF", "PROBLEM", 88, 107], ["V2", "ANATOMY", 77, 79], ["complete", "OBSERVATION_MODIFIER", 92, 100], ["CP", "OBSERVATION_MODIFIER", 101, 103], ["ORF", "OBSERVATION", 104, 107]]], ["Primers MA1197, MA1198, and MA1199 were used for sequencing molecular clones of TYLCMaV, TYLCSV, and, TYLCV, respectively, whereas primer MA1365 was used for all of them.Sequence Analysis and Mutant Spectra CharacterizationEditSeq, SeqBuilder and SeqMan software (DNAStar Inc., USA) were used for sequence assembly and analysis.", [["MA1199", "GENE_OR_GENE_PRODUCT", 28, 34], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 80, 87], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 89, 95], ["TYLCV", "ORGANISM", 102, 107], ["MA1198", "DNA", 16, 22], ["MA1199", "DNA", 28, 34], ["TYLCMaV", "DNA", 80, 87], ["TYLCSV", "DNA", 89, 95], ["primer MA1365", "DNA", 131, 144], ["TYLCV", "SPECIES", 102, 107], ["Primers MA1197", "TEST", 0, 14], ["MA1198", "TEST", 16, 22], ["sequencing molecular clones of TYLCMaV", "PROBLEM", 49, 87], ["TYLCSV", "TEST", 89, 95], ["Sequence Analysis", "TEST", 170, 187], ["Mutant Spectra CharacterizationEditSeq", "TEST", 192, 230], ["SeqBuilder", "TEST", 232, 242], ["analysis", "TEST", 319, 327], ["TYLCV", "ANATOMY", 102, 107]]], ["Mutations were scored relative to the consensus sequence of each mutant spectrum.", [["consensus sequence", "DNA", 38, 56], ["Mutations", "PROBLEM", 0, 9]]], ["To analyze virus quasispecies genetic complexity (mutational composition of the ensemble) mutation frequencies were calculated by dividing the number of different mutations (repeated mutations in each quasispecies were computed only once) by the total number of nucleotides sequenced (Domingo et al., 2006) .", [["nucleotides", "CHEMICAL", 262, 273], ["analyze virus quasispecies genetic complexity", "PROBLEM", 3, 48], ["mutation frequencies", "PROBLEM", 90, 110], ["different mutations", "PROBLEM", 153, 172], ["repeated mutations in each quasispecies", "PROBLEM", 174, 213]]], ["Virus quasispecies genetic complexity was also assessed by analyzing the average genetic distance (d), defined as to the average number of mutations per site between any pair of sequences chosen at random from the population.", [["Virus", "ORGANISM", 0, 5], ["Virus quasispecies genetic complexity", "PROBLEM", 0, 37], ["mutations per site", "PROBLEM", 139, 157]]], ["Genetic distances were estimated for each genomic region by Kimura's two-parameter method (Kimura, 1980) in MEGA version 4 (Tamura et al., 2007) in the different host-begomovirus combinations at 15, 30, and 45 dpi.", [["genomic region", "DNA", 42, 56], ["Genetic distances", "PROBLEM", 0, 17], ["begomovirus combinations", "TREATMENT", 167, 191]]], ["Standard error was calculated by the bootstrap method with 1,000 repeats (Nei and Kumar, 2000) .Sequence Analysis and Mutant Spectra CharacterizationMutant spectra heterogeneity was determined using the normalized Shannon entropy (SE) calculation according to the formula \u2212 [ i (pi x lnpi)] / lnN], where pi is the frequency of each sequence in the mutant spectrum and N is the total number of sequences compared (Volkenstein, 1994) .", [["Sequence Analysis", "TEST", 96, 113], ["Mutant Spectra CharacterizationMutant spectra heterogeneity", "PROBLEM", 118, 177], ["the normalized Shannon entropy (SE) calculation", "TREATMENT", 199, 246], ["the formula \u2212 [ i (pi x lnpi)", "TREATMENT", 260, 289]]], ["SE values range from 0 (all sequences are identical) to 1 (all sequences are different).Sequence Analysis and Mutant Spectra CharacterizationTo analyze the effect of selection on mutant spectra the rate of substitutions per synonymous (d S ) and nonsynonymous (d NS ) site was estimated using the Pamilo-Bianchi-Li method (Pamilo and Bianchi, 1993) implemented in MEGA.", [["SE", "DISEASE", 0, 2], ["nonsynonymous (d NS ) site", "DNA", 246, 272], ["Sequence Analysis", "TEST", 88, 105], ["synonymous (d S )", "TREATMENT", 224, 241], ["nonsynonymous (d NS ) site", "TREATMENT", 246, 272], ["the Pamilo-Bianchi-Li method (Pamilo and Bianchi", "TREATMENT", 293, 341]]], ["The structuregenetic (SG) matrix of Feng et al. (1984) was used to obtain the acceptability values of amino acid changes found in each genomic coding region.", [["amino acid", "CHEMICAL", 102, 112], ["amino acid", "CHEMICAL", 102, 112], ["amino acid", "AMINO_ACID", 102, 112], ["genomic coding region", "DNA", 135, 156], ["amino acid changes", "PROBLEM", 102, 120]]], ["The values range from 0 (drastic amino acid changes) to 6 (synonymous replacements) and take into account structural similarities and probabilities of amino acid changes.", [["amino acid", "CHEMICAL", 33, 43], ["amino acid", "CHEMICAL", 151, 161], ["amino acid", "CHEMICAL", 33, 43], ["amino acid", "CHEMICAL", 151, 161], ["amino acid", "AMINO_ACID", 33, 43], ["amino acid", "AMINO_ACID", 151, 161], ["The values", "TEST", 0, 10], ["drastic amino acid changes", "TREATMENT", 25, 51], ["synonymous replacements", "TREATMENT", 59, 82], ["amino acid changes", "PROBLEM", 151, 169], ["amino acid", "OBSERVATION", 151, 161]]], ["The probability of occurrence of amino acid replacements found in quasispecies was calculated according to the PAM-250 substitution matrix (Feng and Doolittle, 1996) .", [["amino acid", "CHEMICAL", 33, 43], ["amino acid", "CHEMICAL", 33, 43], ["amino acid", "AMINO_ACID", 33, 43], ["amino acid replacements", "TREATMENT", 33, 56], ["quasispecies", "PROBLEM", 66, 78], ["amino acid replacements", "OBSERVATION", 33, 56]]], ["Mutations in overlapping genes were only considered for the computation of mutation types or the estimation of d, mutation frequency or Shannon entropy of each ORF but not of the entire sequenced zone.", [["overlapping genes", "DNA", 13, 30], ["ORF", "DNA", 160, 163], ["Mutations in overlapping genes", "PROBLEM", 0, 30], ["mutation types", "PROBLEM", 75, 89], ["d, mutation frequency", "PROBLEM", 111, 132], ["Shannon entropy of each ORF", "PROBLEM", 136, 163]]], ["Also, since the Rep and C4 ORFs are not in frame, neither V2 and CP, the resulting amino acid changes in the overlapping sequence were considered for the d NS /d S calculation.Sequence Analysis and Mutant Spectra CharacterizationThe statistical significance of differences in ORF mutation frequencies between samples was evaluated by a generalized linear model with logit link function assuming a binary distribution, and followed by post hoc analysis of pairwise comparisons with least square (LSD) correction to test for differences between treatments, using IBM SPSS Statistics v. 22 software (P < 0.05 was considered statistically significant).", [["samples", "ANATOMY", 309, 316], ["amino acid", "CHEMICAL", 83, 93], ["amino acid", "CHEMICAL", 83, 93], ["Rep", "GENE_OR_GENE_PRODUCT", 16, 19], ["amino acid", "AMINO_ACID", 83, 93], ["samples", "CANCER", 309, 316], ["Rep and C4 ORFs", "DNA", 16, 31], ["V2", "DNA", 58, 60], ["ORF", "DNA", 276, 279], ["the Rep and C4 ORFs", "TEST", 12, 31], ["CP", "PROBLEM", 65, 67], ["the resulting amino acid changes", "PROBLEM", 69, 101], ["the d NS /d S calculation", "TREATMENT", 150, 175], ["Sequence Analysis", "TEST", 176, 193], ["Mutant Spectra Characterization", "TEST", 198, 229], ["ORF mutation frequencies", "TEST", 276, 300], ["hoc analysis", "TEST", 439, 451], ["test", "TEST", 514, 518], ["treatments", "TREATMENT", 543, 553], ["not in", "UNCERTAINTY", 36, 42], ["amino acid", "OBSERVATION", 83, 93]]], ["To check for a random distribution of mutations in the overlapping Rep and C4 a Wald-Wolfowitz runs test was conducted.Viral Fitness DeterminationTo determine absolute fitness the accumulation ability of a virus genotype in a given host, that is, the number of viral genomes produced after a given time (per unit of total DNA extracted from the plant tissue) in apical leaves was measured.", [["tissue", "ANATOMY", 351, 357], ["apical leaves", "ANATOMY", 362, 375], ["Rep", "GENE_OR_GENE_PRODUCT", 67, 70], ["DNA", "CELLULAR_COMPONENT", 322, 325], ["tissue", "TISSUE", 351, 357], ["apical leaves", "MULTI-TISSUE_STRUCTURE", 362, 375], ["Rep", "DNA", 67, 70], ["C4", "DNA", 75, 77], ["viral genomes", "DNA", 261, 274], ["a random distribution of mutations", "PROBLEM", 13, 47], ["Wolfowitz runs test", "TEST", 85, 104], ["a virus genotype", "PROBLEM", 204, 220], ["viral genomes", "PROBLEM", 261, 274], ["total DNA", "TREATMENT", 316, 325], ["viral genomes", "OBSERVATION", 261, 274], ["plant tissue", "OBSERVATION", 345, 357], ["apical", "ANATOMY_MODIFIER", 362, 368], ["leaves", "ANATOMY_MODIFIER", 369, 375]]], ["Absolute fitness was approximated as the Malthusian growth rate per day, m, calculated according to the formula m = 1 t logQ, where Q is the number of pg of begomovirus ssDNA per 100 ng of total plant DNA (Lali\u0107 et al., 2011) , which is estimated from the qPCR determination of the accumulated viral load in the apical part of each plant being monitored during the 15 days that have elapsed between each collection time (15, 30, and 45 dpi).Viral Fitness DeterminationQuantification of viral DNA in test plants was carried out on total DNA extracts previously analyzed by agarose gel electrophoresis and UV-spectrophotometry (ND-1,000 spectrophotometer, NanoDrop, Fisher Thermo).", [["apical part", "ANATOMY", 312, 323], ["extracts", "ANATOMY", 540, 548], ["begomovirus", "CHEMICAL", 157, 168], ["DNA", "CELLULAR_COMPONENT", 201, 204], ["apical part", "MULTI-TISSUE_STRUCTURE", 312, 323], ["DNA", "CELLULAR_COMPONENT", 492, 495], ["DNA extracts", "ORGANISM_SUBSTANCE", 536, 548], ["agarose", "SIMPLE_CHEMICAL", 572, 579], ["viral DNA", "DNA", 486, 495], ["Absolute fitness", "PROBLEM", 0, 16], ["begomovirus ssDNA", "TREATMENT", 157, 174], ["total plant DNA", "TREATMENT", 189, 204], ["the qPCR", "TEST", 252, 260], ["the accumulated viral load", "PROBLEM", 278, 304], ["Viral Fitness", "PROBLEM", 441, 454], ["viral DNA in test plants", "PROBLEM", 486, 510], ["total DNA extracts", "TREATMENT", 530, 548], ["agarose gel electrophoresis", "TEST", 572, 599], ["UV-spectrophotometry (ND", "TREATMENT", 604, 628], ["NanoDrop", "TREATMENT", 654, 662], ["viral load", "OBSERVATION", 294, 304], ["apical", "ANATOMY_MODIFIER", 312, 318], ["viral DNA", "OBSERVATION", 486, 495]]], ["Quantification was done in triplicate with a final volume of 20 \u00b5l with SYBR Premix Ex Taq Perfect Real Time (Takara), 0.125 \u00b5M of specific primers and 10 ng of total DNA.", [["DNA", "CELLULAR_COMPONENT", 167, 170], ["Quantification", "TEST", 0, 14], ["SYBR Premix Ex Taq Perfect Real Time (Takara)", "TREATMENT", 72, 117], ["specific primers", "TREATMENT", 131, 147], ["total DNA", "TREATMENT", 161, 170]]], ["An amplicon of 169 bp within the Rep ORF of TYLCV and TYLCMaV was amplified with primers MA1508 and MA1509 (Table 1 ).", [["Rep", "GENE_OR_GENE_PRODUCT", 33, 36], ["TYLCV", "ORGANISM", 44, 49], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 54, 61], ["Rep ORF", "DNA", 33, 40], ["TYLCV", "DNA", 44, 49], ["TYLCMaV", "DNA", 54, 61], ["TYLCV", "SPECIES", 44, 49], ["An amplicon", "TEST", 0, 11], ["bp", "TEST", 19, 21], ["TYLCV and TYLCMaV", "TREATMENT", 44, 61], ["TYLCV", "OBSERVATION", 44, 49]]], ["In the case of TYLCSV, a fragment of 240 bp also in Rep was amplified with primers MA1506 and MA1507.", [["TYLCSV", "GENE_OR_GENE_PRODUCT", 15, 21], ["Rep", "GENE_OR_GENE_PRODUCT", 52, 55], ["TYLCSV", "DNA", 15, 21], ["Rep", "PROTEIN", 52, 55], ["a fragment", "PROBLEM", 23, 33], ["bp", "TEST", 41, 43], ["TYLCSV", "ANATOMY", 15, 21]]], ["PCR amplification was performed in an iCycler PCR System (BioRad) and consisted of an initial denaturation step at 95 \u2022 C for 30 s, followed by 40 cycles at 95 \u2022 C for 5 s and 60 \u2022 C for 34 s.", [["PCR amplification", "TEST", 0, 17], ["an initial denaturation step", "TREATMENT", 83, 111]]], ["Specificity of the amplified products was assessed by melting curve analysis.", [["the amplified products", "TREATMENT", 15, 37], ["melting curve analysis", "TEST", 54, 76]]], ["Data from total DNA plant extracts were normalized to the 25S ribosomal RNA gene amplified using primers 25S rRNA UNIV (+ and -) (Mason et al., 2008 ; Table 1) .", [["extracts", "ANATOMY", 26, 34], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["extracts", "ORGANISM_SUBSTANCE", 26, 34], ["25S", "CELLULAR_COMPONENT", 58, 61], ["ribosomal", "CELLULAR_COMPONENT", 62, 71], ["25S ribosomal RNA gene", "DNA", 58, 80], ["primers 25S rRNA UNIV", "DNA", 97, 118], ["total DNA plant extracts", "TREATMENT", 10, 34], ["primers", "TEST", 97, 104]]], ["To obtain the total number of ssDNA molecules, values were multiplied by two as each standard dsDNA molecule (a phagemid harbors the infectious clone) contains two ssDNAs (virion sense and complementary sense).Viral Fitness DeterminationFor the absolute quantification of TYLCV-like viruses, standard curves were prepared using pBluescript II SK (+) containing full-length viral genomes.", [["clone", "ANATOMY", 144, 149], ["SK", "CHEMICAL", 343, 345], ["clone", "CELL", 144, 149], ["ssDNAs", "GENE_OR_GENE_PRODUCT", 164, 170], ["TYLCV-like viruses", "ORGANISM", 272, 290], ["SK", "GENE_OR_GENE_PRODUCT", 343, 345], ["ssDNA molecules", "PROTEIN", 30, 45], ["dsDNA molecule", "PROTEIN", 94, 108], ["ssDNAs", "PROTEIN", 164, 170], ["pBluescript II SK (+) containing full-length viral genomes", "DNA", 328, 386], ["TYLCV", "SPECIES", 272, 277], ["a phagemid harbors", "TREATMENT", 110, 128], ["Viral Fitness Determination", "PROBLEM", 210, 237], ["TYLCV-like viruses", "PROBLEM", 272, 290], ["standard curves", "TEST", 292, 307], ["TYLCV", "OBSERVATION", 272, 277], ["viral genomes", "OBSERVATION", 373, 386]]], ["Phagemids were serially diluted tenfold in 5 ng/\u00b5l of DNA extracted from either noninoculated tomato, common bean or S. nigrum plants, to obtain 10 2 to 10 9 viral genome copies per \u00b5l.", [["Phagemids", "SIMPLE_CHEMICAL", 0, 9], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["tomato", "ORGANISM_SUBDIVISION", 94, 100], ["bean", "ORGANISM_SUBDIVISION", 109, 113], ["S. nigrum", "ORGANISM", 117, 126], ["viral genome copies", "DNA", 158, 177], ["tomato", "SPECIES", 94, 100], ["bean", "SPECIES", 109, 113], ["S. nigrum", "SPECIES", 117, 126], ["tomato", "SPECIES", 94, 100], ["bean", "SPECIES", 109, 113], ["S. nigrum", "SPECIES", 117, 126], ["Phagemids", "TREATMENT", 0, 9], ["DNA", "PROBLEM", 54, 57], ["S. nigrum plants", "PROBLEM", 117, 133]]], ["For each PCR system (primer pair and background host DNA), standard curves were obtained by linear regression analysis of the threshold cycle (Cq) values of three standard dilution replicates over the Log of the number of genome copies present in each sample.", [["sample", "ANATOMY", 252, 258], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["PCR system", "DNA", 9, 19], ["primer pair", "DNA", 21, 32], ["background host DNA", "DNA", 37, 56], ["each PCR system", "TEST", 4, 19], ["standard curves", "TEST", 59, 74], ["the threshold cycle", "TEST", 122, 141]]], ["A generalized linear model was fitted to the Malthusian growth rate and the log value of viral load data.", [["A generalized linear model", "PROBLEM", 0, 26], ["the Malthusian growth rate", "TEST", 41, 67], ["viral load data", "TEST", 89, 104], ["generalized", "OBSERVATION_MODIFIER", 2, 13], ["linear", "OBSERVATION_MODIFIER", 14, 20], ["viral load", "OBSERVATION", 89, 99]]], ["Post hoc analysis of pairwise comparisons via Bonferroni correction were used to test for differences between hosts at 45 dpi (P < 5.56 \u00d7 10 \u22123 ) or along the time course of viral infections (P < 0.010 or 6.25 \u00d7 10 \u22123 ).Host-Virus Interactions Determine Differences in Viral FitnessTo evaluate how the host affects the behavior of the different begomoviruses first we measured the viral load of the three begomoviruses in the four hosts.", [["viral infections", "DISEASE", 174, 190], ["Virus", "ORGANISM", 225, 230], ["Post hoc analysis", "TEST", 0, 17], ["P", "TEST", 127, 128], ["viral infections", "PROBLEM", 174, 190], ["Host-Virus Interactions", "TREATMENT", 220, 243], ["Viral Fitness", "PROBLEM", 269, 282], ["the different begomoviruses", "PROBLEM", 331, 358], ["viral", "OBSERVATION_MODIFIER", 174, 179], ["infections", "OBSERVATION", 180, 190], ["Virus", "OBSERVATION", 225, 230], ["viral load", "OBSERVATION", 381, 391]]], ["Under the conditions studied, no effective amplification was possible from young apical noninoculated leaves for TYLCSV in common bean or for TYLCV in S. nigrum.", [["leaves", "ANATOMY", 102, 108], ["TYLCSV", "CHEMICAL", 113, 119], ["TYLCSV", "SIMPLE_CHEMICAL", 113, 119], ["bean", "ORGANISM_SUBDIVISION", 130, 134], ["TYLCV", "ORGANISM", 142, 147], ["S. nigrum", "ORGANISM", 151, 160], ["bean", "SPECIES", 130, 134], ["S. nigrum", "SPECIES", 151, 160], ["TYLCSV", "SPECIES", 113, 119], ["bean", "SPECIES", 130, 134], ["TYLCV", "SPECIES", 142, 147], ["S. nigrum", "SPECIES", 151, 160], ["effective amplification", "PROBLEM", 33, 56], ["TYLCSV", "TREATMENT", 113, 119], ["TYLCV", "PROBLEM", 142, 147], ["apical", "ANATOMY_MODIFIER", 81, 87]]], ["As shown in Figure 2 , it was clear that the presence of the Ty-1 resistance allele repressed accumulation of TYLCSV, and TYLCV to some extent, whereas no such repression was observed for TYLCMaV.", [["Ty-1", "GENE_OR_GENE_PRODUCT", 61, 65], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 110, 116], ["Ty-1 resistance allele", "DNA", 61, 83], ["TYLCSV", "PROTEIN", 110, 116], ["TYLCMaV", "PROTEIN", 188, 195], ["TYLCV", "SPECIES", 122, 127], ["accumulation of TYLCSV", "PROBLEM", 94, 116], ["TYLCV", "PROBLEM", 122, 127], ["TYLCMaV", "PROBLEM", 188, 195], ["TYLCSV", "ANATOMY", 110, 116]]], ["Significantly higher TYLCV accumulation was observed in common bean at 45 dpi than in susceptible (510-fold; P = 0.005) or resistant (1 \u00d7 10 3fold; P = 0.000) tomato plants.", [["TYLCV", "ORGANISM", 21, 26], ["bean", "ORGANISM_SUBDIVISION", 63, 67], ["tomato", "ORGANISM", 159, 165], ["bean", "SPECIES", 63, 67], ["tomato", "SPECIES", 159, 165], ["TYLCV", "SPECIES", 21, 26], ["bean", "SPECIES", 63, 67], ["tomato", "SPECIES", 159, 165], ["Significantly higher TYLCV accumulation", "PROBLEM", 0, 39], ["P", "TEST", 109, 110], ["higher", "OBSERVATION_MODIFIER", 14, 20], ["TYLCV accumulation", "OBSERVATION", 21, 39]]], ["Also, significantly more TYLCSV molecules accumulated in the wild reservoir S. nigrum at 45 dpi than in susceptible (60-fold, P=0.005) or resistant (3.6 \u00d7 10 6 -fold, P=0.0004) tomatoes (Figure 2) .", [["TYLCSV", "GENE_OR_GENE_PRODUCT", 25, 31], ["S. nigrum", "ORGANISM", 76, 85], ["TYLCSV molecules", "PROTEIN", 25, 41], ["S. nigrum", "SPECIES", 76, 85], ["S. nigrum", "SPECIES", 76, 85], ["significantly more TYLCSV molecules", "PROBLEM", 6, 41], ["P", "TEST", 126, 127], ["P", "TEST", 167, 168], ["significantly", "OBSERVATION_MODIFIER", 6, 19], ["more", "OBSERVATION_MODIFIER", 20, 24], ["TYLCSV molecules", "OBSERVATION", 25, 41]]], ["Thus, TYLCV and TYLCSV infections in common bean and S. nigrum, respectively, resulted in the generation of larger virus populations suggesting higher viral fitness compared to tomato.", [["TYLCSV", "CHEMICAL", 16, 22], ["infections", "DISEASE", 23, 33], ["TYLCV", "ORGANISM", 6, 11], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 16, 22], ["bean", "ORGANISM_SUBDIVISION", 44, 48], ["S. nigrum", "ORGANISM", 53, 62], ["tomato", "ORGANISM", 177, 183], ["bean", "SPECIES", 44, 48], ["S. nigrum", "SPECIES", 53, 62], ["tomato", "SPECIES", 177, 183], ["TYLCV", "SPECIES", 6, 11], ["TYLCSV", "SPECIES", 16, 22], ["bean", "SPECIES", 44, 48], ["S. nigrum", "SPECIES", 53, 62], ["tomato", "SPECIES", 177, 183], ["TYLCV", "PROBLEM", 6, 11], ["TYLCSV infections", "PROBLEM", 16, 33], ["larger virus populations", "PROBLEM", 108, 132], ["higher viral fitness", "PROBLEM", 144, 164], ["TYLCV", "OBSERVATION", 6, 11], ["TYLCSV", "ANATOMY", 16, 22], ["infections", "OBSERVATION", 23, 33], ["larger", "OBSERVATION_MODIFIER", 108, 114], ["virus", "OBSERVATION", 115, 120], ["higher", "OBSERVATION_MODIFIER", 144, 150], ["viral fitness", "OBSERVATION", 151, 164]]], ["Our results also suggest better adaptation of TYLCMaV to common bean (with an accumulation level similar to TYLCV) than to S. nigrum (much lower accumulation than TYLCSV).Host-Virus Interactions Determine Differences in Viral FitnessTo better understand the effect of the different hosts on the three begomoviruses absolute fitness was assessed.", [["TYLCMaV", "CHEMICAL", 46, 53], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 46, 53], ["bean", "ORGANISM_SUBDIVISION", 64, 68], ["TYLCV", "ORGANISM", 108, 113], ["S. nigrum", "ORGANISM", 123, 132], ["Virus", "ORGANISM", 176, 181], ["S. nigrum", "SPECIES", 123, 132], ["bean", "SPECIES", 64, 68], ["TYLCV", "SPECIES", 108, 113], ["S. nigrum", "SPECIES", 123, 132], ["TYLCMaV to common bean", "PROBLEM", 46, 68], ["an accumulation level", "PROBLEM", 75, 96], ["S. nigrum", "PROBLEM", 123, 132], ["Host-Virus Interactions", "TREATMENT", 171, 194], ["Virus", "OBSERVATION", 176, 181]]], ["Since we used single-sequence variants as inoculum the Malthusian growth rate (m) during viral infection time-courses was calculated as an estimate for absolute fitness (Lali\u0107 et al., 2011) .", [["infection", "DISEASE", 95, 104], ["single-sequence variants", "TREATMENT", 14, 38], ["the Malthusian growth rate", "TEST", 51, 77], ["viral infection", "PROBLEM", 89, 104], ["infection", "OBSERVATION", 95, 104]]], ["The results shown in Figure 3 indicate differences in fitness across hosts during time-course infections.", [["infections", "DISEASE", 94, 104], ["course infections", "PROBLEM", 87, 104]]], ["The presence of the Ty-1 allele significantly restricted the growth rate of TYLCSV (P = 0.004) in apical leaves at 45 dpi, and of both TYLCSV and TYLCV during the time-course infection (P = 0.000).", [["apical leaves", "ANATOMY", 98, 111], ["infection", "DISEASE", 175, 184], ["Ty-1", "GENE_OR_GENE_PRODUCT", 20, 24], ["apical leaves", "MULTI-TISSUE_STRUCTURE", 98, 111], ["Ty-1 allele", "DNA", 20, 31], ["TYLCV", "SPECIES", 146, 151], ["infection", "PROBLEM", 175, 184], ["growth", "OBSERVATION_MODIFIER", 61, 67], ["apical", "ANATOMY_MODIFIER", 98, 104], ["both", "ANATOMY_MODIFIER", 130, 134], ["TYLCSV", "ANATOMY", 135, 141], ["TYLCV", "OBSERVATION", 146, 151]]], ["However, as previously shown , the presence of the Ty-1 resistance allele in tomato had no evident effect on TYLCMaV fitness at 45 dpi (P > 5.56 \u00d7 10 \u22123 ) or during the infection (P > 6.25 \u00d7 10 \u22123 ).", [["infection", "DISEASE", 169, 178], ["Ty-1", "GENE_OR_GENE_PRODUCT", 51, 55], ["tomato", "ORGANISM", 77, 83], ["Ty-1 resistance allele", "DNA", 51, 73], ["tomato", "SPECIES", 77, 83], ["tomato", "SPECIES", 77, 83], ["TYLCMaV fitness", "PROBLEM", 109, 124], ["P", "TEST", 136, 137], ["the infection", "PROBLEM", 165, 178], ["P", "TEST", 180, 181], ["no evident", "UNCERTAINTY", 88, 98], ["infection", "OBSERVATION", 169, 178]]], ["Despite being a recombinant of the former two viruses, TYLCMaV maintained similar fitness throughout the whole experiment in all four hosts (P > 6.25 \u00d7 10 \u22123 or 0.010).", [["TYLCMaV", "GENE_OR_GENE_PRODUCT", 55, 62], ["TYLCMaV", "TREATMENT", 55, 62], ["viruses", "OBSERVATION", 46, 53]]], ["Moreover, viral fitness in common bean and in S. nigrum was sustained along the experiment (P >0.010).", [["bean", "ANATOMY", 34, 38], ["bean", "ORGANISM_SUBDIVISION", 34, 38], ["S. nigrum", "ORGANISM", 46, 55], ["bean", "SPECIES", 34, 38], ["S. nigrum", "SPECIES", 46, 55], ["bean", "SPECIES", 34, 38], ["S. nigrum", "SPECIES", 46, 55], ["viral fitness in common bean", "PROBLEM", 10, 38], ["S. nigrum", "PROBLEM", 46, 55], ["viral fitness", "OBSERVATION", 10, 23], ["common bean", "ANATOMY", 27, 38], ["nigrum", "OBSERVATION", 49, 55]]], ["In summary, these results suggest better performance of TYLCV and TYLCSV in common bean and S. nigrum, respectively, whereas TYLCMaV accumulates similarly well in all hosts, including the resistant tomato.High Genetic Complexity and Heterogeneity of TYLCD-Associated Begomovirus QuasispeciesNext we analyzed the quasispecies complexity and heterogeneity of the three begomoviruses during the time-course infections.", [["TYLCSV", "CHEMICAL", 66, 72], ["TYLCMaV", "CHEMICAL", 125, 132], ["infections", "DISEASE", 404, 414], ["TYLCV", "ORGANISM", 56, 61], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 66, 72], ["bean", "ORGANISM_SUBDIVISION", 83, 87], ["S. nigrum", "ORGANISM", 92, 101], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 125, 132], ["tomato", "ORGANISM", 198, 204], ["TYLCMaV", "PROTEIN", 125, 132], ["bean", "SPECIES", 83, 87], ["S. nigrum", "SPECIES", 92, 101], ["tomato", "SPECIES", 198, 204], ["TYLCV", "SPECIES", 56, 61], ["bean", "SPECIES", 83, 87], ["S. nigrum", "SPECIES", 92, 101], ["tomato", "SPECIES", 198, 204], ["TYLCV", "PROBLEM", 56, 61], ["TYLCSV", "TREATMENT", 66, 72], ["the resistant tomato", "PROBLEM", 184, 204], ["High Genetic Complexity", "PROBLEM", 205, 228], ["Heterogeneity of TYLCD", "PROBLEM", 233, 255], ["Begomovirus Quasispecies", "PROBLEM", 267, 291], ["the quasispecies complexity", "PROBLEM", 308, 335], ["the three begomoviruses", "PROBLEM", 357, 380], ["infections", "PROBLEM", 404, 414], ["TYLCV", "OBSERVATION", 56, 61], ["Heterogeneity", "OBSERVATION_MODIFIER", 233, 246], ["Begomovirus Quasispecies", "OBSERVATION", 267, 291], ["heterogeneity", "OBSERVATION_MODIFIER", 340, 353], ["three", "OBSERVATION_MODIFIER", 361, 366], ["begomoviruses", "OBSERVATION", 367, 380]]], ["Specifically, viral quasispecies complexity refers to the composition of the mutant spectrum, which can be described both by mutation frequency and average genetic distance (d), whereas viral quasispecies heterogeneity refers to the proportion of different viral genomes in the mutant spectrum, as measured by Shannon entropy (Domingo et al., 2006) .", [["viral genomes", "DNA", 257, 270], ["viral quasispecies complexity", "PROBLEM", 14, 43], ["viral quasispecies heterogeneity", "PROBLEM", 186, 218], ["different viral genomes in the mutant spectrum", "PROBLEM", 247, 293], ["viral quasispecies", "OBSERVATION", 14, 32], ["viral quasispecies", "OBSERVATION", 186, 204], ["viral genomes", "OBSERVATION", 257, 270], ["mutant spectrum", "OBSERVATION_MODIFIER", 278, 293]]], ["DNA samples from one infected plant per virus/host combination at each time point, plus a replicate sample of each combination at 45 dpi, were subjected to rolling circle amplification (RCA) to specifically amplify circular DNA using the high-fidelity \u03d529 DNA polymerase with a reported error rate of 3-6 \u00d7 10 \u22126 (Esteban et al., 1993; Nelson et al., 2002) .", [["samples", "ANATOMY", 4, 11], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 224, 227], ["DNA", "CELLULAR_COMPONENT", 256, 259], ["circular DNA", "DNA", 215, 227], ["\u03d529 DNA polymerase", "PROTEIN", 252, 270], ["DNA samples", "TEST", 0, 11], ["circular DNA", "TEST", 215, 227], ["DNA polymerase", "TEST", 256, 270], ["error rate", "TEST", 287, 297]]], ["As a measure to reduce amplification bias we amplified 3-7 \u00d7 10 8 input viral molecules.", [["viral molecules", "PROTEIN", 72, 87], ["amplification bias", "PROBLEM", 23, 41]]], ["Sequences obtained for each begomovirus region were compared to the consensus sequence to determine mutation frequencies.High Genetic Complexity and Heterogeneity of TYLCD-Associated Begomovirus QuasispeciesDespite large variation among viruses, the highest mutation frequency values calculated for the whole sequenced region were detected in common bean and in S. nigrum ( Figure 4A) .", [["bean", "ORGANISM_SUBDIVISION", 350, 354], ["S. nigrum", "ORGANISM", 362, 371], ["begomovirus region", "DNA", 28, 46], ["consensus sequence", "DNA", 68, 86], ["bean", "SPECIES", 350, 354], ["S. nigrum", "SPECIES", 362, 371], ["bean", "SPECIES", 350, 354], ["S. nigrum", "SPECIES", 362, 371], ["Sequences", "TEST", 0, 9], ["each begomovirus region", "PROBLEM", 23, 46], ["the consensus sequence", "TEST", 64, 86], ["mutation frequencies", "PROBLEM", 100, 120], ["High Genetic Complexity", "PROBLEM", 121, 144], ["Heterogeneity of TYLCD", "PROBLEM", 149, 171], ["Begomovirus Quasispecies", "PROBLEM", 183, 207], ["large variation among viruses", "PROBLEM", 215, 244], ["the highest mutation frequency values", "TEST", 246, 283], ["Heterogeneity", "OBSERVATION_MODIFIER", 149, 162], ["Begomovirus Quasispecies", "OBSERVATION", 183, 207], ["large", "OBSERVATION_MODIFIER", 215, 220], ["variation", "OBSERVATION_MODIFIER", 221, 230], ["viruses", "OBSERVATION", 237, 244]]], ["When analyzed by genomic region, the mutation frequency of the quasispecies varied from <0.616 \u00d7 10 \u22124 to 8.91 \u00d7 10 \u22124 mutations/nt (mut/nt) ( Table 2) .", [["genomic region", "DNA", 17, 31], ["the quasispecies", "TEST", 59, 75]]], ["The most complex region was V2 (e.g., 8.91 \u00d7 10 \u22124 for TYLCV in resistant tomato, 8.6 \u00d7 10 \u22124 and 8.0 \u00d7 10 \u22124 mut/nt in common bean for TYLCV and TYLCMaV, respectively, or 8.4 \u00d7 10 \u22124 mut/nt in S. nigrum for TYLCSV).", [["tomato", "ORGANISM_SUBDIVISION", 74, 80], ["bean", "ORGANISM", 127, 131], ["TYLCV", "ORGANISM", 136, 141], ["S. nigrum", "ORGANISM", 194, 203], ["V2", "DNA", 28, 30], ["tomato", "SPECIES", 74, 80], ["bean", "SPECIES", 127, 131], ["S. nigrum", "SPECIES", 194, 203], ["TYLCV", "SPECIES", 55, 60], ["tomato", "SPECIES", 74, 80], ["bean", "SPECIES", 127, 131], ["TYLCV", "SPECIES", 136, 141], ["S. nigrum", "SPECIES", 194, 203], ["e.g.", "TEST", 32, 36], ["TYLCV", "PROBLEM", 55, 60], ["TYLCV", "PROBLEM", 136, 141], ["TYLCMaV", "TEST", 146, 153]]], ["In contrast, the least complex mutant spectra were found in the Rep and C4 genomic regions with values generally below 3 \u00d7 10 \u22124 mut/nt ( Table 2) .", [["Rep", "GENE_OR_GENE_PRODUCT", 64, 67], ["Rep and C4 genomic regions", "DNA", 64, 90], ["the least complex mutant spectra", "PROBLEM", 13, 45], ["least", "OBSERVATION_MODIFIER", 17, 22], ["complex", "OBSERVATION_MODIFIER", 23, 30], ["mutant spectra", "OBSERVATION", 31, 45], ["Rep", "ANATOMY_MODIFIER", 64, 67], ["C4", "ANATOMY_MODIFIER", 72, 74], ["genomic", "ANATOMY_MODIFIER", 75, 82], ["regions", "ANATOMY_MODIFIER", 83, 90]]], ["Higher complexity values were found in common bean or S. nigrum than in tomato for CP or IR in all viral species.", [["CP", "CHEMICAL", 83, 85], ["bean", "ORGANISM_SUBDIVISION", 46, 50], ["S. nigrum", "ORGANISM", 54, 63], ["tomato", "ORGANISM", 72, 78], ["bean", "SPECIES", 46, 50], ["S. nigrum", "SPECIES", 54, 63], ["tomato", "SPECIES", 72, 78], ["bean", "SPECIES", 46, 50], ["S. nigrum", "SPECIES", 54, 63], ["tomato", "SPECIES", 72, 78], ["Higher complexity values", "PROBLEM", 0, 24], ["S. nigrum", "PROBLEM", 54, 63], ["CP", "PROBLEM", 83, 85], ["IR in all viral species", "PROBLEM", 89, 112], ["viral species", "OBSERVATION", 99, 112]]], ["Thus, CP mutation frequency of TYLCV in common bean was higher than in resistant tomato at 15 dpi (P = 0.025), and also higher at 30 dpi than in susceptible (P = 0.034) and resistant tomato (P = 0.034).", [["TYLCV", "ORGANISM", 31, 36], ["bean", "ORGANISM", 47, 51], ["tomato", "ORGANISM_SUBDIVISION", 81, 87], ["tomato", "ORGANISM", 183, 189], ["bean", "SPECIES", 47, 51], ["tomato", "SPECIES", 81, 87], ["TYLCV", "SPECIES", 31, 36], ["bean", "SPECIES", 47, 51], ["tomato", "SPECIES", 81, 87], ["tomato", "SPECIES", 183, 189], ["CP mutation frequency of TYLCV in common bean", "PROBLEM", 6, 51], ["TYLCV", "OBSERVATION", 31, 36]]], ["Only in TYLCV, CP (P = 0.030) and V2 (P = 0.045) regions showed more complexity in resistant tomato than in common bean at 45 dpi.", [["TYLCV", "ORGANISM", 8, 13], ["tomato", "ORGANISM", 93, 99], ["bean", "ORGANISM_SUBDIVISION", 115, 119], ["tomato", "SPECIES", 93, 99], ["bean", "SPECIES", 115, 119], ["TYLCV", "SPECIES", 8, 13], ["tomato", "SPECIES", 93, 99], ["bean", "SPECIES", 115, 119], ["CP", "PROBLEM", 15, 17], ["P", "TEST", 19, 20], ["resistant tomato", "PROBLEM", 83, 99], ["TYLCV", "OBSERVATION", 8, 13], ["resistant tomato", "OBSERVATION", 83, 99]]], ["Additionally, our results suggest that CP and IR were differentially enriched in mutations respect to other regions within a particular quasispecies.", [["CP", "CHEMICAL", 39, 41], ["CP", "PROBLEM", 39, 41], ["IR", "TREATMENT", 46, 48]]], ["In S. nigrum at 45 dpi the complexity of CP (P = 0.001) and IR (P = 0.045) of TYLCSV was higher than that of both Rep and C4 regions.", [["S. nigrum", "ORGANISM", 3, 12], ["Rep", "GENE_OR_GENE_PRODUCT", 114, 117], ["TYLCSV", "PROTEIN", 78, 84], ["Rep", "PROTEIN", 114, 117], ["C4 regions", "PROTEIN", 122, 132], ["S. nigrum", "SPECIES", 3, 12], ["S. nigrum", "SPECIES", 3, 12], ["CP", "PROBLEM", 41, 43], ["TYLCSV", "TREATMENT", 78, 84], ["nigrum", "OBSERVATION_MODIFIER", 6, 12], ["higher", "OBSERVATION_MODIFIER", 89, 95], ["both", "ANATOMY_MODIFIER", 109, 113], ["Rep", "ANATOMY_MODIFIER", 114, 117], ["C4", "ANATOMY_MODIFIER", 122, 124], ["regions", "ANATOMY_MODIFIER", 125, 132]]], ["Also in S. nigrum CP region of TYLCMaV was more complex than Rep, C4, and V2 at 15 (P = 0.045) and 30 dpi (P = 0.005).", [["S. nigrum", "ORGANISM", 8, 17], ["CP", "ORGANISM", 18, 20], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 31, 38], ["Rep", "GENE_OR_GENE_PRODUCT", 61, 64], ["TYLCMaV", "PROTEIN", 31, 38], ["Rep", "PROTEIN", 61, 64], ["C4", "PROTEIN", 66, 68], ["V2", "PROTEIN", 74, 76], ["S. nigrum", "SPECIES", 8, 17], ["S. nigrum", "SPECIES", 8, 17], ["C4", "TEST", 66, 68], ["P", "TEST", 84, 85], ["P", "TEST", 107, 108], ["nigrum", "OBSERVATION_MODIFIER", 11, 17]]], ["In susceptible tomato at 45 dpi the mutation frequency was higher in CP than in C4 (P = 0.025) for TYLCSV and in resistant tomato CP was more complex than Rep (P=0.001) and C4 (P=0.014) for TYLCV.High Genetic Complexity and Heterogeneity of TYLCD-Associated Begomovirus QuasispeciesQuasispecies genetic complexity was also assessed by analyzing average genetic distance (d) values.", [["TYLCSV", "CHEMICAL", 99, 105], ["tomato", "ORGANISM", 15, 21], ["tomato CP", "ORGANISM", 123, 132], ["Rep", "GENE_OR_GENE_PRODUCT", 155, 158], ["TYLCV", "ORGANISM", 190, 195], ["Rep", "PROTEIN", 155, 158], ["C4", "PROTEIN", 173, 175], ["TYLCD", "DNA", 241, 246], ["tomato", "SPECIES", 15, 21], ["tomato", "SPECIES", 15, 21], ["tomato", "SPECIES", 123, 129], ["TYLCV", "SPECIES", 190, 195], ["the mutation frequency", "TEST", 32, 54], ["TYLCSV", "PROBLEM", 99, 105], ["resistant tomato CP", "PROBLEM", 113, 132], ["TYLCV", "PROBLEM", 190, 195], ["High Genetic Complexity", "PROBLEM", 196, 219], ["Heterogeneity of TYLCD", "PROBLEM", 224, 246], ["Begomovirus QuasispeciesQuasispecies genetic complexity", "PROBLEM", 258, 313], ["higher", "OBSERVATION_MODIFIER", 59, 65], ["Heterogeneity", "OBSERVATION_MODIFIER", 224, 237], ["Begomovirus Quasispecies", "OBSERVATION", 258, 282]]], ["As shown in Table 3 , d values varied from 0.00012 to 0.00173.", [["d values", "TEST", 22, 30]]], ["The maximum genetic distance values for the four coding regions and the IR were found in the V2 region (especially for common bean and S. nigrum).", [["bean", "ORGANISM_SUBDIVISION", 126, 130], ["S. nigrum", "ORGANISM", 135, 144], ["V2 region", "DNA", 93, 102], ["bean", "SPECIES", 126, 130], ["S. nigrum", "SPECIES", 135, 144], ["bean", "SPECIES", 126, 130], ["S. nigrum", "SPECIES", 135, 144], ["the IR", "TEST", 68, 74], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["V2", "ANATOMY", 93, 95], ["region", "ANATOMY_MODIFIER", 96, 102]]], ["High d values were also observed for C4 in some cases (e.g., in resistant tomato for TYLCSV at 15 dpi or in common bean for TYLCV at 30 dpi).High Genetic Complexity and Heterogeneity of TYLCD-Associated Begomovirus QuasispeciesBegomovirus mutant spectra heterogeneity was evaluated by calculating the normalized Shannon entropy of viral quasispecies.", [["TYLCSV", "CHEMICAL", 85, 91], ["tomato", "ORGANISM", 74, 80], ["bean", "ORGANISM_SUBDIVISION", 115, 119], ["TYLCD", "GENE_OR_GENE_PRODUCT", 186, 191], ["C4", "PROTEIN", 37, 39], ["TYLCD", "PROTEIN", 186, 191], ["tomato", "SPECIES", 74, 80], ["bean", "SPECIES", 115, 119], ["tomato", "SPECIES", 74, 80], ["bean", "SPECIES", 115, 119], ["TYLCV", "SPECIES", 124, 129], ["High d values", "PROBLEM", 0, 13], ["C4", "PROBLEM", 37, 39], ["TYLCSV", "TREATMENT", 85, 91], ["TYLCV", "PROBLEM", 124, 129], ["High Genetic Complexity", "PROBLEM", 141, 164], ["Heterogeneity of TYLCD", "PROBLEM", 169, 191], ["Begomovirus QuasispeciesBegomovirus mutant spectra heterogeneity", "PROBLEM", 203, 267], ["viral quasispecies", "PROBLEM", 331, 349], ["Heterogeneity", "OBSERVATION_MODIFIER", 169, 182], ["Begomovirus Quasispecies", "OBSERVATION", 203, 227], ["viral quasispecies", "OBSERVATION", 331, 349]]], ["Shannon entropy values calculated for the whole sequenced region were highest in common bean at 15 dpi and no difference between hosts were detected a later times post infection ( Figure 4B ).", [["infection", "DISEASE", 168, 177], ["bean", "ORGANISM_SUBDIVISION", 88, 92], ["bean", "SPECIES", 88, 92], ["bean", "SPECIES", 88, 92], ["Shannon entropy values", "TEST", 0, 22], ["the whole sequenced region", "PROBLEM", 38, 64], ["difference between hosts", "PROBLEM", 110, 134], ["infection", "PROBLEM", 168, 177]]], ["Susceptible tomato begomovirus quasispecies were the least heterogeneous, followed by those of resistant tomato and S. nigrum.", [["tomato begomovirus", "ORGANISM", 12, 30], ["tomato", "ORGANISM", 105, 111], ["S. nigrum", "ORGANISM", 116, 125], ["tomato", "SPECIES", 12, 18], ["tomato", "SPECIES", 105, 111], ["S. nigrum", "SPECIES", 116, 125], ["tomato", "SPECIES", 12, 18], ["tomato", "SPECIES", 105, 111], ["S. nigrum", "SPECIES", 116, 125], ["Susceptible tomato begomovirus quasispecies", "PROBLEM", 0, 43], ["resistant tomato and S. nigrum", "PROBLEM", 95, 125], ["begomovirus quasispecies", "OBSERVATION", 19, 43], ["least", "OBSERVATION_MODIFIER", 53, 58], ["heterogeneous", "OBSERVATION_MODIFIER", 59, 72], ["nigrum", "OBSERVATION", 119, 125]]], ["Analyzed by genomic region, as shown in Table 2 , Shannon entropy values ranged from 0 to 0.340.", [["genomic region", "DNA", 12, 26], ["Shannon entropy values", "TEST", 50, 72]]], ["The CP region showed the highest heterogeneity in all four hosts and viruses, although this was especially pronounced in common bean and S. nigrum.", [["bean", "ORGANISM_SUBDIVISION", 128, 132], ["S. nigrum", "ORGANISM", 137, 146], ["CP region", "DNA", 4, 13], ["bean", "SPECIES", 128, 132], ["S. nigrum", "SPECIES", 137, 146], ["bean", "SPECIES", 128, 132], ["S. nigrum", "SPECIES", 137, 146], ["The CP region", "TEST", 0, 13], ["the highest heterogeneity in all four hosts and viruses", "PROBLEM", 21, 76], ["highest", "OBSERVATION_MODIFIER", 25, 32], ["heterogeneity", "OBSERVATION", 33, 46], ["all four hosts", "OBSERVATION_MODIFIER", 50, 64], ["viruses", "OBSERVATION", 69, 76], ["nigrum", "OBSERVATION", 140, 146]]], ["Conversely, the lowest Shannon entropy values in the four hosts were detected in the C4 genomic region, except for TYLCSV at 15 dpi in resistant tomato.", [["tomato", "ORGANISM", 145, 151], ["C4 genomic region", "DNA", 85, 102], ["tomato", "SPECIES", 145, 151], ["tomato", "SPECIES", 145, 151], ["the lowest Shannon entropy values", "TEST", 12, 45], ["TYLCSV", "TREATMENT", 115, 121], ["C4", "ANATOMY_MODIFIER", 85, 87]]], ["Therefore, heterogeneity of quasispecies was high in all host/begomovirus combinations, with the most heterogeneous populations exhibited by common bean and S. nigrum.", [["bean", "ORGANISM_SUBDIVISION", 148, 152], ["S. nigrum", "ORGANISM", 157, 166], ["bean", "SPECIES", 148, 152], ["S. nigrum", "SPECIES", 157, 166], ["bean", "SPECIES", 148, 152], ["S. nigrum", "SPECIES", 157, 166], ["heterogeneity of quasispecies", "PROBLEM", 11, 40], ["begomovirus combinations", "TREATMENT", 62, 86], ["the most heterogeneous populations", "PROBLEM", 93, 127], ["common bean and S. nigrum", "PROBLEM", 141, 166], ["quasispecies", "OBSERVATION", 28, 40], ["high", "OBSERVATION_MODIFIER", 45, 49], ["begomovirus", "OBSERVATION", 62, 73], ["most", "OBSERVATION_MODIFIER", 97, 101], ["heterogeneous", "OBSERVATION_MODIFIER", 102, 115], ["populations", "OBSERVATION", 116, 127], ["common bean", "OBSERVATION", 141, 152], ["nigrum", "OBSERVATION", 160, 166]]], ["Notably, the wild host S. nigrum contained the most heterogeneous populations at later infection time points for the viruses that were able to infect it.", [["infection", "DISEASE", 87, 96], ["S. nigrum", "ORGANISM", 23, 32], ["S. nigrum", "SPECIES", 23, 32], ["S. nigrum", "SPECIES", 23, 32], ["the viruses", "PROBLEM", 113, 124], ["most", "OBSERVATION_MODIFIER", 47, 51], ["heterogeneous", "OBSERVATION_MODIFIER", 52, 65], ["populations", "OBSERVATION_MODIFIER", 66, 77]]], ["In general, mutation frequency, d and Shannon entropy values at 45 dpi were similar for replicates 1 and 2 for each virus/host combination.High Genetic Complexity and Heterogeneity of TYLCD-Associated Begomovirus QuasispeciesAltogether, our results support the idea that begomovirus infections are characterized by the generation of highly complex and heterogeneous ssDNA mutant spectra in the host species tested, especially in common bean and the wild reservoir S. nigrum.", [["begomovirus infections", "DISEASE", 271, 293], ["begomovirus", "ORGANISM", 271, 282], ["bean", "ORGANISM_SUBDIVISION", 436, 440], ["S. nigrum", "ORGANISM", 464, 473], ["bean", "SPECIES", 436, 440], ["S. nigrum", "SPECIES", 464, 473], ["bean", "SPECIES", 436, 440], ["S. nigrum", "SPECIES", 464, 473], ["Shannon entropy values", "TEST", 38, 60], ["High Genetic Complexity", "PROBLEM", 139, 162], ["Heterogeneity of TYLCD", "PROBLEM", 167, 189], ["Begomovirus Quasispecies", "PROBLEM", 201, 225], ["begomovirus infections", "PROBLEM", 271, 293], ["highly complex and heterogeneous ssDNA mutant spectra in the host species", "PROBLEM", 333, 406], ["Heterogeneity", "OBSERVATION_MODIFIER", 167, 180], ["Begomovirus Quasispecies", "OBSERVATION", 201, 225], ["begomovirus", "OBSERVATION_MODIFIER", 271, 282], ["infections", "OBSERVATION", 283, 293], ["heterogeneous", "OBSERVATION_MODIFIER", 352, 365], ["ssDNA mutant spectra", "OBSERVATION", 366, 386], ["host species", "OBSERVATION", 394, 406]]], ["V2 region supported the most complex spectra, CP was the most heterogeneous, while C4 exhibited both the least complexity and least heterogeneity.", [["V2 region", "DNA", 0, 9], ["C4", "PROTEIN", 83, 85], ["CP", "PROBLEM", 46, 48], ["most", "OBSERVATION_MODIFIER", 57, 61], ["heterogeneous", "OBSERVATION_MODIFIER", 62, 75], ["least", "OBSERVATION_MODIFIER", 105, 110], ["complexity", "OBSERVATION_MODIFIER", 111, 121], ["least", "OBSERVATION_MODIFIER", 126, 131], ["heterogeneity", "OBSERVATION", 132, 145]]], ["Interestingly, despite the high genetic complexity and heterogeneity of TYLCD-associated begomovirus quasispecies, no changes were detected in their whole genomic consensus sequences in any of the four hosts at any time point during infection.Analysis of Mutations Suggests That the CP Region Is the Most Susceptible to ChangeMutation data, comprising 128 base substitutions and 16 indels (complete list shown in Table 4 ), were pooled together irrespective of sampling time, virus or host.", [["TYLCD", "DISEASE", 72, 77], ["infection", "DISEASE", 233, 242], ["TYLCD", "GENE_OR_GENE_PRODUCT", 72, 77], ["TYLCD", "DNA", 72, 77], ["genomic consensus sequences", "DNA", 155, 182], ["the high genetic complexity", "PROBLEM", 23, 50], ["TYLCD-associated begomovirus quasispecies", "PROBLEM", 72, 113], ["infection", "PROBLEM", 233, 242], ["Mutations", "PROBLEM", 255, 264], ["the CP Region", "PROBLEM", 279, 292], ["ChangeMutation data", "TEST", 320, 339], ["base substitutions", "TEST", 356, 374], ["begomovirus quasispecies", "OBSERVATION", 89, 113], ["infection", "OBSERVATION", 233, 242]]], ["Mutation types and their frequency (%) relative to the number of changes found in a given genomic region or the whole sequenced zone are indicated in Table 5 .", [["genomic region", "DNA", 90, 104], ["Mutation types", "PROBLEM", 0, 14]]], ["Independent analysis of Rep, C4, IR, V2, and CP regions, shows that the most abundant mutations were base substitutions (86.7-100%), with indels only absent in C4.", [["Rep", "GENE_OR_GENE_PRODUCT", 24, 27], ["C4", "GENE_OR_GENE_PRODUCT", 29, 31], ["IR", "GENE_OR_GENE_PRODUCT", 33, 35], ["V2", "GENE_OR_GENE_PRODUCT", 37, 39], ["Rep, C4, IR, V2, and CP regions", "DNA", 24, 55], ["C4", "PROTEIN", 160, 162], ["Rep, C4, IR, V2, and CP regions", "PROBLEM", 24, 55], ["base substitutions", "TEST", 101, 119], ["V2", "ANATOMY", 37, 39], ["C4", "ANATOMY_MODIFIER", 160, 162]]], ["The IR contained the highest fraction of insertions, representing 11.1% of all mutations in the region.", [["all mutations in the region", "PROBLEM", 75, 102], ["highest", "OBSERVATION_MODIFIER", 21, 28], ["fraction", "OBSERVATION_MODIFIER", 29, 37], ["insertions", "OBSERVATION_MODIFIER", 41, 51], ["11.1%", "OBSERVATION_MODIFIER", 66, 71], ["all", "OBSERVATION_MODIFIER", 75, 78], ["mutations", "OBSERVATION", 79, 88], ["region", "ANATOMY_MODIFIER", 96, 102]]], ["On the other hand, the highest fraction of deletions was detected in Rep (5.3% of total mutations).", [["Rep", "GENE_OR_GENE_PRODUCT", 69, 72], ["Rep", "PROTEIN", 69, 72], ["deletions", "PROBLEM", 43, 52], ["Rep", "TEST", 69, 72], ["total mutations", "TEST", 82, 97]]], ["Of the base substitutions, the most common transition was C\u2192T, which was highly enriched in C4 and V2 regions.", [["C\u2192T", "GENE_OR_GENE_PRODUCT", 58, 61], ["C4 and V2 regions", "DNA", 92, 109], ["the base substitutions", "PROBLEM", 3, 25], ["base", "ANATOMY_MODIFIER", 7, 11], ["substitutions", "OBSERVATION_MODIFIER", 12, 25], ["C4", "ANATOMY_MODIFIER", 92, 94], ["V2", "ANATOMY_MODIFIER", 99, 101], ["regions", "ANATOMY_MODIFIER", 102, 109]]], ["G\u2192A was the next most common transition, although it was less common in the IR and absent from C4.", [["G\u2192A", "GENE_OR_GENE_PRODUCT", 0, 3], ["C4", "ANATOMY_MODIFIER", 95, 97]]], ["With regards to transversions, G\u2192T was the most abundant.", [["G\u2192T", "GENE_OR_GENE_PRODUCT", 31, 34], ["G\u2192T", "DNA", 31, 34], ["transversions", "PROBLEM", 16, 29]]], ["Conversely, A\u2192T and A\u2192C and G\u2192T transversions were exceptionally frequent in the IR compared to the other four regions.", [["A\u2192C", "CHEMICAL", 20, 23], ["G\u2192T", "CHEMICAL", 28, 31], ["A\u2192T", "GENE_OR_GENE_PRODUCT", 12, 15], ["A\u2192C", "GENE_OR_GENE_PRODUCT", 20, 23], ["G\u2192T", "SIMPLE_CHEMICAL", 28, 31], ["A\u2192T and A\u2192C and G\u2192T transversions", "DNA", 12, 45], ["A\u2192T", "TEST", 12, 15], ["A\u2192C and G\u2192T transversions", "PROBLEM", 20, 45], ["exceptionally", "OBSERVATION_MODIFIER", 51, 64], ["frequent", "OBSERVATION_MODIFIER", 65, 73]]], ["Interestingly, the transition:transversion ratio was close to 1 in all regions.", [["transversion ratio", "TEST", 30, 48]]], ["Transition:transversion ratios in DNAbased organisms (Begun et al., 2007; Hodgkinson and Eyre-Walker, 2010) as well as in RNA and dsDNA viruses (Duch\u00eane (2)D59Y(2)G2698T( (Noris et al., 1994) . c Ts:Tv, transition:transversion ratio. d Na, not applicable.G2698TNext, we studied the frequency and acceptability of the amino acid changes found in the different gene products under study.", [["Na", "CHEMICAL", 236, 238], ["amino acid", "CHEMICAL", 317, 327], ["Na", "CHEMICAL", 236, 238], ["amino acid", "CHEMICAL", 317, 327], ["c Ts", "GENE_OR_GENE_PRODUCT", 194, 198], ["Na", "SIMPLE_CHEMICAL", 236, 238], ["amino acid", "AMINO_ACID", 317, 327], ["transversion ratios in DNAbased organisms", "PROBLEM", 11, 52], ["Eyre-Walker", "TREATMENT", 89, 100], ["transversion ratio", "TEST", 214, 232], ["Na", "TEST", 236, 238], ["the amino acid changes", "PROBLEM", 313, 335], ["amino acid", "OBSERVATION", 317, 327]]], ["Firstly, amino acid changes were analyzed using the SG matrix as described previously (Feng et al., 1984) generating values from 0 to 6, with 0 indicating the most drastic amino acid changes and 6 the least, and their relative frequencies shown in Figure 5A .", [["amino acid", "CHEMICAL", 9, 19], ["amino acid", "CHEMICAL", 172, 182], ["amino acid", "CHEMICAL", 9, 19], ["amino acid", "CHEMICAL", 172, 182], ["amino acid", "AMINO_ACID", 9, 19], ["amino acid", "AMINO_ACID", 172, 182], ["amino acid changes", "PROBLEM", 9, 27], ["the SG matrix", "TREATMENT", 48, 61], ["the most drastic amino acid changes", "PROBLEM", 155, 190], ["amino acid", "OBSERVATION", 9, 19], ["amino acid", "OBSERVATION", 172, 182]]], ["The results show that amino acid changes in Rep were poorly tolerated, since 83.9% of changes have acceptability values above 3, with 38.7% having a value of 6 (synonymous changes).", [["amino acid", "CHEMICAL", 22, 32], ["amino acid", "CHEMICAL", 22, 32], ["amino acid", "AMINO_ACID", 22, 32], ["Rep", "GENE_OR_GENE_PRODUCT", 44, 47], ["Rep", "PROTEIN", 44, 47], ["amino acid changes", "PROBLEM", 22, 40], ["acceptability values", "TEST", 99, 119], ["a value", "TEST", 147, 154], ["amino acid", "OBSERVATION", 22, 32]]], ["Although the overall degree of amino acid change was similar in all regions, the higher relative frequency of more pronounced changes (with values of 2 or less) found in the CP might indicate that this protein is more tolerant to drastic amino acid changes.", [["amino acid", "CHEMICAL", 31, 41], ["amino acid", "CHEMICAL", 238, 248], ["amino acid", "CHEMICAL", 31, 41], ["amino acid", "CHEMICAL", 238, 248], ["amino acid", "AMINO_ACID", 31, 41], ["amino acid", "AMINO_ACID", 238, 248], ["amino acid change", "PROBLEM", 31, 48], ["drastic amino acid changes", "PROBLEM", 230, 256], ["amino acid", "OBSERVATION", 31, 41], ["higher", "OBSERVATION_MODIFIER", 81, 87], ["more pronounced", "OBSERVATION_MODIFIER", 110, 125], ["amino acid", "OBSERVATION", 238, 248]]], ["We analyzed the probability of amino acid substitution occurrence using a PAM-250 substitution matrix (Feng and Doolittle, 1996) .", [["amino acid", "CHEMICAL", 31, 41], ["amino acid", "CHEMICAL", 31, 41], ["amino acid", "AMINO_ACID", 31, 41], ["amino acid substitution", "TREATMENT", 31, 54], ["a PAM-250 substitution matrix", "TREATMENT", 72, 101], ["amino acid substitution", "OBSERVATION", 31, 54]]], ["The results shown in Figure 5B indicate that the highest frequency of probable amino acid replacements occurred in Rep and that unlikely amino acid changes were most prevalent in the CP protein.", [["amino acid", "CHEMICAL", 79, 89], ["amino acid", "CHEMICAL", 137, 147], ["amino acid", "CHEMICAL", 79, 89], ["amino acid", "CHEMICAL", 137, 147], ["amino acid", "AMINO_ACID", 79, 89], ["Rep", "GENE_OR_GENE_PRODUCT", 115, 118], ["amino acid", "AMINO_ACID", 137, 147], ["Rep", "PROTEIN", 115, 118], ["CP protein", "PROTEIN", 183, 193], ["amino acid replacements", "TREATMENT", 79, 102], ["amino acid changes", "PROBLEM", 137, 155], ["probable", "UNCERTAINTY", 70, 78], ["amino acid replacements", "OBSERVATION", 79, 102], ["unlikely", "UNCERTAINTY", 128, 136], ["amino acid", "OBSERVATION", 137, 147]]], ["Altogether the results indicate that the Rep protein tends to be more conserved and that the CP protein is more amenable to change.Host Influences the Sequence Space Explored by BegomovirusesSequence variations explored during begomovirus infections seemed to be affected by specific virus-host interactions.", [["infections", "DISEASE", 239, 249], ["Rep", "GENE_OR_GENE_PRODUCT", 41, 44], ["Rep protein", "PROTEIN", 41, 52], ["CP protein", "PROTEIN", 93, 103], ["Sequence Space", "DNA", 151, 165], ["the Rep protein", "TEST", 37, 52], ["the CP protein", "PROBLEM", 89, 103], ["the Sequence Space", "TREATMENT", 147, 165], ["BegomovirusesSequence variations", "PROBLEM", 178, 210], ["begomovirus infections", "PROBLEM", 227, 249]]], ["Sequence space distribution of the mutations detected in our time-course assays is summarized in Figure 6 , which shows the location of the mutations found in begomovirus quasispecies by assay time point, host and begomovirus (TYLCSV, TYLCV, or TYLCMaV).", [["TYLCV", "ORGANISM", 235, 240], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 245, 252], ["TYLCMaV", "PROTEIN", 245, 252], ["TYLCSV", "SPECIES", 227, 233], ["TYLCV", "SPECIES", 235, 240], ["the mutations", "PROBLEM", 31, 44], ["the mutations", "PROBLEM", 136, 149], ["begomovirus quasispecies", "PROBLEM", 159, 183], ["begomovirus", "PROBLEM", 214, 225], ["begomovirus quasispecies", "OBSERVATION", 159, 183], ["begomovirus", "OBSERVATION", 214, 225]]], ["Considering the genomic regions explored at each sampling time, we observed that the tomato Ty-1 resistance allele did not significantly influence mutation frequency for any ORF, since no significant differences between susceptible tomato and FIGURE 5 | Acceptability and occurrence probability of the amino acid replacements observed in begomovirus quasispecies of tomato yellow leaf curl Sardinia virus (TYLCSV), tomato yellow leaf curl virus (TYLCV) and tomato yellow leaf curl Malaga virus (TYLCMaV) in quasi-isogenic susceptible (ty-1/ty-1) and resistant (Ty-1/ty-1) tomato, common bean, and Solanum nigrum plants.", [["amino acid", "CHEMICAL", 302, 312], ["begomovirus quasispecies of tomato yellow leaf curl Sardinia", "CHEMICAL", 338, 398], ["amino acid", "CHEMICAL", 302, 312], ["tomato", "ORGANISM", 85, 91], ["Ty-1", "GENE_OR_GENE_PRODUCT", 92, 96], ["amino acid", "AMINO_ACID", 302, 312], ["begomovirus quasispecies", "ORGANISM", 338, 362], ["tomato yellow leaf curl Sardinia virus", "ORGANISM", 366, 404], ["TYLCSV", "ORGANISM", 406, 412], ["tomato yellow leaf curl virus", "ORGANISM", 415, 444], ["TYLCV", "ORGANISM", 446, 451], ["tomato yellow leaf curl Malaga virus", "ORGANISM", 457, 493], ["ty-1", "ORGANISM", 566, 570], ["tomato", "ORGANISM", 572, 578], ["bean", "ORGANISM", 587, 591], ["Solanum nigrum plants", "ORGANISM", 597, 618], ["genomic regions", "DNA", 16, 31], ["tomato Ty-1 resistance allele", "DNA", 85, 114], ["ORF", "DNA", 174, 177], ["tomato", "SPECIES", 85, 91], ["tomato", "SPECIES", 366, 372], ["yellow leaf", "SPECIES", 373, 384], ["curl Sardinia virus", "SPECIES", 385, 404], ["tomato", "SPECIES", 415, 421], ["yellow leaf curl virus", "SPECIES", 422, 444], ["TYLCV", "SPECIES", 446, 451], ["tomato", "SPECIES", 457, 463], ["yellow leaf curl", "SPECIES", 464, 480], ["Malaga virus", "SPECIES", 481, 493], ["tomato", "SPECIES", 572, 578], ["bean", "SPECIES", 587, 591], ["Solanum nigrum", "SPECIES", 597, 611], ["tomato", "SPECIES", 85, 91], ["tomato", "SPECIES", 232, 238], ["tomato yellow leaf curl Sardinia virus", "SPECIES", 366, 404], ["TYLCSV", "SPECIES", 406, 412], ["tomato yellow leaf curl virus", "SPECIES", 415, 444], ["TYLCV", "SPECIES", 446, 451], ["tomato yellow leaf curl Malaga virus", "SPECIES", 457, 493], ["tomato", "SPECIES", 572, 578], ["bean", "SPECIES", 587, 591], ["Solanum nigrum", "SPECIES", 597, 611], ["any ORF", "PROBLEM", 170, 177], ["the amino acid replacements", "TREATMENT", 298, 325], ["begomovirus quasispecies", "PROBLEM", 338, 362], ["tomato yellow leaf curl Sardinia virus (TYLCSV)", "PROBLEM", 366, 413], ["tomato yellow leaf curl virus", "PROBLEM", 415, 444], ["tomato yellow leaf curl Malaga virus", "PROBLEM", 457, 493], ["Solanum nigrum plants", "TREATMENT", 597, 618], ["begomovirus quasispecies", "OBSERVATION", 338, 362], ["yellow leaf", "OBSERVATION", 373, 384], ["Sardinia virus", "OBSERVATION", 390, 404], ["common bean", "ANATOMY", 580, 591], ["Solanum", "ANATOMY", 597, 604], ["nigrum plants", "OBSERVATION", 605, 618]]], ["(A) Acceptability values of amino acid changes found in each genomic coding region determined according to the structure-genetic (SG) matrix of Feng et al. (Feng et al., 1984) .", [["amino acid", "CHEMICAL", 28, 38], ["amino acid", "CHEMICAL", 28, 38], ["amino acid", "AMINO_ACID", 28, 38], ["genomic coding region", "DNA", 61, 82], ["amino acid changes", "PROBLEM", 28, 46]]], ["The values range from 0 (drastic amino acid changes) to 6 (synonymous replacements).", [["amino acid", "CHEMICAL", 33, 43], ["amino acid", "CHEMICAL", 33, 43], ["amino acid", "AMINO_ACID", 33, 43], ["The values", "TEST", 0, 10], ["drastic amino acid changes", "TREATMENT", 25, 51], ["synonymous replacements", "TREATMENT", 59, 82]]], ["(B) Probability of occurrence of amino acid replacements calculated according to the PAM-250 substitution matrix. resistant tomato were found at any time point (generalized linear model assuming binary distribution and using logit link function, P \u2265 0.05).", [["amino acid", "CHEMICAL", 33, 43], ["amino acid", "CHEMICAL", 33, 43], ["amino acid", "AMINO_ACID", 33, 43], ["matrix", "CELLULAR_COMPONENT", 106, 112], ["tomato", "ORGANISM", 124, 130], ["tomato", "SPECIES", 124, 130], ["tomato", "SPECIES", 124, 130], ["amino acid replacements", "TREATMENT", 33, 56], ["resistant tomato", "PROBLEM", 114, 130], ["amino acid", "OBSERVATION", 33, 43]]], ["However, differences between hosts were observed with respect to where mutations occurred over time.", [["mutations", "PROBLEM", 71, 80]]], ["Thus, for example, mutation frequency of the CP increased for TYLCSV in susceptible tomato between 15 and 45 dpi (P = 0.048) and between 30 and 45 dpi (P = 0.003), and for TYLCV in resistant tomato between 15 and 45 dpi (P = 0.001).", [["tomato", "ANATOMY", 191, 197], ["TYLCSV", "CHEMICAL", 62, 68], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 62, 68], ["tomato", "ORGANISM", 84, 90], ["TYLCV", "ORGANISM", 172, 177], ["tomato", "ORGANISM", 191, 197], ["TYLCSV", "PROTEIN", 62, 68], ["tomato", "SPECIES", 84, 90], ["tomato", "SPECIES", 191, 197], ["tomato", "SPECIES", 84, 90], ["TYLCV", "SPECIES", 172, 177], ["tomato", "SPECIES", 191, 197], ["mutation frequency", "PROBLEM", 19, 37], ["the CP", "PROBLEM", 41, 47], ["TYLCSV", "PROBLEM", 62, 68], ["P", "TEST", 114, 115], ["TYLCV", "PROBLEM", 172, 177]]], ["This increase in CP mutation frequency might be related to the decrease in fitness in tomato.", [["tomato", "ORGANISM", 86, 92], ["tomato", "SPECIES", 86, 92], ["tomato", "SPECIES", 86, 92], ["CP mutation frequency", "PROBLEM", 17, 38], ["the decrease in fitness in tomato", "PROBLEM", 59, 92], ["increase", "OBSERVATION_MODIFIER", 5, 13], ["decrease", "OBSERVATION_MODIFIER", 63, 71]]], ["In S. nigrum, TYLCMaV (replicates 1 and 2 at 45 dpi) showed a significant increase in the number of mutations in Rep between 15 and 45 dpi (P = 0.044) and between 30 and 45 dpi (P = 0.005) but not in the overlapping C4 ORF.", [["S. nigrum", "ORGANISM", 3, 12], ["Rep", "GENE_OR_GENE_PRODUCT", 113, 116], ["Rep", "PROTEIN", 113, 116], ["C4 ORF", "DNA", 216, 222], ["S. nigrum", "SPECIES", 3, 12], ["S. nigrum", "SPECIES", 3, 12], ["a significant increase", "PROBLEM", 60, 82], ["the overlapping C4 ORF", "PROBLEM", 200, 222], ["nigrum", "OBSERVATION", 6, 12], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["C4 ORF", "OBSERVATION", 216, 222]]], ["A random distribution of mutations was found both in Rep and C4 (runs test, P > 0.05) so mutational hotspots were ruled out.", [["Rep", "GENE_OR_GENE_PRODUCT", 53, 56], ["Rep", "PROTEIN", 53, 56], ["C4", "PROTEIN", 61, 63], ["A random distribution of mutations", "PROBLEM", 0, 34], ["runs test", "TEST", 65, 74], ["P", "TEST", 76, 77], ["mutational hotspots", "PROBLEM", 89, 108], ["C4", "ANATOMY", 61, 63]]], ["This result suggests an active exploration of sequence space in Rep but not in C4 for the recombinant virus.", [["Rep", "GENE_OR_GENE_PRODUCT", 64, 67], ["C4", "GENE_OR_GENE_PRODUCT", 79, 81], ["recombinant virus", "ORGANISM", 90, 107], ["Rep", "PROTEIN", 64, 67], ["C4", "PROTEIN", 79, 81], ["an active exploration of sequence space in Rep", "TEST", 21, 67], ["the recombinant virus", "PROBLEM", 86, 107], ["active", "OBSERVATION_MODIFIER", 24, 30], ["exploration", "OBSERVATION", 31, 42], ["virus", "OBSERVATION", 102, 107]]], ["No parallel mutations were found in replicate samples at 45 dpi.", [["samples", "ANATOMY", 46, 53], ["parallel mutations", "PROBLEM", 3, 21], ["parallel", "OBSERVATION_MODIFIER", 3, 11], ["mutations", "OBSERVATION", 12, 21]]], ["Our results suggest that begomoviruses explore different sequence space depending on host species, although further studies are needed to confirm this including additional replicates (at 15 and 30 dpi).", [["begomoviruses explore different sequence space", "PROBLEM", 25, 71], ["host species", "PROBLEM", 85, 97], ["further studies", "TEST", 108, 123], ["begomoviruses", "OBSERVATION", 25, 38]]], ["They also suggest that the presence of the Ty-1 gene in tomato does not affect how begomoviruses move in sequence space at each time point.", [["Ty-1", "GENE_OR_GENE_PRODUCT", 43, 47], ["tomato", "ORGANISM", 56, 62], ["Ty-1 gene", "DNA", 43, 52], ["tomato", "SPECIES", 56, 62], ["tomato", "SPECIES", 56, 62]]], ["Furthermore, it is interesting to note that begomovirus consensus sequences were completely invariant throughout the infection time-courses regardless of mutant spectra or host, and despite the large number of mutations found.Direction of Selective Forces Depends on Host and Is Not Influenced by Ty-1To assess begomovirus mutant spectra adaptation to hosts, we studied the direction of selective forces on their coding regions.", [["infection", "DISEASE", 117, 126], ["Ty-1To", "SIMPLE_CHEMICAL", 297, 303], ["begomovirus mutant", "ORGANISM", 311, 329], ["begomovirus consensus sequences", "DNA", 44, 75], ["Ty", "DNA", 297, 299], ["coding regions", "DNA", 413, 427], ["begomovirus consensus sequences", "PROBLEM", 44, 75], ["mutant spectra or host", "PROBLEM", 154, 176], ["mutations", "PROBLEM", 210, 219], ["large", "OBSERVATION_MODIFIER", 194, 199], ["Selective", "OBSERVATION_MODIFIER", 239, 248], ["Forces", "OBSERVATION", 249, 255]]], ["To this end the average rate of synonymous substitutions per synonymous site (d S ) and of nonsynonymous substitutions per nonsynonymous site (d NS ) for each mutant spectrum were estimated as reported previously (Pamilo and Bianchi, 1993) .", [["synonymous substitutions", "TREATMENT", 32, 56], ["nonsynonymous substitutions", "TREATMENT", 91, 118], ["nonsynonymous site (d NS", "TREATMENT", 123, 147], ["each mutant spectrum", "PROBLEM", 154, 174], ["synonymous substitutions", "OBSERVATION", 32, 56]]], ["Where possible, the d NS /d S ratio was also calculated.", [["the d NS /d S ratio", "TEST", 16, 35]]], ["The results in Table 6 show that d NS /d S ratios of begomovirus quasispecies evolving in tomato ranged from 0.149 to 0.616 in Rep, V2, and CP.", [["begomovirus", "GENE_OR_GENE_PRODUCT", 53, 64], ["tomato", "ORGANISM", 90, 96], ["Rep", "GENE_OR_GENE_PRODUCT", 127, 130], ["Rep", "PROTEIN", 127, 130], ["V2", "PROTEIN", 132, 134], ["tomato", "SPECIES", 90, 96], ["tomato", "SPECIES", 90, 96], ["NS /d S ratios", "TEST", 35, 49], ["begomovirus quasispecies", "PROBLEM", 53, 77], ["tomato", "TEST", 90, 96], ["CP", "PROBLEM", 140, 142], ["begomovirus quasispecies", "OBSERVATION", 53, 77], ["V2", "ANATOMY", 132, 134]]], ["Ratios calculated for TYLCSV and TYLCMaV were below 1, (Noris et al., 1994) .", [["Ratios", "TEST", 0, 6], ["TYLCSV and TYLCMaV", "TREATMENT", 22, 40]]], ["Consensus sequences of the quasispecies were determined for whole viral genomic sequences.", [["viral genomic sequences", "DNA", 66, 89], ["Consensus sequences", "TEST", 0, 19], ["the quasispecies", "PROBLEM", 23, 39], ["whole viral genomic sequences", "TEST", 60, 89]]], ["Mutations detected in separate quasispecies in the same host/time combination are indicated by the number of times they appeared.", [["Mutations", "PROBLEM", 0, 9]]], ["Mutations found in replicate samples are denoted with an asterisk.", [["samples", "ANATOMY", 29, 36], ["Mutations", "PROBLEM", 0, 9]]], ["Our data also support positive selection of virus variants in the CP region in common bean and S. nigrum, whereas Rep, C4, and V2 coding regions are under purifying selection.", [["bean", "ORGANISM_SUBDIVISION", 86, 90], ["S. nigrum", "ORGANISM", 95, 104], ["Rep", "GENE_OR_GENE_PRODUCT", 114, 117], ["C4", "GENE_OR_GENE_PRODUCT", 119, 121], ["CP region", "DNA", 66, 75], ["Rep, C4, and V2 coding regions", "DNA", 114, 144], ["bean", "SPECIES", 86, 90], ["S. nigrum", "SPECIES", 95, 104], ["common bean", "SPECIES", 79, 90], ["S. nigrum", "SPECIES", 95, 104], ["Our data", "TEST", 0, 8], ["virus variants", "PROBLEM", 44, 58], ["S. nigrum", "PROBLEM", 95, 104], ["whereas Rep, C4, and V2 coding regions", "PROBLEM", 106, 144], ["virus variants", "OBSERVATION", 44, 58], ["CP", "ANATOMY", 66, 68], ["region", "ANATOMY_MODIFIER", 69, 75], ["common bean", "ANATOMY", 79, 90], ["nigrum", "OBSERVATION", 98, 104]]], ["Positive selection of CP region variants in common bean and S. nigrum together with higher virus fitness and diversity, and differential mutation distribution occur without alterations to begomovirus consensus sequences.", [["bean", "ORGANISM_SUBDIVISION", 51, 55], ["S. nigrum", "ORGANISM", 60, 69], ["CP region variants", "DNA", 22, 40], ["begomovirus consensus sequences", "DNA", 188, 219], ["bean", "SPECIES", 51, 55], ["S. nigrum", "SPECIES", 60, 69], ["common bean", "SPECIES", 44, 55], ["S. nigrum", "SPECIES", 60, 69], ["CP region variants", "PROBLEM", 22, 40], ["common bean", "PROBLEM", 44, 55], ["S. nigrum", "PROBLEM", 60, 69], ["higher virus fitness", "PROBLEM", 84, 104], ["differential mutation distribution", "PROBLEM", 124, 158], ["alterations to begomovirus consensus sequences", "PROBLEM", 173, 219], ["CP region", "OBSERVATION_MODIFIER", 22, 31], ["common bean", "ANATOMY", 44, 55]]], ["These results suggest that the mutant spectrum plays an important role in begomovirus infections in each host.DISCUSSIONSingle-stranded DNA viruses belonging to Parvoviridae, Geminiviridae, and Nanoviridae have been shown to be as variable as RNA viruses.", [["begomovirus", "ANATOMY", 74, 85], ["infections", "DISEASE", 86, 96], ["begomovirus", "CANCER", 74, 85], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["Parvoviridae", "GENE_OR_GENE_PRODUCT", 161, 173], ["Geminiviridae", "GENE_OR_GENE_PRODUCT", 175, 188], ["Nanoviridae", "GENE_OR_GENE_PRODUCT", 194, 205], ["begomovirus", "SPECIES", 74, 85], ["begomovirus infections", "PROBLEM", 74, 96], ["stranded DNA viruses", "PROBLEM", 127, 147], ["Parvoviridae", "TREATMENT", 161, 173], ["Geminiviridae", "TREATMENT", 175, 188], ["Nanoviridae", "TREATMENT", 194, 205], ["RNA viruses", "PROBLEM", 243, 254]]], ["Moreover, ssDNA virus populations, composed of mutant spectra, have shown strong adaptive capacities similar to those observed in RNA virus populations (Isnard et al., 1998; Nishizawa et al., 1999; L\u00f3pez-Bueno et al., 2006; Urbino et al., 2008; Grigoras et al., 2010) .", [["ssDNA virus populations", "PROBLEM", 10, 33], ["mutant spectra", "PROBLEM", 47, 61], ["strong adaptive capacities", "PROBLEM", 74, 100], ["L\u00f3pez", "TEST", 198, 203]]], ["The origin of this variability, however, remains unknown for these viruses.", [["these viruses", "PROBLEM", 61, 74], ["origin", "ANATOMY_MODIFIER", 4, 10], ["variability", "OBSERVATION", 19, 30], ["viruses", "OBSERVATION", 67, 74]]], ["Quasispecies-like evolution combined with invariance of the Rep, C4, and IR genomic consensus sequences has been previously described for the begomovirus tomato yellow leaf curl China virus (TYLCCNV) (Ge et al., 2007) in naturally infected tomato, and in tomato and Nicotiana benthamiana plants experimentally infected with TYLCCNV clones.", [["Rep", "GENE_OR_GENE_PRODUCT", 60, 63], ["C4", "GENE_OR_GENE_PRODUCT", 65, 67], ["begomovirus tomato", "ORGANISM", 142, 160], ["yellow leaf curl China virus", "ORGANISM", 161, 189], ["tomato", "ORGANISM", 240, 246], ["tomato", "ORGANISM", 255, 261], ["Nicotiana benthamiana", "ORGANISM", 266, 287], ["plants", "ORGANISM", 288, 294], ["TYLCCNV clones", "CELL", 324, 338], ["Rep, C4, and IR genomic consensus sequences", "DNA", 60, 103], ["TYLCCNV clones", "CELL_LINE", 324, 338], ["tomato", "SPECIES", 154, 160], ["yellow leaf curl China virus", "SPECIES", 161, 189], ["tomato", "SPECIES", 240, 246], ["tomato", "SPECIES", 255, 261], ["Nicotiana benthamiana", "SPECIES", 266, 287], ["begomovirus tomato yellow leaf curl China virus", "SPECIES", 142, 189], ["TYLCCNV", "SPECIES", 191, 198], ["tomato", "SPECIES", 240, 246], ["tomato", "SPECIES", 255, 261], ["Nicotiana benthamiana", "SPECIES", 266, 287], ["TYLCCNV", "SPECIES", 324, 331], ["Quasispecies", "PROBLEM", 0, 12], ["invariance of the Rep, C4, and IR genomic consensus sequences", "PROBLEM", 42, 103], ["the begomovirus tomato yellow leaf curl China virus", "PROBLEM", 138, 189], ["Nicotiana benthamiana plants", "TREATMENT", 266, 294], ["TYLCCNV clones", "TREATMENT", 324, 338], ["Nicotiana", "OBSERVATION", 266, 275], ["benthamiana plants", "OBSERVATION", 276, 294]]], ["Here we have looked at the evolution of the whole genomic consensus sequence and mutant spectra variability of the Rep, C4, IR, V2, and CP ORFs of three TYLCD-associated begomoviruses in species of the family Solanaceae family, that is, susceptible tomato, resistant tomato carrying the Ty-1 allele and the wild reservoir S. nigrum, as well as to common bean, a species of the distantly-related family Fabaceae.DISCUSSIONIn this work we noticed differences in the fitness of viral isolates between hosts.", [["Rep", "GENE_OR_GENE_PRODUCT", 115, 118], ["C4", "GENE_OR_GENE_PRODUCT", 120, 122], ["IR", "GENE_OR_GENE_PRODUCT", 124, 126], ["V2", "GENE_OR_GENE_PRODUCT", 128, 130], ["TYLCD", "GENE_OR_GENE_PRODUCT", 153, 158], ["Solanaceae", "ORGANISM", 209, 219], ["tomato", "ORGANISM", 249, 255], ["tomato", "ORGANISM", 267, 273], ["Ty-1", "GENE_OR_GENE_PRODUCT", 287, 291], ["S. nigrum", "ORGANISM", 322, 331], ["bean", "ORGANISM_SUBDIVISION", 354, 358], ["genomic consensus sequence", "DNA", 50, 76], ["Rep, C4, IR, V2, and CP ORFs", "DNA", 115, 143], ["TYLCD", "PROTEIN", 153, 158], ["Ty-1 allele", "DNA", 287, 298], ["tomato", "SPECIES", 249, 255], ["tomato", "SPECIES", 267, 273], ["S. nigrum", "SPECIES", 322, 331], ["bean", "SPECIES", 354, 358], ["tomato", "SPECIES", 249, 255], ["tomato", "SPECIES", 267, 273], ["S. nigrum", "SPECIES", 322, 331], ["bean", "SPECIES", 354, 358], ["the whole genomic consensus sequence", "PROBLEM", 40, 76], ["mutant spectra variability of the Rep, C4, IR, V2, and CP ORFs", "PROBLEM", 81, 143], ["viral isolates between hosts", "PROBLEM", 475, 503], ["begomoviruses", "OBSERVATION", 170, 183]]], ["We used daily Malthusian growth rates (m) to estimate viral fitness since differences in growth rate reflect fitness to a great extent and also because single sequence variants were used to infect hosts (Lali\u0107 et al., 2011) .", [["daily Malthusian growth rates", "TREATMENT", 8, 37], ["viral fitness", "PROBLEM", 54, 67], ["single sequence variants", "PROBLEM", 152, 176], ["viral fitness", "OBSERVATION", 54, 67], ["great extent", "OBSERVATION_MODIFIER", 122, 134]]], ["Further, because monopartite begomoviruses are restricted to the phloem and replicate only in companion cells perturbations in copy numbers are reduced.", [["phloem", "ANATOMY", 65, 71], ["cells", "ANATOMY", 104, 109], ["monopartite begomoviruses", "ORGANISM", 17, 42], ["phloem", "TISSUE", 65, 71], ["cells", "CELL", 104, 109], ["companion cells", "CELL_TYPE", 94, 109], ["monopartite begomoviruses", "PROBLEM", 17, 42], ["begomoviruses", "OBSERVATION", 29, 42], ["reduced", "OBSERVATION_MODIFIER", 144, 151]]], ["Thus, at the last assay time point (45 dpi) fitness in tomato of either TYLCSV or TYLCV was lower than in S. nigrum or common bean, respectively.", [["TYLCSV", "CHEMICAL", 72, 78], ["tomato", "ORGANISM", 55, 61], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 72, 78], ["TYLCV", "ORGANISM", 82, 87], ["S. nigrum", "ORGANISM", 106, 115], ["bean", "ORGANISM_SUBDIVISION", 126, 130], ["tomato", "SPECIES", 55, 61], ["S. nigrum", "SPECIES", 106, 115], ["bean", "SPECIES", 126, 130], ["tomato", "SPECIES", 55, 61], ["TYLCSV", "SPECIES", 72, 78], ["TYLCV", "SPECIES", 82, 87], ["S. nigrum", "SPECIES", 106, 115], ["bean", "SPECIES", 126, 130], ["TYLCV", "PROBLEM", 82, 87]]], ["This was clearly evident in tomato plants bearing the Ty-1 resistance allele, where negative growth rate values were obtained for both TYLCSV and TYLCV, in contrast to TYLCMaV.", [["tomato plants", "ORGANISM", 28, 41], ["Ty-1", "GENE_OR_GENE_PRODUCT", 54, 58], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 135, 141], ["TYLCV", "ORGANISM", 146, 151], ["Ty-1 resistance allele", "DNA", 54, 76], ["TYLCMaV", "PROTEIN", 168, 175], ["tomato", "SPECIES", 28, 34], ["tomato", "SPECIES", 28, 34], ["TYLCV", "SPECIES", 146, 151], ["TYLCV", "ANATOMY", 146, 151]]], ["The fitness of this latter virus remained stable over time in resistant tomato and no significant differences were seen between hosts.", [["tomato", "ORGANISM", 72, 78], ["tomato", "SPECIES", 72, 78], ["tomato", "SPECIES", 72, 78], ["this latter virus", "PROBLEM", 15, 32], ["stable", "OBSERVATION_MODIFIER", 42, 48]]], ["Indeed, the statistics support that there are no significant differences in TYLCMaV accumulation between susceptible and resistant tomato.", [["TYLCMaV", "CHEMICAL", 76, 83], ["TYLCMaV", "SIMPLE_CHEMICAL", 76, 83], ["tomato", "ORGANISM", 131, 137], ["tomato", "SPECIES", 131, 137], ["tomato", "SPECIES", 131, 137], ["significant differences in TYLCMaV accumulation", "PROBLEM", 49, 96], ["susceptible and resistant tomato", "PROBLEM", 105, 137], ["no", "UNCERTAINTY", 46, 48], ["significant", "OBSERVATION_MODIFIER", 49, 60]]], ["It is interesting that in genotypes with the resistance gene the accumulation of TYLCMaV does not decrease much, compared with the other two TYLCD-associated viruses tested.", [["TYLCMaV", "GENE_OR_GENE_PRODUCT", 81, 88], ["TYLCD", "GENE_OR_GENE_PRODUCT", 141, 146], ["TYLCMaV", "PROTEIN", 81, 88], ["the resistance gene the accumulation of TYLCMaV", "PROBLEM", 41, 88], ["viruses", "OBSERVATION", 158, 165]]], ["Its better adaptation in resistant genotypes can have important ecological consequences Therefore, our results corroborate that TYLCMAV is a virus with resistance-breaking properties.", [["TYLCMAV", "CHEMICAL", 128, 135], ["TYLCMAV", "GENE_OR_GENE_PRODUCT", 128, 135], ["resistant genotypes", "PROBLEM", 25, 44], ["a virus", "PROBLEM", 139, 146]]], ["How TYLCMaV, is able to overcome the growth restriction conferred by the Ty-1 gene, despite the genome sequences of the recombinant virus sharing 99% identity with the corresponding parental virus sequences, is an interesting open question.", [["TYLCMaV", "CHEMICAL", 4, 11], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 4, 11], ["Ty-1", "GENE_OR_GENE_PRODUCT", 73, 77], ["recombinant virus", "ORGANISM", 120, 137], ["TYLCMaV", "PROTEIN", 4, 11], ["Ty-1 gene", "DNA", 73, 82], ["genome sequences", "DNA", 96, 112], ["the growth restriction", "PROBLEM", 33, 55]]], ["An improved combination of coding and/or nonconding regions may have been selected after a recombination event in TYLCMaV that better overcame Ty-1 resistance allele limitations.", [["Ty-1", "GENE_OR_GENE_PRODUCT", 143, 147], ["coding and/or nonconding regions", "DNA", 27, 59], ["Ty-1 resistance allele", "DNA", 143, 165], ["coding and/or nonconding regions", "PROBLEM", 27, 59], ["improved", "OBSERVATION_MODIFIER", 3, 11]]], ["The Ty-1 allele has been shown to impair the accumulation of begomoviruses involved in TYLCD (Garc\u00eda-Andr\u00e9s et al., 2009) , although, similar to the results obtained here, it has been shown to have little effect on TYLCMaV .", [["Ty-1", "GENE_OR_GENE_PRODUCT", 4, 8], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 215, 222], ["Ty-1 allele", "DNA", 4, 15], ["TYLCMaV", "PROTEIN", 215, 222], ["begomoviruses", "PROBLEM", 61, 74], ["begomoviruses", "OBSERVATION", 61, 74]]], ["Ty-1 encodes a \u03b3 type RNA-directed RNA polymerase (RDRP) (Verlaan et al., 2013) , with Ty-1 resistance involving enhanced transcriptional gene silencing against TYLCV, as revealed by the enrichment of siRNAs directed against CP and REn, and cytosine methylation of the CP promoter region (Butterbach et al., 2014) .", [["cytosine", "CHEMICAL", 241, 249], ["cytosine", "CHEMICAL", 241, 249], ["Ty-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ty-1", "GENE_OR_GENE_PRODUCT", 87, 91], ["TYLCV", "ORGANISM", 161, 166], ["CP", "GENE_OR_GENE_PRODUCT", 225, 227], ["REn", "GENE_OR_GENE_PRODUCT", 232, 235], ["cytosine", "SIMPLE_CHEMICAL", 241, 249], ["Ty-1", "DNA", 0, 4], ["\u03b3 type RNA-directed RNA polymerase", "PROTEIN", 15, 49], ["RDRP", "PROTEIN", 51, 55], ["REn", "DNA", 232, 235], ["CP promoter region", "DNA", 269, 287], ["TYLCV", "SPECIES", 161, 166], ["TYLCV", "PROBLEM", 161, 166], ["siRNAs", "TREATMENT", 201, 207], ["CP", "PROBLEM", 225, 227], ["cytosine methylation of the CP promoter region", "TREATMENT", 241, 287]]], ["We did not detect differences in the complexity or heterogeneity of the three begomovirus mutant spectra in the presence or absence of the Ty-1 allele for any of the genomic regions analyzed in this study.", [["Ty-1", "GENE_OR_GENE_PRODUCT", 139, 143], ["Ty-1 allele", "DNA", 139, 150], ["genomic regions", "DNA", 166, 181], ["the three begomovirus mutant spectra", "PROBLEM", 68, 104], ["this study", "TEST", 194, 204]]], ["Nevertheless, in resistant tomato, our data show that a high mutation frequency value was observed for the C4 region of TYLCSV, the most restricted virus , suggesting exploration of TYLCSV for better adapted variants to overcome restriction imposed by this host.", [["tomato", "ORGANISM", 27, 33], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 120, 126], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 182, 188], ["C4 region", "PROTEIN", 107, 116], ["TYLCSV", "PROTEIN", 182, 188], ["tomato", "SPECIES", 27, 33], ["tomato", "SPECIES", 27, 33], ["our data", "TEST", 35, 43], ["a high mutation frequency value", "PROBLEM", 54, 85], ["TYLCSV", "PROBLEM", 120, 126], ["the most restricted virus", "PROBLEM", 128, 153], ["exploration of TYLCSV", "TREATMENT", 167, 188], ["C4", "ANATOMY_MODIFIER", 107, 109], ["TYLCSV", "ANATOMY", 120, 126]]], ["As C4 has been shown to be a mild suppressor of gene silencing (Luna et al., 2012) and a viral determinant in overcoming the genetic resistance of some wild tomato species (Tom\u00e1s et al., 2011) , the role of this region in permitting viral accumulation in the presence of Ty-1 merits further study.", [["C4", "GENE_OR_GENE_PRODUCT", 3, 5], ["tomato", "ORGANISM", 157, 163], ["Ty-1", "GENE_OR_GENE_PRODUCT", 271, 275], ["C4", "PROTEIN", 3, 5], ["Ty", "DNA", 271, 273], ["tomato", "SPECIES", 157, 163], ["tomato", "SPECIES", 157, 163], ["a mild suppressor of gene silencing", "PROBLEM", 27, 62], ["a viral determinant", "PROBLEM", 87, 106], ["some wild tomato species", "PROBLEM", 147, 171], ["permitting viral accumulation", "PROBLEM", 222, 251], ["further study", "TEST", 283, 296], ["mild", "OBSERVATION_MODIFIER", 29, 33], ["suppressor", "OBSERVATION", 34, 44], ["gene silencing", "OBSERVATION", 48, 62], ["tomato species", "OBSERVATION", 157, 171], ["viral accumulation", "OBSERVATION", 233, 251]]], ["Since the sequence of the TYLCMaV isolate used in this work only differs in 7 and 15 nucleotide changes to the corresponding sequences of the parental TYLCV and TYLCSV viruses, respectively, it seems reasonable to hypothesize that the key to overcoming Ty-1 resistance resides in this particular combination of nucleotide changes, with those detected in the C4 ORF being prime candidates.", [["nucleotide", "CHEMICAL", 311, 321], ["nucleotide", "CHEMICAL", 85, 95], ["nucleotide", "CHEMICAL", 311, 321], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 26, 33], ["TYLCV", "ORGANISM", 151, 156], ["TYLCSV viruses", "ORGANISM", 161, 175], ["Ty-1", "GENE_OR_GENE_PRODUCT", 253, 257], ["Ty", "DNA", 253, 255], ["C4 ORF", "DNA", 358, 364], ["TYLCV", "SPECIES", 151, 156], ["TYLCSV viruses", "SPECIES", 161, 175], ["the TYLCMaV isolate", "TREATMENT", 22, 41], ["15 nucleotide changes", "PROBLEM", 82, 103], ["nucleotide changes", "PROBLEM", 311, 329], ["parental TYLCV", "ANATOMY", 142, 156], ["TYLCSV viruses", "OBSERVATION", 161, 175]]], ["Alternatively, an optimized combination of genome fragments to overcome Ty-1 resistance might be achieved in this virus driven by a recombination event then supporting the importance of modular evolution to adapt to a fluctuating environment (Botstein, 1980; Stavrinides and Guttman, 2004; Belabess et al., 2016) .DISCUSSIONThe presence of putative low fitness variants in mutant spectra could be the result of compensatory mutations to maintain RNA secondary structure.", [["fragments", "ANATOMY", 50, 59], ["Ty-1", "GENE_OR_GENE_PRODUCT", 72, 76], ["genome fragments", "DNA", 43, 59], ["Ty", "DNA", 72, 74], ["genome fragments", "PROBLEM", 43, 59], ["this virus", "PROBLEM", 109, 119], ["putative low fitness variants in mutant spectra", "PROBLEM", 340, 387], ["compensatory mutations", "PROBLEM", 411, 433], ["genome fragments", "OBSERVATION", 43, 59], ["low fitness", "OBSERVATION", 349, 360], ["compensatory mutations", "OBSERVATION", 411, 433], ["secondary structure", "OBSERVATION", 450, 469]]], ["Our analysis of mutant spectra identified insertions, deletions, nonsense mutations and readthrough mutations.", [["Our analysis", "TEST", 0, 12], ["mutant spectra identified insertions, deletions", "PROBLEM", 16, 63], ["nonsense mutations and readthrough mutations", "PROBLEM", 65, 109]]], ["Such changes often have deleterious or lethal effects on proteins.", [["Such changes", "PROBLEM", 0, 12], ["lethal effects on proteins", "PROBLEM", 39, 65]]], ["Others may affect secondary structure or fall in regulatory elements needed to maintain structure for function like some of the mutations found in the IR adjacent to or within a regulatory element (see Table 4 and Figure 7) .", [["regulatory elements", "DNA", 49, 68], ["regulatory element", "DNA", 178, 196], ["secondary structure", "PROBLEM", 18, 37], ["fall in regulatory elements", "PROBLEM", 41, 68], ["the mutations", "PROBLEM", 124, 137]]], ["Among mutations found in TYLCSV, TYLCV and TYLCMaV during infection time-courses in the four hosts (included in Table 4) we highlight the following.", [["infection", "DISEASE", 58, 67], ["TYLCSV", "GENE_OR_GENE_PRODUCT", 25, 31], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 43, 50], ["TYLCV", "SPECIES", 33, 38], ["Among mutations", "PROBLEM", 0, 15], ["TYLCV", "PROBLEM", 33, 38]]], ["The nonsense mutation Q81Stop (C395T) found in the TYLCV V2 protein in infected common bean lacks residues C84 and C86 that have been shown to be essential for PTGS suppression and interaction with the tomato SGS3 protein (Zrachya et al., 2007; Glick et al., 2008) .", [["TYLCV V2", "ORGANISM", 51, 59], ["bean", "ORGANISM", 87, 91], ["C84", "GENE_OR_GENE_PRODUCT", 107, 110], ["C86", "AMINO_ACID", 115, 118], ["tomato", "ORGANISM", 202, 208], ["SGS3", "GENE_OR_GENE_PRODUCT", 209, 213], ["TYLCV V2 protein", "PROTEIN", 51, 67], ["C86", "PROTEIN", 115, 118], ["tomato SGS3 protein", "PROTEIN", 202, 221], ["bean", "SPECIES", 87, 91], ["tomato", "SPECIES", 202, 208], ["TYLCV", "SPECIES", 51, 56], ["tomato", "SPECIES", 202, 208], ["The nonsense mutation", "PROBLEM", 0, 21], ["the TYLCV V2 protein", "PROBLEM", 47, 67], ["PTGS suppression", "PROBLEM", 160, 176], ["infected", "OBSERVATION", 71, 79]]], ["The Rep missense mutation C2466T in TYLCMaV-infected resistant tomato, results in an E52K (C2466T) amino acid change between the RCR-1 and RCR-2 DNA binding motifs involved in the specific binding of Rep to DNA (Jupin et al., 1995) .", [["amino acid", "CHEMICAL", 99, 109], ["amino acid", "CHEMICAL", 99, 109], ["Rep", "GENE_OR_GENE_PRODUCT", 4, 7], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 36, 43], ["tomato", "ORGANISM", 63, 69], ["E52K", "GENE_OR_GENE_PRODUCT", 85, 89], ["amino acid", "AMINO_ACID", 99, 109], ["RCR-1", "GENE_OR_GENE_PRODUCT", 129, 134], ["RCR-2", "GENE_OR_GENE_PRODUCT", 139, 144], ["DNA", "CELLULAR_COMPONENT", 145, 148], ["Rep", "GENE_OR_GENE_PRODUCT", 200, 203], ["DNA", "CELLULAR_COMPONENT", 207, 210], ["Rep missense mutation C2466T", "DNA", 4, 32], ["RCR-1 and RCR-2 DNA binding motifs", "DNA", 129, 163], ["Rep", "PROTEIN", 200, 203], ["tomato", "SPECIES", 63, 69], ["tomato", "SPECIES", 63, 69], ["The Rep missense mutation", "TEST", 0, 25], ["infected resistant tomato", "PROBLEM", 44, 69], ["an E52K", "TEST", 82, 89], ["amino acid change", "PROBLEM", 99, 116], ["the RCR", "TEST", 125, 132], ["RCR", "TEST", 139, 142]]], ["The TYLCSV CP V135I and M136I (G711A and G716A, respectively) mutations are in the critical 129-152 region required for effective capsid assembly and transmissibility by Bemisia tabaci, the virus vector (Noris et al., 1998; Hallan and Gafni, 2001; Caciagli et al., 2009) , although in our experimental design the latter is not a limiting factor.", [["Bemisia tabaci", "ORGANISM", 170, 184], ["129-152 region", "DNA", 92, 106], ["Bemisia tabaci", "SPECIES", 170, 184], ["Bemisia tabaci", "SPECIES", 170, 184], ["The TYLCSV CP", "TEST", 0, 13], ["G716A", "TEST", 41, 46]]], ["The TYLCMaV CP R18C (C360T) amino acid change is adjacent to R19L, a change which has been shown to deeply impact both TYLCV capsid assembly, as well as CP protein interaction with the tomato nuclear receptor karyopherin \u03b11 and the GroEL protein of B. tabaci bacterial endosymbiont (Yaakov et al., 2011) .", [["nuclear", "ANATOMY", 192, 199], ["amino acid", "CHEMICAL", 28, 38], ["amino acid", "CHEMICAL", 28, 38], ["amino acid", "AMINO_ACID", 28, 38], ["karyopherin \u03b11", "GENE_OR_GENE_PRODUCT", 209, 223], ["GroEL", "GENE_OR_GENE_PRODUCT", 232, 237], ["B. tabaci", "ORGANISM", 249, 258], ["R19L", "PROTEIN", 61, 65], ["CP protein", "PROTEIN", 153, 163], ["tomato nuclear receptor", "PROTEIN", 185, 208], ["karyopherin \u03b11", "PROTEIN", 209, 223], ["GroEL protein", "PROTEIN", 232, 245], ["B. tabaci", "SPECIES", 249, 258], ["TYLCV", "SPECIES", 119, 124], ["tomato", "SPECIES", 185, 191], ["B. tabaci", "SPECIES", 249, 258], ["The TYLCMaV CP R18C", "TREATMENT", 0, 19], ["amino acid change", "PROBLEM", 28, 45], ["CP protein interaction", "PROBLEM", 153, 175], ["TYLCV capsid", "OBSERVATION", 119, 131]]], ["CP mutations Q76E, Y78H, K80T, and R82C (C540G, T546C, A568C, and C585T, respectively) of TYLCV, and Q79H, R80L and D82V (G545T, G547T, and A553T) of TYLCMaV would affect the putative zinc finger motif, thus potentially impairing the ssDNA binding capacity of this protein.DISCUSSIONIt could be argued that the probability of sequencing genomes with low frequency is expected to be extremely low because of a potential RCA bias (only 0.05% available genomes amplified with RCA) (Gallet et al., 2017) and because of the limited number of sequenced genomes (about 20).", [["zinc", "CHEMICAL", 184, 188], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 150, 157], ["ssDNA", "CELLULAR_COMPONENT", 234, 239], ["TYLCMaV", "PROTEIN", 150, 157], ["zinc finger motif", "PROTEIN", 184, 201], ["RCA", "DNA", 419, 422], ["TYLCV", "SPECIES", 90, 95], ["CP mutations", "TEST", 0, 12], ["K80T", "TEST", 25, 29], ["TYLCV", "TEST", 90, 95], ["G547T", "TEST", 129, 134], ["TYLCMaV", "TREATMENT", 150, 157], ["the putative zinc finger motif", "PROBLEM", 171, 201], ["a potential RCA bias", "PROBLEM", 407, 427]]], ["In this sense, as a measure to reduce the amplification bias, 3-7 \u00d7 10 8 viral genomes were used as input for RCA, which means that roughly 1.5-3.5 \u00d7 10 5 molecules may have served as template for amplification so no bottlenecks were created at this step.", [["viral genomes", "DNA", 73, 86], ["RCA", "DNA", 110, 113], ["the amplification bias", "TEST", 38, 60], ["8 viral genomes", "TREATMENT", 71, 86], ["RCA", "TEST", 110, 113], ["bottlenecks", "PROBLEM", 217, 228]]], ["Notwithstanding, there is a previous report with the same experimental nanovirus system (Grigoras et al., 2009) in which the relative quantity of the eight segments of FBNSV, measured by qPCR in total DNA of infected plant tissue, was similar.", [["tissue", "ANATOMY", 223, 229], ["FBNSV", "GENE_OR_GENE_PRODUCT", 168, 173], ["DNA", "CELLULAR_COMPONENT", 201, 204], ["plant tissue", "TISSUE", 217, 229], ["FBNSV", "PROTEIN", 168, 173], ["FBNSV", "TEST", 168, 173], ["qPCR", "TEST", 187, 191], ["infected plant tissue", "PROBLEM", 208, 229], ["eight segments", "ANATOMY_MODIFIER", 150, 164], ["infected plant tissue", "OBSERVATION", 208, 229], ["similar", "OBSERVATION_MODIFIER", 235, 242]]], ["In addition, the same relative abundance was found in qPCR analysis after performing RCA of the same total DNA or after restriction of the same RCA product with a single-cut enzyme, which ruled out a bias in the RCA.", [["DNA", "CELLULAR_COMPONENT", 107, 110], ["RCA", "DNA", 85, 88], ["total DNA", "DNA", 101, 110], ["RCA product", "PROTEIN", 144, 155], ["RCA", "DNA", 212, 215], ["qPCR analysis", "TEST", 54, 67], ["a bias in the RCA", "PROBLEM", 198, 215], ["bias", "OBSERVATION", 200, 204], ["RCA", "ANATOMY", 212, 215]]], ["Finally, the analysis of 20 clones per quasispecies may appear insufficient, but assuming each clone is present with a relative frequency of at least 5% within the quasispecies, it means that we might be detecting at least a portion of the most frequent viral variants that are high fitness variants.DISCUSSIONHere we have shown that, after the inoculation of a single sequence variant, complex populations arise with a high number of different begomovirus genomes accumulating within each individual plant.", [["clone", "CELL", 95, 100], ["begomovirus genomes", "DNA", 445, 464], ["the analysis", "TEST", 9, 21], ["20 clones per quasispecies", "PROBLEM", 25, 51], ["the most frequent viral variants", "PROBLEM", 236, 268], ["a single sequence variant", "TREATMENT", 360, 385], ["complex populations", "PROBLEM", 387, 406], ["different begomovirus genomes", "PROBLEM", 435, 464], ["most frequent", "OBSERVATION_MODIFIER", 240, 253], ["viral variants", "OBSERVATION", 254, 268], ["high fitness", "OBSERVATION", 278, 290], ["high number", "OBSERVATION_MODIFIER", 420, 431], ["different", "OBSERVATION_MODIFIER", 435, 444], ["begomovirus genomes", "OBSERVATION", 445, 464]]], ["We estimate that an average of 2 \u00d7 10 11 begomovirus genomic variants coexist per gram of fresh tissue in apical tomato leaves.", [["tissue", "ANATOMY", 96, 102], ["leaves", "ANATOMY", 120, 126], ["tissue", "TISSUE", 96, 102], ["tomato leaves", "ORGANISM_SUBSTANCE", 113, 126], ["begomovirus genomic variants", "DNA", 41, 69], ["tomato", "SPECIES", 113, 119], ["tomato", "SPECIES", 113, 119], ["begomovirus genomic variants", "PROBLEM", 41, 69], ["fresh tissue", "OBSERVATION_MODIFIER", 90, 102], ["apical", "ANATOMY_MODIFIER", 106, 112], ["tomato leaves", "OBSERVATION", 113, 126]]], ["Tenfold higher-numbers are reached in common bean and the wild reservoir, S. nigrum.", [["bean", "ORGANISM_SUBDIVISION", 45, 49], ["S. nigrum", "ORGANISM", 74, 83], ["bean", "SPECIES", 45, 49], ["S. nigrum", "SPECIES", 74, 83], ["bean", "SPECIES", 45, 49], ["S. nigrum", "SPECIES", 74, 83], ["higher", "OBSERVATION_MODIFIER", 8, 14], ["common bean", "ANATOMY", 38, 49], ["wild", "OBSERVATION_MODIFIER", 58, 62], ["reservoir", "OBSERVATION_MODIFIER", 63, 72], ["nigrum", "OBSERVATION", 77, 83]]], ["This allows begomovirus quasispecies to explore intensively and efficiently sequence space conferring them an enormous capacity to adapt and overcome selective constraints imposed by the host such as the innate or adaptive immune response or post transcriptional gene silencing (Vanitharani et al., 2005; Chen et al., 2010; Raja et al., 2010) .", [["begomovirus quasispecies", "PROBLEM", 12, 36], ["an enormous capacity", "PROBLEM", 107, 127]]], ["The presence of high viral loads of highly diverse geminiviruses is of particular importance for viral emergence.", [["high viral loads of highly diverse geminiviruses", "PROBLEM", 16, 64], ["viral emergence", "PROBLEM", 97, 112], ["high", "OBSERVATION_MODIFIER", 16, 20], ["viral loads", "OBSERVATION", 21, 32], ["diverse", "OBSERVATION_MODIFIER", 43, 50], ["geminiviruses", "OBSERVATION", 51, 64]]], ["In the infection time-courses, TYLCMaV was able to infect and accumulate sustained high titers within every individual plant species tested, even in the resistant tomato.", [["infection", "DISEASE", 7, 16], ["TYLCMaV", "CHEMICAL", 31, 38], ["TYLCMaV", "SIMPLE_CHEMICAL", 31, 38], ["tomato", "ORGANISM", 163, 169], ["TYLCMaV", "PROTEIN", 31, 38], ["tomato", "SPECIES", 163, 169], ["TYLCMaV", "SPECIES", 31, 38], ["tomato", "SPECIES", 163, 169], ["TYLCMaV", "TREATMENT", 31, 38], ["sustained high titers", "PROBLEM", 73, 94], ["infection", "OBSERVATION", 7, 16], ["high titers", "OBSERVATION", 83, 94]]], ["We showed that quasispecies complexity is especially high in common bean and S. nigrum.", [["bean", "ORGANISM_SUBDIVISION", 68, 72], ["S. nigrum", "ORGANISM", 77, 86], ["bean", "SPECIES", 68, 72], ["S. nigrum", "SPECIES", 77, 86], ["bean", "SPECIES", 68, 72], ["S. nigrum", "SPECIES", 77, 86], ["quasispecies complexity", "PROBLEM", 15, 38], ["quasispecies", "OBSERVATION", 15, 27], ["high", "OBSERVATION_MODIFIER", 53, 57], ["nigrum", "OBSERVATION", 80, 86]]], ["Common bean is usually employed as a transition host between tomato crops in field rotations, for example in Spain , which might favor diversification of the begomovirus population between tomato crops.", [["bean", "ORGAN", 7, 11], ["tomato", "ORGANISM", 61, 67], ["tomato", "ORGANISM", 189, 195], ["tomato", "SPECIES", 61, 67], ["tomato", "SPECIES", 189, 195], ["tomato", "SPECIES", 61, 67], ["tomato", "SPECIES", 189, 195], ["the begomovirus population", "PROBLEM", 154, 180], ["begomovirus", "OBSERVATION", 158, 169]]], ["S. nigrum is a common wild reservoir in growing areas (Garc\u00eda-Andr\u00e9s et al., 2006) , therefore its presence can ensure the maintenance of begomovirus diversity for new epidemics.", [["S. nigrum", "ORGANISM", 0, 9], ["S. nigrum", "SPECIES", 0, 9], ["S. nigrum", "SPECIES", 0, 9], ["begomovirus diversity", "TREATMENT", 138, 159], ["new epidemics", "PROBLEM", 164, 177], ["nigrum", "OBSERVATION", 3, 9], ["reservoir", "OBSERVATION_MODIFIER", 27, 36], ["growing", "OBSERVATION_MODIFIER", 40, 47]]], ["Importantly, mutations arising in wild reservoirs could be transmitted to crop plants by the insect vector B. tabaci, potentially resulting in the emergence and spread of new better fit variants.", [["B. tabaci", "ORGANISM", 107, 116], ["B. tabaci", "SPECIES", 107, 116], ["B. tabaci", "SPECIES", 107, 116], ["mutations", "PROBLEM", 13, 22], ["new", "OBSERVATION_MODIFIER", 171, 174], ["better fit variants", "OBSERVATION", 175, 194]]], ["TYLCMaV can efficiently infect the Ty-1-resistant tomato frequently used to contain TYLCD epidemics, as well as the wild host S. nigrum and common bean (Noris et al., 1994) .", [["TYLCMaV", "CHEMICAL", 0, 7], ["Ty-1", "CHEMICAL", 35, 39], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 0, 7], ["Ty-1", "GENE_OR_GENE_PRODUCT", 35, 39], ["tomato", "ORGANISM", 50, 56], ["TYLCD", "GENE_OR_GENE_PRODUCT", 84, 89], ["S. nigrum", "ORGANISM", 126, 135], ["bean", "ORGANISM_SUBDIVISION", 147, 151], ["TYLCMaV", "PROTEIN", 0, 7], ["tomato", "SPECIES", 50, 56], ["S. nigrum", "SPECIES", 126, 135], ["bean", "SPECIES", 147, 151], ["TYLCMaV", "SPECIES", 0, 7], ["tomato", "SPECIES", 50, 56], ["S. nigrum", "SPECIES", 126, 135], ["bean", "SPECIES", 147, 151], ["TYLCMaV", "TREATMENT", 0, 7], ["TYLCD epidemics", "PROBLEM", 84, 99]]], ["Therefore, the high viral diversity of TYLCMaV infections might favor the appearance of ecologically-better adapted emergent variants.DISCUSSIONPositive selection in the CP region was observed in all three begomovirus quasispecies evolving in common bean and S. nigrum, but not in tomato.", [["TYLCMaV", "CHEMICAL", 39, 46], ["infections", "DISEASE", 47, 57], ["TYLCMaV", "GENE_OR_GENE_PRODUCT", 39, 46], ["bean", "ORGANISM_SUBDIVISION", 250, 254], ["S. nigrum", "ORGANISM", 259, 268], ["tomato", "ORGANISM", 281, 287], ["CP region", "DNA", 170, 179], ["bean", "SPECIES", 250, 254], ["S. nigrum", "SPECIES", 259, 268], ["tomato", "SPECIES", 281, 287], ["TYLCMaV", "SPECIES", 39, 46], ["bean", "SPECIES", 250, 254], ["S. nigrum", "SPECIES", 259, 268], ["tomato", "SPECIES", 281, 287], ["TYLCMaV infections", "PROBLEM", 39, 57], ["DISCUSSIONPositive selection in the CP region", "PROBLEM", 134, 179], ["all three begomovirus quasispecies", "PROBLEM", 196, 230], ["high", "OBSERVATION_MODIFIER", 15, 19], ["viral diversity", "OBSERVATION", 20, 35], ["TYLCMaV infections", "OBSERVATION", 39, 57], ["CP", "ANATOMY", 170, 172], ["region", "ANATOMY_MODIFIER", 173, 179], ["begomovirus quasispecies", "OBSERVATION", 206, 230], ["common bean", "ANATOMY", 243, 254]]], ["This finding is unexpected because capsid proteins are involved in vector recognition and particle formation (Noris et al., 1998) , and are therefore usually more resistant to selective pressures, as evidenced by lower d NS /d S ratios in other viruses (Chare and Holmes, 2004) .", [["capsid proteins", "PROTEIN", 35, 50], ["capsid proteins", "PROBLEM", 35, 50], ["selective pressures", "TEST", 176, 195], ["lower d NS /d S ratios", "PROBLEM", 213, 235], ["particle", "OBSERVATION_MODIFIER", 90, 98]]], ["However, our results indicate that under the conditions studied begomovirus CP region incorporated nonsynonymous mutations and accepted more drastic amino acid changes than other genomic regions.", [["amino acid", "CHEMICAL", 149, 159], ["amino acid", "CHEMICAL", 149, 159], ["amino acid", "AMINO_ACID", 149, 159], ["begomovirus CP region", "DNA", 64, 85], ["genomic regions", "DNA", 179, 194], ["begomovirus CP region", "PROBLEM", 64, 85], ["nonsynonymous mutations", "PROBLEM", 99, 122], ["more drastic amino acid changes", "PROBLEM", 136, 167], ["nonsynonymous mutations", "OBSERVATION", 99, 122], ["drastic", "OBSERVATION_MODIFIER", 141, 148], ["amino acid", "OBSERVATION", 149, 159]]], ["Purifying selection might occur in nature during the transmission process, which was not included in our experimental design, as CP strongly determines insect recognition (Noris et al., 1998) .", [["CP", "CHEMICAL", 129, 131]]], ["Nevertheless, under the same experimental conditions, the absence of positive selection in tomato suggests that additional selective constraints on quasispecies development exist in tomato that are absent from the other hosts.", [["tomato", "ORGANISM", 91, 97], ["tomato", "ORGANISM", 182, 188], ["tomato", "SPECIES", 91, 97], ["tomato", "SPECIES", 182, 188], ["tomato", "SPECIES", 91, 97], ["tomato", "SPECIES", 182, 188], ["positive selection in tomato", "PROBLEM", 69, 97], ["additional selective constraints on quasispecies development", "PROBLEM", 112, 172]]], ["Another reason why positive selection in the CP region is surprising is because we showed that quasispecies consensus sequences did not change in any of the hosts.", [["CP region", "DNA", 45, 54], ["quasispecies consensus sequences", "DNA", 95, 127], ["positive selection in the CP region", "PROBLEM", 19, 54], ["quasispecies consensus sequences", "PROBLEM", 95, 127], ["CP", "ANATOMY", 45, 47], ["region", "ANATOMY_MODIFIER", 48, 54], ["quasispecies", "OBSERVATION", 95, 107]]], ["It has been suggested that rates of mutation fixation can be higher when viruses are under positive selection, such as when they are adapting to a new host or to cell culture, thus allowing beneficial mutations to become dominant in a short period of time (Carrigan and Knox, 1990; Fares et al., 2001; Acosta-Leal et al., 2011; Domingo et al., 2012) .", [["cell culture", "ANATOMY", 162, 174], ["cell culture", "CELL", 162, 174], ["mutation fixation", "TREATMENT", 36, 53], ["cell culture", "TEST", 162, 174], ["beneficial mutations", "PROBLEM", 190, 210]]], ["It is worth mentioning that the host change between the plant from which the viral clones were isolated, where they were probably better adapted, and the test plants could constitute such an environmental change (Ba\u00f1uelos-Hern\u00e1ndez et al., 2012) .", [["the host change", "PROBLEM", 28, 43], ["the viral clones", "PROBLEM", 73, 89], ["the test plants", "TREATMENT", 150, 165], ["host", "OBSERVATION_MODIFIER", 32, 36], ["change", "OBSERVATION", 37, 43], ["viral clones", "OBSERVATION", 77, 89]]], ["The nonanucleotide sequence conserved in all geminiviruses and the cleavage site for the initiation of rolling-circle replication in the stem-loop are also shown.", [["stem-loop", "ANATOMY", 137, 146], ["nonanucleotide sequence", "DNA", 4, 27], ["cleavage site", "DNA", 67, 80], ["The nonanucleotide sequence", "TEST", 0, 27], ["all geminiviruses", "PROBLEM", 41, 58], ["the cleavage site", "PROBLEM", 63, 80], ["rolling-circle replication in the stem-loop", "TREATMENT", 103, 146], ["geminiviruses", "OBSERVATION", 45, 58], ["rolling", "OBSERVATION_MODIFIER", 103, 110], ["stem", "ANATOMY", 137, 141]]], ["(B) Representation of the nucleotide mutations found in clones obtained from susceptible (\u2022) and resistant tomato ( ), common bean (\u2666) and Solanum nigrum ( ) plants inoculated with TYLCSV (red), TYLCV (blue) or TYLCMaV (green) infectious clones.", [["clones", "ANATOMY", 56, 62], ["clones", "ANATOMY", 238, 244], ["nucleotide", "CHEMICAL", 26, 36], ["nucleotide", "CHEMICAL", 26, 36], ["clones", "CELL", 56, 62], ["tomato", "ORGANISM", 107, 113], ["bean", "ORGANISM_SUBDIVISION", 126, 130], ["Solanum nigrum ( ) plants", "ORGANISM", 139, 164], ["TYLCSV (red)", "ORGANISM", 181, 193], ["TYLCV (blue)", "ORGANISM", 195, 207], ["TYLCMaV (green)", "GENE_OR_GENE_PRODUCT", 211, 226], ["TYLCMaV (green) infectious clones", "CELL_LINE", 211, 244], ["tomato", "SPECIES", 107, 113], ["bean", "SPECIES", 126, 130], ["Solanum nigrum", "SPECIES", 139, 153], ["tomato", "SPECIES", 107, 113], ["bean", "SPECIES", 126, 130], ["Solanum nigrum", "SPECIES", 139, 153], ["TYLCV", "SPECIES", 195, 200], ["the nucleotide mutations", "PROBLEM", 22, 46], ["common bean (\u2666) and Solanum nigrum", "PROBLEM", 119, 153], ["TYLCSV (red), TYLCV (blue)", "PROBLEM", 181, 207], ["TYLCMaV (green) infectious clones", "PROBLEM", 211, 244], ["Solanum nigrum", "ANATOMY", 139, 153], ["TYLCV", "ANATOMY", 195, 200], ["infectious clones", "OBSERVATION", 227, 244]]], ["Nucleotide numbers on the left-hand side of sequences refer to GenBank accession numbers Z25751 (TYLCSV), AF071228 (TYLCV) and AF271234 (TYLCMaV).", [["left-hand", "ANATOMY", 26, 35], ["TYLCV", "SPECIES", 116, 121], ["Nucleotide numbers", "TEST", 0, 18], ["left", "ANATOMY_MODIFIER", 26, 30]]], ["Note that Ins141 appeared twice in TYLCSV-infected susceptible tomato at 45 dpi (replicate 1).DISCUSSIONthat would lead to the evolution and novel exploration of the sequence space.", [["Ins141", "CHEMICAL", 10, 16], ["TYLCSV", "CHEMICAL", 35, 41], ["Ins141", "GENE_OR_GENE_PRODUCT", 10, 16], ["tomato", "ORGANISM", 63, 69], ["tomato", "SPECIES", 63, 69], ["tomato", "SPECIES", 63, 69], ["novel exploration of the sequence space", "TEST", 141, 180]]], ["However, in the course of this experiment, we have not found evidence of begomovirus adaptation to different hosts by changing the consensus sequence.", [["consensus sequence", "DNA", 131, 149], ["begomovirus adaptation", "PROBLEM", 73, 95], ["not found evidence of", "UNCERTAINTY", 51, 72], ["begomovirus", "OBSERVATION", 73, 84]]], ["Successive passaging of the viruses through the hosts for a longer period of time would have allowed fixation of novel mutations and might have revealed adaptive evolution and perhaps changes in the consensus sequence.", [["consensus sequence", "DNA", 199, 217], ["the viruses", "PROBLEM", 24, 35], ["fixation", "TREATMENT", 101, 109], ["novel mutations", "PROBLEM", 113, 128], ["adaptive evolution", "PROBLEM", 153, 171], ["changes in the consensus sequence", "PROBLEM", 184, 217], ["viruses", "OBSERVATION", 28, 35]]], ["Nevertheless, our work suggests that differences in fitness across hosts could be influenced by the distribution of mutations in the mutant spectra.", [["mutations in the mutant spectra", "PROBLEM", 116, 147]]], ["We have shown in previous studies the remarkable continuity of the TYLCSV consensus sequence over an 8-year period .", [["TYLCSV consensus sequence", "DNA", 67, 92]]], ["In this work we have shown that high genetic diversity is generated in all four hosts, especially in common bean and the wild reservoir S. nigrum after infection with single sequence variants of three TYLCD-associated begomoviruses in spite of the invariance of the viral consensus sequences.", [["infection", "DISEASE", 152, 161], ["bean", "ORGANISM_SUBDIVISION", 108, 112], ["S. nigrum", "ORGANISM", 136, 145], ["TYLCD", "GENE_OR_GENE_PRODUCT", 201, 206], ["viral consensus sequences", "DNA", 266, 291], ["bean", "SPECIES", 108, 112], ["S. nigrum", "SPECIES", 136, 145], ["bean", "SPECIES", 108, 112], ["S. nigrum", "SPECIES", 136, 145], ["high genetic diversity", "PROBLEM", 32, 54], ["infection", "PROBLEM", 152, 161], ["single sequence variants", "PROBLEM", 167, 191], ["three TYLCD-associated begomoviruses", "PROBLEM", 195, 231], ["the viral consensus sequences", "TEST", 262, 291], ["begomoviruses", "OBSERVATION", 218, 231]]], ["Therefore, our results imply that quasispecies diversity need to be addressed to understand the adaptive potential of these economically important emergent viruses in their different hosts in order to design more durable control strategies.DATA AVAILABILITYThe raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.FUNDINGThis work was supported by grants P09-CVI-5428 and P10-CVI-6561 to AG-P, and grant P10-AGR-6516 to EM, from the Consejer\u00eda de Econom\u00eda, Innovaci\u00f3n y Ciencia, Junta de Andaluc\u00eda, Spain; and grants AGL2013-48913-C02 and AGL2016-75819-C2-2-R to JN-C, and EM, from the Ministerio de Econom\u00eda y Competitividad, and Ministerio de Econom\u00eda, Industria y Competitividad, Spain, respectively, with assistance from the European Regional Development Fund (ERDF) and the European Social Fund (ESF); and a JAE-DOC postdoctoral contract to SS-C, from the Consejo Superior de Investigaciones Cient\u00edficas (CSIC) with assistance from ESF; and grants to Research Group AGR-214 to JN-C, EM, and CVI-264 to AG-P, from the Consejer\u00eda de Econom\u00eda, Innovaci\u00f3n y Ciencia of the Junta de Andaluc\u00eda with assistance from the ERDF and ESF; and grant from the Primer Plan Propio de Investigaci\u00f3n y Transferencia de la Universidad de M\u00e1laga to AG-P.", [["DOC", "CHEMICAL", 913, 916], ["CVI", "DISEASE", 1092, 1095], ["P10-CVI-6561", "CELL", 468, 480], ["JN-C", "CELL", 659, 663], ["JN-C", "CELL", 1078, 1082], ["P", "DNA", 487, 488], ["quasispecies diversity", "PROBLEM", 34, 56], ["durable control strategies", "TREATMENT", 213, 239], ["CVI", "TEST", 455, 458], ["P10", "TEST", 468, 471], ["CVI", "TEST", 472, 475], ["AG", "TEST", 484, 486], ["AGR", "TEST", 504, 507], ["C02", "TEST", 627, 630], ["AGL2016-75819-C2", "TEST", 635, 651], ["AGR", "TEST", 1067, 1070], ["JN", "TEST", 1078, 1080], ["CVI", "TEST", 1092, 1095], ["AG", "TEST", 1103, 1105]]], ["LD-M was supported by Junta de Andaluc\u00eda grant P10-CVI-6561.", [["P10-CVI-6561", "CHEMICAL", 47, 59], ["CVI", "TEST", 51, 54]]], ["The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.", [["data collection", "TEST", 41, 56], ["analysis", "TEST", 61, 69], ["no", "UNCERTAINTY", 16, 18]]]], "5cded487793694de49b640b3972285bfc8431cfb": [["INTRODUCTIONCoccidiosis and necrotic enteritis (NE) are major intestinal disorders of chickens and were identified as the top two issues affecting broiler production by US poultry veterinarians in a recent survey (Hofacre and Mathis, 2015) .", [["intestinal", "ANATOMY", 62, 72], ["necrotic enteritis", "DISEASE", 28, 46], ["NE", "CHEMICAL", 48, 50], ["intestinal disorders", "DISEASE", 62, 82], ["intestinal", "ORGAN", 62, 72], ["chickens", "ORGANISM", 86, 94], ["chickens", "SPECIES", 86, 94], ["chickens", "SPECIES", 86, 94], ["INTRODUCTIONCoccidiosis", "TREATMENT", 0, 23], ["necrotic enteritis", "PROBLEM", 28, 46], ["major intestinal disorders of chickens", "PROBLEM", 56, 94], ["necrotic", "OBSERVATION_MODIFIER", 28, 36], ["enteritis", "OBSERVATION", 37, 46], ["intestinal", "ANATOMY", 62, 72], ["disorders", "OBSERVATION", 73, 82], ["broiler production", "OBSERVATION", 147, 165]]], ["It is estimated that coccidiosis and NE cost the poultry industry around US$ 3 and 6 billion per annum, respectively, through lost productivity, prevention strategies, and/or therapeutic interventions (Wade and Keyburn, 2015) .", [["coccidiosis", "DISEASE", 21, 32], ["NE", "CHEMICAL", 37, 39], ["coccidiosis", "PROBLEM", 21, 32], ["therapeutic interventions", "TREATMENT", 175, 200], ["coccidiosis", "OBSERVATION", 21, 32], ["NE", "OBSERVATION_MODIFIER", 37, 39], ["cost", "OBSERVATION_MODIFIER", 40, 44]]], ["1 Corresponding author: guthealthconsultancy@gmail.com however, be significantly greater due to subclinical or undiagnosed disease.", [["subclinical or undiagnosed disease", "PROBLEM", 96, 130], ["undiagnosed", "OBSERVATION_MODIFIER", 111, 122], ["disease", "OBSERVATION", 123, 130]]], ["In addition, there is a close association between coccidiosis and NE, with coccidiosis being a recognized predisposing factor for the development of NE (Williams, 2005) .", [["coccidiosis", "DISEASE", 50, 61], ["NE", "CHEMICAL", 66, 68], ["coccidiosis", "DISEASE", 75, 86], ["NE", "CHEMICAL", 149, 151], ["coccidiosis", "PROBLEM", 50, 61], ["coccidiosis", "PROBLEM", 75, 86], ["coccidiosis", "OBSERVATION", 50, 61], ["NE", "OBSERVATION_MODIFIER", 66, 68], ["coccidiosis", "OBSERVATION", 75, 86]]], ["Following the European Union ban on the use of antibiotics for growth promotion in 2006, there has been a global focus on reducing overall antibiotic use in animal production and reserving their use for appropriate therapeutic purposes.", [["antibiotics", "TREATMENT", 47, 58], ["global", "OBSERVATION_MODIFIER", 106, 112], ["focus", "OBSERVATION_MODIFIER", 113, 118]]], ["Even here, there is a desire to review production practices and evaluate strategies that may facilitate reduced therapeutic use.", [["production practices", "TREATMENT", 39, 59], ["strategies", "TREATMENT", 73, 83]]], ["The US has also seen significant changes with major producers implementing \"no antibiotics ever\" or \"reduced use\" production systems.", [["The US", "TEST", 0, 6], ["antibiotics", "TREATMENT", 79, 90], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["changes", "OBSERVATION", 33, 40]]], ["However, these changes can increase the occurrence of coccidiosis and NE (Gaucher et al., 2015) , the significance of other, for example immunosuppressive, diseases, the need to fundamentally review the way in which birds are raised and managed, and the thorough consideration of alternative strategies that can underpin future production practices.", [["coccidiosis", "DISEASE", 54, 65], ["NE", "CHEMICAL", 70, 72], ["birds", "ORGANISM", 216, 221], ["coccidiosis", "PROBLEM", 54, 65], ["diseases", "PROBLEM", 156, 164], ["alternative strategies", "TREATMENT", 280, 302], ["coccidiosis", "OBSERVATION", 54, 65]]], ["1634 These significant developments in the poultry industry are necessitating a holistic overview and approach to disease prevention and control, and profitable productivity.", [["1634", "SPECIES", 0, 4], ["disease prevention", "TREATMENT", 114, 132], ["significant", "OBSERVATION_MODIFIER", 11, 22]]], ["The immune system is obviously fundamental to bird health, and there is much focus on optimizing immunity, ideally in ways that do not compromise, but rather enhance, overall bird/flock performance.", [["immune system", "ANATOMY", 4, 17]]], ["In this regard, some chicken breeds and lines naturally demonstrate increased relative resistance or susceptibility to common poultry pathogens, influenced by genetics, including genes within the major histocompatibility complex (MHC) region of the genome (Kim et al., 2009) .", [["poultry pathogens", "DISEASE", 126, 143], ["chicken", "ORGANISM", 21, 28], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 196, 228], ["major histocompatibility complex (MHC) region", "DNA", 196, 241], ["chicken", "SPECIES", 21, 28], ["chicken", "SPECIES", 21, 28], ["some chicken breeds and lines", "PROBLEM", 16, 45], ["increased relative resistance", "PROBLEM", 68, 97], ["common poultry pathogens", "PROBLEM", 119, 143], ["chicken breeds", "OBSERVATION", 21, 35], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["relative resistance", "OBSERVATION", 78, 97]]], ["Understanding the key, perhaps even subtle, differences between more resistant or susceptible birds could be fundamental to exploiting key immune pathways or processes to improve bird health without compromising, or even enhancing, (efficient) performance.COCCCIDOSISCoccidiosis is caused by species of the Eimeria parasite and is probably the most significant enteric disease affecting chickens.", [["Eimeria parasite", "DISEASE", 307, 323], ["enteric disease", "DISEASE", 361, 376], ["birds", "ORGANISM", 94, 99], ["Eimeria parasite", "ORGANISM", 307, 323], ["chickens", "ORGANISM", 387, 395], ["chickens", "SPECIES", 387, 395], ["chickens", "SPECIES", 387, 395], ["the Eimeria parasite", "PROBLEM", 303, 323], ["significant enteric disease affecting chickens", "PROBLEM", 349, 395], ["Eimeria parasite", "OBSERVATION", 307, 323], ["probably the most", "UNCERTAINTY", 331, 348], ["significant", "OBSERVATION_MODIFIER", 349, 360], ["enteric", "OBSERVATION_MODIFIER", 361, 368], ["disease", "OBSERVATION", 369, 376]]], ["There are seven species of Eimeria that are known to infect chickens, with Eimeria acervulina, Eimeria maxima, and Eimeria tenella being the most prevalent and pathogenic for broilers (McDougald, 1998) .", [["Eimeria acervulina", "DISEASE", 75, 93], ["Eimeria tenella", "DISEASE", 115, 130], ["Eimeria", "ORGANISM", 27, 34], ["chickens", "ORGANISM", 60, 68], ["Eimeria acervulina", "ORGANISM", 75, 93], ["Eimeria maxima", "ORGANISM", 95, 109], ["Eimeria tenella", "ORGANISM", 115, 130], ["broilers", "ORGANISM", 175, 183], ["chickens", "SPECIES", 60, 68], ["Eimeria acervulina", "SPECIES", 75, 93], ["Eimeria maxima", "SPECIES", 95, 109], ["Eimeria tenella", "SPECIES", 115, 130], ["broilers", "SPECIES", 175, 183], ["chickens", "SPECIES", 60, 68], ["Eimeria acervulina", "SPECIES", 75, 93], ["Eimeria maxima", "SPECIES", 95, 109], ["Eimeria tenella", "SPECIES", 115, 130], ["broilers", "SPECIES", 175, 183], ["seven species of Eimeria", "PROBLEM", 10, 34], ["Eimeria acervulina", "PROBLEM", 75, 93], ["Eimeria maxima", "PROBLEM", 95, 109], ["Eimeria tenella", "PROBLEM", 115, 130], ["seven", "OBSERVATION_MODIFIER", 10, 15], ["species", "OBSERVATION_MODIFIER", 16, 23], ["Eimeria", "OBSERVATION", 27, 34], ["known to", "UNCERTAINTY", 44, 52], ["infect chickens", "OBSERVATION", 53, 68], ["Eimeria acervulina", "OBSERVATION", 75, 93], ["Eimeria maxima", "OBSERVATION", 95, 109], ["Eimeria tenella", "OBSERVATION", 115, 130], ["most prevalent", "OBSERVATION_MODIFIER", 141, 155]]], ["Each Eimeria species is recognized for targeting specific regions of the gut.", [["gut", "ANATOMY", 73, 76], ["gut", "ORGANISM_SUBDIVISION", 73, 76], ["Each Eimeria species", "PROBLEM", 0, 20], ["Eimeria species", "OBSERVATION", 5, 20], ["gut", "ANATOMY", 73, 76]]], ["E. acervulina affects the proximal small intestine, E. maxima affects the mid-intestine, and E. tenella affects the ceca (Hammond and Long, 1973) .", [["small intestine", "ANATOMY", 35, 50], ["mid-intestine", "ANATOMY", 74, 87], ["ceca", "ANATOMY", 116, 120], ["E. acervulina", "ORGANISM", 0, 13], ["small intestine", "ORGAN", 35, 50], ["E. maxima", "ORGANISM", 52, 61], ["mid-intestine", "CANCER", 74, 87], ["E. tenella", "ORGANISM", 93, 103], ["ceca", "ORGAN", 116, 120], ["E. acervulina", "SPECIES", 0, 13], ["E. maxima", "SPECIES", 52, 61], ["E. tenella", "SPECIES", 93, 103], ["E. acervulina", "SPECIES", 0, 13], ["E. maxima", "SPECIES", 52, 61], ["E. tenella", "SPECIES", 93, 103], ["acervulina", "OBSERVATION", 3, 13], ["proximal", "ANATOMY_MODIFIER", 26, 34], ["small intestine", "ANATOMY", 35, 50], ["E. maxima", "OBSERVATION_MODIFIER", 52, 61], ["mid-intestine", "ANATOMY", 74, 87], ["ceca", "ANATOMY", 116, 120]]], ["Following ingestion of a sporulated Eimeria oocyst, mechanical disruption and digestive processes release four sporocysts and subsequently their sporozoites, which attach to, and invade, epithelial cells in the susceptible region of the intestine (Blake and Tomley, 2014) .", [["oocyst", "ANATOMY", 44, 50], ["digestive", "ANATOMY", 78, 87], ["sporocysts", "ANATOMY", 111, 121], ["sporozoites", "ANATOMY", 145, 156], ["epithelial cells", "ANATOMY", 187, 203], ["intestine", "ANATOMY", 237, 246], ["Eimeria oocyst", "DISEASE", 36, 50], ["Eimeria oocyst", "ORGANISM", 36, 50], ["sporozoites", "CELL", 145, 156], ["epithelial cells", "CELL", 187, 203], ["intestine", "ORGAN", 237, 246], ["epithelial cells", "CELL_TYPE", 187, 203], ["a sporulated Eimeria oocyst", "TREATMENT", 23, 50], ["mechanical disruption", "PROBLEM", 52, 73], ["digestive processes", "TREATMENT", 78, 97], ["their sporozoites", "PROBLEM", 139, 156], ["Eimeria oocyst", "OBSERVATION", 36, 50], ["mechanical disruption", "OBSERVATION", 52, 73], ["sporocysts", "OBSERVATION_MODIFIER", 111, 121], ["epithelial cells", "OBSERVATION", 187, 203], ["susceptible", "ANATOMY_MODIFIER", 211, 222], ["region", "ANATOMY_MODIFIER", 223, 229], ["intestine", "ANATOMY", 237, 246]]], ["The sporozoite then proceeds through further developmental phases (e.g., trophozoite, merozoite, gamete, zygote, etc.,) in the host before the formation of an unsporulated oocyst that is excreted into the environment, where it eventually sporulates.", [["trophozoite", "ANATOMY", 73, 84], ["merozoite", "ANATOMY", 86, 95], ["gamete", "ANATOMY", 97, 103], ["zygote", "ANATOMY", 105, 111], ["oocyst", "ANATOMY", 172, 178], ["trophozoite", "CELL", 73, 84], ["merozoite", "CELLULAR_COMPONENT", 86, 95], ["gamete", "CELLULAR_COMPONENT", 97, 103], ["zygote", "CELLULAR_COMPONENT", 105, 111], ["further developmental phases", "TEST", 37, 65], ["trophozoite", "PROBLEM", 73, 84], ["zygote", "TREATMENT", 105, 111], ["an unsporulated oocyst", "PROBLEM", 156, 178], ["oocyst", "OBSERVATION", 172, 178]]], ["Invasion of epithelial cells causes damage to the epithelium and leads to haemorrhagic or malabsorptive disease, which results in poor growth performance or even death.", [["epithelial cells", "ANATOMY", 12, 28], ["epithelium", "ANATOMY", 50, 60], ["haemorrhagic", "DISEASE", 74, 86], ["death", "DISEASE", 162, 167], ["epithelial cells", "CELL", 12, 28], ["epithelium", "TISSUE", 50, 60], ["epithelial cells", "CELL_TYPE", 12, 28], ["epithelial cells", "PROBLEM", 12, 28], ["damage to the epithelium", "PROBLEM", 36, 60], ["haemorrhagic", "PROBLEM", 74, 86], ["malabsorptive disease", "PROBLEM", 90, 111], ["poor growth performance", "PROBLEM", 130, 153], ["epithelial cells", "OBSERVATION", 12, 28], ["epithelium", "ANATOMY_MODIFIER", 50, 60], ["haemorrhagic", "OBSERVATION_MODIFIER", 74, 86], ["malabsorptive disease", "OBSERVATION", 90, 111], ["poor", "OBSERVATION_MODIFIER", 130, 134], ["growth", "OBSERVATION_MODIFIER", 135, 141]]], ["Whilst good husbandry can play a part in managing coccidiosis, anticoccidial drugs and vaccination are necessary options for coccidiosis control, but each has their own drawbacks.", [["coccidiosis", "DISEASE", 50, 61], ["coccidiosis", "DISEASE", 125, 136], ["coccidiosis", "SPECIES", 50, 61], ["coccidiosis", "PROBLEM", 50, 61], ["anticoccidial drugs", "TREATMENT", 63, 82], ["vaccination", "TREATMENT", 87, 98], ["coccidiosis control", "TREATMENT", 125, 144]]], ["Resistance to anticoccidial drugs has been a problem for many years, and vaccination costs can be prohibitive for the broiler industry (Blake and Tomley, 2014) .COCCCIDOSISInbred lines of chickens have been reported to have differing susceptibility to Eimeria, with relatively resistant lines having higher in-vitro peripheral blood lymphocyte and T-cell proliferative responses to sporozoite antigen, before and after Eimeria infection, than more susceptible lines (Lillehoj, 1986; Bumstead et al., 1995) .", [["peripheral blood lymphocyte", "ANATOMY", 316, 343], ["T-cell", "ANATOMY", 348, 354], ["Eimeria", "DISEASE", 252, 259], ["Eimeria infection", "DISEASE", 419, 436], [".COCCCIDOSISInbred lines", "CELL", 160, 184], ["chickens", "ORGANISM", 188, 196], ["Eimeria", "ORGANISM", 252, 259], ["lines", "CELL", 287, 292], ["peripheral blood lymphocyte", "CELL", 316, 343], ["T-cell", "CELL", 348, 354], ["sporozoite antigen", "GENE_OR_GENE_PRODUCT", 382, 400], ["lines", "CELL", 460, 465], ["resistant lines", "CELL_LINE", 277, 292], ["sporozoite antigen", "PROTEIN", 382, 400], ["chickens", "SPECIES", 188, 196], ["chickens", "SPECIES", 188, 196], ["anticoccidial drugs", "TREATMENT", 14, 33], ["vaccination costs", "TREATMENT", 73, 90], ["differing susceptibility to Eimeria", "PROBLEM", 224, 259], ["relatively resistant lines", "PROBLEM", 266, 292], ["blood lymphocyte", "TEST", 327, 343], ["sporozoite antigen", "TEST", 382, 400], ["Eimeria infection", "PROBLEM", 419, 436], ["anticoccidial drugs", "OBSERVATION", 14, 33], ["higher", "OBSERVATION_MODIFIER", 300, 306], ["peripheral", "ANATOMY_MODIFIER", 316, 326], ["blood lymphocyte", "ANATOMY", 327, 343], ["cell proliferative", "OBSERVATION", 350, 368], ["infection", "OBSERVATION", 427, 436]]], ["Subsequent studies with bird lines differing in their susceptibility to Eimeria have shown that more resistant birds had higher serum and duodenal IL-2 (after secondary infection; Li et al., 2002) and greater cecal nitric oxide (NO; Lillehoj and Li, 2004) following E. tenella infection, while downregulation of jejunal liver-expressed antimicrobial peptide 2 has been associated with greater susceptibility to E. maxima infection when comparing two commercial broiler lines (Casterlow et al., 2011) .", [["serum", "ANATOMY", 128, 133], ["jejunal liver", "ANATOMY", 312, 325], ["infection", "DISEASE", 169, 178], ["nitric oxide", "CHEMICAL", 215, 227], ["NO", "CHEMICAL", 229, 231], ["tenella infection", "DISEASE", 269, 286], ["E. maxima infection", "DISEASE", 411, 430], ["nitric oxide", "CHEMICAL", 215, 227], ["NO", "CHEMICAL", 229, 231], ["bird lines", "CELL", 24, 34], ["Eimeria", "ORGANISM", 72, 79], ["birds", "ORGANISM", 111, 116], ["serum", "ORGANISM_SUBSTANCE", 128, 133], ["IL-2", "GENE_OR_GENE_PRODUCT", 147, 151], ["cecal nitric oxide", "SIMPLE_CHEMICAL", 209, 227], ["NO", "SIMPLE_CHEMICAL", 229, 231], ["E. tenella", "ORGANISM", 266, 276], ["jejunal", "MULTI-TISSUE_STRUCTURE", 312, 319], ["liver", "ORGAN", 320, 325], ["antimicrobial peptide 2", "GENE_OR_GENE_PRODUCT", 336, 359], ["E. maxima", "ORGANISM", 411, 420], ["E. tenella", "SPECIES", 266, 276], ["E. maxima", "SPECIES", 411, 420], ["E. tenella", "SPECIES", 266, 276], ["E. maxima", "SPECIES", 411, 420], ["Subsequent studies", "TEST", 0, 18], ["bird lines", "TREATMENT", 24, 34], ["more resistant birds", "PROBLEM", 96, 116], ["higher serum and duodenal IL", "PROBLEM", 121, 149], ["secondary infection", "PROBLEM", 159, 178], ["greater cecal nitric oxide", "TREATMENT", 201, 227], ["E. tenella infection", "PROBLEM", 266, 286], ["jejunal liver", "PROBLEM", 312, 325], ["E. maxima infection", "PROBLEM", 411, 430], ["bird lines", "OBSERVATION", 24, 34], ["more resistant", "OBSERVATION_MODIFIER", 96, 110], ["duodenal", "ANATOMY", 138, 146], ["infection", "OBSERVATION", 169, 178], ["cecal", "ANATOMY", 209, 214], ["nitric oxide", "OBSERVATION", 215, 227], ["infection", "OBSERVATION", 277, 286], ["jejunal liver", "ANATOMY", 312, 325], ["E. maxima", "OBSERVATION_MODIFIER", 411, 420], ["infection", "OBSERVATION", 421, 430], ["broiler lines", "OBSERVATION", 461, 474]]], ["More recently, a chicken line more susceptible to E. maxima infection (15I) had a greater increase in serum IL-10 than a more resistant line (C.B12), while there were earlier increases in the expression of in the gut of the more resistant line (Bremner, 2018) .", [["serum", "ANATOMY", 102, 107], ["line", "ANATOMY", 136, 140], ["gut", "ANATOMY", 213, 216], ["infection", "DISEASE", 60, 69], ["chicken", "ORGANISM", 17, 24], ["E. maxima", "ORGANISM", 50, 59], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["IL-10", "GENE_OR_GENE_PRODUCT", 108, 113], ["C.B12", "CELL", 142, 147], ["gut", "ORGANISM_SUBDIVISION", 213, 216], ["serum IL-10", "PROTEIN", 102, 113], ["C.B12", "CELL_LINE", 142, 147], ["chicken", "SPECIES", 17, 24], ["E. maxima", "SPECIES", 50, 59], ["chicken", "SPECIES", 17, 24], ["E. maxima", "SPECIES", 50, 59], ["a chicken line", "TREATMENT", 15, 29], ["E. maxima infection", "PROBLEM", 50, 69], ["a greater increase in serum IL", "PROBLEM", 80, 110], ["maxima infection", "OBSERVATION", 53, 69], ["greater", "OBSERVATION_MODIFIER", 82, 89], ["increase", "OBSERVATION_MODIFIER", 90, 98], ["increases", "OBSERVATION_MODIFIER", 175, 184], ["resistant line", "OBSERVATION", 229, 243]]], ["Table 1 outlines some of the key observations from studies employing quantitative RT-PCR to compare immunerelated gene expression in inbred White Leghorn (WL) and Fayoumi (F) (Kim et al., 2008) lines differing in susceptibility to E. maxima.", [["Fayoumi (F", "CELL", 163, 173], ["lines", "CELL", 194, 199], ["White Leghorn", "SPECIES", 140, 153], ["E. maxima", "SPECIES", 231, 240], ["quantitative RT-PCR", "TEST", 69, 88]]], ["In resistant lines of both breeds, expression of IFN-\u03b3 was, generally, relatively increased in the spleen and intestine (F) of resistant birds on various days up to 6 d postinfection (dpi), while IL-10 was relatively reduced (constitutive and 2 to 9 dpi), compared to more susceptible birds.", [["lines", "ANATOMY", 13, 18], ["spleen", "ANATOMY", 99, 105], ["intestine", "ANATOMY", 110, 119], ["lines", "CELL", 13, 18], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 49, 54], ["spleen", "ORGAN", 99, 105], ["intestine", "ORGAN", 110, 119], ["birds", "ORGANISM", 137, 142], ["IL-10", "GENE_OR_GENE_PRODUCT", 196, 201], ["birds", "ORGANISM", 285, 290], ["resistant lines", "CELL_LINE", 3, 18], ["IFN", "PROTEIN", 49, 52], ["\u03b3", "PROTEIN", 53, 54], ["IL", "PROTEIN", 196, 198], ["IFN", "TEST", 49, 52], ["resistant birds", "PROBLEM", 127, 142], ["IL", "TEST", 196, 198], ["resistant lines", "OBSERVATION", 3, 18], ["both breeds", "OBSERVATION", 22, 33], ["relatively", "OBSERVATION_MODIFIER", 71, 81], ["increased", "OBSERVATION", 82, 91], ["spleen", "ANATOMY", 99, 105], ["intestine", "ANATOMY", 110, 119]]], ["Other notable features of more resistant F birds were relative upregulation of IFN-\u03b1 (4 and 5 dpi) and IL-17D (4 dpi) in jejunal intraepithelial lymphocytes (IEL) and IFN-\u03b1 (4 dpi) in the spleen, and relative downregulation of IL-12 (5 dpi), IFN-\u03b1 (5 dpi), and IL-17D (4 and 5 dpi) in the spleen and IL-17D (5 dpi) in jejunal IEL.NECROTIC ENTERITISPathogenic strains of Clostridium perfringens are responsible for NE, with those expressing the NetB toxin a definitive cause in disease models (Keyburn et al., 2008) .", [["jejunal intraepithelial lymphocytes", "ANATOMY", 121, 156], ["IEL", "ANATOMY", 158, 161], ["spleen", "ANATOMY", 188, 194], ["spleen", "ANATOMY", 289, 295], ["jejunal IEL", "ANATOMY", 318, 329], ["Clostridium perfringens", "DISEASE", 370, 393], ["NE", "CHEMICAL", 414, 416], ["F birds", "ORGANISM", 41, 48], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 79, 84], ["IL-17D", "GENE_OR_GENE_PRODUCT", 103, 109], ["jejunal intraepithelial lymphocytes", "CELL", 121, 156], ["IEL", "CELL", 158, 161], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 167, 172], ["spleen", "ORGAN", 188, 194], ["IL-12", "GENE_OR_GENE_PRODUCT", 227, 232], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 242, 247], ["IL-17D", "GENE_OR_GENE_PRODUCT", 261, 267], ["spleen", "ORGAN", 289, 295], ["IL-17D", "GENE_OR_GENE_PRODUCT", 300, 306], ["jejunal IEL", "CELL", 318, 329], ["Clostridium perfringens", "ORGANISM", 370, 393], ["NetB", "GENE_OR_GENE_PRODUCT", 444, 448], ["IFN", "PROTEIN", 79, 82], ["\u03b1", "PROTEIN", 83, 84], ["IL", "PROTEIN", 103, 105], ["jejunal intraepithelial lymphocytes", "CELL_TYPE", 121, 156], ["IEL", "CELL_TYPE", 158, 161], ["IFN", "PROTEIN", 167, 170], ["IL-12", "PROTEIN", 227, 232], ["IFN", "PROTEIN", 242, 245], ["\u03b1", "PROTEIN", 246, 247], ["IL", "PROTEIN", 261, 263], ["17D", "PROTEIN", 264, 267], ["jejunal IEL", "CELL_TYPE", 318, 329], ["NE", "PROTEIN", 414, 416], ["NetB toxin", "PROTEIN", 444, 454], ["Clostridium perfringens", "SPECIES", 370, 393], ["Clostridium perfringens", "SPECIES", 370, 393], ["IFN", "TEST", 79, 82], ["IL", "TEST", 103, 105], ["jejunal intraepithelial lymphocytes", "TEST", 121, 156], ["IFN", "TEST", 167, 170], ["IL", "TEST", 227, 229], ["IFN", "TEST", 242, 245], ["IL", "TEST", 261, 263], ["IL", "TEST", 300, 302], ["NECROTIC ENTERITISPathogenic strains", "PROBLEM", 330, 366], ["Clostridium perfringens", "PROBLEM", 370, 393], ["NE", "PROBLEM", 414, 416], ["more resistant", "OBSERVATION_MODIFIER", 26, 40], ["jejunal", "ANATOMY", 121, 128], ["intraepithelial lymphocytes", "OBSERVATION", 129, 156], ["spleen", "ANATOMY", 188, 194], ["downregulation", "OBSERVATION_MODIFIER", 209, 223], ["spleen", "ANATOMY", 289, 295], ["jejunal IEL", "ANATOMY", 318, 329], ["Clostridium perfringens", "OBSERVATION", 370, 393]]], ["C. perfringens normally inhabit the gastrointestinal tract (GIT) but these are typically nonpathogenic strains.", [["gastrointestinal tract", "ANATOMY", 36, 58], ["GIT", "ANATOMY", 60, 63], ["C. perfringens", "ORGANISM", 0, 14], ["gastrointestinal tract", "ORGAN", 36, 58], ["GIT", "ORGAN", 60, 63], ["C. perfringens", "SPECIES", 0, 14], ["C. perfringens", "SPECIES", 0, 14], ["C. perfringens", "PROBLEM", 0, 14], ["typically nonpathogenic strains", "PROBLEM", 79, 110], ["perfringens", "OBSERVATION", 3, 14], ["inhabit", "OBSERVATION", 24, 31], ["gastrointestinal tract", "ANATOMY", 36, 58], ["nonpathogenic strains", "OBSERVATION", 89, 110]]], ["Compromised intestinal health allows pathogenic, toxin-secreting strains of C. perfringens to become established and proliferate.", [["intestinal", "ANATOMY", 12, 22], ["intestinal", "ORGAN", 12, 22], ["C. perfringens", "ORGANISM", 76, 90], ["C. perfringens", "SPECIES", 76, 90], ["C. perfringens", "SPECIES", 76, 90], ["Compromised intestinal health", "PROBLEM", 0, 29], ["pathogenic", "PROBLEM", 37, 47], ["toxin", "PROBLEM", 49, 54], ["C. perfringens", "PROBLEM", 76, 90], ["intestinal", "ANATOMY", 12, 22]]], ["The toxin(s) causes pore formation in the plasma membrane of cells, leading to epithelial cell death and the formation of necrotic lesions in the (small) intestine (Timbermont et al., 2011) .", [["pore", "ANATOMY", 20, 24], ["plasma membrane", "ANATOMY", 42, 57], ["cells", "ANATOMY", 61, 66], ["epithelial cell", "ANATOMY", 79, 94], ["necrotic lesions", "ANATOMY", 122, 138], ["intestine", "ANATOMY", 154, 163], ["death", "DISEASE", 95, 100], ["necrotic", "DISEASE", 122, 130], ["pore", "CELLULAR_COMPONENT", 20, 24], ["plasma membrane", "CELLULAR_COMPONENT", 42, 57], ["cells", "CELL", 61, 66], ["epithelial cell", "CELL", 79, 94], ["necrotic lesions", "PATHOLOGICAL_FORMATION", 122, 138], ["intestine", "ORGAN", 154, 163], ["The toxin(s", "PROBLEM", 0, 11], ["pore formation in the plasma membrane of cells", "PROBLEM", 20, 66], ["epithelial cell death", "PROBLEM", 79, 100], ["necrotic lesions in the (small) intestine", "PROBLEM", 122, 163], ["plasma membrane", "ANATOMY", 42, 57], ["epithelial cell death", "OBSERVATION", 79, 100], ["necrotic", "OBSERVATION_MODIFIER", 122, 130], ["lesions", "OBSERVATION", 131, 138], ["small", "OBSERVATION_MODIFIER", 147, 152], ["intestine", "ANATOMY", 154, 163]]], ["Simple infection with pathogenic C. perfringens alone is not sufficient to cause NE (Moore, 2016) , and thus other factors contribute to the proliferation of pathogenic strains, increased production of toxin(s) and the development of disease.", [["infection", "DISEASE", 7, 16], ["C. perfringens", "DISEASE", 33, 47], ["NE", "CHEMICAL", 81, 83], ["C. perfringens", "ORGANISM", 33, 47], ["toxin", "PROTEIN", 202, 207], ["C. perfringens", "SPECIES", 33, 47], ["C. perfringens", "SPECIES", 33, 47], ["Simple infection", "PROBLEM", 0, 16], ["pathogenic C. perfringens", "PROBLEM", 22, 47], ["pathogenic strains", "PROBLEM", 158, 176], ["increased production of toxin(s", "PROBLEM", 178, 209], ["disease", "PROBLEM", 234, 241], ["infection", "OBSERVATION", 7, 16], ["pathogenic", "OBSERVATION_MODIFIER", 22, 32], ["C. perfringens", "OBSERVATION_MODIFIER", 33, 47], ["pathogenic strains", "OBSERVATION", 158, 176], ["disease", "OBSERVATION", 234, 241]]], ["As mentioned previously, coccidiosis is a key predisposing factor, along with excess protein, nonstarch polysaccharides, wet litter, and mycotoxins.", [["coccidiosis", "DISEASE", 25, 36], ["nonstarch polysaccharides", "SIMPLE_CHEMICAL", 94, 119], ["coccidiosis", "PROBLEM", 25, 36], ["excess protein", "PROBLEM", 78, 92], ["nonstarch polysaccharides", "TREATMENT", 94, 119], ["mycotoxins", "TREATMENT", 137, 147], ["coccidiosis", "OBSERVATION", 25, 36]]], ["Birds are typically affected between 2 and 6 wk of age, which likely reflects diminishing passive immunity, while the bird's immune system remains functionally suboptimal.", [["diminishing passive immunity", "PROBLEM", 78, 106], ["the bird's immune system", "TEST", 114, 138], ["likely reflects", "UNCERTAINTY", 62, 77], ["diminishing", "OBSERVATION_MODIFIER", 78, 89], ["passive immunity", "OBSERVATION", 90, 106]]], ["As noted, NENECROTIC ENTERITISIL-10 \u2193(6 and 9 dpi) \u2193(C and 6 dpi) has emerged as a significant intestinal disease since the use of antibiotics as growth promoters began to be phased out (Van Immerseel et al., 2016) .", [["intestinal", "ANATOMY", 95, 105], ["intestinal disease", "DISEASE", 95, 113], ["intestinal", "ORGAN", 95, 105], ["growth promoters", "DNA", 146, 162], ["NENECROTIC ENTERITISIL", "TREATMENT", 10, 32], ["a significant intestinal disease", "PROBLEM", 81, 113], ["antibiotics", "TREATMENT", 131, 142], ["growth promoters", "TREATMENT", 146, 162], ["significant", "OBSERVATION_MODIFIER", 83, 94], ["intestinal", "ANATOMY", 95, 105], ["disease", "OBSERVATION", 106, 113]]], ["Thus, vaccination could be an attractive alternative to antibiotic use but there remain many gaps in our knowledge, particularly with regards to the pathogenesis of NE and immunity.", [["NE", "CHEMICAL", 165, 167], ["vaccination", "TREATMENT", 6, 17], ["antibiotic use", "TREATMENT", 56, 70], ["many", "OBSERVATION_MODIFIER", 88, 92], ["gaps", "OBSERVATION", 93, 97]]], ["While NetB seems key to the onset of NE, the target cell(s), cell receptor, or how this toxin causes necrotic lesions with inflammation are currently unknown (Van Immerseel et al., 2016) , and this lack of knowledge currently undermines attempts to develop effective vaccines.", [["cell", "ANATOMY", 52, 56], ["cell", "ANATOMY", 61, 65], ["necrotic lesions", "ANATOMY", 101, 117], ["NE", "CHEMICAL", 37, 39], ["necrotic", "DISEASE", 101, 109], ["inflammation", "DISEASE", 123, 135], ["NetB", "GENE_OR_GENE_PRODUCT", 6, 10], ["NE", "GENE_OR_GENE_PRODUCT", 37, 39], ["cell", "CELL", 52, 56], ["cell", "CELL", 61, 65], ["necrotic lesions", "PATHOLOGICAL_FORMATION", 101, 117], ["NetB", "PROTEIN", 6, 10], ["NE", "PROTEIN", 37, 39], ["cell receptor", "PROTEIN", 61, 74], ["NE", "PROBLEM", 37, 39], ["cell receptor", "TEST", 61, 74], ["necrotic lesions", "PROBLEM", 101, 117], ["inflammation", "PROBLEM", 123, 135], ["effective vaccines", "TREATMENT", 257, 275], ["necrotic", "OBSERVATION_MODIFIER", 101, 109], ["lesions", "OBSERVATION", 110, 117], ["inflammation", "OBSERVATION", 123, 135]]], ["Studies with chicken breeds/lines seemingly differing in their susceptibility to experimental NE have identified some differences in immune parameters.", [["NE", "CHEMICAL", 94, 96], ["chicken", "ORGANISM", 13, 20], ["lines", "CELL", 28, 33], ["NE", "PROTEIN", 94, 96], ["chicken", "SPECIES", 13, 20], ["chicken", "SPECIES", 13, 20], ["Studies", "TEST", 0, 7], ["chicken breeds/lines", "TREATMENT", 13, 33], ["some differences in immune parameters", "PROBLEM", 113, 150]]], ["Hong et al., (2012) reported that a commercial broiler line more resistant to NE (Jang et al., 2013) showed increased relative expression of jejunal mucosal IL-17F and various avian \u03b2-defensins (AvBD; AvBD 1, 3, 4, 6, 8, and 10), while a few AvBD (11 and 13) were relatively decreased, compared to a more susceptible broiler line at 2 dpi with C. perfringens (6 dpi with E. maxima).NECROTIC ENTERITISOther studies have utilized the highly inbred WL Avian Disease and Oncology Laboratory lines 6.2 and 7.3 or F chicken lines M5.1 and M15.2, which were originally identified/selected based on their susceptibility to Marek's disease and/or avian leukosis retroviruses (Bacon et al., 2000; Kim et al., 2008) , respectively.", [["jejunal mucosal", "ANATOMY", 141, 156], ["NE", "CHEMICAL", 78, 80], ["Avian Disease", "DISEASE", 449, 462], ["Marek's disease", "DISEASE", 615, 630], ["avian leukosis retroviruses", "DISEASE", 638, 665], ["IL-17F", "GENE_OR_GENE_PRODUCT", 157, 163], ["\u03b2-defensins", "GENE_OR_GENE_PRODUCT", 182, 193], ["AvBD 1", "GENE_OR_GENE_PRODUCT", 201, 207], ["C. perfringens", "ORGANISM", 344, 358], ["F chicken lines M5.1", "CELL", 508, 528], ["M15.2", "CELL", 533, 538], ["Marek's disease", "ORGANISM", 615, 630], ["avian leukosis retroviruses", "ORGANISM", 638, 665], ["jejunal mucosal IL-17F", "PROTEIN", 141, 163], ["avian \u03b2-defensins", "PROTEIN", 176, 193], ["AvBD", "PROTEIN", 195, 199], ["F chicken lines", "CELL_LINE", 508, 523], ["M5.1", "CELL_LINE", 524, 528], ["M15.2", "CELL_LINE", 533, 538], ["C. perfringens", "SPECIES", 344, 358], ["chicken", "SPECIES", 510, 517], ["avian leukosis", "SPECIES", 638, 652], ["C. perfringens", "SPECIES", 344, 358], ["E. maxima", "SPECIES", 371, 380], ["F chicken", "SPECIES", 508, 517], ["a commercial broiler line", "TREATMENT", 34, 59], ["jejunal mucosal IL", "TEST", 141, 159], ["AvBD", "TEST", 201, 205], ["a few AvBD", "TEST", 236, 246], ["a more susceptible broiler line", "TREATMENT", 298, 329], ["C. perfringens", "PROBLEM", 344, 358], ["NECROTIC ENTERITISOther studies", "TEST", 382, 413], ["Oncology Laboratory lines", "TEST", 467, 492], ["F chicken lines", "TEST", 508, 523], ["Marek's disease", "PROBLEM", 615, 630], ["avian leukosis retroviruses", "PROBLEM", 638, 665], ["increased", "OBSERVATION_MODIFIER", 108, 117], ["jejunal mucosal", "ANATOMY", 141, 156], ["decreased", "OBSERVATION", 275, 284], ["leukosis retroviruses", "OBSERVATION", 644, 665]]], ["These lines have demonstrated some differences in susceptibility to experimental NE (Kim et al., 2014; Kim et al., 2015) and reported differences in the relative expression of various immune-related genes (e.g., BCL2, TAB3, TCF12, VEGFA, etc.,) in the intestine and spleen between the lines Kim at al., 2014; Kim et al., 2015) , as well as the expression of some of their regulating microRNAs .", [["intestine", "ANATOMY", 252, 261], ["spleen", "ANATOMY", 266, 272], ["NE", "CHEMICAL", 81, 83], ["BCL2", "GENE_OR_GENE_PRODUCT", 212, 216], ["TAB3", "GENE_OR_GENE_PRODUCT", 218, 222], ["TCF12", "GENE_OR_GENE_PRODUCT", 224, 229], ["VEGFA", "GENE_OR_GENE_PRODUCT", 231, 236], ["intestine", "ORGAN", 252, 261], ["spleen", "ORGAN", 266, 272], ["BCL2", "DNA", 212, 216], ["TAB3", "DNA", 218, 222], ["TCF12", "DNA", 224, 229], ["VEGFA", "DNA", 231, 236], ["microRNAs", "DNA", 383, 392], ["BCL2", "TEST", 212, 216], ["TAB3", "TEST", 218, 222], ["TCF12", "TEST", 224, 229], ["VEGFA", "TEST", 231, 236], ["some", "OBSERVATION_MODIFIER", 30, 34], ["differences", "OBSERVATION_MODIFIER", 35, 46], ["susceptibility", "OBSERVATION_MODIFIER", 50, 64], ["intestine", "ANATOMY", 252, 261], ["spleen", "ANATOMY", 266, 272], ["regulating microRNAs", "OBSERVATION", 372, 392]]], ["Table 1 again highlights the relative expression of some specific genes in the intestinal mucosa and spleen of the WL lines (6.3 and 7.2).", [["intestinal mucosa", "ANATOMY", 79, 96], ["spleen", "ANATOMY", 101, 107], ["WL lines", "ANATOMY", 115, 123], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 79, 96], ["spleen", "ORGAN", 101, 107], ["WL lines", "CELL", 115, 123], ["some", "OBSERVATION_MODIFIER", 52, 56], ["specific genes", "OBSERVATION", 57, 71], ["intestinal mucosa", "ANATOMY", 79, 96], ["spleen", "ANATOMY", 101, 107], ["WL lines", "OBSERVATION", 115, 123]]], ["Following E. maxima challenge at 14 doa and C. perfringens at 18 doa, IL-12 and IL-17D were relatively upregulated in the spleen or intestinal mucosa or both at 20 doa in the seemingly more resistant line, while IFN-\u03b1 and IL-10 were both shown to be relatively downregulated in both sites.", [["spleen", "ANATOMY", 122, 128], ["intestinal mucosa", "ANATOMY", 132, 149], ["line", "ANATOMY", 200, 204], ["sites", "ANATOMY", 283, 288], ["E. maxima", "ORGANISM", 10, 19], ["C. perfringens", "ORGANISM", 44, 58], ["IL-12", "GENE_OR_GENE_PRODUCT", 70, 75], ["IL-17D", "GENE_OR_GENE_PRODUCT", 80, 86], ["spleen", "ORGAN", 122, 128], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 132, 149], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 212, 217], ["IL-10", "GENE_OR_GENE_PRODUCT", 222, 227], ["IL", "PROTEIN", 80, 82], ["IFN", "PROTEIN", 212, 215], ["IL", "PROTEIN", 222, 224], ["C. perfringens", "SPECIES", 44, 58], ["E. maxima", "SPECIES", 10, 19], ["C. perfringens", "SPECIES", 44, 58], ["E. maxima challenge", "TEST", 10, 29], ["C. perfringens", "PROBLEM", 44, 58], ["IL", "TEST", 70, 72], ["IL", "TREATMENT", 80, 82], ["intestinal mucosa", "PROBLEM", 132, 149], ["IFN", "TEST", 212, 215], ["IL", "TEST", 222, 224], ["spleen", "ANATOMY", 122, 128], ["intestinal mucosa", "ANATOMY", 132, 149], ["resistant line", "OBSERVATION", 190, 204], ["relatively", "OBSERVATION_MODIFIER", 250, 260], ["downregulated", "OBSERVATION", 261, 274]]], ["Data for IFN-\u03b3 were less consistent with relatively increased expression reported in the intestinal mucosa and spleen of the more resistant line, but also a relative decrease in the spleen in another study at the same timepoint (20 doa).INTERPRETATION OF IMMUNE-RELATED GENE EXPRESSION IN BIRDS MORE OR LESS RESISTANT TO COCCIDIOSIS AND NEAlthough gene expression data has its limitations due to only being a (n initial) step in the production of a functional protein, these data are, nevertheless, informative.", [["intestinal mucosa", "ANATOMY", 89, 106], ["spleen", "ANATOMY", 111, 117], ["line", "ANATOMY", 140, 144], ["spleen", "ANATOMY", 182, 188], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 9, 14], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 89, 106], ["spleen", "ORGAN", 111, 117], ["spleen", "ORGAN", 182, 188], ["IFN", "PROTEIN", 9, 12], ["\u03b3", "PROTEIN", 13, 14], ["IFN", "TEST", 9, 12], ["relatively increased expression", "PROBLEM", 41, 72], ["the more resistant line", "PROBLEM", 121, 144], ["a relative decrease in the spleen", "PROBLEM", 155, 188], ["another study", "TEST", 192, 205], ["COCCIDIOSIS", "PROBLEM", 321, 332], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["expression", "OBSERVATION", 62, 72], ["intestinal mucosa", "ANATOMY", 89, 106], ["spleen", "ANATOMY", 111, 117], ["more resistant", "OBSERVATION_MODIFIER", 125, 139], ["line", "OBSERVATION", 140, 144], ["relative", "OBSERVATION_MODIFIER", 157, 165], ["decrease", "OBSERVATION_MODIFIER", 166, 174], ["spleen", "ANATOMY", 182, 188], ["COCCIDIOSIS", "OBSERVATION", 321, 332]]], ["It is of interest to consider whether there are common immune-related features that may contribute to greater resistance to coccidiosis and necrotic enteritis.", [["coccidiosis", "DISEASE", 124, 135], ["necrotic enteritis", "DISEASE", 140, 158], ["common immune-related features", "PROBLEM", 48, 78], ["coccidiosis", "PROBLEM", 124, 135], ["necrotic enteritis", "PROBLEM", 140, 158], ["coccidiosis", "OBSERVATION", 124, 135], ["necrotic", "OBSERVATION_MODIFIER", 140, 148], ["enteritis", "OBSERVATION", 149, 158]]], ["Of course, such interpretation must keep in mind that time (e.g., day) post infection that samples for analysis are obtained only provide a snapshot in time of (relative) gene expression in a dynamic environment.", [["samples", "ANATOMY", 91, 98], ["infection", "DISEASE", 76, 85], ["post infection", "PROBLEM", 71, 85], ["analysis", "TEST", 103, 111], ["infection", "OBSERVATION", 76, 85]]], ["For example, Kim et al., (2008) reported that at 3 dpi IFN-\u03b3 was relatively upregulated, downregulated 4 dpi, and upregulated again 5 dpi in jejunal IEL of the more resistant line.", [["jejunal IEL", "ANATOMY", 141, 152], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 55, 60], ["jejunal IEL", "CELL", 141, 152], ["IFN", "PROTEIN", 55, 58], ["\u03b3", "PROTEIN", 59, 60], ["jejunal IEL", "CELL_TYPE", 141, 152], ["IFN", "TEST", 55, 58], ["jejunal IEL", "ANATOMY", 141, 152], ["resistant line", "OBSERVATION", 165, 179]]], ["In addition, site of investigation is also an important consideration.", [["important consideration", "UNCERTAINTY", 46, 69]]], ["Most studies have interrogated the primary site of infection (intestine) or a key secondary lymphoid organ central to systemic immune responses (spleen).", [["site", "ANATOMY", 43, 47], ["intestine", "ANATOMY", 62, 71], ["lymphoid organ", "ANATOMY", 92, 106], ["spleen", "ANATOMY", 145, 151], ["infection", "DISEASE", 51, 60], ["intestine", "ORGAN", 62, 71], ["lymphoid", "PATHOLOGICAL_FORMATION", 92, 100], ["organ", "ORGAN", 101, 106], ["spleen", "ORGAN", 145, 151], ["Most studies", "TEST", 0, 12], ["infection", "PROBLEM", 51, 60], ["infection", "OBSERVATION", 51, 60], ["intestine", "ANATOMY", 62, 71], ["secondary lymphoid organ", "OBSERVATION", 82, 106], ["systemic immune", "OBSERVATION", 118, 133], ["spleen", "ANATOMY", 145, 151]]], ["The most consistent feature from Table 1 is that IL-10 is either constitutively or in response to infection relatively down-regulated/less upregulated in chicken lines apparently more resistant to coccidiosis and NE.", [["lines", "ANATOMY", 162, 167], ["infection", "DISEASE", 98, 107], ["coccidiosis", "DISEASE", 197, 208], ["NE", "CHEMICAL", 213, 215], ["IL-10", "GENE_OR_GENE_PRODUCT", 49, 54], ["chicken", "ORGANISM", 154, 161], ["lines", "CELL", 162, 167], ["NE", "SIMPLE_CHEMICAL", 213, 215], ["IL", "PROTEIN", 49, 51], ["chicken lines", "CELL_LINE", 154, 167], ["chicken", "SPECIES", 154, 161], ["chicken", "SPECIES", 154, 161], ["infection", "PROBLEM", 98, 107], ["coccidiosis", "PROBLEM", 197, 208], ["most consistent", "OBSERVATION_MODIFIER", 4, 19], ["infection", "OBSERVATION", 98, 107], ["less upregulated", "OBSERVATION_MODIFIER", 134, 150], ["chicken lines", "OBSERVATION", 154, 167], ["more resistant", "OBSERVATION_MODIFIER", 179, 193], ["coccidiosis", "OBSERVATION", 197, 208]]], ["IL-10 is generally considered an anti-inflammatory cytokine that helps regulate inflammatory responses to various pathogens (Couper et al., 2008) and contributes to intestinal homeostasis (Manzanillo et al., 2015) .", [["intestinal", "ANATOMY", 165, 175], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["intestinal", "ORGAN", 165, 175], ["IL-10", "PROTEIN", 0, 5], ["anti-inflammatory cytokine", "PROTEIN", 33, 59], ["an anti-inflammatory cytokine", "TREATMENT", 30, 59], ["inflammatory responses", "PROBLEM", 80, 102], ["various pathogens", "PROBLEM", 106, 123], ["intestinal homeostasis", "PROBLEM", 165, 187], ["anti-inflammatory cytokine", "OBSERVATION", 33, 59], ["inflammatory", "OBSERVATION_MODIFIER", 80, 92], ["intestinal", "ANATOMY", 165, 175]]], ["IL-10 maybe produced by a variety of innate (e.g., dendritic cells, macrophages, monocytes, etc.,) and acquired (various T cell subsets and B cells) immune cells (Wu et al., 2016) . chIL-10 has been shown to inhibit the expression of IFN-\u03b3 by mitogen-activated splenocytes , and thus it is not surprising to see that more resistant lines, with relatively reduced expression of IL-10, generally have relatively increased expression of IFN-\u03b3 in the spleen and intestine (or cells; Table 1 ).", [["dendritic cells", "ANATOMY", 51, 66], ["macrophages", "ANATOMY", 68, 79], ["monocytes", "ANATOMY", 81, 90], ["T cell", "ANATOMY", 121, 127], ["B cells", "ANATOMY", 140, 147], ["immune cells", "ANATOMY", 149, 161], ["splenocytes", "ANATOMY", 261, 272], ["lines", "ANATOMY", 332, 337], ["spleen", "ANATOMY", 447, 453], ["intestine", "ANATOMY", 458, 467], ["cells", "ANATOMY", 472, 477], ["chIL-10", "CHEMICAL", 182, 189], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["dendritic cells", "CELL", 51, 66], ["macrophages", "CELL", 68, 79], ["monocytes", "CELL", 81, 90], ["T cell subsets", "CELL", 121, 135], ["B cells", "CELL", 140, 147], ["immune cells", "CELL", 149, 161], ["chIL-10", "GENE_OR_GENE_PRODUCT", 182, 189], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 234, 239], ["splenocytes", "CELL", 261, 272], ["lines", "CELL", 332, 337], ["IL-10", "GENE_OR_GENE_PRODUCT", 377, 382], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 434, 439], ["spleen", "ORGAN", 447, 453], ["intestine", "ORGAN", 458, 467], ["cells", "CELL", 472, 477], ["IL-10", "PROTEIN", 0, 5], ["dendritic cells", "CELL_TYPE", 51, 66], ["macrophages", "CELL_TYPE", 68, 79], ["monocytes", "CELL_TYPE", 81, 90], ["T cell subsets", "CELL_TYPE", 121, 135], ["B cells", "CELL_TYPE", 140, 147], ["immune cells", "CELL_TYPE", 149, 161], ["chIL-10", "PROTEIN", 182, 189], ["IFN", "PROTEIN", 234, 237], ["\u03b3", "PROTEIN", 238, 239], ["mitogen", "PROTEIN", 243, 250], ["activated splenocytes", "CELL_TYPE", 251, 272], ["resistant lines", "CELL_LINE", 322, 337], ["IL-10", "PROTEIN", 377, 382], ["IFN-\u03b3", "PROTEIN", 434, 439], ["IL", "TEST", 0, 2], ["macrophages", "TEST", 68, 79], ["monocytes", "TEST", 81, 90], ["acquired (various T cell subsets", "PROBLEM", 103, 135], ["chIL", "TEST", 182, 186], ["IFN", "TEST", 234, 237], ["activated splenocytes", "PROBLEM", 251, 272], ["more resistant lines", "PROBLEM", 317, 337], ["IFN", "TEST", 434, 437], ["dendritic cells", "OBSERVATION", 51, 66], ["relatively", "OBSERVATION_MODIFIER", 399, 409], ["increased", "OBSERVATION_MODIFIER", 410, 419], ["expression", "OBSERVATION_MODIFIER", 420, 430], ["IFN", "OBSERVATION", 434, 437], ["spleen", "ANATOMY", 447, 453], ["intestine", "ANATOMY", 458, 467]]], ["In addition, neutralization of chIL-10 by monoclonal antibodies upregulated the production of NO (cytotoxic towards various pathogens) by lipopolysaccharide-stimulated chicken bone marrow-derived macrophages (Wu et al., 2016) .", [["bone marrow-derived macrophages", "ANATOMY", 176, 207], ["NO", "CHEMICAL", 94, 96], ["lipopolysaccharide", "CHEMICAL", 138, 156], ["NO", "CHEMICAL", 94, 96], ["chIL-10", "GENE_OR_GENE_PRODUCT", 31, 38], ["NO", "SIMPLE_CHEMICAL", 94, 96], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 138, 156], ["chicken", "ORGANISM", 168, 175], ["bone marrow-derived macrophages", "CELL", 176, 207], ["chIL-10", "PROTEIN", 31, 38], ["monoclonal antibodies", "PROTEIN", 42, 63], ["lipopolysaccharide-stimulated chicken bone marrow-derived macrophages", "CELL_LINE", 138, 207], ["chicken", "SPECIES", 168, 175], ["chicken", "SPECIES", 168, 175], ["chIL", "TEST", 31, 35], ["monoclonal antibodies", "TEST", 42, 63], ["various pathogens", "PROBLEM", 116, 133], ["lipopolysaccharide", "TEST", 138, 156], ["bone marrow", "ANATOMY", 176, 187]]], ["It is also interesting to note that IL-10 was not detected in the serum of healthy (uninfected) birds, whereas a substantial increase in serum IL-10 was reported 5 dpi in birds challenged with both a high and low dose of E. tenella, leading to the suggestion that Eimeria infections may cause systemic immunosuppression and that serum IL-10 could be a marker for infection (Wu et al., 2016) .", [["serum", "ANATOMY", 66, 71], ["serum", "ANATOMY", 137, 142], ["serum", "ANATOMY", 329, 334], ["Eimeria infections", "DISEASE", 264, 282], ["infection", "DISEASE", 363, 372], ["IL-10", "GENE_OR_GENE_PRODUCT", 36, 41], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["birds", "ORGANISM", 96, 101], ["serum", "ORGANISM_SUBSTANCE", 137, 142], ["IL-10", "GENE_OR_GENE_PRODUCT", 143, 148], ["birds", "ORGANISM", 171, 176], ["E. tenella", "ORGANISM", 221, 231], ["Eimeria", "ORGANISM", 264, 271], ["serum", "ORGANISM_SUBSTANCE", 329, 334], ["IL-10", "GENE_OR_GENE_PRODUCT", 335, 340], ["IL", "PROTEIN", 36, 38], ["IL", "PROTEIN", 143, 145], ["serum IL-10", "PROTEIN", 329, 340], ["E. tenella", "SPECIES", 221, 231], ["E. tenella", "SPECIES", 221, 231], ["IL", "TEST", 36, 38], ["serum IL", "TEST", 137, 145], ["E. tenella", "PROBLEM", 221, 231], ["Eimeria infections", "PROBLEM", 264, 282], ["systemic immunosuppression", "TREATMENT", 293, 319], ["serum IL", "TEST", 329, 337], ["infection", "PROBLEM", 363, 372], ["substantial", "OBSERVATION_MODIFIER", 113, 124], ["increase", "OBSERVATION_MODIFIER", 125, 133], ["Eimeria infections", "OBSERVATION", 264, 282], ["may cause", "UNCERTAINTY", 283, 292], ["systemic", "OBSERVATION_MODIFIER", 293, 301], ["immunosuppression", "OBSERVATION", 302, 319]]], ["Moreover, IL-10 inhibits the proliferation of Th cells and production of various associated cytokines (Couper et al., 2008) , and, in conjunction with the observations outlined above, the immunoregulatory activities of IL-10 may compromise vaccine efficacy and anti-IL-10 interventions may prove effective methods to improve vaccine responses (Darrah et al., 2010) .", [["Th cells", "ANATOMY", 46, 54], ["IL-10", "GENE_OR_GENE_PRODUCT", 10, 15], ["Th cells", "CELL", 46, 54], ["IL-10", "GENE_OR_GENE_PRODUCT", 219, 224], ["anti-IL-10", "GENE_OR_GENE_PRODUCT", 261, 271], ["IL-10", "PROTEIN", 10, 15], ["Th cells", "CELL_TYPE", 46, 54], ["cytokines", "PROTEIN", 92, 101], ["IL", "PROTEIN", 219, 221], ["IL", "TEST", 10, 12], ["the proliferation of Th cells", "PROBLEM", 25, 54], ["various associated cytokines", "PROBLEM", 73, 101], ["the immunoregulatory activities of IL", "TREATMENT", 184, 221], ["vaccine efficacy", "TREATMENT", 240, 256], ["anti-IL-10 interventions", "TREATMENT", 261, 285], ["Th cells", "OBSERVATION", 46, 54]]], ["Whilst concern is often expressed about the potential negative effects of inflammation on the growth performance of animals (Broom and Kogut, 2017) , it is important to note that, where provided, better growth performance is a parameter used to determine the more resistant chicken line to coccidiosis or NE challenge in the studies discussed above.", [["inflammation", "DISEASE", 74, 86], ["coccidiosis", "DISEASE", 290, 301], ["NE", "CHEMICAL", 305, 307], ["chicken", "ORGANISM", 274, 281], ["chicken", "SPECIES", 274, 281], ["chicken", "SPECIES", 274, 281], ["inflammation", "PROBLEM", 74, 86], ["coccidiosis", "PROBLEM", 290, 301], ["NE challenge", "TREATMENT", 305, 317], ["the studies", "TEST", 321, 332], ["inflammation", "OBSERVATION", 74, 86], ["coccidiosis", "OBSERVATION", 290, 301]]], ["Therefore, (relative) reduction of IL-10 can be associated with improved indicators of gut status (e.g., reduced lesions; Kim et al., 2015) and growth performance when birds are confronted with ubiquitous intestinal pathogens.", [["gut", "ANATOMY", 87, 90], ["lesions", "ANATOMY", 113, 120], ["intestinal", "ANATOMY", 205, 215], ["IL-10", "GENE_OR_GENE_PRODUCT", 35, 40], ["gut", "ORGANISM_SUBDIVISION", 87, 90], ["lesions", "PATHOLOGICAL_FORMATION", 113, 120], ["birds", "ORGANISM", 168, 173], ["intestinal", "ORGAN", 205, 215], ["IL", "PROTEIN", 35, 37], ["relative) reduction of IL", "TREATMENT", 12, 37], ["reduced lesions", "PROBLEM", 105, 120], ["ubiquitous intestinal pathogens", "PROBLEM", 194, 225], ["intestinal", "ANATOMY", 205, 215], ["pathogens", "OBSERVATION", 216, 225]]], ["With this in mind, it has been reported that feeding antibodies against IL-10 improves the performance of E. acervulina, E. maxima, and E. tenella challenged broiler chickens and thus may offer an alternative strategy to alleviate the impact of coccidiosis Sand et al., 2016) .INTERPRETATION OF IMMUNE-RELATED GENE EXPRESSION IN BIRDS MORE OR LESS RESISTANT TO COCCIDIOSIS AND NEAn (excessively) immunoregulatory cellular environment may not, therefore, be beneficial, while the relative enhancement of IFN-\u03b3 (type II interferon) appears to contribute to the resistance of birds to coccidiosis and NE.", [["cellular", "ANATOMY", 413, 421], ["coccidiosis", "DISEASE", 245, 256], ["coccidiosis", "DISEASE", 582, 593], ["NE", "CHEMICAL", 598, 600], ["IL-10", "GENE_OR_GENE_PRODUCT", 72, 77], ["E. acervulina", "ORGANISM", 106, 119], ["E. maxima", "ORGANISM", 121, 130], ["E. tenella", "ORGANISM", 136, 146], ["broiler chickens", "ORGANISM", 158, 174], ["cellular", "CELL", 413, 421], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 503, 508], ["type II interferon", "GENE_OR_GENE_PRODUCT", 510, 528], ["birds", "ORGANISM", 573, 578], ["IL", "PROTEIN", 72, 74], ["IFN-\u03b3", "PROTEIN", 503, 508], ["type II interferon", "PROTEIN", 510, 528], ["E. acervulina", "SPECIES", 106, 119], ["E. maxima", "SPECIES", 121, 130], ["E. tenella", "SPECIES", 136, 146], ["chickens", "SPECIES", 166, 174], ["E. acervulina", "SPECIES", 106, 119], ["E. maxima", "SPECIES", 121, 130], ["E. tenella", "SPECIES", 136, 146], ["chickens", "SPECIES", 166, 174], ["feeding antibodies", "TEST", 45, 63], ["IL", "TEST", 72, 74], ["E. acervulina", "TREATMENT", 106, 119], ["E. maxima", "TREATMENT", 121, 130], ["broiler chickens", "TREATMENT", 158, 174], ["an alternative strategy", "TREATMENT", 194, 217], ["COCCIDIOSIS", "PROBLEM", 361, 372], ["IFN", "TEST", 503, 506], ["type II interferon", "TREATMENT", 510, 528], ["coccidiosis", "PROBLEM", 582, 593], ["COCCIDIOSIS", "OBSERVATION", 361, 372], ["coccidiosis", "OBSERVATION", 582, 593]]], ["IFN-\u03b3 is regarded as a key effector of cell-mediated immunity and numerous antimicrobial functions.", [["cell", "ANATOMY", 39, 43], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 39, 43], ["IFN", "PROTEIN", 0, 3], ["\u03b3", "PROTEIN", 4, 5], ["cell-mediated immunity", "TREATMENT", 39, 61], ["antimicrobial functions", "OBSERVATION", 75, 98]]], ["IFN-\u03b3 is produced by various innate and acquired immune cells and increases antigen processing/presentation, leukocyte trafficking, natural killer (NK) cell and macrophage activity, ROS and NOS production, autophagy, secretion of proinflammatory cytokines, and influences antibody responses (Kak et al., 2018) .", [["immune cells", "ANATOMY", 49, 61], ["leukocyte", "ANATOMY", 109, 118], ["natural killer (NK) cell", "ANATOMY", 132, 156], ["macrophage", "ANATOMY", 161, 171], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["immune cells", "CELL", 49, 61], ["leukocyte", "CELL", 109, 118], ["natural killer", "CELL", 132, 146], ["NK) cell", "CELL", 148, 156], ["macrophage", "CELL", 161, 171], ["ROS", "SIMPLE_CHEMICAL", 182, 185], ["NOS", "GENE_OR_GENE_PRODUCT", 190, 193], ["IFN-\u03b3", "PROTEIN", 0, 5], ["immune cells", "CELL_TYPE", 49, 61], ["natural killer (NK) cell", "CELL_TYPE", 132, 156], ["NOS", "PROTEIN", 190, 193], ["proinflammatory cytokines", "PROTEIN", 230, 255], ["IFN", "TEST", 0, 3], ["acquired immune cells", "PROBLEM", 40, 61], ["increases antigen processing", "PROBLEM", 66, 94], ["leukocyte trafficking", "TEST", 109, 130], ["macrophage activity", "TEST", 161, 180], ["NOS production", "TEST", 190, 204], ["autophagy", "PROBLEM", 206, 215], ["proinflammatory cytokines", "TEST", 230, 255], ["macrophage activity", "OBSERVATION", 161, 180], ["proinflammatory cytokines", "OBSERVATION", 230, 255]]], ["These functions are coordinated to control and eliminate the pathogen (and minimize associated tissue injury), notably intracellular pathogens such as Eimeria.", [["tissue", "ANATOMY", 95, 101], ["intracellular", "ANATOMY", 119, 132], ["tissue", "TISSUE", 95, 101], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 119, 132], ["the pathogen", "PROBLEM", 57, 69], ["associated tissue injury", "PROBLEM", 84, 108], ["intracellular pathogens", "PROBLEM", 119, 142], ["Eimeria", "PROBLEM", 151, 158], ["intracellular pathogens", "OBSERVATION", 119, 142]]], ["The data available for IFN-\u03b1, IL-12, and IL-17D are somewhat less consistent.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 23, 28], ["IL-12", "GENE_OR_GENE_PRODUCT", 30, 35], ["IL-17D", "GENE_OR_GENE_PRODUCT", 41, 47], ["IFN", "PROTEIN", 23, 26], ["IL", "PROTEIN", 30, 32], ["IL", "PROTEIN", 41, 43], ["The data", "TEST", 0, 8], ["IFN", "TEST", 23, 26], ["IL", "TEST", 30, 32], ["IL", "TEST", 41, 43]]], ["IFN-\u03b1 is a prominent type I interferon (along with IFN-\u03b2) predominantly produced by hematopoietic cells, notably plasmacytoid dendritic cells, in mammals (Ivashkiv and Donlin, 2014) .", [["hematopoietic cells", "ANATOMY", 84, 103], ["plasmacytoid dendritic cells", "ANATOMY", 113, 141], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["type I interferon", "GENE_OR_GENE_PRODUCT", 21, 38], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 51, 56], ["hematopoietic cells", "CELL", 84, 103], ["plasmacytoid dendritic cells", "CELL", 113, 141], ["IFN-\u03b1", "PROTEIN", 0, 5], ["type I interferon", "PROTEIN", 21, 38], ["IFN-\u03b2", "PROTEIN", 51, 56], ["hematopoietic cells", "CELL_TYPE", 84, 103], ["plasmacytoid dendritic cells", "CELL_TYPE", 113, 141], ["a prominent type I interferon", "PROBLEM", 9, 38], ["IFN", "TREATMENT", 51, 54], ["hematopoietic cells", "PROBLEM", 84, 103], ["plasmacytoid dendritic cells", "PROBLEM", 113, 141], ["prominent", "OBSERVATION_MODIFIER", 11, 20], ["type I", "OBSERVATION_MODIFIER", 21, 27], ["interferon", "OBSERVATION_MODIFIER", 28, 38], ["hematopoietic cells", "OBSERVATION", 84, 103], ["plasmacytoid dendritic cells", "OBSERVATION", 113, 141]]], ["When type I IFNs bind to their cognate receptor (interferon-alpha receptor), it leads to activation of pathways regulating interferon-stimulated genes (ISG) and enhanced antigen presentation, regulated inflammasome activation, and upregulation of pro-inflammatory cytokines (Garrido et al., 2018) .", [["type I IFNs", "GENE_OR_GENE_PRODUCT", 5, 16], ["interferon-alpha receptor", "GENE_OR_GENE_PRODUCT", 49, 74], ["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 123, 150], ["ISG", "GENE_OR_GENE_PRODUCT", 152, 155], ["type I IFNs", "PROTEIN", 5, 16], ["cognate receptor", "PROTEIN", 31, 47], ["interferon-alpha receptor", "PROTEIN", 49, 74], ["interferon-stimulated genes", "DNA", 123, 150], ["ISG", "DNA", 152, 155], ["pro-inflammatory cytokines", "PROTEIN", 247, 273], ["type I IFNs bind", "TREATMENT", 5, 21], ["interferon-alpha receptor", "TREATMENT", 49, 74], ["pathways regulating interferon", "TREATMENT", 103, 133], ["pro-inflammatory cytokines", "PROBLEM", 247, 273], ["inflammasome activation", "OBSERVATION", 202, 225], ["pro-inflammatory cytokines", "OBSERVATION", 247, 273]]], ["Garrido et al., (2018) reported that IFN-\u03b1 induced the expression of ISG (at 6h post stimulation) by chicken macrophages to a greater extent than IFN-\u03b2 (while IFN-\u03b2 was a stronger inducer of pro-inflammatory cytokine gene expression (IL-1\u03b2, IL-6, and IL-8)).", [["macrophages", "ANATOMY", 109, 120], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 37, 42], ["ISG", "GENE_OR_GENE_PRODUCT", 69, 72], ["chicken", "ORGANISM", 101, 108], ["macrophages", "CELL", 109, 120], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 146, 151], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 159, 164], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 234, 239], ["IL-6", "GENE_OR_GENE_PRODUCT", 241, 245], ["IL-8", "GENE_OR_GENE_PRODUCT", 251, 255], ["IFN-\u03b1", "PROTEIN", 37, 42], ["ISG", "PROTEIN", 69, 72], ["chicken macrophages", "CELL_TYPE", 101, 120], ["IFN-\u03b2", "PROTEIN", 146, 151], ["IFN-\u03b2", "PROTEIN", 159, 164], ["pro-inflammatory cytokine", "PROTEIN", 191, 216], ["chicken", "SPECIES", 101, 108], ["chicken", "SPECIES", 101, 108], ["chicken macrophages", "PROBLEM", 101, 120], ["IFN", "TEST", 146, 149], ["pro-inflammatory cytokine gene expression", "TREATMENT", 191, 232], ["IL", "TEST", 234, 236], ["IL", "TEST", 241, 243], ["greater extent", "OBSERVATION_MODIFIER", 126, 140]]], ["IL-12, produced by various immune cells (e.g., dendritic cells, macrophages, neutrophils), drives inflammatory Th1 responses, production of IFN-\u03b3, and the cytotoxic activity of NK and CD8+ T cells (Issaranggun Na Ayuthaya et al., 2018) .", [["immune cells", "ANATOMY", 27, 39], ["dendritic cells", "ANATOMY", 47, 62], ["macrophages", "ANATOMY", 64, 75], ["neutrophils", "ANATOMY", 77, 88], ["NK", "ANATOMY", 177, 179], ["CD8+ T cells", "ANATOMY", 184, 196], ["Na", "CHEMICAL", 210, 212], ["IL-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["immune cells", "CELL", 27, 39], ["dendritic cells", "CELL", 47, 62], ["macrophages", "CELL", 64, 75], ["neutrophils", "CELL", 77, 88], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 140, 145], ["NK", "CELL", 177, 179], ["CD8", "GENE_OR_GENE_PRODUCT", 184, 187], ["IL-12", "PROTEIN", 0, 5], ["immune cells", "CELL_TYPE", 27, 39], ["dendritic cells", "CELL_TYPE", 47, 62], ["macrophages", "CELL_TYPE", 64, 75], ["neutrophils", "CELL_TYPE", 77, 88], ["IFN-\u03b3", "PROTEIN", 140, 145], ["NK and CD8+ T cells", "CELL_TYPE", 177, 196], ["IL", "TEST", 0, 2], ["dendritic cells", "PROBLEM", 47, 62], ["macrophages", "PROBLEM", 64, 75], ["neutrophils", "TEST", 77, 88], ["inflammatory Th1 responses", "PROBLEM", 98, 124], ["IFN", "TEST", 140, 143], ["the cytotoxic activity", "TEST", 151, 173], ["NK", "TEST", 177, 179], ["CD8", "TEST", 184, 187], ["immune cells", "OBSERVATION", 27, 39], ["dendritic cells", "OBSERVATION", 47, 62], ["macrophages", "ANATOMY", 64, 75], ["inflammatory", "OBSERVATION_MODIFIER", 98, 110]]], ["IL-17D is a member of the IL-17 family of cytokines produced by Th17 cells, is expressed in a wide range of tissues and organs, and stimulates the expression of IL-6 and IL-8 by various cells (Min et al., 2013) .", [["Th17 cells", "ANATOMY", 64, 74], ["tissues", "ANATOMY", 108, 115], ["organs", "ANATOMY", 120, 126], ["cells", "ANATOMY", 186, 191], ["IL-17D", "GENE_OR_GENE_PRODUCT", 0, 6], ["IL-17", "GENE_OR_GENE_PRODUCT", 26, 31], ["Th17 cells", "CELL", 64, 74], ["tissues", "TISSUE", 108, 115], ["organs", "ORGAN", 120, 126], ["IL-6", "GENE_OR_GENE_PRODUCT", 161, 165], ["IL-8", "GENE_OR_GENE_PRODUCT", 170, 174], ["cells", "CELL", 186, 191], ["IL-17D", "PROTEIN", 0, 6], ["IL-17 family", "PROTEIN", 26, 38], ["cytokines", "PROTEIN", 42, 51], ["Th17 cells", "CELL_TYPE", 64, 74], ["IL-6", "PROTEIN", 161, 165], ["IL-8", "PROTEIN", 170, 174], ["IL", "TEST", 161, 163], ["organs", "ANATOMY", 120, 126]]], ["Therefore, the various identified cytokines contribute to determining the (degree of) inflammatory milieu, with various interactions, that influence effector cells and their functions in response to pathogens.INTERPRETATION OF IMMUNE-RELATED GENE EXPRESSION IN BIRDS MORE OR LESS RESISTANT TO COCCIDIOSIS AND NEThe focus so far has been on those genes/cytokines that have, historically, been regarded as of particular interest and/or have been selected for interrogation.", [["effector cells", "ANATOMY", 149, 163], ["effector cells", "CELL", 149, 163], ["cytokines", "PROTEIN", 34, 43], ["effector cells", "CELL_TYPE", 149, 163], ["cytokines", "PROTEIN", 352, 361], ["inflammatory milieu", "PROBLEM", 86, 105], ["influence effector cells", "PROBLEM", 139, 163], ["pathogens", "PROBLEM", 199, 208], ["interrogation", "TEST", 457, 470], ["cytokines", "OBSERVATION", 34, 43], ["inflammatory", "OBSERVATION", 86, 98], ["COCCIDIOSIS", "OBSERVATION", 293, 304]]], ["However, in time, some of these genes and their respective pathways could be particularly important in determining the susceptibility or resistance of chickens to diseases.", [["chickens", "ORGANISM", 151, 159], ["chickens", "SPECIES", 151, 159], ["chickens", "SPECIES", 151, 159], ["chickens to diseases", "PROBLEM", 151, 171]]], ["Table 2 outlines some genes, and their functions, from NE studies that maybe particularly relevant in determining disease susceptibility/resistance based on consistent (relative) up or downregulation in more resistant birds.SALMONELLA AND CAMPYLOBACTERSalmonella and Campylobacter, specifically C. jejuni, are the leading causes of foodborne illness in humans and can be carried at high numbers in the GIT of poultry.", [["GIT", "ANATOMY", 402, 405], ["C. jejuni", "DISEASE", 295, 304], ["foodborne illness", "DISEASE", 332, 349], ["C. jejuni", "ORGANISM", 295, 304], ["humans", "ORGANISM", 353, 359], ["GIT", "ORGANISM_SUBDIVISION", 402, 405], ["NE", "PROTEIN", 55, 57], ["C. jejuni", "SPECIES", 295, 304], ["humans", "SPECIES", 353, 359], ["C. jejuni", "SPECIES", 295, 304], ["humans", "SPECIES", 353, 359], ["NE studies", "TEST", 55, 65], ["disease susceptibility/resistance", "PROBLEM", 114, 147], ["downregulation in more resistant birds", "PROBLEM", 185, 223], ["SALMONELLA", "PROBLEM", 224, 234], ["CAMPYLOBACTERSalmonella", "TREATMENT", 239, 262], ["Campylobacter", "PROBLEM", 267, 280], ["C. jejuni", "PROBLEM", 295, 304], ["foodborne illness", "PROBLEM", 332, 349], ["more resistant", "OBSERVATION_MODIFIER", 203, 217], ["Campylobacter", "OBSERVATION", 267, 280], ["jejuni", "ANATOMY", 298, 304], ["foodborne", "OBSERVATION_MODIFIER", 332, 341], ["illness", "OBSERVATION", 342, 349], ["GIT", "ANATOMY", 402, 405]]], ["Salmonella enterica are typically divided into broad host range and host-adapted serovars.", [["Salmonella enterica", "ORGANISM", 0, 19], ["Salmonella enterica", "SPECIES", 0, 19], ["Salmonella enterica", "SPECIES", 0, 19], ["Salmonella enterica", "PROBLEM", 0, 19], ["broad host", "OBSERVATION_MODIFIER", 47, 57]]], ["Broad host range serovars (e.g., S. Typhimurium and S. Enteritidis) may cause limited, low-level systemic infection in healthy chickens over 1 wk of age but principally colonize the GIT where they may persist, asymptomatically, for several weeks/months (carrier state; Wigley, 2014).", [["GIT", "ANATOMY", 182, 185], ["infection", "DISEASE", 106, 115], ["S. Typhimurium", "ORGANISM", 33, 47], ["S. Enteritidis", "ORGANISM", 52, 66], ["chickens", "ORGANISM", 127, 135], ["GIT", "ORGAN", 182, 185], ["S. Typhimurium", "SPECIES", 33, 47], ["S. Enteritidis", "SPECIES", 52, 66], ["chickens", "SPECIES", 127, 135], ["S. Typhimurium", "SPECIES", 33, 47], ["S. Enteritidis", "SPECIES", 52, 66], ["chickens", "SPECIES", 127, 135], ["S. Enteritidis", "PROBLEM", 52, 66], ["low-level systemic infection", "PROBLEM", 87, 115], ["systemic", "OBSERVATION_MODIFIER", 97, 105], ["infection", "OBSERVATION", 106, 115]]], ["Host-adapted serovars (e.g., S. Gallinarum and S. Pullorum) are generally poor colonizers of the GIT but do cause systemic infection, which can lead to significant morbidity and mortality (Wigley, 2014) .", [["GIT", "ANATOMY", 97, 100], ["systemic infection", "DISEASE", 114, 132], ["S. Gallinarum", "ORGANISM", 29, 42], ["S. Pullorum", "ORGANISM", 47, 58], ["GIT", "ORGAN", 97, 100], ["S. Gallinarum", "SPECIES", 29, 42], ["S. Pullorum", "SPECIES", 47, 58], ["S. Gallinarum", "SPECIES", 29, 42], ["S. Pullorum", "SPECIES", 47, 58], ["systemic infection", "PROBLEM", 114, 132], ["significant morbidity", "PROBLEM", 152, 173], ["GIT", "ANATOMY", 97, 100], ["infection", "OBSERVATION", 123, 132], ["significant", "OBSERVATION_MODIFIER", 152, 163], ["morbidity", "OBSERVATION", 164, 173]]], ["Campylobacter jejuni colonizes the chicken GIT, principally the caeca.", [["GIT", "ANATOMY", 43, 46], ["caeca", "ANATOMY", 64, 69], ["Campylobacter jejuni", "DISEASE", 0, 20], ["Campylobacter jejuni", "ORGANISM", 0, 20], ["chicken", "ORGANISM", 35, 42], ["GIT", "ORGAN", 43, 46], ["caeca", "ORGAN", 64, 69], ["Campylobacter jejuni", "SPECIES", 0, 20], ["chicken", "SPECIES", 35, 42], ["Campylobacter jejuni", "SPECIES", 0, 20], ["chicken", "SPECIES", 35, 42], ["Campylobacter jejuni colonizes", "PROBLEM", 0, 30], ["jejuni colonizes", "OBSERVATION", 14, 30], ["caeca", "ANATOMY", 64, 69]]], ["Traditionally, C. jejuni was considered a harmless gut commensal for chickens and has only really been considered in the context of the risk that poultry intestinal carriage poses to humans.", [["gut", "ANATOMY", 51, 54], ["intestinal", "ANATOMY", 154, 164], ["poultry intestinal carriage", "DISEASE", 146, 173], ["C. jejuni", "ORGANISM", 15, 24], ["gut", "ORGANISM_SUBDIVISION", 51, 54], ["chickens", "ORGANISM", 69, 77], ["intestinal", "ORGAN", 154, 164], ["humans", "ORGANISM", 183, 189], ["C. jejuni", "SPECIES", 15, 24], ["chickens", "SPECIES", 69, 77], ["humans", "SPECIES", 183, 189], ["C. jejuni", "SPECIES", 15, 24], ["chickens", "SPECIES", 69, 77], ["humans", "SPECIES", 183, 189], ["chickens", "PROBLEM", 69, 77], ["jejuni", "OBSERVATION", 18, 24]]], ["The bacterium can, however, be recognized by Toll-like receptors (4 and 21), initiating an innate, inflammatory response in the chicken intestine, and thus adaptive responses, and may alter the gut epithelial structure and be recovered from the liver and spleen, making the traditional perspective of C. jejuni somewhat inaccurate (Humphrey et al., 2014) .", [["intestine", "ANATOMY", 136, 145], ["gut epithelial", "ANATOMY", 194, 208], ["liver", "ANATOMY", 245, 250], ["spleen", "ANATOMY", 255, 261], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 45, 64], ["chicken", "ORGANISM", 128, 135], ["intestine", "ORGAN", 136, 145], ["gut epithelial", "TISSUE", 194, 208], ["liver", "ORGAN", 245, 250], ["spleen", "ORGAN", 255, 261], ["C. jejuni", "ORGANISM", 301, 310], ["Toll-like receptors", "PROTEIN", 45, 64], ["chicken", "SPECIES", 128, 135], ["C. jejuni", "SPECIES", 301, 310], ["chicken", "SPECIES", 128, 135], ["C. jejuni", "SPECIES", 301, 310], ["The bacterium", "PROBLEM", 0, 13], ["C. jejuni", "PROBLEM", 301, 310], ["bacterium", "OBSERVATION", 4, 13], ["inflammatory", "OBSERVATION", 99, 111], ["chicken intestine", "ANATOMY", 128, 145], ["gut epithelial", "ANATOMY", 194, 208], ["liver", "ANATOMY", 245, 250], ["spleen", "ANATOMY", 255, 261]]], ["It is of interest to consider whether there are common features of the chicken (immune) response to coccidiosis and NE in more resistant and/or susceptible birds that also influence the susceptibility of birds to Salmonella and/or Campylobacter infection and/or carriage.", [["coccidiosis", "DISEASE", 100, 111], ["NE", "CHEMICAL", 116, 118], ["Salmonella", "CHEMICAL", 213, 223], ["Campylobacter infection", "DISEASE", 231, 254], ["chicken", "ORGANISM", 71, 78], ["birds", "ORGANISM", 156, 161], ["birds", "ORGANISM", 204, 209], ["chicken", "SPECIES", 71, 78], ["chicken", "SPECIES", 71, 78], ["Salmonella", "SPECIES", 213, 223], ["the chicken (immune) response", "PROBLEM", 67, 96], ["coccidiosis", "PROBLEM", 100, 111], ["NE", "TREATMENT", 116, 118], ["susceptible birds", "PROBLEM", 144, 161], ["Salmonella", "PROBLEM", 213, 223], ["Campylobacter infection", "PROBLEM", 231, 254], ["carriage", "PROBLEM", 262, 270], ["coccidiosis", "OBSERVATION", 100, 111], ["Campylobacter infection", "OBSERVATION", 231, 254]]], ["The caeca are the major reservoirs of microorganisms, including Salmonella and Campylobacter, and the caecal tonsils, situated at the ileal-caecal junction, are major lymphoid aggregates of the chicken GIT and have thus been studied.", [["caeca", "ANATOMY", 4, 9], ["caecal tonsils", "ANATOMY", 102, 116], ["ileal-caecal junction", "ANATOMY", 134, 155], ["lymphoid aggregates", "ANATOMY", 167, 186], ["GIT", "ANATOMY", 202, 205], ["caeca", "ORGAN", 4, 9], ["caecal tonsils", "MULTI-TISSUE_STRUCTURE", 102, 116], ["ileal", "MULTI-TISSUE_STRUCTURE", 134, 139], ["caecal junction", "MULTI-TISSUE_STRUCTURE", 140, 155], ["lymphoid aggregates", "CELL", 167, 186], ["chicken", "ORGANISM", 194, 201], ["GIT", "ORGAN", 202, 205], ["chicken", "SPECIES", 194, 201], ["Salmonella", "SPECIES", 64, 74], ["chicken", "SPECIES", 194, 201], ["microorganisms", "PROBLEM", 38, 52], ["Salmonella", "PROBLEM", 64, 74], ["Campylobacter", "PROBLEM", 79, 92], ["the caecal tonsils", "PROBLEM", 98, 116], ["caeca", "ANATOMY", 4, 9], ["major", "OBSERVATION_MODIFIER", 18, 23], ["reservoirs", "OBSERVATION_MODIFIER", 24, 34], ["microorganisms", "OBSERVATION", 38, 52], ["Salmonella", "OBSERVATION_MODIFIER", 64, 74], ["Campylobacter", "OBSERVATION_MODIFIER", 79, 92], ["caecal tonsils", "ANATOMY", 102, 116], ["ileal", "ANATOMY", 134, 139], ["caecal junction", "ANATOMY", 140, 155], ["major lymphoid aggregates", "OBSERVATION", 161, 186]]], ["At a young age (1 week of age (woa)), prolonged downregulation of IFN-\u03b3 expression in the caecal tonsils of one inbred line (6 1 ) was associated with much greater numbers of caecal Salmonella than another inbred line (15I) following oral inoculation with S. enterica serovar Enteritidis 1009 (Sadeyen et al., 2004) .", [["caecal tonsils", "ANATOMY", 90, 104], ["oral", "ANATOMY", 234, 238], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 66, 71], ["caecal tonsils", "ORGAN", 90, 104], ["caecal Salmonella", "ORGANISM", 175, 192], ["oral", "ORGANISM_SUBDIVISION", 234, 238], ["S. enterica serovar Enteritidis", "ORGANISM", 256, 287], ["1009", "ORGANISM", 288, 292], ["IFN", "PROTEIN", 66, 69], ["\u03b3", "PROTEIN", 70, 71], ["S.", "SPECIES", 256, 258], ["enterica serovar Enteritidis", "SPECIES", 259, 287], ["S. enterica serovar Enteritidis 1009", "SPECIES", 256, 292], ["prolonged downregulation of IFN", "PROBLEM", 38, 69], ["caecal Salmonella", "PROBLEM", 175, 192], ["another inbred line", "TREATMENT", 198, 217], ["oral inoculation", "TREATMENT", 234, 250], ["S. enterica serovar Enteritidis", "TREATMENT", 256, 287], ["caecal tonsils", "ANATOMY", 90, 104], ["caecal Salmonella", "ANATOMY", 175, 192]]], ["Chausse et al., (2014) reported that susceptibility to carrier-state (6 1 line) is associated with a bias towards Th2 responses in caecal enterocytes at 21 dpi with S. enterica serovar Enteritidis 751 at 1 woa.", [["caecal enterocytes", "ANATOMY", 131, 149], ["Th2", "GENE_OR_GENE_PRODUCT", 114, 117], ["caecal enterocytes", "MULTI-TISSUE_STRUCTURE", 131, 149], ["S. enterica", "ORGANISM", 165, 176], ["serovar Enteritidis", "ORGANISM", 177, 196], ["caecal enterocytes", "CELL_TYPE", 131, 149], ["S.", "SPECIES", 165, 167], ["enterica serovar Enteritidis", "SPECIES", 168, 196], ["S. enterica serovar Enteritidis", "SPECIES", 165, 196], ["caecal enterocytes", "PROBLEM", 131, 149], ["S. enterica serovar Enteritidis", "TREATMENT", 165, 196], ["caecal enterocytes", "ANATOMY", 131, 149]]], ["In older birds (30 woa), increased Salmonella resistance was associated with increased expression of IFN-\u03b3, AvBD1, and AvBD2 (as well as IL-8, MIM-1, TLR4 (earlier), iNOS, IL-18) by caecal tonsils, although, at this age, line 6 1 birds were more resistant to both caecal persistence and systemic colonization than line 15I (Sadeyen et al., 2006) .", [["caecal tonsils", "ANATOMY", 182, 196], ["caecal", "ANATOMY", 264, 270], ["Salmonella", "CHEMICAL", 35, 45], ["birds", "ORGANISM", 9, 14], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 101, 106], ["AvBD1", "GENE_OR_GENE_PRODUCT", 108, 113], ["AvBD2", "GENE_OR_GENE_PRODUCT", 119, 124], ["IL-8", "GENE_OR_GENE_PRODUCT", 137, 141], ["MIM-1", "GENE_OR_GENE_PRODUCT", 143, 148], ["TLR4", "GENE_OR_GENE_PRODUCT", 150, 154], ["iNOS", "GENE_OR_GENE_PRODUCT", 166, 170], ["IL-18", "GENE_OR_GENE_PRODUCT", 172, 177], ["caecal tonsils", "MULTI-TISSUE_STRUCTURE", 182, 196], ["birds", "ORGANISM", 230, 235], ["caecal", "ORGANISM_SUBDIVISION", 264, 270], ["IFN", "PROTEIN", 101, 104], ["\u03b3", "PROTEIN", 105, 106], ["AvBD1", "PROTEIN", 108, 113], ["AvBD2", "PROTEIN", 119, 124], ["IL-8", "PROTEIN", 137, 141], ["MIM", "PROTEIN", 143, 146], ["TLR4", "PROTEIN", 150, 154], ["iNOS", "PROTEIN", 166, 170], ["IL-18", "PROTEIN", 172, 177], ["Salmonella", "SPECIES", 35, 45], ["increased Salmonella resistance", "PROBLEM", 25, 56], ["IFN", "TEST", 101, 104], ["AvBD1", "PROBLEM", 108, 113], ["AvBD2", "TEST", 119, 124], ["IL", "TEST", 137, 139], ["MIM", "TEST", 143, 146], ["TLR4", "PROBLEM", 150, 154], ["iNOS", "TEST", 166, 170], ["IL", "TEST", 172, 174], ["caecal tonsils", "PROBLEM", 182, 196], ["systemic colonization", "PROBLEM", 287, 308], ["Salmonella resistance", "OBSERVATION", 35, 56], ["caecal tonsils", "ANATOMY", 182, 196], ["caecal", "ANATOMY", 264, 270], ["persistence", "OBSERVATION", 271, 282], ["systemic", "OBSERVATION_MODIFIER", 287, 295], ["colonization", "OBSERVATION", 296, 308]]], ["After breaching the intestinal epithelium, Salmonella principally interact with macrophages (primary target) and heterophils (primary responders to infection in chickens; Wigley, 2014) , and thus the characteristics of these cells, isolated from more or less resistant chicken lines, have been assessed.", [["intestinal epithelium", "ANATOMY", 20, 41], ["macrophages", "ANATOMY", 80, 91], ["heterophils", "ANATOMY", 113, 124], ["cells", "ANATOMY", 225, 230], ["lines", "ANATOMY", 277, 282], ["infection", "DISEASE", 148, 157], ["intestinal epithelium", "TISSUE", 20, 41], ["macrophages", "CELL", 80, 91], ["heterophils", "CELL", 113, 124], ["chickens", "ORGANISM", 161, 169], ["cells", "CELL", 225, 230], ["chicken", "ORGANISM", 269, 276], ["lines", "CELL", 277, 282], ["macrophages", "CELL_TYPE", 80, 91], ["heterophils", "CELL_TYPE", 113, 124], ["resistant chicken lines", "CELL_LINE", 259, 282], ["chickens", "SPECIES", 161, 169], ["chicken", "SPECIES", 269, 276], ["Salmonella", "SPECIES", 43, 53], ["chickens", "SPECIES", 161, 169], ["chicken", "SPECIES", 269, 276], ["breaching the intestinal epithelium", "PROBLEM", 6, 41], ["Salmonella", "PROBLEM", 43, 53], ["heterophils", "PROBLEM", 113, 124], ["infection", "PROBLEM", 148, 157], ["these cells", "PROBLEM", 219, 230], ["less resistant chicken lines", "PROBLEM", 254, 282], ["intestinal epithelium", "ANATOMY", 20, 41], ["less resistant", "OBSERVATION_MODIFIER", 254, 268], ["chicken lines", "OBSERVATION", 269, 282]]], ["Peripheral blood macrophages and heterophils, derived from 8 to 12 woa and 1 doa chicken lines, respectively, demonstrated greater basal and/or more rapid expression of IL-6, CXCLi2/IL-8, and IL-18 by cells from more resistant lines following stimulation with Salmonella (or other related phagocytic agonists; Swaggerty et al., 2004; Wigley et al., 2006) .SALMONELLA AND CAMPYLOBACTERIn C. jejuni inoculated chickens (1 doa) at 7 dpi, AvBD 10 and 12 were significantly upregulated in the caeca of birds more resistant to caecal colonization by C. jejuni (Li et al., 2010) .", [["Peripheral blood macrophages", "ANATOMY", 0, 28], ["heterophils", "ANATOMY", 33, 44], ["woa", "ANATOMY", 67, 70], ["lines", "ANATOMY", 89, 94], ["cells", "ANATOMY", 201, 206], ["lines", "ANATOMY", 227, 232], ["caeca", "ANATOMY", 488, 493], ["caecal", "ANATOMY", 521, 527], ["Peripheral blood macrophages", "CELL", 0, 28], ["heterophils", "CELL", 33, 44], ["chicken", "ORGANISM", 81, 88], ["IL-6", "GENE_OR_GENE_PRODUCT", 169, 173], ["CXCLi2", "GENE_OR_GENE_PRODUCT", 175, 181], ["IL-8", "GENE_OR_GENE_PRODUCT", 182, 186], ["IL-18", "GENE_OR_GENE_PRODUCT", 192, 197], ["cells", "CELL", 201, 206], ["lines", "CELL", 227, 232], ["CAMPYLOBACTERIn C. jejuni", "ORGANISM", 371, 396], ["chickens", "ORGANISM", 408, 416], ["caeca", "ORGAN", 488, 493], ["birds", "ORGANISM", 497, 502], ["caecal", "ORGANISM_SUBDIVISION", 521, 527], ["C. jejuni", "ORGANISM", 544, 553], ["Peripheral blood macrophages", "CELL_TYPE", 0, 28], ["heterophils", "CELL_TYPE", 33, 44], ["IL-6", "PROTEIN", 169, 173], ["CXCLi2", "PROTEIN", 175, 181], ["IL-8", "PROTEIN", 182, 186], ["IL-18", "PROTEIN", 192, 197], ["resistant lines", "CELL_LINE", 217, 232], ["chicken", "SPECIES", 81, 88], ["C. jejuni", "SPECIES", 387, 396], ["chickens", "SPECIES", 408, 416], ["C. jejuni", "SPECIES", 544, 553], ["chicken", "SPECIES", 81, 88], ["Salmonella", "SPECIES", 260, 270], ["C. jejuni", "SPECIES", 387, 396], ["chickens", "SPECIES", 408, 416], ["C. jejuni", "SPECIES", 544, 553], ["Peripheral blood macrophages", "TEST", 0, 28], ["heterophils", "TEST", 33, 44], ["IL", "TEST", 169, 171], ["CXCLi2/IL", "TEST", 175, 184], ["IL", "TEST", 192, 194], ["Salmonella", "PROBLEM", 260, 270], ["SALMONELLA", "TREATMENT", 356, 366], ["CAMPYLOBACTERIn C. jejuni inoculated chickens", "TREATMENT", 371, 416], ["AvBD", "TEST", 435, 439], ["caecal colonization", "PROBLEM", 521, 540], ["blood", "ANATOMY", 11, 16], ["macrophages", "OBSERVATION", 17, 28], ["heterophils", "OBSERVATION", 33, 44], ["resistant lines", "OBSERVATION", 217, 232], ["jejuni inoculated chickens", "OBSERVATION", 390, 416], ["caeca", "ANATOMY", 488, 493], ["caecal", "ANATOMY", 521, 527]]], ["In addition, NALP1 was also upregulated in the caeca of more resistant chickens, and the NALP1 inflammasome is an intracellular pattern recognition receptor multiprotein complex, activation of which leads to the production of the active forms of IL-1\u03b2 and IL-18, although their gene expression was not upregulated in the study at the timepoint analyzed.INFECTIOUS BURSAL DISEASE AND INFECTIOUS BRONCHITISInfectious bursal disease (IBD) and infectious bronchitis (IB) are both significant diseases afflicting the poultry industry (Hofacre and Mathis, 2015) .", [["caeca", "ANATOMY", 47, 52], ["intracellular", "ANATOMY", 114, 127], ["bursal", "ANATOMY", 415, 421], ["bursal disease", "DISEASE", 415, 429], ["IBD", "DISEASE", 431, 434], ["infectious bronchitis", "DISEASE", 440, 461], ["IB", "DISEASE", 463, 465], ["NALP1", "GENE_OR_GENE_PRODUCT", 13, 18], ["caeca", "ORGAN", 47, 52], ["chickens", "ORGANISM", 71, 79], ["NALP1", "GENE_OR_GENE_PRODUCT", 89, 94], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 246, 251], ["IL-18", "GENE_OR_GENE_PRODUCT", 256, 261], ["NALP1", "PROTEIN", 13, 18], ["NALP1 inflammasome", "PROTEIN", 89, 107], ["intracellular pattern recognition receptor multiprotein complex", "PROTEIN", 114, 177], ["IL-1\u03b2", "PROTEIN", 246, 251], ["IL-18", "PROTEIN", 256, 261], ["chickens", "SPECIES", 71, 79], ["chickens", "SPECIES", 71, 79], ["NALP1", "TREATMENT", 13, 18], ["more resistant chickens", "PROBLEM", 56, 79], ["the NALP1 inflammasome", "PROBLEM", 85, 107], ["IL", "TEST", 246, 248], ["IL", "TEST", 256, 258], ["the study", "TEST", 317, 326], ["INFECTIOUS BURSAL DISEASE", "PROBLEM", 353, 378], ["INFECTIOUS BRONCHITISInfectious bursal disease", "PROBLEM", 383, 429], ["IBD)", "PROBLEM", 431, 435], ["infectious bronchitis", "PROBLEM", 440, 461], ["significant diseases", "PROBLEM", 476, 496], ["caeca", "ANATOMY", 47, 52], ["resistant chickens", "OBSERVATION", 61, 79], ["intracellular pattern", "OBSERVATION", 114, 135], ["active", "OBSERVATION_MODIFIER", 230, 236], ["INFECTIOUS", "OBSERVATION_MODIFIER", 383, 393], ["BRONCHITISInfectious bursal disease", "OBSERVATION", 394, 429], ["infectious", "OBSERVATION_MODIFIER", 440, 450], ["bronchitis", "OBSERVATION", 451, 461], ["significant", "OBSERVATION_MODIFIER", 476, 487], ["diseases", "OBSERVATION", 488, 496]]], ["IBD (also known as Gumboro disease) is a highly contagious disease of young chickens that is caused by the IBD virus, which is a member of the Birnaviridae family (Smith et al., 2015a) .", [["IBD", "DISEASE", 0, 3], ["Gumboro disease", "DISEASE", 19, 34], ["chickens", "ORGANISM", 76, 84], ["IBD virus", "ORGANISM", 107, 116], ["chickens", "SPECIES", 76, 84], ["chickens", "SPECIES", 76, 84], ["IBD virus", "SPECIES", 107, 116], ["IBD", "PROBLEM", 0, 3], ["Gumboro disease", "PROBLEM", 19, 34], ["a highly contagious disease of young chickens", "PROBLEM", 39, 84], ["the IBD virus", "PROBLEM", 103, 116], ["highly", "OBSERVATION_MODIFIER", 41, 47], ["contagious", "OBSERVATION_MODIFIER", 48, 58], ["young", "OBSERVATION_MODIFIER", 70, 75], ["chickens", "OBSERVATION", 76, 84], ["IBD virus", "OBSERVATION", 107, 116]]], ["The virus primarily replicates in B cells expressing Bu-1 and surface immunoglobulin, resulting in apoptosis and atrophy of the bursa of Fabricius (Tippenhauer et al., 2013) .", [["B cells", "ANATOMY", 34, 41], ["surface", "ANATOMY", 62, 69], ["bursa", "ANATOMY", 128, 133], ["atrophy", "DISEASE", 113, 120], ["B cells", "CELL", 34, 41], ["Bu-1", "GENE_OR_GENE_PRODUCT", 53, 57], ["surface immunoglobulin", "GENE_OR_GENE_PRODUCT", 62, 84], ["bursa", "ORGAN", 128, 133], ["B cells", "CELL_TYPE", 34, 41], ["Bu-1", "PROTEIN", 53, 57], ["surface immunoglobulin", "PROTEIN", 62, 84], ["The virus", "PROBLEM", 0, 9], ["Bu", "TEST", 53, 55], ["surface immunoglobulin", "TEST", 62, 84], ["apoptosis", "PROBLEM", 99, 108], ["atrophy of the bursa of Fabricius", "PROBLEM", 113, 146], ["virus", "OBSERVATION", 4, 9], ["B cells", "OBSERVATION", 34, 41], ["apoptosis", "OBSERVATION", 99, 108], ["atrophy", "OBSERVATION", 113, 120], ["bursa", "ANATOMY", 128, 133], ["Fabricius", "ANATOMY", 137, 146]]], ["The apoptosis of the immature B cells results in severe immunosuppression with impaired antibody and vaccine responses, and increased susceptibility to other pathogens, especially when birds are infected before 3 woa (Aricibasi et al., 2010) .", [["B cells", "ANATOMY", 30, 37], ["B cells", "CELL", 30, 37], ["birds", "ORGANISM", 185, 190], ["immature B cells", "CELL_TYPE", 21, 37], ["the immature B cells", "PROBLEM", 17, 37], ["severe immunosuppression", "TREATMENT", 49, 73], ["impaired antibody and vaccine responses", "PROBLEM", 79, 118], ["increased susceptibility to other pathogens", "PROBLEM", 124, 167], ["immature B cells", "OBSERVATION", 21, 37], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["immunosuppression", "OBSERVATION", 56, 73], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["infected", "OBSERVATION", 195, 203]]], ["Very virulent strains cause acute disease and high mortality in chickens less than 6 woa.", [["chickens", "ORGANISM", 64, 72], ["chickens", "SPECIES", 64, 72], ["chickens", "SPECIES", 64, 72], ["Very virulent strains", "PROBLEM", 0, 21], ["acute disease", "PROBLEM", 28, 41], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["disease", "OBSERVATION", 34, 41], ["high", "OBSERVATION_MODIFIER", 46, 50], ["mortality", "OBSERVATION_MODIFIER", 51, 60]]], ["IB virus, a coronavirus, replicates in tissues of the upper respiratory tract, although some strains cause more widespread issues by replicating in the kidney, oviduct, and intestinal tract (Awad et al., 2014) .", [["tissues", "ANATOMY", 39, 46], ["upper respiratory tract", "ANATOMY", 54, 77], ["kidney", "ANATOMY", 152, 158], ["oviduct", "ANATOMY", 160, 167], ["intestinal tract", "ANATOMY", 173, 189], ["IB virus", "ORGANISM", 0, 8], ["tissues", "TISSUE", 39, 46], ["upper respiratory", "ORGANISM_SUBDIVISION", 54, 71], ["tract", "ORGANISM_SUBDIVISION", 72, 77], ["kidney", "ORGAN", 152, 158], ["oviduct", "ORGAN", 160, 167], ["intestinal", "ORGAN", 173, 183], ["tract", "ORGANISM_SUBDIVISION", 184, 189], ["IB virus", "SPECIES", 0, 8], ["IB virus", "PROBLEM", 0, 8], ["a coronavirus", "PROBLEM", 10, 23], ["some strains", "PROBLEM", 88, 100], ["virus", "OBSERVATION", 3, 8], ["coronavirus", "OBSERVATION", 12, 23], ["upper", "ANATOMY_MODIFIER", 54, 59], ["respiratory tract", "ANATOMY", 60, 77], ["widespread", "OBSERVATION_MODIFIER", 112, 122], ["kidney", "ANATOMY", 152, 158], ["oviduct", "ANATOMY", 160, 167], ["intestinal tract", "ANATOMY", 173, 189]]], ["IBV can cause severe disease in young birds with morbidity close to 100%.", [["IBV", "ORGANISM", 0, 3], ["birds", "ORGANISM", 38, 43], ["IBV", "SPECIES", 0, 3], ["IBV", "TREATMENT", 0, 3], ["severe disease", "PROBLEM", 14, 28], ["morbidity", "PROBLEM", 49, 58], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["disease", "OBSERVATION", 21, 28], ["young birds", "OBSERVATION_MODIFIER", 32, 43]]], ["Vaccination, and supporting antimicrobial therapy for complicating/secondary bacterial infections, is the primary methods to prevent and/or counteract the impact of IBD and IB but the continuous emergence of new variant viruses ensures that these diseases remain economically important (Chhabra et al., 2018) .INFECTIOUS BURSAL DISEASE AND INFECTIOUS BRONCHITISAgain, it is of interest to see whether there is commonality in terms of immune-related mediators that are associated with greater resistance/susceptibility to IBD and IB.", [["bacterial infections", "DISEASE", 77, 97], ["IBD", "DISEASE", 165, 168], ["IBD", "DISEASE", 521, 524], ["Vaccination", "TREATMENT", 0, 11], ["supporting antimicrobial therapy", "TREATMENT", 17, 49], ["secondary bacterial infections", "PROBLEM", 67, 97], ["IBD", "PROBLEM", 165, 168], ["IB", "TREATMENT", 173, 175], ["new variant viruses", "PROBLEM", 208, 227], ["these diseases", "PROBLEM", 241, 255], ["INFECTIOUS BURSAL DISEASE", "PROBLEM", 310, 335], ["immune-related mediators", "PROBLEM", 434, 458], ["greater resistance/susceptibility to IBD", "PROBLEM", 484, 524], ["secondary", "OBSERVATION_MODIFIER", 67, 76], ["bacterial", "OBSERVATION_MODIFIER", 77, 86], ["infections", "OBSERVATION", 87, 97], ["IBD", "OBSERVATION", 165, 168], ["INFECTIOUS", "OBSERVATION_MODIFIER", 340, 350]]], ["A more rapid inflammatory response, characterized by upregulation of genes including IL-2, IL-6, CXCLi2/IL-8, IL-18, IFN-\u03b1, IFN-\u03b3, and iNOS in the bursa at 1 dpi, was found for a chicken line considered more resistant to IBD following IBDV infection at 1 to 2 doa (Ruby et al., 2006) .", [["bursa", "ANATOMY", 147, 152], ["IBD", "DISEASE", 221, 224], ["IBDV infection", "DISEASE", 235, 249], ["IL-2", "GENE_OR_GENE_PRODUCT", 85, 89], ["IL-6", "GENE_OR_GENE_PRODUCT", 91, 95], ["CXCLi2", "GENE_OR_GENE_PRODUCT", 97, 103], ["IL-8", "GENE_OR_GENE_PRODUCT", 104, 108], ["IL-18", "GENE_OR_GENE_PRODUCT", 110, 115], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 117, 122], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 124, 129], ["iNOS", "GENE_OR_GENE_PRODUCT", 135, 139], ["bursa", "ORGAN", 147, 152], ["chicken", "ORGANISM", 179, 186], ["IBDV", "ORGANISM", 235, 239], ["CXCLi2", "PROTEIN", 97, 103], ["IFN", "PROTEIN", 117, 120], ["\u03b1", "PROTEIN", 121, 122], ["IFN", "PROTEIN", 124, 127], ["\u03b3", "DNA", 128, 129], ["iNOS", "PROTEIN", 135, 139], ["chicken", "SPECIES", 179, 186], ["chicken", "SPECIES", 179, 186], ["IBDV", "SPECIES", 235, 239], ["A more rapid inflammatory response", "PROBLEM", 0, 34], ["IL", "TEST", 85, 87], ["IL", "TEST", 91, 93], ["CXCLi2", "TEST", 97, 103], ["IL", "TEST", 104, 106], ["IL", "TEST", 110, 112], ["IFN", "TEST", 117, 120], ["IFN", "TEST", 124, 127], ["iNOS in the bursa", "PROBLEM", 135, 152], ["a chicken line", "TREATMENT", 177, 191], ["IBD", "PROBLEM", 221, 224], ["IBDV infection", "PROBLEM", 235, 249], ["rapid", "OBSERVATION_MODIFIER", 7, 12], ["inflammatory", "OBSERVATION", 13, 25], ["bursa", "ANATOMY", 147, 152]]], ["Other studies in young chickens (3 to 5 woa) have, however, reported that increased, perhaps less well controlled, inflammatory mediators (e.g., IL-1\u03b2, CXCLi2/IL-8, IFN-\u03b2 and IFN-\u03b3) in serum, spleen, and bursa, up to 7 dpi, enhance susceptibility to/pathogenesis of IBDV, particularly more virulent strains (Aricibasi et al., 2010; Tippenhauer et al., 2013; Smith et al., 2015a) , although the overall (anti/pro) inflammatory context is not always assessed.", [["serum", "ANATOMY", 185, 190], ["spleen", "ANATOMY", 192, 198], ["bursa", "ANATOMY", 204, 209], ["IBDV", "DISEASE", 266, 270], ["chickens", "ORGANISM", 23, 31], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 145, 150], ["CXCLi2", "GENE_OR_GENE_PRODUCT", 152, 158], ["IL-8", "GENE_OR_GENE_PRODUCT", 159, 163], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 165, 170], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 175, 180], ["serum", "ORGANISM_SUBSTANCE", 185, 190], ["spleen", "ORGAN", 192, 198], ["bursa", "ORGAN", 204, 209], ["IBDV", "ORGANISM", 266, 270], ["inflammatory mediators", "PROTEIN", 115, 137], ["IL", "PROTEIN", 145, 147], ["CXCLi2", "PROTEIN", 152, 158], ["IL-8", "PROTEIN", 159, 163], ["IFN", "PROTEIN", 165, 168], ["\u03b2", "PROTEIN", 169, 170], ["IFN", "PROTEIN", 175, 178], ["chickens", "SPECIES", 23, 31], ["chickens", "SPECIES", 23, 31], ["IBDV", "SPECIES", 266, 270], ["Other studies", "TEST", 0, 13], ["inflammatory mediators", "PROBLEM", 115, 137], ["IL", "TEST", 145, 147], ["CXCLi2", "TEST", 152, 158], ["IL", "TEST", 159, 161], ["IFN", "TEST", 165, 168], ["IFN-\u03b3) in serum", "TEST", 175, 190], ["bursa", "PROBLEM", 204, 209], ["IBDV", "PROBLEM", 266, 270], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["less well controlled", "OBSERVATION_MODIFIER", 93, 113], ["inflammatory", "OBSERVATION_MODIFIER", 115, 127], ["spleen", "ANATOMY", 192, 198], ["bursa", "ANATOMY", 204, 209], ["IBDV", "ANATOMY", 266, 270], ["inflammatory", "OBSERVATION", 413, 425]]], ["With regards to IB, Dawes et al., (2014) evaluated some functional characteristics of macrophages derived from 5 to 12 woa birds apparently more or less resistant to IB and showed that greater resistance was associated with peripheral blood monocytes that differentiated into macrophages more readily and were more responsive (by way of NO production) to (poly I:C or IFN\u03b3) stimulation.", [["macrophages", "ANATOMY", 86, 97], ["peripheral blood monocytes", "ANATOMY", 224, 250], ["macrophages", "ANATOMY", 276, 287], ["NO", "CHEMICAL", 337, 339], ["NO", "CHEMICAL", 337, 339], ["macrophages", "CELL", 86, 97], ["birds", "ORGANISM", 123, 128], ["peripheral blood monocytes", "ORGANISM_SUBSTANCE", 224, 250], ["macrophages", "CELL", 276, 287], ["NO", "SIMPLE_CHEMICAL", 337, 339], ["poly I:C", "GENE_OR_GENE_PRODUCT", 356, 364], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 368, 372], ["macrophages", "CELL_TYPE", 86, 97], ["peripheral blood monocytes", "CELL_TYPE", 224, 250], ["macrophages", "CELL_TYPE", 276, 287], ["IFN\u03b3", "PROTEIN", 368, 372], ["peripheral blood monocytes", "PROBLEM", 224, 250], ["IFN\u03b3) stimulation", "TREATMENT", 368, 385], ["macrophages", "OBSERVATION", 86, 97], ["greater resistance", "OBSERVATION", 185, 203], ["peripheral", "ANATOMY_MODIFIER", 224, 234], ["blood monocytes", "ANATOMY", 235, 250]]], ["From a slightly different perspective, and similar to some of the data for IBD, the greater pathogenicity and lesion severity in infected tissues of chickens inoculated with one of three different strains of IBV have been associated with upregulation of the proinflammatory cytokines IL-1\u03b2 and IL-6 (as well as TLR3, MDA5, and IFN-\u03b2), indicating that differential innate immune responses to different IBV strains contribute to disease severity (Chhabra et al., 2018) .CONCLUSIONS AND PERSPECTIVESBased on the available data, it seems that immune cells isolated from more resistant birds show enhanced functional characteristics (e.g., proliferation, NO production, etc.,) and/or more rapid responses.", [["lesion", "ANATOMY", 110, 116], ["tissues", "ANATOMY", 138, 145], ["immune cells", "ANATOMY", 539, 551], ["IBD", "DISEASE", 75, 78], ["NO", "CHEMICAL", 650, 652], ["NO", "CHEMICAL", 650, 652], ["tissues", "TISSUE", 138, 145], ["chickens", "ORGANISM", 149, 157], ["IBV", "ORGANISM", 208, 211], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 284, 289], ["IL-6", "GENE_OR_GENE_PRODUCT", 294, 298], ["TLR3", "GENE_OR_GENE_PRODUCT", 311, 315], ["MDA5", "GENE_OR_GENE_PRODUCT", 317, 321], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 327, 332], ["IBV", "ORGANISM", 401, 404], ["immune cells", "CELL", 539, 551], ["birds", "ORGANISM", 581, 586], ["NO", "SIMPLE_CHEMICAL", 650, 652], ["proinflammatory cytokines", "PROTEIN", 258, 283], ["IL-1\u03b2", "PROTEIN", 284, 289], ["IL-6", "PROTEIN", 294, 298], ["TLR3", "PROTEIN", 311, 315], ["MDA5", "PROTEIN", 317, 321], ["IFN-\u03b2", "PROTEIN", 327, 332], ["immune cells", "CELL_TYPE", 539, 551], ["chickens", "SPECIES", 149, 157], ["chickens", "SPECIES", 149, 157], ["IBV", "SPECIES", 208, 211], ["IBV", "SPECIES", 401, 404], ["IBD", "PROBLEM", 75, 78], ["the greater pathogenicity", "PROBLEM", 80, 105], ["lesion severity", "PROBLEM", 110, 125], ["IBV", "PROBLEM", 208, 211], ["the proinflammatory cytokines IL", "TEST", 254, 286], ["IL", "TEST", 294, 296], ["TLR3", "TEST", 311, 315], ["MDA5", "TEST", 317, 321], ["different IBV strains", "PROBLEM", 391, 412], ["disease severity", "PROBLEM", 427, 443], ["the available data", "TEST", 505, 523], ["immune cells", "PROBLEM", 539, 551], ["enhanced functional characteristics", "PROBLEM", 592, 627], ["slightly different", "OBSERVATION_MODIFIER", 7, 25], ["greater", "OBSERVATION_MODIFIER", 84, 91], ["pathogenicity", "OBSERVATION_MODIFIER", 92, 105], ["lesion", "OBSERVATION_MODIFIER", 110, 116], ["severity", "OBSERVATION_MODIFIER", 117, 125], ["infected", "OBSERVATION_MODIFIER", 129, 137], ["tissues", "OBSERVATION_MODIFIER", 138, 145], ["chickens", "OBSERVATION_MODIFIER", 149, 157], ["inoculated", "OBSERVATION_MODIFIER", 158, 168], ["IBV", "OBSERVATION", 208, 211], ["associated with", "UNCERTAINTY", 222, 237], ["upregulation", "OBSERVATION_MODIFIER", 238, 250], ["proinflammatory", "OBSERVATION_MODIFIER", 258, 273]]], ["In addition, relevant cells/sites in more resistant chickens appear to, mainly, be supporting a more inflammatory environment as evidenced by the, generally, increased production of pro-inflammatory or relative downregulation of anti-inflammatory/regulatory mediators.", [["cells", "ANATOMY", 22, 27], ["sites", "ANATOMY", 28, 33], ["cells", "CELL", 22, 27], ["chickens", "ORGANISM", 52, 60], ["regulatory mediators", "PROTEIN", 247, 267], ["chickens", "SPECIES", 52, 60], ["chickens", "SPECIES", 52, 60], ["relevant cells/sites", "PROBLEM", 13, 33], ["a more inflammatory environment", "PROBLEM", 94, 125], ["anti-inflammatory/regulatory mediators", "TREATMENT", 229, 267], ["relevant cells", "OBSERVATION", 13, 27], ["sites", "OBSERVATION_MODIFIER", 28, 33], ["more resistant", "OBSERVATION_MODIFIER", 37, 51], ["chickens", "OBSERVATION", 52, 60], ["inflammatory", "OBSERVATION", 101, 113]]], ["Given this review primarily covers intracellular pathogens (Eimeria, Salmonella, IBDV and IBV), it is perhaps not surprising that a more pronounced proinflammatory, Th1-skewed response maybe observed for more resistant birds.", [["intracellular", "ANATOMY", 35, 48], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 48], ["Eimeria, Salmonella, IBDV", "ORGANISM", 60, 85], ["IBV", "ORGANISM", 90, 93], ["IBDV", "SPECIES", 81, 85], ["IBV", "SPECIES", 90, 93], ["intracellular pathogens", "PROBLEM", 35, 58], ["Salmonella", "TREATMENT", 69, 79], ["IBDV", "TREATMENT", 81, 85], ["IBV", "PROBLEM", 90, 93]]], ["In fact, a key immunoregulatory cytokine, IL-10, was not detected in the serum of healthy birds, and elevated levels were associated with Eimeria infection and/or disease susceptibility, leading to suggestions that IL-10 could be employed as a biomarker for (Eimeria) infection and/or anti-IL-10 treatment could be used to improve vaccine efficacy (Wu et al., 2016; Bremner, 2018) .", [["serum", "ANATOMY", 73, 78], ["Eimeria infection", "DISEASE", 138, 155], ["Eimeria) infection", "DISEASE", 259, 277], ["IL-10", "GENE_OR_GENE_PRODUCT", 42, 47], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["birds", "ORGANISM", 90, 95], ["Eimeria", "ORGANISM", 138, 145], ["IL-10", "GENE_OR_GENE_PRODUCT", 215, 220], ["Eimeria", "ORGANISM", 259, 266], ["anti-IL-10", "GENE_OR_GENE_PRODUCT", 285, 295], ["immunoregulatory cytokine", "PROTEIN", 15, 40], ["IL-10", "PROTEIN", 42, 47], ["IL", "PROTEIN", 215, 217], ["IL", "TEST", 42, 44], ["elevated levels", "PROBLEM", 101, 116], ["Eimeria infection", "PROBLEM", 138, 155], ["disease susceptibility", "PROBLEM", 163, 185], ["a biomarker", "TEST", 242, 253], ["Eimeria) infection", "PROBLEM", 259, 277], ["anti-IL", "TREATMENT", 285, 292], ["treatment", "TREATMENT", 296, 305], ["associated with", "UNCERTAINTY", 122, 137], ["Eimeria infection", "OBSERVATION", 138, 155]]], ["However, even where IL-10 was more upregulated in more susceptible birds, IL-10 was still expressed in the intestine and spleen of resistant birds, suggesting it helps temper the effector response, rather than (excessively) suppressing it.", [["intestine", "ANATOMY", 107, 116], ["spleen", "ANATOMY", 121, 127], ["IL-10", "GENE_OR_GENE_PRODUCT", 20, 25], ["birds", "ORGANISM", 67, 72], ["IL-10", "GENE_OR_GENE_PRODUCT", 74, 79], ["intestine", "ORGAN", 107, 116], ["spleen", "ORGAN", 121, 127], ["birds", "ORGANISM", 141, 146], ["IL", "PROTEIN", 20, 22], ["IL-10", "PROTEIN", 74, 79], ["resistant birds", "PROBLEM", 131, 146], ["intestine", "ANATOMY", 107, 116], ["spleen", "ANATOMY", 121, 127], ["resistant birds", "OBSERVATION", 131, 146]]], ["With this in mind, data proposing that a more pronounced inflammatory response to certain strains of pathogens influences/drives greater pathogenesis should not be overlooked and indicates that the balance of pro, antiinflammatory, and regulatory mediators at a given site is probably more relevant than any in isolation.", [["pro, antiinflammatory, and regulatory mediators", "PROTEIN", 209, 256], ["a more pronounced inflammatory response", "PROBLEM", 39, 78], ["pathogens", "PROBLEM", 101, 110], ["antiinflammatory", "TREATMENT", 214, 230], ["inflammatory", "OBSERVATION_MODIFIER", 57, 69]]], ["Therefore, relevant studies reporting all relevant (pro and anti) inflammatory mediator responses maybe more informative.CONCLUSIONS AND PERSPECTIVESWe have highlighted the limitations of gene expression data for interpreting important responses of more or less resistant birds.", [["birds", "ORGANISM", 272, 277], ["relevant studies", "TEST", 11, 27], ["gene expression data", "TEST", 188, 208]]], ["In addition, the specific study variables (e.g., disease model (strain, dose, etc.,), bird age/type, cells/site analzsed, etc.,) and, in particular, sampling point(s) post infection will strongly influence the results obtained.", [["cells", "ANATOMY", 101, 106], ["site", "ANATOMY", 107, 111], ["infection", "DISEASE", 172, 181], ["cells", "CELL", 101, 106], ["the specific study variables", "TEST", 13, 41], ["post infection", "PROBLEM", 167, 181]]], ["Age at infection may also be a very pertinent factor that explains some of the differences identified.", [["infection", "DISEASE", 7, 16], ["Age at infection", "PROBLEM", 0, 16], ["infection", "OBSERVATION", 7, 16], ["may also be", "UNCERTAINTY", 17, 28]]], ["Enhanced inflammatory responses in young birds maybe more beneficial due to their inherently, relatively impaired/suboptimal ability to respond to infection (Broom and Kogut, 2018a) , whereas older, more immunologically mature birds may have the capability to respond excessively.", [["infection", "DISEASE", 147, 156], ["birds", "ORGANISM", 41, 46], ["birds", "ORGANISM", 227, 232], ["Enhanced inflammatory responses", "PROBLEM", 0, 31], ["infection", "PROBLEM", 147, 156], ["inflammatory", "OBSERVATION", 9, 21]]], ["As shown in this review, rapid changes can occur in the dynamic infection environment and relevant genes maybe reported as up or downregulated depending on the time/day sampled.", [["infection", "DISEASE", 64, 73], ["rapid changes", "PROBLEM", 25, 38], ["the dynamic infection environment", "PROBLEM", 52, 85], ["infection", "OBSERVATION", 64, 73]]], ["Rothwell et al., (2004) reported no differences in caecal tonsil responses of E. maxima infected birds, underlining region-specific responses and the need to sample/analyze relevant site(s).", [["caecal tonsil", "ANATOMY", 51, 64], ["caecal tonsil", "MULTI-TISSUE_STRUCTURE", 51, 64], ["E. maxima", "ORGANISM", 78, 87], ["birds", "ORGANISM", 97, 102], ["E. maxima", "SPECIES", 78, 87], ["E. maxima", "SPECIES", 78, 87], ["E. maxima infected birds", "PROBLEM", 78, 102], ["caecal tonsil", "ANATOMY", 51, 64]]], ["Moreover, clear demonstration/description that a specific study is utilising more or less resistant phenotypes is not always evident and is sometimes based on previous observations.", [["a specific study", "TEST", 47, 63], ["less resistant phenotypes", "PROBLEM", 85, 110], ["previous observations", "TEST", 159, 180]]], ["Studies that show clear differences between phenotypes and characterize immune responses in the same study are important.", [["Studies", "TEST", 0, 7], ["clear differences between phenotypes", "PROBLEM", 18, 54], ["immune responses", "TEST", 72, 88], ["the same study", "TEST", 92, 106], ["clear", "OBSERVATION", 18, 23]]], ["Characterization of the gut microbiome could also be an important parameter influencing disease phenotype and differences in immune parameters (Broom and Kogut et al., 2018b) .CONCLUSIONS AND PERSPECTIVESIt is also interesting that a chicken line described as more resistant at a younger age can be more susceptible at an older age, while greater resistance to one parameter (e.g., carriage) does not necessarily equate to resistance for another (e.g., organ infection).", [["gut microbiome", "ANATOMY", 24, 38], ["organ", "ANATOMY", 453, 458], ["organ infection", "DISEASE", 453, 468], ["gut", "ORGANISM_SUBDIVISION", 24, 27], ["chicken", "ORGANISM", 234, 241], ["organ", "ORGAN", 453, 458], ["chicken", "SPECIES", 234, 241], ["chicken", "SPECIES", 234, 241], ["an important parameter influencing disease phenotype", "PROBLEM", 53, 105], ["a chicken line", "TREATMENT", 232, 246], ["another (e.g., organ infection", "PROBLEM", 438, 468], ["gut", "ANATOMY", 24, 27], ["organ", "ANATOMY", 453, 458], ["infection", "OBSERVATION", 459, 468]]], ["The former may relate to changes mentioned above in immune capability/responses as the immune system matures (Broom and Kogut et al., 2018a) , while the latter may reflect differing mechanisms conferring resistance at different sites.", [["immune system", "ANATOMY", 87, 100], ["may relate to", "UNCERTAINTY", 11, 24]]], ["We should also consider that fundamental mechanisms contributing to the more resistant phenotype may not be related to well-recognized immune pathways.", [["fundamental mechanisms", "PROBLEM", 29, 51], ["the more resistant phenotype", "PROBLEM", 68, 96]]], ["For example, there maybe differences in the expression of host proteins that bind pathogen proteins (Smith et al., 2015b) , that affect speed of expulsion/egress of the organism during functional development (e.g., Eimeria sporozoites; Lee et al., 2016) , and the ability of (infected) cells to recover (Casterlow et al., 2011) , etc. With this in mind, key genes conferring enhanced resistance maybe as yet unidentified or have less well-defined immune-related functions.", [["cells", "ANATOMY", 286, 291], ["Eimeria sporozoites", "ORGANISM", 215, 234], ["cells", "CELL", 286, 291], ["host proteins", "PROTEIN", 58, 71], ["pathogen proteins", "PROTEIN", 82, 99], ["(infected) cells", "CELL_TYPE", 275, 291], ["host proteins", "PROBLEM", 58, 71], ["bind pathogen proteins", "PROBLEM", 77, 99], ["expulsion", "PROBLEM", 145, 154], ["the organism", "PROBLEM", 165, 177], ["Eimeria sporozoites", "PROBLEM", 215, 234], ["expulsion", "OBSERVATION", 145, 154], ["enhanced resistance", "OBSERVATION", 375, 394]]], ["Some of the genes outlined in Table 2 (related to NE) have been associated with resistance/susceptibility to other poultry pathogens (e.g., IBDV, Smith et al., 2015a; IBV, Smith et al., 2015b) and warrant further investigation.CONCLUSIONS AND PERSPECTIVESIn practical terms, recent studies have confirmed the benefit of steering bird responses towards a more proinflammatory state through, for example, breeding (for increased expression of IL-1\u03b2, IL-6, CXCLi2, and CCLi2) or feeding of antibodies (e.g., anti-IL-10) to improve resistance to Salmonella enterica serovar Enteritidis (Swaggerty et al., 2014) , Eimeria (Swaggerty et al., 2015; Sand et al., 2016) , and Clostridium perfringens-induced NE (Swaggerty et al., 2016) .", [["NE", "CHEMICAL", 50, 52], ["poultry pathogens", "DISEASE", 115, 132], ["Clostridium perfringens", "DISEASE", 667, 690], ["NE", "CHEMICAL", 699, 701], ["Table 2", "GENE_OR_GENE_PRODUCT", 30, 37], ["NE", "GENE_OR_GENE_PRODUCT", 50, 52], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 441, 446], ["IL-6", "GENE_OR_GENE_PRODUCT", 448, 452], ["CXCLi2", "GENE_OR_GENE_PRODUCT", 454, 460], ["CCLi2", "GENE_OR_GENE_PRODUCT", 466, 471], ["IL-10", "GENE_OR_GENE_PRODUCT", 510, 515], ["Salmonella enterica serovar Enteritidis", "ORGANISM", 542, 581], ["Clostridium perfringens", "ORGANISM", 667, 690], ["NE", "CELL", 699, 701], ["NE", "DNA", 50, 52], ["IL", "PROTEIN", 441, 443], ["1\u03b2", "PROTEIN", 444, 446], ["IL-6", "PROTEIN", 448, 452], ["CXCLi2", "PROTEIN", 454, 460], ["CCLi2", "PROTEIN", 466, 471], ["antibodies", "PROTEIN", 487, 497], ["anti", "PROTEIN", 505, 509], ["IL", "PROTEIN", 510, 512], ["Salmonella", "SPECIES", 542, 552], ["enterica serovar Enteritidis", "SPECIES", 553, 581], ["Clostridium perfringens", "SPECIES", 667, 690], ["IBDV", "SPECIES", 140, 144], ["Salmonella enterica serovar Enteritidis", "SPECIES", 542, 581], ["Clostridium perfringens", "SPECIES", 667, 690], ["resistance/susceptibility to other poultry pathogens", "PROBLEM", 80, 132], ["further investigation", "TEST", 205, 226], ["recent studies", "TEST", 275, 289], ["IL", "TEST", 441, 443], ["IL", "TEST", 448, 450], ["CXCLi2", "TREATMENT", 454, 460], ["CCLi2", "TREATMENT", 466, 471], ["feeding of antibodies", "TREATMENT", 476, 497], ["anti-IL", "TREATMENT", 505, 512], ["Salmonella enterica serovar Enteritidis", "PROBLEM", 542, 581], ["Clostridium perfringens", "PROBLEM", 667, 690]]], ["The use of proinflammatory cytokines as vaccine adjuvants against poultry relevant pathogens has also been investigated (Umar et al., 2015) .", [["proinflammatory cytokines", "PROTEIN", 11, 36], ["proinflammatory cytokines", "TREATMENT", 11, 36], ["vaccine adjuvants", "TREATMENT", 40, 57], ["poultry relevant pathogens", "PROBLEM", 66, 92]]], ["Given coccidiosis is a primary predisposing factor for necrotic enteritis, effective prevention and control strategies for Eimeria should have the added benefit of reducing the incidence and/or severity of NE.", [["coccidiosis", "DISEASE", 6, 17], ["necrotic enteritis", "DISEASE", 55, 73], ["Eimeria", "DISEASE", 123, 130], ["NE", "CHEMICAL", 206, 208], ["Eimeria", "ORGANISM", 123, 130], ["NE", "PROTEIN", 206, 208], ["coccidiosis", "PROBLEM", 6, 17], ["necrotic enteritis", "PROBLEM", 55, 73], ["control strategies", "TREATMENT", 100, 118], ["Eimeria", "PROBLEM", 123, 130], ["severity of NE", "PROBLEM", 194, 208], ["coccidiosis", "OBSERVATION", 6, 17], ["necrotic", "OBSERVATION_MODIFIER", 55, 63], ["enteritis", "OBSERVATION", 64, 73]]], ["As mentioned previously, growth performance is often a parameter assessed to determine relative disease resistance, but not always.", [["growth performance", "TEST", 25, 43], ["relative disease resistance", "PROBLEM", 87, 114], ["disease", "OBSERVATION", 96, 103]]], ["It would be much more informative if all relevant studies included growth performance analysis to better understand the relationship between immune responses, growth, and disease resistance.CONCLUSIONS AND PERSPECTIVESOverall, this review highlights some of the genes more consistently associated with relative resistance (or susceptibility) to some of the most important diseases and foodborne pathogens of commercial poultry and helps to inform/support appropriate immune-based strategies to optimize poultry health and productivity.", [["poultry", "SPECIES", 503, 510], ["growth performance analysis", "TEST", 67, 94], ["disease resistance", "PROBLEM", 171, 189], ["appropriate immune-based strategies", "TREATMENT", 455, 490], ["resistance", "OBSERVATION", 311, 321]]], ["The optimum immune response is balanced to effectively counteract the pathogen and minimize tissue damage and associated nutrient costs.", [["tissue", "ANATOMY", 92, 98], ["tissue", "TISSUE", 92, 98], ["the pathogen", "PROBLEM", 66, 78], ["tissue damage", "PROBLEM", 92, 105], ["minimize tissue", "OBSERVATION_MODIFIER", 83, 98], ["damage", "OBSERVATION", 99, 105], ["nutrient costs", "OBSERVATION", 121, 135]]], ["However, it does seem that steering the immune system towards a more proinflammatory capability (in different compartments) provides better protection against pathogens and (thus) improved growth performance.", [["immune system", "ANATOMY", 40, 53], ["compartments", "ANATOMY", 110, 122], ["steering the immune system", "PROBLEM", 27, 53], ["a more proinflammatory capability", "PROBLEM", 62, 95], ["pathogens", "PROBLEM", 159, 168]]], ["Global gene expression profiling is providing a greater overview of genes and pathways involved in the bird's response to pathogen challenge and mechanisms of resistance.", [["Global gene expression profiling", "PROBLEM", 0, 32], ["pathogen challenge", "TREATMENT", 122, 140], ["resistance", "PROBLEM", 159, 169]]], ["Further studies, particularly incorporating bird growth performance, are, however, necessary to better develop our understanding and application of informed outcomes.", [["Further studies", "TEST", 0, 15]]]], "535f9953ddc3aed036af13cb48fa2a148c6572b4": [["IntroductionMathematical models of infectious disease transmission dynamics are now ubiquitous.", [["infectious disease transmission", "DISEASE", 35, 66], ["infectious", "OBSERVATION_MODIFIER", 35, 45]]], ["Such models play an important role in helping to quantify possible infectious disease control and mitigation strategies [1, 2, 3] .", [["infectious disease control", "TREATMENT", 67, 93]]], ["There exist a number of models for infectious diseases; as for compartmental models, starting from the very classical SIR model to more complex proposals [4] .IntroductionCoronavirus disease 2019 (COVID- 19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["infectious diseases", "DISEASE", 35, 54], ["Coronavirus disease", "DISEASE", 171, 190], ["COVID- 19", "CHEMICAL", 197, 206], ["infectious disease", "DISEASE", 214, 232], ["acute respiratory syndrome coronavirus", "DISEASE", 250, 288], ["COVID- 19", "ORGANISM", 197, 206], ["SARS-CoV-2", "ORGANISM", 292, 302], ["IntroductionCoronavirus disease 2019 (COVID- 19", "SPECIES", 159, 206], ["severe acute respiratory syndrome coronavirus", "SPECIES", 243, 288], ["SARS-CoV-2", "SPECIES", 292, 302], ["infectious diseases", "PROBLEM", 35, 54], ["IntroductionCoronavirus disease", "PROBLEM", 159, 190], ["COVID", "TEST", 197, 202], ["an infectious disease", "PROBLEM", 211, 232], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 243, 288], ["SARS", "TEST", 292, 296], ["CoV", "TEST", 297, 300], ["infectious", "OBSERVATION", 35, 45], ["infectious", "OBSERVATION", 214, 224], ["severe", "OBSERVATION_MODIFIER", 243, 249], ["acute", "OBSERVATION_MODIFIER", 250, 255], ["respiratory syndrome", "OBSERVATION", 256, 276]]], ["The disease was first identified December 2019 in Wuhan, the capital of Hubei, China, and has since spread globally, resulting in the ongoing 2020 pandemic outbreak [5] .", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["The COVID-19 pandemic is considered as the biggest global threat worldwide because of thousands of confirmed infections, accompanied by thousands deaths over the world.", [["infections", "DISEASE", 109, 119], ["deaths", "DISEASE", 146, 152], ["COVID-19", "SPECIES", 4, 12], ["The COVID", "TEST", 0, 9], ["infections", "PROBLEM", 109, 119], ["infections", "OBSERVATION", 109, 119]]], ["Notice, by March 26, 2020, report 503,274 confirmed cumulative cases with 22,342 deaths.", [["deaths", "DISEASE", 81, 87]]], ["At the time of this revision, the numbers have increased to 1,353,361 confirmed cumulative cases with 79,235 deaths, according to the report dated by April 8, 2020 , by the Word Health Organization.IntroductionThe global problem of the outbreak has attracted the interest of researchers of different areas, giving rise to a number of proposals to analyze and predict the evolution of the pandemic [6, 7] .", [["deaths", "DISEASE", 109, 115], ["this revision", "TREATMENT", 15, 28], ["the numbers", "TEST", 30, 41], ["revision", "OBSERVATION", 20, 28], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["global", "OBSERVATION_MODIFIER", 214, 220]]], ["Our main contribution is related with considering the class of super-spreaders, which is now appearing in medical journals (see, e.g., [8, 9] ).", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["This new class, as added to any compartmental model, implies a number of analysis about disease free equilibrium points, which is also considered in this work.IntroductionThe manuscript is organized as follows.", [["disease free equilibrium points", "PROBLEM", 88, 119]]], ["In Section 2, we propose a new model for COVID-19.", [["COVID", "TEST", 41, 46]]], ["A qualitative analysis of the model is investigated in Section 3: in Section 3.1, we compute the basic reproduction number R 0 of the COVID-19 system model; in Section 3.2, we study the local stability of the disease free equilibrium in terms of R 0 .", [["A qualitative analysis", "TEST", 0, 22], ["the disease free equilibrium", "PROBLEM", 205, 233], ["stability", "OBSERVATION_MODIFIER", 192, 201], ["disease", "OBSERVATION", 209, 216], ["free equilibrium", "OBSERVATION", 217, 233]]], ["We end with Section 6 of conclusions, discussion, and future research.The Proposed COVID-19 Compartment ModelBased on a 2016 model [10] , and taking into account the existence of super-spreaders in the family of corona virus [11] , we propose a new epidemiological compartment model that takes into account the super-spreading phenomenon of some individuals.", [["corona virus", "ORGANISM", 212, 224], ["a new epidemiological compartment model", "TREATMENT", 243, 282]]], ["Moreover, we consider a fatality compartment, related to death due to the virus infection.", [["death", "DISEASE", 57, 62], ["infection", "DISEASE", 80, 89], ["a fatality compartment", "PROBLEM", 22, 44], ["death", "PROBLEM", 57, 62], ["the virus infection", "PROBLEM", 70, 89], ["virus", "OBSERVATION", 74, 79]]], ["In doing so, the constant total population size N is subdivided into eight epidemiological classes: susceptible class (S), exposed class (E), symptomatic and infectious class (I), super-spreaders class (P ), infectious but asymptomatic class (A), hospitalized (H), recovery class (R), and fatality class (F ).", [["symptomatic", "PROBLEM", 142, 153], ["size", "OBSERVATION_MODIFIER", 43, 47], ["symptomatic", "OBSERVATION_MODIFIER", 142, 153], ["infectious", "OBSERVATION_MODIFIER", 158, 168], ["infectious", "OBSERVATION_MODIFIER", 208, 218]]], ["The model takes the following form:The Proposed COVID-19 Compartment Modelwith \u03b2 quantifying the human-to-human transmission coefficient per unit time (days) per person, \u03b2 quantifies a high transmission coefficient due to super-spreaders, and l quantifies the relative transmissibility of hospitalized patients.", [["human", "ORGANISM", 97, 102], ["human", "ORGANISM", 106, 111], ["patients", "ORGANISM", 302, 310], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 106, 111], ["person", "SPECIES", 162, 168], ["patients", "SPECIES", 302, 310], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 106, 111]]], ["Here \u03ba is the rate at which an individual leaves the exposed class by becoming infectious (symptomatic, super-spreaders or asymptomatic); \u03c1 1 is the proportion of progression from exposed class E to symptomatic infectious class I; \u03c1 2 is a relative very low rate at which exposed individuals become super-spreaders while 1 \u2212 \u03c1 1 \u2212 \u03c1 2 is the progression from exposed to asymptomatic class; \u03b3 a is the average rate at which symptomatic and super-spreaders individuals become hospitalized; \u03b3 i is the recovery rate without being hospitalized; \u03b3 r is the recovery rate of hospitalized patients; and \u03b4 i , \u03b4 p , and \u03b4 h are the disease induced death rates due to infected, super-spreaders, and hospitalized individuals, respectively.", [["death", "DISEASE", 640, 645], ["patients", "ORGANISM", 582, 590], ["\u03b4 p", "GENE_OR_GENE_PRODUCT", 602, 605], ["patients", "SPECIES", 582, 590], ["infectious", "PROBLEM", 79, 89], ["a relative very low rate", "PROBLEM", 238, 262], ["the disease induced death rates", "PROBLEM", 620, 651], ["infected", "PROBLEM", 659, 667], ["infectious", "OBSERVATION", 79, 89], ["symptomatic", "OBSERVATION_MODIFIER", 199, 210], ["infectious", "OBSERVATION", 211, 221], ["disease", "OBSERVATION", 624, 631], ["infected", "OBSERVATION", 659, 667]]], ["At each instant of time,The Proposed COVID-19 Compartment Modelgives the number of death due to the disease.", [["death", "DISEASE", 83, 88], ["the disease", "PROBLEM", 96, 107], ["disease", "OBSERVATION", 100, 107]]], ["The transmissibility from asymptomatic individuals has been modeled in this way since it was not apparent their behavior.", [["asymptomatic individuals", "PROBLEM", 26, 50], ["asymptomatic", "OBSERVATION_MODIFIER", 26, 38]]], ["A flowchart of model (1) is presented in Figure 1 .Qualitative Analysis of the ModelOne of the most significant thresholds when studying infectious disease models, which quantifies disease invasion or extinction in a population, is the basic reproduction number [12] .", [["infectious disease", "DISEASE", 137, 155], ["Qualitative Analysis", "TEST", 51, 71], ["studying infectious disease models", "PROBLEM", 128, 162], ["disease invasion", "PROBLEM", 181, 197], ["extinction", "OBSERVATION_MODIFIER", 201, 211]]], ["In this section we obtain the basic reproduction number for our model (1) and study the locally asymptotically stability of its disease free equilibrium (see Theorem 1).The Basic Reproduction NumberThe basic reproduction number, as a measure for disease spread in a population, plays an important role in the course and control of an ongoing outbreak.", [["its disease free equilibrium", "PROBLEM", 124, 152], ["disease spread", "PROBLEM", 246, 260], ["an ongoing outbreak", "PROBLEM", 331, 350]]], ["It can be understood as the average number of cases one infected individual generates, over the course of its infectious period, in an otherwise uninfected population.", [["infected", "OBSERVATION", 56, 64], ["infectious", "OBSERVATION", 110, 120], ["uninfected", "OBSERVATION_MODIFIER", 145, 155], ["population", "OBSERVATION", 156, 166]]], ["Using the next generation matrix approach outlined in [13] to our model (1), the basic reproduction number can be computed by considering the below generation matrices F and V , that is, the Jacobian matrices associated to the rate of appearance of new infections and the net rate out of the corresponding compartments, respectively,The Basic Reproduction NumberThe basic reproduction number R 0 is obtained as the spectral radius of F \u00b7 V \u22121 , precisely,The Basic Reproduction NumberFor the parameters used in our simulations (see Table 1 ), one computes this basic reproduction number to obtain R 0 = 0.945.", [["infections", "DISEASE", 253, 263], ["the next generation matrix approach", "TREATMENT", 6, 41], ["new infections", "PROBLEM", 249, 263], ["the net rate", "TEST", 268, 280], ["new", "OBSERVATION_MODIFIER", 249, 252], ["infections", "OBSERVATION", 253, 263]]], ["This means that the epidemic outbreak that has occurred in Wuhan was well controlled by the Chinese authorities.Local Stability in Terms of the Basic Reproduction NumberNoting that the two last equations and the fifth of system (1) are uncoupled to the remaining equations of the system, we can easily obtain, by direct integration, the following analytical results:Local Stability in Terms of the Basic Reproduction NumberFurthermore, since the total population size N is constant, one hasLocal Stability in Terms of the Basic Reproduction NumberTherefore, the local stability of model (1) can be studied through the remaining coupled system of states variables, namely, the variables E, I, P , and H in (1).", [["P", "CHEMICAL", 692, 693], ["H", "CHEMICAL", 700, 701], ["the epidemic outbreak", "PROBLEM", 16, 37], ["epidemic", "OBSERVATION_MODIFIER", 20, 28], ["Stability", "OBSERVATION", 118, 127], ["Local Stability", "OBSERVATION", 366, 381], ["total", "OBSERVATION_MODIFIER", 446, 451], ["population", "OBSERVATION_MODIFIER", 452, 462], ["size", "OBSERVATION_MODIFIER", 463, 467], ["constant", "OBSERVATION_MODIFIER", 473, 481], ["Local", "OBSERVATION_MODIFIER", 490, 495], ["Stability", "OBSERVATION_MODIFIER", 496, 505], ["stability", "OBSERVATION_MODIFIER", 568, 577]]], ["The Jacobian matrix associated to these variables of (1) is the following one:Local Stability in Terms of the Basic Reproduction Numberwhere i , p , and h are defined in (3).", [["Jacobian matrix", "OBSERVATION", 4, 19], ["Stability", "OBSERVATION", 84, 93]]], ["The eigenvalues of the matrix J M are the roots of the following characteristic polynomial:Local Stability in Terms of the Basic Reproduction NumberwhereLocal Stability in Terms of the Basic Reproduction NumberNext, by using the Li\u00e9nard-Chipard test [14, 15] , all the roots of Z(\u03bb) are negative or have negative real part if, and only if, the following conditions are satisfied:Local Stability in Terms of the Basic Reproduction Number1. a i > 0, i = 1, 2, 3, 4;Local Stability in Terms of the Basic Reproduction Number2. a 1 a 2 > a 3 .Local Stability in Terms of the Basic Reproduction NumberIn order to check these conditions of the Li\u00e9nard-Chipard test, we rewrite the coefficients a 1 , a 2 , a 3 , and a 4 of the characteristic polynomial in terms of the basic reproduction number given by (4):Local Stability in Terms of the Basic Reproduction NumberMoreover, we also compute, in terms of R 0 , the following expression:Local Stability in Terms of the Basic Reproduction NumberFrom these previous expressions, it is clear that if R 0 < 1, then the conditions of the Li\u00e9nard-Chipard test are satisfied and, as a consequence, the disease free equilibrium is stable.", [["roots", "ANATOMY", 269, 274], ["a i", "TEST", 439, 442], ["the Li\u00e9nard-Chipard test", "TEST", 633, 657], ["the Li\u00e9nard-Chipard test", "TEST", 1070, 1094], ["the disease free equilibrium", "PROBLEM", 1132, 1160], ["matrix J M", "OBSERVATION_MODIFIER", 23, 33], ["Local Stability", "OBSERVATION", 91, 106], ["Stability", "OBSERVATION_MODIFIER", 159, 168], ["negative", "OBSERVATION", 287, 295], ["Stability", "OBSERVATION", 469, 478], ["Stability", "OBSERVATION", 544, 553], ["disease", "OBSERVATION", 1136, 1143], ["stable", "OBSERVATION_MODIFIER", 1164, 1170]]], ["In the case when R 0 > 1, we have that a 4 < 0 and, by using Descartes' rule of signs, we conclude that at least one of the eigenvalues is positive.", [["signs", "PROBLEM", 80, 85], ["positive", "OBSERVATION", 139, 147]]], ["Therefore, the system is unstable.", [["unstable", "OBSERVATION", 25, 33]]], ["The disease free equilibrium of system (1), that is, (N, 0, 0, 0, 0, 0, 0), is locally asymptotically stable if R 0 < 1 and unstable if R 0 > 1.Local Stability in Terms of the Basic Reproduction NumberNext we investigate the sensitiveness of the COVID-19 model (1), with respect to the variation of each one of its parameters, for the endemic threshold (4).Sensitivity AnalysisAs we saw in Section 3, the basic reproduction number for the COVID-19 model (1), which we propose in Section 2, is given by (4) .", [["The disease free equilibrium of system", "PROBLEM", 0, 38], ["the COVID", "TEST", 242, 251], ["the COVID", "TEST", 435, 444], ["disease", "OBSERVATION", 4, 11], ["free", "OBSERVATION_MODIFIER", 12, 16], ["equilibrium", "OBSERVATION_MODIFIER", 17, 28], ["Stability", "OBSERVATION", 150, 159]]], ["The sensitivity analysis for the endemic threshold (4) tells us how important each parameter is to disease transmission.", [["The sensitivity analysis", "TEST", 0, 24], ["the endemic threshold", "TEST", 29, 50]]], ["Sensitivity analysis is commonly used to determine the robustness of model predictions to parameter values, since there are usually errors in collected data and presumed parameter values.", [["Sensitivity analysis", "TEST", 0, 20], ["collected data", "TEST", 142, 156]]], ["It is used to discover parameters that have a high impact on the threshold R 0 and should be targeted by intervention strategies.", [["intervention strategies", "TREATMENT", 105, 128]]], ["For that purpose, we use the normalized forward sensitivity index of a variable with respect to a given parameter, which is defined as the ratio of the relative change in the variable to the relative change in the parameter.", [["the normalized forward sensitivity index", "TEST", 25, 65]]], ["If such variable is differentiable with respect to the parameter, then the sensitivity index is defined as follows.Sensitivity AnalysisDefinition 1.1 (See [17, 18] ).", [["the sensitivity index", "TEST", 71, 92], ["Sensitivity", "TEST", 115, 126], ["AnalysisDefinition", "TEST", 127, 145]]], ["The normalized forward sensitivity index of R 0 , which is differentiable with respect to a given parameter \u03b8, is defined bySensitivity AnalysisThe values of the sensitivity indices for the parameters values of Table 1 , are presented in Table 2 .Sensitivity AnalysisThese values have been determined experimentally in such a way the mathematical model describes well the real data, giving rise to Figures 2 and 3 .", [["The normalized forward sensitivity index", "TEST", 0, 40], ["the sensitivity indices", "TEST", 158, 181], ["the parameters values", "TEST", 186, 207], ["Sensitivity Analysis", "TEST", 247, 267]]], ["Other values for the parameters can be found, e.g., in [19] .", [["Other values", "TEST", 0, 12], ["the parameters", "TEST", 17, 31]]], ["Note that the sensitivity index may depend on several parameters of the system, but also can be constant, independent of any parameter.", [["the sensitivity index", "TEST", 10, 31]]], ["For example, \u03a5 R0 \u03b8 = +1 means that increasing (decreasing) \u03b8 by a given percentage increases (decreases) always R 0 by that same percentage.", [["example", "TEST", 4, 11], ["increasing", "OBSERVATION_MODIFIER", 36, 46], ["decreasing", "OBSERVATION_MODIFIER", 48, 58], ["increases", "OBSERVATION_MODIFIER", 84, 93], ["decreases", "OBSERVATION_MODIFIER", 95, 104]]], ["The estimation of a sensitive parameter should be carefully done, since a small perturbation in such parameter leads to relevant quantitative changes.", [["a small perturbation in such parameter", "PROBLEM", 72, 110], ["relevant quantitative changes", "PROBLEM", 120, 149], ["small", "OBSERVATION_MODIFIER", 74, 79], ["perturbation", "OBSERVATION", 80, 92]]], ["On the other hand, the estimation of a parameter with a rather small value for the sensitivity index does not require as much attention to estimate, because a small perturbation in that parameter leads to small changes.Sensitivity AnalysisFrom Table 2 , we conclude that the most sensitive parameters to the basic reproduction number R 0 of the COVID-19 model (1) are \u03b2, \u03c1 1 and \u03b4 i .", [["the sensitivity index", "TEST", 79, 100], ["a small perturbation in that parameter", "PROBLEM", 157, 195], ["small changes", "PROBLEM", 205, 218], ["Sensitivity Analysis", "TEST", 219, 239], ["the COVID", "TEST", 341, 350], ["small", "OBSERVATION_MODIFIER", 159, 164], ["perturbation", "OBSERVATION", 165, 177], ["small", "OBSERVATION_MODIFIER", 205, 210]]], ["In concrete, an increase of the value of \u03b2 will increase the basic reproduction number by 96.3% and this happens, in a similar way, for the parameter \u03c1 1 .", [["\u03b2", "PROTEIN", 41, 42], ["increase", "OBSERVATION_MODIFIER", 16, 24]]], ["In contrast, an increase of the value of \u03b4 i will decrease R 0 by 69.9%.Numerical Simulations: The Case Study of WuhanWe perform numerical simulations to compare the results of our model with the real data obtained from several reports published by WHO [20, 21] and worldometer [5] .Numerical Simulations: The Case Study of WuhanThe starting point of our simulations is 4 January 2020 (day 0), when the Chinese authorities informed about the new virus [20] , with already 6 confirmed cases in one day.", [["the value", "TEST", 28, 37], ["the new virus", "PROBLEM", 438, 451], ["increase", "OBSERVATION_MODIFIER", 16, 24]]], ["From this period up to January 19, there is less information about the number of people contracting the disease.", [["people", "ORGANISM", 81, 87], ["people", "SPECIES", 81, 87], ["the disease", "PROBLEM", 100, 111], ["disease", "OBSERVATION", 104, 111]]], ["Thus, the infection gained much more attention from 21 January 2020, with 1739 confirmed cases and 38 the dead, up to 4 March 2020, when the numbers in that day were as low as 11 and 7, respectively infected and dead, after a pick of 3892 confirmed cases on 27 January 2020 and a pick of 254 dead on 4 February 2020.", [["infection", "DISEASE", 10, 19], ["the infection", "PROBLEM", 6, 19], ["the numbers", "TEST", 137, 148], ["infection", "OBSERVATION", 10, 19]]], ["We show that our COVID-19 model describes well the real data of daily confirmed cases during the 2 months outbreak (66 days to be precise, from January 4 to March 9, 2020).Numerical Simulations: The Case Study of WuhanThe total population of Wuhan is about 11 million.", [["our COVID", "TEST", 13, 22]]], ["During the COVID-19 outbreak, there was a restriction of movements of individuals due to quarantine in the city.", [["the COVID", "TEST", 7, 16], ["a restriction of movements of individuals", "PROBLEM", 40, 81]]], ["As a consequence, there was a limitation on the spread of the disease.", [["the disease", "PROBLEM", 58, 69], ["disease", "OBSERVATION", 62, 69]]], ["As for the initial conditions, the following values have been fixed: S 0 = N \u2212 6, E 0 = 0, I 0 = 1, P 0 = 5, A 0 = 0, H 0 = 0, R 0 = 0, and F 0 = 0.", [["S", "TEST", 69, 70], ["\u2212", "TEST", 77, 78], ["E", "TEST", 82, 83], ["I", "TEST", 91, 92], ["P", "TEST", 100, 101], ["A", "TEST", 109, 110], ["H", "TEST", 118, 119]]], ["[20, 21, 5] while the black line (I + P + H) has been obtained by solving numerically the system of ordinary differential equations (1), by using the Matlab code ode45.Numerical Simulations: The Case Study of WuhanWe would like to mention that there exist gaps in the reports of the WHO at the beginning of the outbreak.", [["H", "CHEMICAL", 42, 43]]], ["For completeness, we give here the list L C of the number of confirmed cases in Wuhan per day, corresponding to the green line of Figure 2 , and the list L D of the number of dead individuals in Wuhan per day, corresponding to the red line of Figure 3 : [6, 12, 19, 25, 31, 38, 44, 60, 80, 131, 131, 259, 467, 688, 776, 1776, 1460, 1739, 1984, 2101, 2590 Lists L C and L D have 66 numbers, where L C (0) represents the number of confirmed cases 04 January 2020 (day 0) and L C (65) the number of confirmed cases 09 March 2020 (day 65) and, analogously, L D (0) represents the number of dead on January 4 and L D (65) the number of dead on March 9, 2020.Conclusions and DiscussionClassical models consider SIR populations.", [["L C", "TEST", 361, 364], ["L D", "TEST", 369, 372], ["numbers", "TEST", 381, 388], ["green line", "OBSERVATION", 116, 126]]], ["Here we have taken into consideration the superspreaders (P ), hospitalized (H), and fatality class (F ), so that its derivative (see formula (2)) gives the number of deaths (D).", [["deaths", "DISEASE", 167, 173]]], ["Our model is an ad hoc compartmental model of the COVID-19, taking into account its particularities, some of them still not well-known, giving a good approximation of the reality of the Wuhan outbreak (see Figure 2 ) and predicting a diminishing on the daily number of confirmed cases of the disease.", [["the COVID", "TREATMENT", 46, 55], ["the disease", "PROBLEM", 288, 299], ["diminishing", "OBSERVATION_MODIFIER", 234, 245], ["disease", "OBSERVATION", 292, 299]]], ["Moreover, it is worth to mention that our model fits also enough well the real data of daily confirmed deaths, as shown in Figure 3 .", [["deaths", "DISEASE", 103, 109]]], ["[20, 21, 5] while the black line has been obtained by solving numerically, using the Matlab code ode45, our system of ordinary differential equations (1) to derive D(t) given in (2).Conclusions and DiscussionOur theoretical findings and numerical results adapt well to the real data and it reflects or reflected the reality in Wuhan, China.", [["the real data", "TEST", 269, 282]]], ["The number of hospitalized persons is relevant to give an estimate of the Intensive Care Units (ICU) needed.", [["persons", "ORGANISM", 27, 34], ["persons", "SPECIES", 27, 34]]], ["We claim that some mathematical models like the one we have proposed here will contribute to reveal some important aspects of this pandemia.Conclusions and DiscussionOf course, this investigation has some limitations, being the first on the relative recent spread of the new coronavirus and therefore the limited data accessible at the beginning of this study.", [["pandemia", "DISEASE", 131, 139], ["coronavirus", "DISEASE", 275, 286], ["pandemia", "CANCER", 131, 139], ["coronavirus", "ORGANISM", 275, 286], ["this pandemia", "PROBLEM", 126, 139], ["this investigation", "TEST", 177, 195], ["the new coronavirus", "PROBLEM", 267, 286], ["this study", "TEST", 349, 359]]], ["Finally, we suggest new directions for further research:Conclusions and Discussion1. the transmissibility from asymptomatic individuals; 2. compare, in the near future, our results with other models;Declaration of interestsThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.", [["the transmissibility from asymptomatic individuals", "PROBLEM", 85, 135], ["asymptomatic", "OBSERVATION_MODIFIER", 111, 123]]]], "8ebda5e6df67c04e812dfdffeeb22940de142931": [["HintergrundEnde des Jahres 2019 und Anfang des Jahres 2020 kommt es zum Ausbruch einer Pandemie der Erkrankung COVID-19 durch das SARS-CoV-2 (Corona-Virus, 2019-nCoV; [16] ).", [["Corona-Virus", "ORGANISM", 142, 154], ["HintergrundEnde des Jahres 2019 und Anfang des Jahres 2020 kommt es zum Ausbruch einer Pandemie der Erkrankung COVID-19 durch das SARS-CoV-2 (Corona-Virus, 2019-nCoV", "SPECIES", 0, 165], ["Ausbruch", "TEST", 72, 80], ["COVID", "TEST", 111, 116], ["SARS", "TEST", 130, 134], ["CoV", "TEST", 135, 138]]], ["Menschen.", [["Menschen", "CHEMICAL", 0, 8]]], ["Um die Ausbreitung einzud\u00e4mmen bzw. den Peak der Infektionszahlen abzuflachen, wurden von Bundesregierung und Landesregierungen verschiedene Verordnungen etabliert -sog.", [["sog", "ANATOMY", 165, 168]]], ["Die in ganz Deutschland ab dem 23.", [["ganz Deutschland ab dem 23", "SPECIES", 7, 33], ["ganz", "ANATOMY", 7, 11]]], ["M\u00e4rz geltende Beschr\u00e4nkung sozialer Kontakte bedeutet also eine einschneidende Ver\u00e4nderung im allt\u00e4glichen Leben von in der Bundesrepublik lebenden Personen.HintergrundDer Begriff \"Ausgangsbeschr\u00e4nkungen\" wird im Folgenden als Oberbegriff f\u00fcr jegliche in Deutschland im Rahmen der Corona-Pandemie erlassene Form der Ausgangsbeschr\u00e4nkung, d. h. f\u00fcr Kontaktverbote, Beschr\u00e4nkungen sozialer Kontakte und Ausgangssperren genutzt.HintergrundDie Autoren Johannes Schillings und Mara Mohr teilen sich die Erstautorschaft.HintergrundDie Ausgangsbeschr\u00e4nkungen dauern zum jetzigen Zeitpunkt \u00fcber mehrere Wochen an und sind sowohl im privaten, als auch im beruflichen und schulischen sowie im wirtschaftlichen Lebensbereich sp\u00fcrbar.", [["HintergrundDer Begriff \"Ausgangsbeschr\u00e4nkungen\" wird im Folgenden als Oberbegriff f\u00fcr jegliche in Deutschland im Rahmen der Corona-Pandemie erlassene Form der Ausgangsbeschr\u00e4nkung, d. h. f\u00fcr Kontaktverbote, Beschr\u00e4nkungen sozialer Kontakte und Ausgangssperren genutzt", "SPECIES", 157, 424], ["HintergrundDie Ausgangsbeschr\u00e4nkungen dauern zum jetzigen Zeitpunkt \u00fcber mehrere Wochen an und sind sowohl im privaten, als auch im beruflichen und schulischen sowie im wirtschaftlichen Lebensbereich sp\u00fcrbar", "SPECIES", 514, 721], ["M\u00e4rz", "TREATMENT", 0, 4], ["Kontakte bedeutet", "TREATMENT", 36, 53], ["Kontaktverbote", "TEST", 348, 362], ["an und sind sowohl im privaten", "TREATMENT", 602, 632]]], ["Teil der Ausgangsbeschr\u00e4nkungen sind u. a. die Schlie\u00dfung von Schulen, Universit\u00e4ten und sonstigen Bildungseinrichtungen sowie nicht-essentieller Bereiche im Einzelhandel, von Sportst\u00e4tten und das Verbot von Personenansammlungen.", [["Teil der Ausgangsbeschr\u00e4nkungen sind u. a. die Schlie\u00dfung von Schulen, Universit\u00e4ten und sonstigen Bildungseinrichtungen sowie nicht-essentieller Bereiche im Einzelhandel, von Sportst\u00e4tten und das Verbot von Personenansammlungen", "SPECIES", 0, 228]]], ["Bundesweit ist der Aufenthalt im \u00f6ffentlichen Raum nur noch alleine, mit einer weiteren nicht im selben Haushalt lebenden Person oder im Kreise des eigenen Hausstands erlaubt.", [["Bundesweit ist der Aufenthalt im \u00f6ffentlichen Raum nur noch alleine, mit einer weiteren nicht im selben Haushalt lebenden Person oder im Kreise des eigenen Hausstands erlaubt", "SPECIES", 0, 174]]], ["Feiern und Veranstaltungen im \u00f6ffentlichen und privaten Bereich sind zur Zeit untersagt.HintergrundErlaubt sind ausdr\u00fccklich individueller Sport sowie notwendige Wege wie z.", [["Feiern und Veranstaltungen im \u00f6ffentlichen und privaten Bereich sind zur Zeit untersagt", "SPECIES", 0, 87], ["Feiern und Veranstaltungen im \u00f6ffentlichen", "TREATMENT", 0, 42]]], ["M\u00e4rz verh\u00e4ngte und bis zum 19.", [["M\u00e4rz verh\u00e4ngte und bis zum 19", "SPECIES", 0, 29]]], ["April 2020 gelten l\u00e4sst, der Aufenthalt in der \u00d6ffentlichkeit ausschlie\u00dflich alleine oder mit einer Person aus dem eigenen Hausstand gestattet [2] .HintergrundBei Verst\u00f6\u00dfen hat der Betroffene mit Sanktionen zu rechnen.", [["Bei Verst\u00f6\u00dfen hat der Betroffene mit Sanktionen zu rechnen", "SPECIES", 159, 217]]], ["Hier sind Geld-strafen bis zu 25.000 \u20ac sowie Haftstrafen m\u00f6glich [17] .HintergrundBei der \"theory of reasoned action\" (TORA; [1]Schl\u00fcsselw\u00f6rterPandemie \u00b7 Covid19 \u00b7 Gesundheitsverhalten \u00b7 Sanktionsantizipation \u00b7 Pr\u00e4ventionNo way out?", [["strafen bis zu", "TREATMENT", 15, 29], ["Schl\u00fcsselw\u00f6rterPandemie", "TREATMENT", 128, 151]]], ["Intention to comply with corona restrictions in the context of an extended theory of reasoned action AbstractBackground.", [["corona restrictions", "TREATMENT", 25, 44]]], ["In March 2020, it was necessary to impose so-called curfews for several weeks across Germany due to the COVID-19 pandemic.", [["the COVID", "TEST", 100, 109], ["pandemic", "PROBLEM", 113, 121]]], ["This meant massive restraints for the population.No way out?", [["massive restraints", "TREATMENT", 11, 29], ["the population", "TREATMENT", 34, 48], ["massive", "OBSERVATION_MODIFIER", 11, 18], ["restraints", "OBSERVATION", 19, 29]]], ["Intention to comply with corona restrictions in the context of an extended theory of reasoned action AbstractObjectives.", [["corona restrictions", "TREATMENT", 25, 44]]], ["There are two key questions: (1) is the TORA suitable for explaining the intention to comply with the imposed curfews? and (2) does an extension of TORA by the variable sanction-anticipation influence the intention to obey the imposed curfews?", [["TORA", "GENE_OR_GENE_PRODUCT", 148, 152], ["TORA", "PROTEIN", 148, 152]]], ["Using an online survey, it was investigated the individual's intention, attitudes and subjective norm to follow the restrictions, and also the anticipation of sanctions for noncompliance using a rating scale (1-7).", [["a rating scale", "TEST", 193, 207]]], ["Multiple linear regression and hierarchical regression analysis were used to clarify key questions.No way out?", [["Multiple linear regression", "PROBLEM", 0, 26], ["hierarchical regression analysis", "TEST", 31, 63], ["linear", "OBSERVATION_MODIFIER", 9, 15], ["regression", "OBSERVATION_MODIFIER", 16, 26], ["hierarchical regression", "OBSERVATION", 31, 54]]], ["Intention to comply with corona restrictions in the context of an extended theory of reasoned action AbstractResults.", [["corona restrictions", "TREATMENT", 25, 44]]], ["In all, 1269 evaluable records demonstrated that the intention to follow the curfews is high (mean 6.24, standard deviation 1.2) and that this can be elucidated through the attitudes and subjective norm to 67% (p < 0.001).", [["the curfews", "TEST", 73, 84]]], ["There is no impact of impending sanctions for noncompliance (\u0394R 2 = 0.002).", [["noncompliance", "PROBLEM", 46, 59], ["\u0394R", "TEST", 61, 63], ["no", "UNCERTAINTY", 9, 11]]], ["The TORA is suitable for explaining the intention to comply with the curfews.No way out?", [["TORA", "DNA", 4, 8]]], ["Intention to comply with corona restrictions in the context of an extended theory of reasoned action AbstractKey political decision-makers should avoid threatening sanctions during speeches to increase compliance but instead emphasize the meaning and benefit of the measures for society and also for the individual's own social environment in order to positively influence the intended goals.KeywordsCurfew \u00b7 SARS-CoV-2 \u00b7 Behaviour \u00b7 Compliance \u00b7 Prevention gen und subjektive Norm verwendet.", [["corona restrictions", "TREATMENT", 25, 44], ["threatening sanctions", "TREATMENT", 152, 173]]], ["Diese Frage l\u00e4sst sich vor dem Hintergrund der hochsignifikanten Gesamtvarianzaufkl\u00e4rung aus der Regressionsanalyse klar positiv beantworten.", [["Diese Frage l\u00e4sst sich vor dem Hintergrund der hochsignifikanten Gesamtvarianzaufkl\u00e4rung aus der Regressionsanalyse klar positiv beantworten", "SPECIES", 0, 140]]], ["Den gr\u00f6\u00dften Einfluss auf die Intention haben die Einstellungen des Einzelnen zu den Ausgangsbeschr\u00e4nkungen, ebenfalls hoch ist der Einfluss der subjektiven Norm die sich aus dem Umfeld des Einzelnen bestimmt.Diskussion der ersten ForschungsfrageDa die Intention hoch ist und damit auch die Wahrscheinlichkeit, dass sich die jeweiligen Personen gem\u00e4\u00df ihrer Absicht tats\u00e4chlich an die Ausgangsbeschr\u00e4nkungen halten, d. h. ihre Absicht in die Tat umsetzen, l\u00e4sst sich das Modell der TORA [1] gegebenenfalls nutzen, um das tats\u00e4chliche Verhalten vorauszusagen [11] .Diskussion der ersten ForschungsfrageWeil die Pandemie bzw. die Erkrankung im Einzelfall nicht nur den Einzelnen selber, sondern auch sein nahes Umfeld betrifft, hat das Verhalten des Einzelnen direkten Einfluss auf die Personen im nahen Umfeld, die aus einer Ansteckung mit SARS-CoV-2 gegebenenfalls Schaden nehmen bzw. die durch Verhinderung einer Ansteckung im Sinne der Ausgangsbeschr\u00e4nkungen aktiv durch den Einzelnen gesch\u00fctzt werden.Diskussion der zweiten ForschungsfrageDie 2.", [["SARS", "DISEASE", 837, 841], ["Den gr\u00f6\u00dften Einfluss auf die Intention haben die Einstellungen des Einzelnen zu den Ausgangsbeschr\u00e4nkungen, ebenfalls hoch ist der Einfluss der subjektiven Norm die sich aus dem Umfeld des Einzelnen bestimmt", "SPECIES", 0, 207], ["Diskussion der ersten ForschungsfrageWeil die Pandemie bzw", "SPECIES", 562, 620], ["die Erkrankung im Einzelfall nicht nur den Einzelnen selber, sondern auch sein nahes Umfeld betrifft, hat das Verhalten des Einzelnen direkten Einfluss auf die Personen im nahen Umfeld, die aus einer Ansteckung mit SARS-CoV-2 gegebenenfalls Schaden nehmen bzw", "SPECIES", 622, 881], ["Verhalten des Einzelnen direkten", "TREATMENT", 732, 764], ["CoV", "TEST", 842, 845]]], ["Forschungsfrage galt der Frage, ob die Sanktionsantizipation Einfluss auf die Intention, sich an die verordneten Ausgangsbeschr\u00e4nkungen zu halten, nimmt.", [["galt der Frage", "OBSERVATION", 16, 30]]], ["Diese Fragestellung war negativ zu beantworten, da der Sanktionsantizipation kein aussagekr\u00e4ftiger Einfluss auf die Intention nachgewiesen werden konnte.", [["Diese Fragestellung war negativ zu beantworten, da der Sanktionsantizipation kein aussagekr\u00e4ftiger Einfluss auf die Intention nachgewiesen werden konnte", "SPECIES", 0, 152]]], ["Obwohl die angedrohten Sanktionen bei Nichteinhalten der Ausgangsbeschr\u00e4nkungen im Vergleich zu anderen Ordnungswidrigkeiten als massiv zu bewerten sind, wurde die wahrgenommene Wahrscheinlichkeit, auf das Einhalten der Ausgangsbeschr\u00e4nkungen kontrolliert zu werden und die Wahrscheinlichkeit, bei Nichteinhaltung eine Sanktion auferlegt zu bekommen, eher niedrig eingesch\u00e4tzt.", [["Obwohl die angedrohten Sanktionen bei Nichteinhalten der Ausgangsbeschr\u00e4nkungen im Vergleich zu anderen Ordnungswidrigkeiten als massiv zu bewerten sind, wurde die wahrgenommene Wahrscheinlichkeit, auf das Einhalten der Ausgangsbeschr\u00e4nkungen kontrolliert zu werden und die Wahrscheinlichkeit, bei Nichteinhaltung eine Sanktion auferlegt zu bekommen, eher niedrig eingesch\u00e4tzt", "SPECIES", 0, 376]]], ["Eine m\u00f6gliche Erkl\u00e4rung f\u00fcr den geringen Sanktionsantizipationswert k\u00f6nnte darin liegen, dass die Vorstellung beispielsweise beim Spazierengehen oder Picknicken von einer Ordnungsbeh\u00f6rde kontrolliert und mit hohen Geldstrafen sanktioniert zu werden, als utopisch angesehen wird.", [["Eine m\u00f6gliche Erkl\u00e4rung f\u00fcr den geringen Sanktionsantizipationswert k\u00f6nnte darin liegen, dass die Vorstellung beispielsweise beim Spazierengehen oder Picknicken von einer Ordnungsbeh\u00f6rde kontrolliert und mit hohen Geldstrafen sanktioniert zu werden, als utopisch angesehen wird", "SPECIES", 0, 277], ["Eine m\u00f6gliche", "TREATMENT", 0, 13]]], ["Aufgrund der gro\u00dfen Masse an zu kontrollierenden Personen ist es zudem denkbar, dass das eigene Risiko, bei Nichteinhaltung der Ausgangsbeschr\u00e4nkungen erwischt und sanktioniert zu werden, im Sinne eines optimistischen Fehlschlusses, als gering eingesch\u00e4tzt wird [14] .", [["Aufgrund der gro\u00dfen Masse an zu kontrollierenden Personen ist es zudem denkbar, dass das eigene Risiko, bei Nichteinhaltung der Ausgangsbeschr\u00e4nkungen erwischt und sanktioniert zu werden, im Sinne eines optimistischen Fehlschlusses, als gering eingesch\u00e4tzt wird", "SPECIES", 0, 261]]], ["Unabh\u00e4ngig von den m\u00f6glichen Gr\u00fcnden f\u00fcr den nicht gegebenen Einfluss der Sanktionsantizipation auf die Intention, sich an die Ausgangsbeschr\u00e4nkungen zu halten, l\u00e4sst sich festhalten, dass die Androhung", [["von den m\u00f6glichen Gr\u00fcnden f\u00fcr den nicht gegebenen Einfluss der Sanktionsantizipation auf die Intention, sich an die Ausgangsbeschr\u00e4nkungen zu halten, l\u00e4sst sich festhalten, dass die Androhung", "SPECIES", 11, 202]]]], "PMC7196384": [["IntroductionThe rapid spread of coronavirus disease 2019 (COVID-19), caused by the a novel betacoronavirus known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), throughout the world has had dramatic effects on individuals and health care systems far beyond those infected with SARS-CoV-2 [1].", [["coronavirus disease", "DISEASE", 32, 51], ["COVID-19", "CHEMICAL", 58, 66], ["acute respiratory syndrome coronavirus", "DISEASE", 123, 161], ["SARS", "DISEASE", 294, 298], ["coronavirus", "ORGANISM", 32, 43], ["severe acute respiratory syndrome coronavirus-2", "ORGANISM", 116, 163], ["SARS-CoV-2", "ORGANISM", 165, 175], ["SARS-CoV-2", "ORGANISM", 294, 304], ["syndrome coronavirus", "SPECIES", 141, 161], ["coronavirus disease 2019 (COVID-19", "SPECIES", 32, 66], ["severe acute respiratory syndrome coronavirus", "SPECIES", 116, 161], ["SARS-CoV-2", "SPECIES", 165, 175], ["SARS-CoV", "SPECIES", 294, 302], ["coronavirus disease", "PROBLEM", 32, 51], ["COVID", "TEST", 58, 63], ["a novel betacoronavirus", "PROBLEM", 83, 106], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 116, 161], ["dramatic effects on individuals and health care systems", "PROBLEM", 207, 262], ["rapid", "OBSERVATION_MODIFIER", 16, 21], ["spread", "OBSERVATION_MODIFIER", 22, 28], ["coronavirus disease", "OBSERVATION", 32, 51], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory syndrome", "OBSERVATION", 129, 149]]], ["The heavy demand for resources, exacerbated by limited excess health system capacity, means that health care systems have become quickly overwhelmed and hospitals have become sources for virus transmission.", [["virus transmission", "PROBLEM", 187, 205]]], ["In response, professional bodies have recommended reprioritizing surgical cases [2] depending on the risks of COVID-19 to individual patients and health care workers caring for patients potentially infected with SARS-CoV-2, and the need to conserve health care resources along with the risk from delaying cancer care.IntroductionA severe SARS-CoV-2 phenotype is seen more commonly in men and older, more comorbid patients [3].", [["cancer", "ANATOMY", 305, 311], ["SARS", "DISEASE", 212, 216], ["cancer", "DISEASE", 305, 311], ["SARS", "DISEASE", 338, 342], ["patients", "ORGANISM", 133, 141], ["patients", "ORGANISM", 177, 185], ["cancer", "CANCER", 305, 311], ["men", "ORGANISM", 384, 387], ["patients", "ORGANISM", 413, 421], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 177, 185], ["men", "SPECIES", 384, 387], ["patients", "SPECIES", 413, 421], ["SARS-CoV", "SPECIES", 212, 220], ["COVID", "TEST", 110, 115], ["delaying cancer care", "TREATMENT", 296, 316], ["IntroductionA severe SARS", "PROBLEM", 317, 342], ["cancer", "OBSERVATION", 305, 311]]], ["These characteristics are common in many patients with urologic malignancies.", [["urologic malignancies", "ANATOMY", 55, 76], ["urologic malignancies", "DISEASE", 55, 76], ["patients", "ORGANISM", 41, 49], ["urologic malignancies", "CANCER", 55, 76], ["patients", "SPECIES", 41, 49], ["urologic malignancies", "PROBLEM", 55, 76], ["malignancies", "OBSERVATION", 64, 76]]], ["Baseline characteristics among 1591 patients admitted to the intensive care unit (ICU) in the Lombardy region, Italy, showed that the median age was 63 yr (interquartile range [IQR] 56\u201370), 82% were male, 68% had more than one comorbidity, 88% required ventilator support, and the mortality rate was 26%, with a large proportion requiring ongoing ICU-level care at the time of data cut-off [4].", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["IQR", "TEST", 177, 180], ["ventilator support", "TREATMENT", 253, 271], ["the mortality rate", "TEST", 277, 295], ["ongoing ICU-level care", "TREATMENT", 339, 361], ["large", "OBSERVATION_MODIFIER", 312, 317]]], ["Work from China further demonstrated that patients with cancer had a higher incidence of COVID-19 than expected in the general population and had more severe manifestation of the disease, with a significantly higher proportion requiring invasive ventilation in the ICU or dying [5].IntroductionRecent data suggest that approximately 20% of asymptomatic COVID-19\u2013positive patients may die after an elective operation [6].", [["cancer", "ANATOMY", 56, 62], ["cancer", "DISEASE", 56, 62], ["patients", "ORGANISM", 42, 50], ["cancer", "CANCER", 56, 62], ["patients", "ORGANISM", 371, 379], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 371, 379], ["cancer", "PROBLEM", 56, 62], ["COVID", "TEST", 89, 94], ["the disease", "PROBLEM", 175, 186], ["invasive ventilation", "TREATMENT", 237, 257], ["IntroductionRecent data", "TEST", 282, 305], ["asymptomatic COVID", "PROBLEM", 340, 358], ["an elective operation", "TREATMENT", 394, 415], ["cancer", "OBSERVATION", 56, 62], ["disease", "OBSERVATION", 179, 186]]], ["To better inform decision making regarding deferring treatment of urologic cancers at this time, we undertook a collaborative review of the available data on the association between treatment delays and important oncologic outcomes including survival in patients with urologic cancers.Evidence acquisitionTo rapidly provide information, a formal systematic review was not undertaken.", [["urologic cancers", "ANATOMY", 66, 82], ["urologic cancers", "ANATOMY", 268, 284], ["urologic cancers", "DISEASE", 66, 82], ["urologic cancers", "DISEASE", 268, 284], ["urologic cancers", "CANCER", 66, 82], ["patients", "ORGANISM", 254, 262], ["urologic cancers", "CANCER", 268, 284], ["patients", "SPECIES", 254, 262], ["urologic cancers", "PROBLEM", 66, 82], ["treatment delays", "TREATMENT", 182, 198], ["urologic cancers", "PROBLEM", 268, 284], ["a formal systematic review", "TEST", 337, 363], ["cancers", "OBSERVATION", 75, 82], ["cancers", "OBSERVATION", 277, 284]]], ["Instead, a scoping narrative review was performed.", [["a scoping narrative review", "TEST", 9, 35]]], ["Following agreement on manuscript structure, a literature review was performed by teams based on clinical specialty (urologic oncology, radiation oncology, and medical oncology).", [["a literature review", "TEST", 45, 64]]], ["To this end, PubMed was searched from inception until April 2, 2020 to identify studies examining the association between delays in treatment and clinical outcomes, including upstaging, recurrence, and mortality for patients with bladder cancer (BC; both muscle-invasive and non\u2013muscle-invasive disease), prostate cancer (PCa), kidney cancer, upper tract urothelial cancer, germ cell tumors, and penile cancer.Evidence acquisitionWhere available, we relied on previously published systematic reviews and meta-analyses, supplemented by a narrative review of key studies and those published since the systematic review.", [["bladder cancer", "ANATOMY", 230, 244], ["BC", "ANATOMY", 246, 248], ["muscle", "ANATOMY", 255, 261], ["invasive", "ANATOMY", 262, 270], ["non\u2013muscle-invasive disease", "ANATOMY", 275, 302], ["prostate cancer", "ANATOMY", 305, 320], ["PCa", "ANATOMY", 322, 325], ["kidney cancer", "ANATOMY", 328, 341], ["upper tract urothelial cancer", "ANATOMY", 343, 372], ["germ cell tumors", "ANATOMY", 374, 390], ["penile cancer", "ANATOMY", 396, 409], ["bladder cancer", "DISEASE", 230, 244], ["BC", "DISEASE", 246, 248], ["muscle-invasive and non\u2013muscle-invasive disease", "DISEASE", 255, 302], ["prostate cancer", "DISEASE", 305, 320], ["PCa", "DISEASE", 322, 325], ["kidney cancer", "DISEASE", 328, 341], ["upper tract urothelial cancer", "DISEASE", 343, 372], ["germ cell tumors", "DISEASE", 374, 390], ["penile cancer", "DISEASE", 396, 409], ["patients", "ORGANISM", 216, 224], ["bladder cancer", "CANCER", 230, 244], ["BC", "CANCER", 246, 248], ["muscle-invasive", "CANCER", 255, 270], ["non\u2013muscle-invasive disease", "CANCER", 275, 302], ["prostate cancer", "CANCER", 305, 320], ["PCa", "CANCER", 322, 325], ["kidney cancer", "CANCER", 328, 341], ["upper tract urothelial cancer", "CANCER", 343, 372], ["germ cell tumors", "CANCER", 374, 390], ["penile cancer", "CANCER", 396, 409], ["patients", "SPECIES", 216, 224], ["treatment", "TREATMENT", 132, 141], ["upstaging", "TEST", 175, 184], ["recurrence", "PROBLEM", 186, 196], ["bladder cancer", "PROBLEM", 230, 244], ["BC", "TEST", 246, 248], ["both muscle-invasive and non\u2013muscle-invasive disease)", "PROBLEM", 250, 303], ["prostate cancer (PCa)", "PROBLEM", 305, 326], ["kidney cancer", "PROBLEM", 328, 341], ["upper tract urothelial cancer", "PROBLEM", 343, 372], ["germ cell tumors", "PROBLEM", 374, 390], ["penile cancer", "PROBLEM", 396, 409], ["key studies", "TEST", 557, 568], ["the systematic review", "TEST", 595, 616], ["bladder", "ANATOMY", 230, 237], ["cancer", "OBSERVATION", 238, 244], ["muscle", "ANATOMY", 255, 261], ["invasive disease", "OBSERVATION", 286, 302], ["prostate", "ANATOMY", 305, 313], ["cancer", "OBSERVATION", 314, 320], ["kidney", "ANATOMY", 328, 334], ["cancer", "OBSERVATION", 335, 341], ["upper", "ANATOMY_MODIFIER", 343, 348], ["tract", "ANATOMY_MODIFIER", 349, 354], ["urothelial", "ANATOMY", 355, 365], ["cancer", "OBSERVATION", 366, 372], ["germ cell tumors", "OBSERVATION", 374, 390], ["penile", "ANATOMY", 396, 402], ["cancer", "OBSERVATION", 403, 409]]], ["The available data were qualitatively synthesized and presented, stratified by tumor site and urologic versus medical oncology intervention.", [["tumor site", "ANATOMY", 79, 89], ["tumor", "DISEASE", 79, 84], ["tumor", "CANCER", 79, 84], ["tumor site", "PROBLEM", 79, 89], ["medical oncology intervention", "TREATMENT", 110, 139], ["tumor", "OBSERVATION", 79, 84]]], ["In the absence of high-quality literature evidence, an expert opinion was given by the authors for this review.Evidence acquisitionFollowing agreement on manuscript structure, the authors drafted relevant sections of this narrative review according to their expertise.", [["high", "OBSERVATION_MODIFIER", 18, 22]]], ["The final manuscript represents the consensus of the authors.Summary ::: Low-grade non\u2013muscle-invasive bladder cancer ::: Bladder cancer ::: Evidence synthesisThese data suggest that it is safe to defer cystoscopic surveillance and transurethral resection of bladder tumor (TURBT) for recurrence in patients with known low-grade (including low and intermediate European Organisation for Research and Treatment of Cancer [EORTC] risk) NMIBC bladder tumors during the COVID-19 pandemic.", [["Low-grade non\u2013muscle-invasive bladder cancer", "ANATOMY", 73, 117], ["Bladder cancer", "ANATOMY", 122, 136], ["bladder tumor", "ANATOMY", 259, 272], ["NMIBC bladder tumors", "ANATOMY", 434, 454], ["bladder cancer", "DISEASE", 103, 117], ["Bladder cancer", "DISEASE", 122, 136], ["bladder tumor", "DISEASE", 259, 272], ["TURBT", "DISEASE", 274, 279], ["Cancer", "DISEASE", 413, 419], ["EORTC", "DISEASE", 421, 426], ["NMIBC bladder tumors", "DISEASE", 434, 454], ["Low-grade non\u2013muscle-invasive bladder cancer", "CANCER", 73, 117], ["Bladder cancer", "CANCER", 122, 136], ["bladder tumor", "CANCER", 259, 272], ["TURBT", "CANCER", 274, 279], ["patients", "ORGANISM", 299, 307], ["Cancer", "CANCER", 413, 419], ["NMIBC bladder tumors", "CANCER", 434, 454], ["patients", "SPECIES", 299, 307], ["Low-grade non\u2013muscle-invasive bladder cancer", "PROBLEM", 73, 117], ["Bladder cancer", "PROBLEM", 122, 136], ["Evidence synthesis", "PROBLEM", 141, 159], ["cystoscopic surveillance", "TEST", 203, 227], ["transurethral resection of bladder tumor (TURBT", "TREATMENT", 232, 279], ["recurrence", "PROBLEM", 285, 295], ["known low-grade (including low", "PROBLEM", 313, 343], ["Cancer", "PROBLEM", 413, 419], ["EORTC] risk)", "TREATMENT", 421, 433], ["NMIBC bladder tumors", "PROBLEM", 434, 454], ["the COVID", "TEST", 462, 471], ["pandemic", "PROBLEM", 475, 483], ["-grade", "OBSERVATION_MODIFIER", 76, 82], ["non\u2013muscle", "OBSERVATION_MODIFIER", 83, 93], ["invasive", "OBSERVATION_MODIFIER", 94, 102], ["bladder", "ANATOMY", 103, 110], ["cancer", "OBSERVATION", 111, 117], ["cancer", "OBSERVATION", 130, 136], ["synthesis", "OBSERVATION", 150, 159], ["bladder", "ANATOMY", 259, 266], ["tumor", "OBSERVATION", 267, 272], ["low-grade", "OBSERVATION_MODIFIER", 319, 328], ["Cancer", "OBSERVATION", 413, 419], ["bladder", "ANATOMY", 440, 447], ["tumors", "OBSERVATION", 448, 454]]], ["Patients presenting with new symptoms, such as the onset of visible hematuria, should be re-evaluated (eg, with cytology and either radiologic imaging or clinic cystoscopy) to assess their disease status.Summary ::: High-grade NMIBC ::: Bladder cancer ::: Evidence synthesisIn patients with high-grade NMIBC, induction BCG and one course of maintenance therapy (6 + 3) should be offered as first-line therapy.", [["Bladder cancer", "ANATOMY", 237, 251], ["high-grade NMIBC", "ANATOMY", 291, 307], ["hematuria", "DISEASE", 68, 77], ["Bladder cancer", "DISEASE", 237, 251], ["NMIBC", "DISEASE", 302, 307], ["Patients", "ORGANISM", 0, 8], ["High-grade NMIBC", "CANCER", 216, 232], ["Bladder cancer", "CANCER", 237, 251], ["patients", "ORGANISM", 277, 285], ["high-grade NMIBC", "CANCER", 291, 307], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 277, 285], ["new symptoms", "PROBLEM", 25, 37], ["visible hematuria", "PROBLEM", 60, 77], ["cytology", "TEST", 112, 120], ["radiologic imaging", "TEST", 132, 150], ["clinic cystoscopy", "TEST", 154, 171], ["their disease status", "PROBLEM", 183, 203], ["Bladder cancer", "PROBLEM", 237, 251], ["high-grade NMIBC", "PROBLEM", 291, 307], ["induction BCG", "TREATMENT", 309, 322], ["maintenance therapy", "TREATMENT", 341, 360], ["first-line therapy", "TREATMENT", 390, 408], ["hematuria", "OBSERVATION", 68, 77], ["-grade", "OBSERVATION_MODIFIER", 220, 226], ["NMIBC", "OBSERVATION", 227, 232], ["cancer", "OBSERVATION", 245, 251], ["NMIBC", "OBSERVATION", 302, 307]]], ["Re-resection may be deferred in lower-risk cases (eg, pTa), but should not be abandoned in higher-stage (pT1) or higher-risk disease, especially if no muscle was present in the initial resection.", [["muscle", "ANATOMY", 151, 157], ["pT1", "CANCER", 105, 108], ["muscle", "ORGAN", 151, 157], ["Re-resection", "TREATMENT", 0, 12], ["higher-risk disease", "PROBLEM", 113, 132], ["the initial resection", "TREATMENT", 173, 194], ["risk disease", "OBSERVATION", 120, 132], ["muscle", "ANATOMY", 151, 157], ["resection", "OBSERVATION", 185, 194]]], ["The decision to start BCG immediately or defer it (following a repeat resection) depends on the risk of infection with SARS-CoV-2 and an unfavorable course of COVID-19, bladder tumor risk, and health care capacity.", [["bladder tumor", "ANATOMY", 169, 182], ["infection", "DISEASE", 104, 113], ["SARS", "DISEASE", 119, 123], ["bladder tumor", "DISEASE", 169, 182], ["bladder tumor", "CANCER", 169, 182], ["BCG", "TREATMENT", 22, 25], ["a repeat resection", "TREATMENT", 61, 79], ["infection", "PROBLEM", 104, 113], ["SARS", "PROBLEM", 119, 123], ["CoV", "TEST", 124, 127], ["COVID", "TEST", 159, 164], ["bladder tumor risk", "PROBLEM", 169, 187], ["resection", "OBSERVATION", 70, 79], ["infection", "OBSERVATION", 104, 113], ["bladder", "ANATOMY", 169, 176], ["tumor", "OBSERVATION", 177, 182]]], ["RC should be offered for higher-risk tumors, if hospital capacity allows and if patient comorbidities do not put them at a higher postoperative risk.", [["tumors", "ANATOMY", 37, 43], ["tumors", "DISEASE", 37, 43], ["tumors", "CANCER", 37, 43], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["RC", "TREATMENT", 0, 2], ["higher-risk tumors", "PROBLEM", 25, 43], ["hospital capacity", "TEST", 48, 65], ["patient comorbidities", "PROBLEM", 80, 101], ["tumors", "OBSERVATION", 37, 43]]], ["Maintenance BCG after the first 3-mo booster series may be omitted until risks of COVID-19 become lower.Summary ::: Muscle-invasive bladder cancer ::: Bladder cancer ::: Evidence synthesisDelays in RC of up to 12 wk may be safe for MIBC.", [["Muscle-invasive bladder cancer", "ANATOMY", 116, 146], ["Bladder cancer", "ANATOMY", 151, 165], ["Muscle-invasive bladder cancer", "DISEASE", 116, 146], ["Bladder cancer", "DISEASE", 151, 165], ["MIBC", "DISEASE", 232, 236], ["COVID-19", "CHEMICAL", 82, 90], ["Muscle-invasive bladder cancer", "CANCER", 116, 146], ["Bladder cancer", "CANCER", 151, 165], ["MIBC", "CANCER", 232, 236], ["Maintenance BCG", "TREATMENT", 0, 15], ["the first 3-mo booster series", "TREATMENT", 22, 51], ["COVID", "TEST", 82, 87], ["Muscle-invasive bladder cancer", "PROBLEM", 116, 146], ["Bladder cancer", "PROBLEM", 151, 165], ["Evidence synthesisDelays in RC", "PROBLEM", 170, 200], ["MIBC", "PROBLEM", 232, 236], ["invasive", "OBSERVATION_MODIFIER", 123, 131], ["bladder", "ANATOMY", 132, 139], ["cancer", "OBSERVATION", 140, 146], ["cancer", "OBSERVATION", 159, 165], ["MIBC", "OBSERVATION", 232, 236]]], ["Oncologic principles and appropriate guidelines should be followed despite COVID-19.", [["Oncologic principles", "TREATMENT", 0, 20], ["COVID", "TEST", 75, 80]]], ["NAC should be considered where feasible, with due attention to the risk of immunosuppression weighed against the benefit.", [["NAC", "CHEMICAL", 0, 3], ["NAC", "CHEMICAL", 0, 3], ["NAC", "SIMPLE_CHEMICAL", 0, 3], ["NAC", "TREATMENT", 0, 3], ["immunosuppression", "TREATMENT", 75, 92]]], ["Clinicians should prioritize RC over other urologic oncology procedures during COVID-19 restrictions.", [["other urologic oncology procedures", "TREATMENT", 37, 71], ["COVID", "TEST", 79, 84]]], ["Additionally, radiotherapy (trimodal therapy with radiosensitizing chemotherapy) could be considered an alternative based on individual hospital and patient factors [38].", [["patient", "ORGANISM", 149, 156], ["patient", "SPECIES", 149, 156], ["radiotherapy (trimodal therapy", "TREATMENT", 14, 44], ["radiosensitizing chemotherapy", "TREATMENT", 50, 79]]], ["Adjuvant therapy has no role.Summary ::: Advanced or metastatic BC ::: Bladder cancer ::: Evidence synthesisOur consensus is that first-line treatment should be commenced when possible for metastatic urothelial carcinoma and should not be stopped without justification (Table 1) [42].", [["metastatic BC", "ANATOMY", 53, 66], ["Bladder cancer", "ANATOMY", 71, 85], ["metastatic urothelial carcinoma", "ANATOMY", 189, 220], ["Bladder cancer", "DISEASE", 71, 85], ["urothelial carcinoma", "DISEASE", 200, 220], ["metastatic BC", "CANCER", 53, 66], ["Bladder cancer", "CANCER", 71, 85], ["urothelial carcinoma", "CANCER", 200, 220], ["Adjuvant therapy", "TREATMENT", 0, 16], ["Bladder cancer", "PROBLEM", 71, 85], ["first-line treatment", "TREATMENT", 130, 150], ["metastatic urothelial carcinoma", "PROBLEM", 189, 220], ["no", "UNCERTAINTY", 21, 23], ["metastatic", "OBSERVATION", 53, 63], ["cancer", "OBSERVATION", 79, 85], ["metastatic", "OBSERVATION_MODIFIER", 189, 199], ["urothelial", "ANATOMY", 200, 210], ["carcinoma", "OBSERVATION", 211, 220]]], ["Immunotherapy rather than chemotherapy may be given preferentially to patients with PD-L1\u2013positive tumors.", [["PD-L1\u2013positive tumors", "ANATOMY", 84, 105], ["tumors", "DISEASE", 99, 105], ["patients", "ORGANISM", 70, 78], ["PD-L1\u2013positive tumors", "CANCER", 84, 105], ["patients", "SPECIES", 70, 78], ["Immunotherapy", "TREATMENT", 0, 13], ["chemotherapy", "TREATMENT", 26, 38], ["PD-L1\u2013positive tumors", "PROBLEM", 84, 105], ["tumors", "OBSERVATION", 99, 105]]], ["During the COVID-19 pandemic, risks and benefits of systemic therapy should be considered on an individual level, taking into account disease characteristics (ie, PD-L1 positivity), tumor load and dynamics, patient performance status, geographical COVID-19 burden, and hospital resources.", [["tumor", "ANATOMY", 182, 187], ["tumor", "DISEASE", 182, 187], ["PD-L1", "GENE_OR_GENE_PRODUCT", 163, 168], ["tumor", "CANCER", 182, 187], ["patient", "ORGANISM", 207, 214], ["patient", "SPECIES", 207, 214], ["the COVID", "TEST", 7, 16], ["systemic therapy", "TREATMENT", 52, 68], ["PD", "TEST", 163, 165], ["tumor load", "PROBLEM", 182, 192], ["geographical COVID", "TEST", 235, 253], ["tumor", "OBSERVATION", 182, 187]]], ["Palliative chemotherapy should be deferred at this time.Summary ::: Localized PCa: low-risk disease ::: Prostate cancer ::: Evidence synthesisAS should be the preferred management strategy for patients with low-risk PCa.", [["PCa", "ANATOMY", 78, 81], ["Prostate cancer", "ANATOMY", 104, 119], ["PCa", "ANATOMY", 216, 219], ["PCa", "DISEASE", 78, 81], ["low-risk disease", "DISEASE", 83, 99], ["Prostate cancer", "DISEASE", 104, 119], ["PCa", "DISEASE", 216, 219], ["PCa", "CANCER", 78, 81], ["Prostate cancer", "CANCER", 104, 119], ["patients", "ORGANISM", 193, 201], ["low-risk PCa", "CANCER", 207, 219], ["patients", "SPECIES", 193, 201], ["Palliative chemotherapy", "TREATMENT", 0, 23], ["Prostate cancer", "PROBLEM", 104, 119], ["Evidence synthesisAS", "PROBLEM", 124, 144], ["low-risk PCa", "TREATMENT", 207, 219], ["PCa", "ANATOMY", 78, 81], ["low", "OBSERVATION_MODIFIER", 83, 86], ["risk disease", "OBSERVATION", 87, 99], ["cancer", "OBSERVATION", 113, 119]]], ["Patients considering focal therapy may safely defer treatment until the pandemic is over.Summary ::: Localized PCa: intermediate- and high-risk disease ::: Prostate cancer ::: Evidence synthesisFor patients with intermediate- and high-risk disease, delays of 3\u20136 mo appear not to be associated with adverse pathologic outcomes, biochemical recurrence, or survival outcomes.", [["PCa", "ANATOMY", 111, 114], ["Prostate cancer", "ANATOMY", 156, 171], ["PCa", "DISEASE", 111, 114], ["Prostate cancer", "DISEASE", 156, 171], ["Patients", "ORGANISM", 0, 8], ["PCa", "CANCER", 111, 114], ["Prostate cancer", "CANCER", 156, 171], ["patients", "ORGANISM", 198, 206], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 198, 206], ["focal therapy", "TREATMENT", 21, 34], ["treatment", "TREATMENT", 52, 61], ["Prostate cancer", "PROBLEM", 156, 171], ["Evidence synthesis", "PROBLEM", 176, 194], ["high-risk disease", "PROBLEM", 230, 247], ["adverse pathologic outcomes", "PROBLEM", 299, 326], ["biochemical recurrence", "PROBLEM", 328, 350], ["survival outcomes", "PROBLEM", 355, 372], ["focal", "OBSERVATION_MODIFIER", 21, 26], ["PCa", "ANATOMY", 111, 114], ["intermediate", "OBSERVATION_MODIFIER", 116, 128], ["cancer", "OBSERVATION", 165, 171]]], ["Some data suggest that these intervals may be longer (up to 12 mo in patients with high-risk disease [55]).", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["high-risk disease", "PROBLEM", 83, 100]]], ["Neoadjuvant ADT prior to radiotherapy is the standard of care usually for 2\u20133 mo.", [["Neoadjuvant ADT", "TREATMENT", 0, 15], ["radiotherapy", "TREATMENT", 25, 37]]], ["It might be prolonged much longer for those at particularly high risk of progression or recurrence if radiotherapy has to be delayed until after peak health care resource utilization associated with COVID-19.", [["COVID-19", "CHEMICAL", 199, 207], ["recurrence", "PROBLEM", 88, 98], ["radiotherapy", "TREATMENT", 102, 114], ["COVID", "TEST", 199, 204], ["progression", "OBSERVATION_MODIFIER", 73, 84]]], ["For surgery, although added value of neoadjuvant ADT is questionable, it might also be considered if a patient is interested in such an approach.Summary ::: Considerations for radiotherapy in PCa ::: Prostate cancer ::: Evidence synthesisMen starting radiotherapy can safely defer treatment for 3\u20136 mo.", [["PCa", "ANATOMY", 192, 195], ["Prostate cancer", "ANATOMY", 200, 215], ["PCa", "DISEASE", 192, 195], ["Prostate cancer", "DISEASE", 200, 215], ["patient", "ORGANISM", 103, 110], ["PCa", "CANCER", 192, 195], ["Prostate cancer", "CANCER", 200, 215], ["patient", "SPECIES", 103, 110], ["surgery", "TREATMENT", 4, 11], ["neoadjuvant ADT", "TREATMENT", 37, 52], ["radiotherapy in PCa", "TREATMENT", 176, 195], ["Prostate cancer", "PROBLEM", 200, 215], ["synthesisMen starting radiotherapy", "TREATMENT", 229, 263], ["treatment", "TREATMENT", 281, 290], ["cancer", "OBSERVATION", 209, 215]]], ["Hypofractionation (either moderate, 19\u201320 fractions over 3.8\u20134 wk [69], or extreme, five to seven fractions\u2014an stereotactic body radiotherapy approach) may decrease health care burden and patient SARS-CoV-2 exposure.", [["body", "ANATOMY", 124, 128], ["SARS", "DISEASE", 196, 200], ["body", "ORGANISM_SUBDIVISION", 124, 128], ["patient", "ORGANISM", 188, 195], ["patient", "SPECIES", 188, 195], ["Hypofractionation", "TEST", 0, 17], ["moderate, 19\u201320 fractions", "PROBLEM", 26, 51], ["seven fractions\u2014an stereotactic body radiotherapy approach", "TREATMENT", 92, 150], ["patient SARS", "PROBLEM", 188, 200], ["CoV", "PROBLEM", 201, 204], ["moderate", "OBSERVATION_MODIFIER", 26, 34]]], ["Neoadjuvant ADT allows safe deferral of radiotherapy until resolution of the current COVID-19\u2013related health care resource pressures.Summary ::: Metastatic PCa ::: Prostate cancer ::: Evidence synthesisPatients with metastatic PCa should commence treatment, prioritizing AR targeted therapies over chemotherapy.", [["Metastatic PCa", "ANATOMY", 145, 159], ["Prostate cancer", "ANATOMY", 164, 179], ["metastatic PCa", "ANATOMY", 216, 230], ["PCa", "DISEASE", 156, 159], ["Prostate cancer", "DISEASE", 164, 179], ["PCa", "DISEASE", 227, 230], ["Metastatic PCa", "CANCER", 145, 159], ["Prostate cancer", "CANCER", 164, 179], ["metastatic PCa", "CANCER", 216, 230], ["AR", "GENE_OR_GENE_PRODUCT", 271, 273], ["AR", "PROTEIN", 271, 273], ["Neoadjuvant ADT", "TREATMENT", 0, 15], ["radiotherapy", "TREATMENT", 40, 52], ["Prostate cancer", "PROBLEM", 164, 179], ["Evidence synthesisPatients", "PROBLEM", 184, 210], ["metastatic PCa", "TREATMENT", 216, 230], ["treatment", "TREATMENT", 247, 256], ["prioritizing AR targeted therapies", "TREATMENT", 258, 292], ["chemotherapy", "TREATMENT", 298, 310], ["cancer", "OBSERVATION", 173, 179], ["metastatic", "OBSERVATION_MODIFIER", 216, 226]]], ["Glucocorticoid use should be minimized and patients should be considered for longer-duration ADT injections.Summary ::: Localized kidney cancer (T1/2) ::: Kidney cancer ::: Evidence synthesisSurveillance of SRMs is safe.", [["kidney cancer", "ANATOMY", 130, 143], ["Kidney cancer", "ANATOMY", 155, 168], ["kidney cancer", "DISEASE", 130, 143], ["Kidney cancer", "DISEASE", 155, 168], ["Glucocorticoid", "SIMPLE_CHEMICAL", 0, 14], ["patients", "ORGANISM", 43, 51], ["kidney cancer", "CANCER", 130, 143], ["Kidney cancer", "CANCER", 155, 168], ["patients", "SPECIES", 43, 51], ["Glucocorticoid use", "TREATMENT", 0, 18], ["longer-duration ADT injections", "TREATMENT", 77, 107], ["Localized kidney cancer", "PROBLEM", 120, 143], ["Kidney cancer", "PROBLEM", 155, 168], ["Evidence synthesisSurveillance of SRMs", "PROBLEM", 173, 211], ["kidney", "ANATOMY", 130, 136], ["cancer", "OBSERVATION", 137, 143], ["cancer", "OBSERVATION", 162, 168], ["SRMs", "OBSERVATION", 207, 211]]], ["When treatment is necessary (ie, SRM growth over time), it should be delayed under the current circumstances.", [["treatment", "TREATMENT", 5, 14]]], ["Although there are fewer data regarding T1b and T2 disease, delays of 3\u20136 mo do not appear to affect outcomes adversely.Summary ::: Locally advanced kidney cancer (T3) ::: Kidney cancer ::: Evidence synthesisThe data are scant regarding the safety of delaying surgery in patients with \u2265 cT3 renal masses, in particular those with renal vein or IVC tumor thrombus involvement.", [["kidney cancer", "ANATOMY", 149, 162], ["Kidney cancer", "ANATOMY", 172, 185], ["cT3 renal masses", "ANATOMY", 287, 303], ["renal vein", "ANATOMY", 330, 340], ["IVC tumor thrombus", "ANATOMY", 344, 362], ["kidney cancer", "DISEASE", 149, 162], ["Kidney cancer", "DISEASE", 172, 185], ["renal vein or IVC tumor thrombus", "DISEASE", 330, 362], ["T1b", "CANCER", 40, 43], ["kidney cancer", "CANCER", 149, 162], ["Kidney cancer", "CANCER", 172, 185], ["patients", "ORGANISM", 271, 279], ["cT3 renal masses", "CANCER", 287, 303], ["renal vein", "MULTI-TISSUE_STRUCTURE", 330, 340], ["IVC tumor thrombus", "PATHOLOGICAL_FORMATION", 344, 362], ["patients", "SPECIES", 271, 279], ["T1b and T2 disease", "PROBLEM", 40, 58], ["Locally advanced kidney cancer", "PROBLEM", 132, 162], ["Kidney cancer", "PROBLEM", 172, 185], ["Evidence synthesis", "PROBLEM", 190, 208], ["The data", "TEST", 208, 216], ["delaying surgery", "TREATMENT", 251, 267], ["\u2265 cT3 renal masses", "PROBLEM", 285, 303], ["renal vein", "PROBLEM", 330, 340], ["IVC tumor thrombus involvement", "PROBLEM", 344, 374], ["advanced", "OBSERVATION_MODIFIER", 140, 148], ["kidney", "ANATOMY", 149, 155], ["cancer", "OBSERVATION", 156, 162], ["cancer", "OBSERVATION", 179, 185], ["synthesis", "OBSERVATION", 199, 208], ["renal", "ANATOMY", 291, 296], ["masses", "OBSERVATION", 297, 303], ["renal vein", "ANATOMY", 330, 340], ["IVC", "ANATOMY", 344, 347], ["tumor", "OBSERVATION", 348, 353], ["thrombus", "OBSERVATION", 354, 362]]], ["These patients should be prioritized for surgical intervention, given the locally advanced nature of their disease, unknown risk of delayed resection, and potential for significant symptomatic complications including bleeding and IVC occlusion.Summary ::: Cytoreductive nephrectomy in metastatic kidney cancer ::: Kidney cancer ::: Evidence synthesisIn the current landscape, upfront systemic therapy should be prioritized over CN in asymptomatic patients with metastatic kidney cancer.", [["IVC", "ANATOMY", 230, 233], ["metastatic kidney cancer", "ANATOMY", 285, 309], ["Kidney cancer", "ANATOMY", 314, 327], ["metastatic kidney cancer", "ANATOMY", 461, 485], ["bleeding", "DISEASE", 217, 225], ["IVC occlusion", "DISEASE", 230, 243], ["kidney cancer", "DISEASE", 296, 309], ["Kidney cancer", "DISEASE", 314, 327], ["kidney cancer", "DISEASE", 472, 485], ["patients", "ORGANISM", 6, 14], ["IVC", "MULTI-TISSUE_STRUCTURE", 230, 233], ["kidney cancer", "CANCER", 296, 309], ["Kidney cancer", "CANCER", 314, 327], ["patients", "ORGANISM", 447, 455], ["kidney cancer", "CANCER", 472, 485], ["CN", "PROTEIN", 428, 430], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 447, 455], ["surgical intervention", "TREATMENT", 41, 62], ["their disease", "PROBLEM", 101, 114], ["delayed resection", "TREATMENT", 132, 149], ["significant symptomatic complications", "PROBLEM", 169, 206], ["bleeding", "PROBLEM", 217, 225], ["IVC occlusion", "PROBLEM", 230, 243], ["Cytoreductive nephrectomy", "TREATMENT", 256, 281], ["metastatic kidney cancer", "PROBLEM", 285, 309], ["Kidney cancer", "PROBLEM", 314, 327], ["Evidence synthesis", "PROBLEM", 332, 350], ["upfront systemic therapy", "TREATMENT", 376, 400], ["metastatic kidney cancer", "PROBLEM", 461, 485], ["disease", "OBSERVATION", 107, 114], ["delayed", "OBSERVATION_MODIFIER", 132, 139], ["resection", "OBSERVATION", 140, 149], ["symptomatic", "OBSERVATION_MODIFIER", 181, 192], ["complications", "OBSERVATION", 193, 206], ["bleeding", "OBSERVATION", 217, 225], ["IVC", "ANATOMY", 230, 233], ["occlusion", "OBSERVATION", 234, 243], ["nephrectomy", "OBSERVATION", 270, 281], ["metastatic", "OBSERVATION_MODIFIER", 285, 295], ["kidney", "ANATOMY", 296, 302], ["cancer", "OBSERVATION", 303, 309], ["cancer", "OBSERVATION", 321, 327], ["synthesis", "OBSERVATION", 341, 350], ["metastatic", "OBSERVATION_MODIFIER", 461, 471], ["kidney", "ANATOMY", 472, 478], ["cancer", "OBSERVATION", 479, 485]]], ["Nephrectomy should be reserved for symptomatic patients.Summary ::: Metastatic RCC ::: Kidney cancer ::: Evidence synthesisPatients with treatment-na\u00efve favorable- and intermediate-risk disease who are asymptomatic or minimally symptomatic with limited disease burden may be considered for AS until disease progression during the COVID-19 pandemic.", [["Metastatic RCC", "ANATOMY", 68, 82], ["Kidney cancer", "ANATOMY", 87, 100], ["RCC", "DISEASE", 79, 82], ["Kidney cancer", "DISEASE", 87, 100], ["patients", "ORGANISM", 47, 55], ["Metastatic RCC", "CANCER", 68, 82], ["Kidney cancer", "CANCER", 87, 100], ["patients", "SPECIES", 47, 55], ["Nephrectomy", "TREATMENT", 0, 11], ["Metastatic RCC", "PROBLEM", 68, 82], ["Kidney cancer", "PROBLEM", 87, 100], ["treatment", "TREATMENT", 137, 146], ["intermediate-risk disease", "PROBLEM", 168, 193], ["asymptomatic", "PROBLEM", 202, 214], ["minimally symptomatic", "PROBLEM", 218, 239], ["limited disease burden", "PROBLEM", 245, 267], ["disease progression", "PROBLEM", 299, 318], ["the COVID", "TEST", 326, 335], ["pandemic", "PROBLEM", 339, 347], ["cancer", "OBSERVATION", 94, 100]]], ["For poor-risk patients and those requiring treatment, there is no consensus regarding the optimal first-line therapy; however, VEGF targeted therapy is less likely to require toxicity-related hospitalization and/or glucocorticoids than immunotherapy regimens.Summary ::: Upper tract urothelial cancer ::: Evidence synthesisPatients with suspected UTUC may be initially investigated with urine cytology and CT urogram, forgoing diagnostic ureteroscopy unless there is considerable diagnostic uncertainty.", [["Upper tract urothelial cancer", "ANATOMY", 271, 300], ["urine", "ANATOMY", 387, 392], ["toxicity", "DISEASE", 175, 183], ["urothelial cancer", "DISEASE", 283, 300], ["UTUC", "DISEASE", 347, 351], ["patients", "ORGANISM", 14, 22], ["VEGF", "GENE_OR_GENE_PRODUCT", 127, 131], ["glucocorticoids", "SIMPLE_CHEMICAL", 215, 230], ["Upper tract urothelial cancer", "CANCER", 271, 300], ["UTUC", "CANCER", 347, 351], ["urine", "ORGANISM_SUBSTANCE", 387, 392], ["VEGF", "PROTEIN", 127, 131], ["patients", "SPECIES", 14, 22], ["treatment", "TREATMENT", 43, 52], ["first-line therapy", "TREATMENT", 98, 116], ["VEGF targeted therapy", "TREATMENT", 127, 148], ["toxicity", "PROBLEM", 175, 183], ["glucocorticoids", "TREATMENT", 215, 230], ["immunotherapy regimens", "TREATMENT", 236, 258], ["Upper tract urothelial cancer", "PROBLEM", 271, 300], ["suspected UTUC", "PROBLEM", 337, 351], ["urine cytology", "TEST", 387, 401], ["CT urogram", "TEST", 406, 416], ["diagnostic ureteroscopy", "TEST", 427, 450], ["tract", "ANATOMY_MODIFIER", 277, 282], ["urothelial", "ANATOMY", 283, 293], ["cancer", "OBSERVATION", 294, 300], ["UTUC", "OBSERVATION", 347, 351]]], ["Patients with low-grade UTUC are often managed with nephron-sparing approaches and thus are likely to have minimal to no risk with a surgical delay.", [["low-grade UTUC", "ANATOMY", 14, 28], ["nephron", "ANATOMY", 52, 59], ["UTUC", "DISEASE", 24, 28], ["Patients", "ORGANISM", 0, 8], ["low-grade UTUC", "CANCER", 14, 28], ["nephron", "MULTI-TISSUE_STRUCTURE", 52, 59], ["Patients", "SPECIES", 0, 8], ["low-grade UTUC", "PROBLEM", 14, 28], ["nephron-sparing approaches", "TREATMENT", 52, 78], ["a surgical delay", "PROBLEM", 131, 147], ["low-grade", "OBSERVATION_MODIFIER", 14, 23], ["UTUC", "OBSERVATION", 24, 28], ["surgical delay", "OBSERVATION", 133, 147]]], ["In patients with high-grade disease, delays of up to 12 wk may not be associated with changes in survival, despite worse pathologic outcomes.Summary ::: Testicular cancer ::: Evidence synthesisGuidelines and expert opinion recommend avoiding surgical delays for radical orchiectomy.", [["Testicular cancer", "ANATOMY", 153, 170], ["Testicular cancer", "DISEASE", 153, 170], ["patients", "ORGANISM", 3, 11], ["high-grade", "PATHOLOGICAL_FORMATION", 17, 27], ["Testicular cancer", "CANCER", 153, 170], ["patients", "SPECIES", 3, 11], ["high-grade disease", "PROBLEM", 17, 35], ["changes in survival", "PROBLEM", 86, 105], ["worse pathologic outcomes", "PROBLEM", 115, 140], ["Testicular cancer", "PROBLEM", 153, 170], ["surgical delays", "TREATMENT", 242, 257], ["radical orchiectomy", "TREATMENT", 262, 281], ["high-grade", "OBSERVATION_MODIFIER", 17, 27], ["disease", "OBSERVATION", 28, 35], ["cancer", "OBSERVATION", 164, 170], ["radical", "OBSERVATION_MODIFIER", 262, 269], ["orchiectomy", "OBSERVATION", 270, 281]]], ["The burden on the health care system is likely minimal, as these operations are short and routinely performed in a same-day surgical setting.", [["burden", "OBSERVATION_MODIFIER", 4, 10], ["likely", "UNCERTAINTY", 40, 46], ["minimal", "OBSERVATION_MODIFIER", 47, 54]]], ["Surveillance should be the preferred option for most patients with clinical stage I disease.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Surveillance", "TEST", 0, 12], ["clinical stage I disease", "PROBLEM", 67, 91]]], ["There are insufficient data to provide guidance on the effects of delaying postchemotherapy RPLND.", [["delaying postchemotherapy RPLND", "TREATMENT", 66, 97]]], ["Patients with intermediate and poor prognosis metastatic GCTs should receive chemotherapy without a delay.Summary ::: Penile cancer ::: Evidence synthesisWe were unable to identify studies assessing the risk of delayed intervention of the primary penile carcinoma; however, given the rarity of this malignancy, symptomatology, and high risk for metastatic progression, it seems reasonable to avoid delays in primary surgical treatment.", [["metastatic GCTs", "ANATOMY", 46, 61], ["Penile cancer", "ANATOMY", 118, 131], ["primary penile carcinoma", "ANATOMY", 239, 263], ["GCTs", "DISEASE", 57, 61], ["Penile cancer", "DISEASE", 118, 131], ["penile carcinoma", "DISEASE", 247, 263], ["malignancy", "DISEASE", 299, 309], ["Patients", "ORGANISM", 0, 8], ["GCTs", "CANCER", 57, 61], ["Penile cancer", "CANCER", 118, 131], ["penile carcinoma", "CANCER", 247, 263], ["malignancy", "CANCER", 299, 309], ["Patients", "SPECIES", 0, 8], ["intermediate and poor prognosis metastatic GCTs", "PROBLEM", 14, 61], ["chemotherapy", "TREATMENT", 77, 89], ["Penile cancer", "PROBLEM", 118, 131], ["studies", "TEST", 181, 188], ["delayed intervention", "TREATMENT", 211, 231], ["the primary penile carcinoma", "PROBLEM", 235, 263], ["this malignancy", "PROBLEM", 294, 309], ["symptomatology", "PROBLEM", 311, 325], ["metastatic progression", "PROBLEM", 345, 367], ["primary surgical treatment", "TREATMENT", 408, 434], ["intermediate", "OBSERVATION_MODIFIER", 14, 26], ["metastatic GCTs", "OBSERVATION", 46, 61], ["cancer", "OBSERVATION", 125, 131], ["primary", "OBSERVATION_MODIFIER", 239, 246], ["penile", "ANATOMY", 247, 253], ["carcinoma", "OBSERVATION", 254, 263], ["malignancy", "OBSERVATION", 299, 309], ["metastatic", "OBSERVATION", 345, 355]]], ["Additionally, inguinal lymphadenectomy for men with clinicopathologic indications should occur within 3 mo of treating the primary lesion.Role of clinical trials during the COVID-19 pandemic ::: Evidence synthesisClinical trials represent a key platform of comprehensive cancer centers and may provide unique therapeutic options in patients with aggressive malignancies with limited standard therapies.", [["inguinal", "ANATOMY", 14, 22], ["primary lesion", "ANATOMY", 123, 137], ["cancer", "ANATOMY", 271, 277], ["malignancies", "ANATOMY", 357, 369], ["cancer", "DISEASE", 271, 277], ["malignancies", "DISEASE", 357, 369], ["men", "ORGANISM", 43, 46], ["lesion", "CANCER", 131, 137], ["cancer", "CANCER", 271, 277], ["patients", "ORGANISM", 332, 340], ["malignancies", "CANCER", 357, 369], ["men", "SPECIES", 43, 46], ["patients", "SPECIES", 332, 340], ["inguinal lymphadenectomy", "TREATMENT", 14, 38], ["clinicopathologic indications", "TREATMENT", 52, 81], ["the primary lesion", "PROBLEM", 119, 137], ["the COVID", "TEST", 169, 178], ["synthesisClinical trials", "TREATMENT", 204, 228], ["aggressive malignancies", "PROBLEM", 346, 369], ["limited standard therapies", "TREATMENT", 375, 401], ["inguinal", "ANATOMY", 14, 22], ["lymphadenectomy", "OBSERVATION", 23, 38], ["primary", "OBSERVATION_MODIFIER", 123, 130], ["lesion", "OBSERVATION", 131, 137], ["cancer", "OBSERVATION", 271, 277]]], ["These opportunities may still be provided to patients during the COVID-19 outbreak, but likely require thorough evaluation on a case-by-case basis [119].Role of clinical trials during the COVID-19 pandemic ::: Evidence synthesisConsiderations should be made as to whether clinical investigators and supporting staff are able to comply safely with the trial requirements and guarantee patients\u2019 compliance.", [["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 384, 392], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 384, 392], ["thorough evaluation", "TEST", 103, 122], ["the COVID", "TEST", 184, 193], ["Evidence synthesis", "PROBLEM", 210, 228], ["the trial requirements", "TREATMENT", 347, 369]]], ["Furthermore, a patient\u2019s ability and risk to travel for therapy during a time of rigorous social distancing and household quarantine must be considered.", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22], ["therapy", "TREATMENT", 56, 63], ["rigorous social distancing and household quarantine", "TREATMENT", 81, 132]]], ["In an attempt to offer optimal therapeutic options with inclusion in clinical trials, investigators should carefully evaluate the risks of adding extra delays in treatment initiation due to administrative issues or bureaucratic constraint related to COVID-19 pandemic and extra visits requiring travel associated with a higher risk of infection in this mostly vulnerable population.", [["infection", "DISEASE", 335, 344], ["optimal therapeutic options", "TREATMENT", 23, 50], ["extra delays", "TREATMENT", 146, 158], ["treatment initiation", "TREATMENT", 162, 182], ["administrative issues", "PROBLEM", 190, 211], ["bureaucratic constraint", "PROBLEM", 215, 238], ["infection", "PROBLEM", 335, 344], ["infection", "OBSERVATION", 335, 344]]], ["Early evidence from China has suggested that investigators who continue to enroll to clinical trials during the COVID-19 pandemic should expect frequent protocol violations, with an average deviation of 27 \u00b1 13 d [120].ConclusionsWhile acknowledging the significant psychologic burden associated with a cancer diagnosis, likely magnified by delays in treatment, physicians who treat cancer patients must be good stewards of limited health care resources, particularly in the time of a pandemic.", [["cancer", "ANATOMY", 303, 309], ["cancer", "ANATOMY", 383, 389], ["cancer", "DISEASE", 303, 309], ["cancer", "DISEASE", 383, 389], ["cancer", "CANCER", 303, 309], ["cancer", "CANCER", 383, 389], ["patients", "ORGANISM", 390, 398], ["patients", "SPECIES", 390, 398], ["the COVID", "TEST", 108, 117], ["frequent protocol violations", "TREATMENT", 144, 172], ["the significant psychologic burden", "PROBLEM", 250, 284], ["a cancer diagnosis", "PROBLEM", 301, 319], ["cancer", "PROBLEM", 383, 389], ["a pandemic", "PROBLEM", 483, 493], ["significant", "OBSERVATION_MODIFIER", 254, 265], ["cancer", "OBSERVATION", 303, 309]]], ["As a result, it is important to prioritize the timely care of patients for whom delays are most likely to result in adverse outcomes, also taking into account the patient\u2019s age, comorbidities, symptoms, and life expectancy.", [["patients", "ORGANISM", 62, 70], ["patient", "ORGANISM", 163, 170], ["patients", "SPECIES", 62, 70], ["patient", "SPECIES", 163, 170], ["comorbidities", "PROBLEM", 178, 191], ["symptoms", "PROBLEM", 193, 201], ["most likely", "UNCERTAINTY", 91, 102]]], ["This review aims to assist with case triage and patient counseling by summarizing the available data on outcomes of delays in treatment for patients with urologic cancers.Conclusions", [["urologic cancers", "ANATOMY", 154, 170], ["urologic cancers", "DISEASE", 154, 170], ["patient", "ORGANISM", 48, 55], ["patients", "ORGANISM", 140, 148], ["urologic cancers", "CANCER", 154, 170], ["patient", "SPECIES", 48, 55], ["patients", "SPECIES", 140, 148], ["case triage", "TEST", 32, 43], ["treatment", "TREATMENT", 126, 135], ["urologic cancers", "PROBLEM", 154, 170], ["cancers", "OBSERVATION", 163, 170]]]], "e4fb6fce3ea15fc45aa63cd75ead9343943bfa5f": [["cells, indicating that ACE2 is likely the cell receptor of SARS-CoV-2 .", [["cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 42, 46], ["cells", "CELL", 0, 5], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["cell", "CELL", 42, 46], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 59, 69], ["cells", "CELL_TYPE", 0, 5], ["ACE2", "PROTEIN", 23, 27], ["ACE2", "TEST", 23, 27], ["CoV", "TEST", 64, 67]]], ["McLellan et al. showed biophysical and structural evidence that SARS-CoV-2 S protein binds ACE2 with higher affinity than SARS-CoV S protein (Wrapp et al. 2020) .", [["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 64, 76], ["ACE2", "GENE_OR_GENE_PRODUCT", 91, 95], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 122, 132], ["SARS-CoV-2 S protein", "PROTEIN", 64, 84], ["ACE2", "PROTEIN", 91, 95], ["SARS-CoV S protein", "PROTEIN", 122, 140], ["SARS-CoV", "SPECIES", 122, 130], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72], ["ACE2", "TEST", 91, 95], ["higher affinity", "PROBLEM", 101, 116], ["SARS", "TEST", 122, 126], ["CoV S protein", "TEST", 127, 140]]]], "f9705ccb796ba4f9957491623f765dfe8c5b4cf6": [["IntroductionSeroprevalence studies in children and adults indicate that human metapneumovirus (HMPV) is not an emerging virus, but a newly recognized pathogen that may mediate serious lower respiratory tract illness in very young children, the elderly and immunocompromised patients [1] [2] [3] .", [["lower respiratory tract", "ANATOMY", 184, 207], ["human metapneumovirus", "DISEASE", 72, 93], ["lower respiratory tract illness", "DISEASE", 184, 215], ["children", "ORGANISM", 38, 46], ["human metapneumovirus", "ORGANISM", 72, 93], ["HMPV", "ORGANISM", 95, 99], ["lower", "ORGANISM_SUBDIVISION", 184, 189], ["respiratory tract", "ORGANISM_SUBDIVISION", 190, 207], ["children", "ORGANISM", 230, 238], ["patients", "ORGANISM", 274, 282], ["children", "SPECIES", 38, 46], ["human", "SPECIES", 72, 77], ["metapneumovirus", "SPECIES", 78, 93], ["children", "SPECIES", 230, 238], ["patients", "SPECIES", 274, 282], ["human metapneumovirus", "SPECIES", 72, 93], ["HMPV", "SPECIES", 95, 99], ["Seroprevalence studies", "TEST", 12, 34], ["human metapneumovirus (HMPV", "PROBLEM", 72, 99], ["an emerging virus", "PROBLEM", 108, 125], ["serious lower respiratory tract illness", "PROBLEM", 176, 215], ["metapneumovirus", "OBSERVATION", 78, 93], ["respiratory tract", "ANATOMY", 190, 207]]], ["The virus has been circulating in the population for at least 50 years [1].", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["circulating", "OBSERVATION_MODIFIER", 19, 30]]], ["Infectious HMPV can be isolated from nasopharyngeal aspirates [4, 5] suggesting that infection is associated with the respiratory epithelium; however, the mechanisms contributing to infection, the cells targeted for infection, the host response to infection, and the pathophysiology associated with infec-tion are not well understood.", [["nasopharyngeal aspirates", "ANATOMY", 37, 61], ["respiratory epithelium", "ANATOMY", 118, 140], ["cells", "ANATOMY", 197, 202], ["infection", "DISEASE", 85, 94], ["infection", "DISEASE", 182, 191], ["infection", "DISEASE", 216, 225], ["infection", "DISEASE", 248, 257], ["HMPV", "ORGANISM", 11, 15], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 37, 61], ["epithelium", "TISSUE", 130, 140], ["cells", "CELL", 197, 202], ["HMPV", "SPECIES", 11, 15], ["Infectious HMPV", "PROBLEM", 0, 15], ["nasopharyngeal aspirates", "PROBLEM", 37, 61], ["infection", "PROBLEM", 85, 94], ["the respiratory epithelium", "PROBLEM", 114, 140], ["infection", "PROBLEM", 182, 191], ["the cells", "PROBLEM", 193, 202], ["infection", "PROBLEM", 216, 225], ["infection", "PROBLEM", 248, 257], ["nasopharyngeal", "ANATOMY", 37, 51], ["aspirates", "OBSERVATION", 52, 61], ["infection", "OBSERVATION", 85, 94], ["respiratory epithelium", "OBSERVATION", 118, 140], ["infection", "OBSERVATION", 182, 191], ["infection", "OBSERVATION", 248, 257]]], ["Based on genetic and clinical similarities between HMPV and respiratory syncytial virus (RSV) [6, 7] , it is likely that HMPV and RSV proteins have similar functions related to replication, pathophysiology and immunity.", [["respiratory syncytial virus", "DISEASE", 60, 87], ["HMPV", "ORGANISM", 51, 55], ["respiratory syncytial virus", "ORGANISM", 60, 87], ["RSV", "ORGANISM", 89, 92], ["HMPV", "ORGANISM", 121, 125], ["RSV", "ORGANISM", 130, 133], ["RSV proteins", "PROTEIN", 130, 142], ["respiratory syncytial virus", "SPECIES", 60, 87], ["respiratory syncytial virus", "SPECIES", 60, 87], ["RSV", "SPECIES", 89, 92], ["HMPV", "SPECIES", 121, 125], ["RSV", "SPECIES", 130, 133], ["HMPV", "PROBLEM", 51, 55], ["respiratory syncytial virus", "PROBLEM", 60, 87], ["HMPV", "PROBLEM", 121, 125], ["RSV proteins", "PROBLEM", 130, 142], ["respiratory syncytial", "ANATOMY", 60, 81], ["is likely", "UNCERTAINTY", 106, 115], ["HMPV", "OBSERVATION", 121, 125]]], ["The current perspective on these processes and HMPV and RSV proteins is discussed.Incidence of HMPV infectionsSeroprevalence studies have shown that HMPV has worldwide distribution, is acquired early in life, and by the age of 5 years, approximately 70% of all children develop antibodies to HMPV [1, [8] [9] [10] .", [["HMPV infections", "DISEASE", 95, 110], ["HMPV", "DISEASE", 292, 296], ["HMPV", "ORGANISM", 47, 51], ["RSV", "ORGANISM", 56, 59], ["HMPV", "ORGANISM", 95, 99], ["HMPV", "ORGANISM", 149, 153], ["children", "ORGANISM", 261, 269], ["HMPV and RSV proteins", "PROTEIN", 47, 68], ["antibodies", "PROTEIN", 278, 288], ["children", "SPECIES", 261, 269], ["HMPV", "SPECIES", 47, 51], ["RSV", "SPECIES", 56, 59], ["HMPV", "SPECIES", 95, 99], ["HMPV", "SPECIES", 149, 153], ["HMPV", "SPECIES", 292, 296], ["HMPV", "PROBLEM", 47, 51], ["RSV proteins", "TREATMENT", 56, 68], ["HMPV infections", "PROBLEM", 95, 110], ["Seroprevalence studies", "TEST", 110, 132], ["HMPV", "PROBLEM", 149, 153], ["HMPV", "TEST", 292, 296], ["HMPV", "OBSERVATION", 47, 51], ["HMPV infections", "OBSERVATION", 95, 110], ["HMPV", "OBSERVATION", 149, 153]]], ["HMPV is often identified in isolates from children hospitalized with acute respiratory tract illness, is associated with clinical diagnosis of pneumonia, asthma exacerbation, and acute bronchiolitis ([1-5, [11] [12] [13] [14] [15] [16] [17] Nissen, unpublished data).", [["respiratory tract", "ANATOMY", 75, 92], ["acute respiratory tract illness", "DISEASE", 69, 100], ["pneumonia", "DISEASE", 143, 152], ["asthma", "DISEASE", 154, 160], ["bronchiolitis", "DISEASE", 185, 198], ["1-5, [11", "CHEMICAL", 201, 209], ["HMPV", "ORGANISM", 0, 4], ["children", "ORGANISM", 42, 50], ["tract", "ORGANISM_SUBDIVISION", 87, 92], ["[11] [12] [13] [14] [15] [16] [17] Nissen", "SIMPLE_CHEMICAL", 206, 247], ["children", "SPECIES", 42, 50], ["HMPV", "SPECIES", 0, 4], ["HMPV", "PROBLEM", 0, 4], ["acute respiratory tract illness", "PROBLEM", 69, 100], ["pneumonia", "PROBLEM", 143, 152], ["asthma exacerbation", "PROBLEM", 154, 173], ["acute bronchiolitis", "PROBLEM", 179, 198], ["Nissen", "TREATMENT", 241, 247], ["respiratory tract", "ANATOMY", 75, 92], ["pneumonia", "OBSERVATION", 143, 152], ["asthma", "OBSERVATION", 154, 160], ["acute", "OBSERVATION_MODIFIER", 179, 184], ["bronchiolitis", "OBSERVATION", 185, 198]]], ["For example, the incidence of HMPV in the Dutch population during the winter months of 2000 was approximately 10% [1]; however, prospective observation for HMPV disease worldwide has shown a wide range of incidence from 1.5% to 41% [9, 11] .", [["HMPV", "DISEASE", 30, 34], ["HMPV disease", "DISEASE", 156, 168], ["HMPV", "ORGANISM", 30, 34], ["HMPV", "ORGANISM", 156, 160], ["HMPV", "SPECIES", 30, 34], ["HMPV", "SPECIES", 156, 160], ["HMPV", "PROBLEM", 30, 34], ["prospective observation", "TEST", 128, 151], ["HMPV disease", "PROBLEM", 156, 168], ["HMPV", "OBSERVATION", 30, 34], ["wide", "OBSERVATION_MODIFIER", 191, 195]]], ["HMPV primarily afflicts children younger than 2 years of age, in particular, those younger than 12 months of age ([1,8] Nissen, unpublished data).", [["HMPV", "DISEASE", 0, 4], ["HMPV", "ORGANISM", 0, 4], ["children", "ORGANISM", 24, 32], ["children", "SPECIES", 24, 32], ["HMPV", "SPECIES", 0, 4], ["HMPV", "PROBLEM", 0, 4], ["Nissen", "TREATMENT", 120, 126]]], ["Several reports of HMPV infection in children have shown a trend toward infection in males compared to females ([1,8] Nissen, unpublished data).", [["HMPV infection", "DISEASE", 19, 33], ["infection", "DISEASE", 72, 81], ["HMPV", "ORGANISM", 19, 23], ["children", "ORGANISM", 37, 45], ["children", "SPECIES", 37, 45], ["HMPV", "SPECIES", 19, 23], ["HMPV infection", "PROBLEM", 19, 33], ["infection in males", "PROBLEM", 72, 90], ["Nissen", "TREATMENT", 118, 124], ["HMPV", "OBSERVATION_MODIFIER", 19, 23], ["infection", "OBSERVATION", 24, 33], ["infection", "OBSERVATION", 72, 81]]], ["HMPV infection in older children and adults has been observed, particularly in immunocompromised and transplant patients, or those having a pre-existing chronic lung condition [16, 17] .", [["lung", "ANATOMY", 161, 165], ["HMPV infection", "DISEASE", 0, 14], ["HMPV", "ORGANISM", 0, 4], ["children", "ORGANISM", 24, 32], ["patients", "ORGANISM", 112, 120], ["lung", "ORGAN", 161, 165], ["children", "SPECIES", 24, 32], ["patients", "SPECIES", 112, 120], ["HMPV", "SPECIES", 0, 4], ["HMPV infection", "PROBLEM", 0, 14], ["a pre-existing chronic lung condition", "PROBLEM", 138, 175], ["infection", "OBSERVATION", 5, 14], ["chronic", "OBSERVATION_MODIFIER", 153, 160], ["lung", "ANATOMY", 161, 165], ["condition", "OBSERVATION", 166, 175]]], ["HMPV has also been identified as a potentially significant pathogen in transplant patients [18] .", [["HMPV", "ORGANISM", 0, 4], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["HMPV", "SPECIES", 0, 4], ["HMPV", "PROBLEM", 0, 4], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["pathogen", "OBSERVATION", 59, 67]]], ["Little is known regarding the impact of differing socio-economic environments on the age of first infection with HMPV, or about the impact on disease severity.Seasonal patternsThe seasonality of HMPV epidemics appears to follow a similar trend to RSV having a seasonal period from winter to spring [19, 20] .", [["infection", "DISEASE", 98, 107], ["HMPV", "DISEASE", 113, 117], ["HMPV epidemics", "DISEASE", 195, 209], ["RSV", "DISEASE", 247, 250], ["HMPV", "ORGANISM", 113, 117], ["HMPV", "ORGANISM", 195, 199], ["RSV", "ORGANISM", 247, 250], ["HMPV", "SPECIES", 113, 117], ["HMPV", "SPECIES", 195, 199], ["RSV", "SPECIES", 247, 250], ["first infection", "PROBLEM", 92, 107], ["HMPV", "PROBLEM", 113, 117], ["disease severity", "PROBLEM", 142, 158], ["Seasonal patterns", "PROBLEM", 159, 176], ["HMPV epidemics", "PROBLEM", 195, 209], ["infection", "OBSERVATION", 98, 107], ["disease", "OBSERVATION", 142, 149], ["HMPV", "OBSERVATION", 195, 199]]], ["Although the disease burden of HMPV is not fully understood, it appears that the appearance of HMPV in the community tends to follow the presence of RSV and influenza which occur in early to mid-winter, but precedes that of Parainfluenza virus 3 (PIV 3) disease activity which generally occurs in late spring to early summer (Nissen, unpublished data).Strain variationLittle is known regarding strain variation and disease pathogenesis associated with HMPV infection.", [["HMPV", "DISEASE", 31, 35], ["HMPV", "DISEASE", 95, 99], ["RSV", "DISEASE", 149, 152], ["influenza", "DISEASE", 157, 166], ["HMPV infection", "DISEASE", 452, 466], ["HMPV", "ORGANISM", 31, 35], ["HMPV", "ORGANISM", 95, 99], ["RSV", "ORGANISM", 149, 152], ["Parainfluenza virus 3", "ORGANISM", 224, 245], ["PIV 3", "ORGANISM", 247, 252], ["HMPV", "ORGANISM", 452, 456], ["Parainfluenza virus", "SPECIES", 224, 243], ["HMPV", "SPECIES", 31, 35], ["HMPV", "SPECIES", 95, 99], ["RSV", "SPECIES", 149, 152], ["Parainfluenza virus", "SPECIES", 224, 243], ["HMPV", "SPECIES", 452, 456], ["the disease burden of HMPV", "PROBLEM", 9, 35], ["HMPV", "PROBLEM", 95, 99], ["RSV", "PROBLEM", 149, 152], ["influenza", "PROBLEM", 157, 166], ["Parainfluenza virus", "PROBLEM", 224, 243], ["PIV", "TREATMENT", 247, 250], ["disease activity", "PROBLEM", 254, 270], ["Nissen", "TREATMENT", 326, 332], ["Strain variationLittle", "PROBLEM", 352, 374], ["strain variation", "PROBLEM", 394, 410], ["disease pathogenesis", "PROBLEM", 415, 435], ["HMPV infection", "PROBLEM", 452, 466], ["disease", "OBSERVATION", 13, 20], ["HMPV", "OBSERVATION", 31, 35], ["HMPV", "OBSERVATION", 95, 99], ["RSV", "OBSERVATION", 149, 152], ["influenza", "OBSERVATION", 157, 166], ["HMPV", "OBSERVATION_MODIFIER", 452, 456], ["infection", "OBSERVATION", 457, 466]]], ["Mounting evidence suggests that both strain A and B HMPV cause annual outbreaks of infection [16, 21] , and this may be mediated by one or more of the four known sub-lineages (A1, A2, B1, B2) of HMPV [22] .", [["infection", "DISEASE", 83, 92], ["B HMPV", "ORGANISM", 50, 56], ["A2", "GENE_OR_GENE_PRODUCT", 180, 182], ["B2", "GENE_OR_GENE_PRODUCT", 188, 190], ["HMPV", "ORGANISM", 195, 199], ["A1", "PROTEIN", 176, 178], ["A2", "PROTEIN", 180, 182], ["B1", "PROTEIN", 184, 186], ["B2", "PROTEIN", 188, 190], ["B HMPV", "SPECIES", 50, 56], ["HMPV", "SPECIES", 195, 199], ["both strain A and B HMPV", "PROBLEM", 32, 56], ["infection", "PROBLEM", 83, 92], ["HMPV", "PROBLEM", 195, 199], ["infection", "OBSERVATION", 83, 92]]], ["Similar to RSV [23] [24] [25] , the predominance of a HMPV strain circulating in the community may be related to amino acid sequence variation in surface protein genes; however, the mechanisms affecting immunity and virus replication are not fully understood.", [["surface", "ANATOMY", 146, 153], ["amino acid", "CHEMICAL", 113, 123], ["amino acid", "CHEMICAL", 113, 123], ["RSV", "ORGANISM", 11, 14], ["HMPV", "ORGANISM", 54, 58], ["amino acid", "AMINO_ACID", 113, 123], ["surface protein genes", "DNA", 146, 167], ["RSV", "SPECIES", 11, 14], ["RSV", "TEST", 11, 14], ["a HMPV strain circulating", "PROBLEM", 52, 77], ["amino acid sequence variation in surface protein genes", "PROBLEM", 113, 167], ["virus replication", "TREATMENT", 216, 233], ["RSV", "OBSERVATION", 11, 14], ["HMPV strain", "OBSERVATION", 54, 65], ["may be related to", "UNCERTAINTY", 95, 112], ["amino acid", "OBSERVATION", 113, 123], ["surface", "OBSERVATION_MODIFIER", 146, 153], ["protein genes", "OBSERVATION", 154, 167]]], ["There is some evidence that HMPV does not elicit a cross-protective immune response [26] , and can persist as infectious virus in the lungs of mice despite the presence of neutralizing antibodies [27] .Route of transmissionThe route of transmission of HMPV infection in the community has yet to be determined, but is likely similar to the pattern described for RSV where the infection may be introduced via an older family member [28] via respiratory droplets as occurs with RSV [29] , or by hand-to-mouth or handto-eye contact with contaminated surfaces [30] .Clinical featuresThe spectrum and severity of acute clinical disease associated with HMPV infection compared to RSV has been inves-tigated in small groups of patients.", [["lungs", "ANATOMY", 134, 139], ["respiratory droplets", "ANATOMY", 439, 459], ["hand", "ANATOMY", 492, 496], ["mouth", "ANATOMY", 500, 505], ["eye", "ANATOMY", 516, 519], ["HMPV infection", "DISEASE", 252, 266], ["infection", "DISEASE", 375, 384], ["HMPV infection", "DISEASE", 646, 660], ["RSV", "DISEASE", 673, 676], ["HMPV", "ORGANISM", 28, 32], ["lungs", "ORGAN", 134, 139], ["mice", "ORGANISM", 143, 147], ["HMPV", "ORGANISM", 252, 256], ["RSV", "ORGANISM", 361, 364], ["RSV", "ORGANISM", 475, 478], ["mouth", "ORGANISM_SUBDIVISION", 500, 505], ["eye", "ORGANISM_SUBDIVISION", 516, 519], ["HMPV", "ORGANISM", 646, 650], ["RSV", "ORGANISM", 673, 676], ["patients", "ORGANISM", 719, 727], ["neutralizing antibodies", "PROTEIN", 172, 195], ["mice", "SPECIES", 143, 147], ["patients", "SPECIES", 719, 727], ["HMPV", "SPECIES", 28, 32], ["mice", "SPECIES", 143, 147], ["HMPV", "SPECIES", 252, 256], ["RSV", "SPECIES", 361, 364], ["RSV", "SPECIES", 475, 478], ["HMPV", "SPECIES", 646, 650], ["RSV", "SPECIES", 673, 676], ["HMPV", "PROBLEM", 28, 32], ["infectious virus", "PROBLEM", 110, 126], ["neutralizing antibodies", "PROBLEM", 172, 195], ["HMPV infection", "PROBLEM", 252, 266], ["RSV", "PROBLEM", 361, 364], ["the infection", "PROBLEM", 371, 384], ["respiratory droplets", "TREATMENT", 439, 459], ["RSV", "PROBLEM", 475, 478], ["Clinical features", "PROBLEM", 561, 578], ["acute clinical disease", "PROBLEM", 607, 629], ["HMPV infection", "PROBLEM", 646, 660], ["RSV", "PROBLEM", 673, 676], ["HMPV", "OBSERVATION", 28, 32], ["infectious", "OBSERVATION", 110, 120], ["lungs", "ANATOMY", 134, 139], ["HMPV", "OBSERVATION_MODIFIER", 252, 256], ["infection", "OBSERVATION", 257, 266], ["infection", "OBSERVATION", 375, 384], ["mouth", "ANATOMY", 500, 505], ["eye", "ANATOMY", 516, 519], ["acute", "OBSERVATION_MODIFIER", 607, 612], ["clinical disease", "OBSERVATION", 613, 629], ["HMPV infection", "OBSERVATION", 646, 660], ["small", "OBSERVATION_MODIFIER", 703, 708]]], ["In the original report by van den Hoogen et al., the clinical symptoms described were largely similar to those caused by RSV which included a range of clinical features from mild respiratory problems to bronchiolitis, severe cough, high fever, myalgia, and pneumonia [1] .", [["respiratory", "ANATOMY", 179, 190], ["RSV", "DISEASE", 121, 124], ["respiratory problems", "DISEASE", 179, 199], ["bronchiolitis", "DISEASE", 203, 216], ["cough", "DISEASE", 225, 230], ["fever", "DISEASE", 237, 242], ["myalgia", "DISEASE", 244, 251], ["pneumonia", "DISEASE", 257, 266], ["RSV", "ORGANISM", 121, 124], ["RSV", "SPECIES", 121, 124], ["the clinical symptoms", "PROBLEM", 49, 70], ["RSV", "PROBLEM", 121, 124], ["clinical features", "PROBLEM", 151, 168], ["mild respiratory problems", "PROBLEM", 174, 199], ["bronchiolitis", "PROBLEM", 203, 216], ["severe cough", "PROBLEM", 218, 230], ["high fever", "PROBLEM", 232, 242], ["myalgia", "PROBLEM", 244, 251], ["pneumonia", "PROBLEM", 257, 266], ["RSV", "OBSERVATION", 121, 124], ["mild", "OBSERVATION_MODIFIER", 174, 178], ["respiratory problems", "OBSERVATION", 179, 199], ["bronchiolitis", "OBSERVATION", 203, 216], ["severe", "OBSERVATION_MODIFIER", 218, 224], ["cough", "OBSERVATION", 225, 230], ["high", "OBSERVATION_MODIFIER", 232, 236], ["fever", "OBSERVATION", 237, 242], ["myalgia", "OBSERVATION", 244, 251], ["pneumonia", "OBSERVATION", 257, 266]]], ["Other studies have confirmed this initial description, and shown that HMPV as an important lower respiratory tract pathogen in children that is difficult to distinguish clinically from RSV ([1, 16, 31] Nissen, unpublished data).", [["lower respiratory tract", "ANATOMY", 91, 114], ["RSV", "DISEASE", 185, 188], ["HMPV", "ORGANISM", 70, 74], ["lower", "ORGANISM_SUBDIVISION", 91, 96], ["respiratory tract", "ORGANISM_SUBDIVISION", 97, 114], ["children", "ORGANISM", 127, 135], ["RSV", "ORGANISM", 185, 188], ["children", "SPECIES", 127, 135], ["HMPV", "SPECIES", 70, 74], ["RSV", "SPECIES", 185, 188], ["Other studies", "TEST", 0, 13], ["HMPV", "PROBLEM", 70, 74], ["an important lower respiratory tract pathogen", "PROBLEM", 78, 123], ["RSV", "PROBLEM", 185, 188], ["Nissen", "TREATMENT", 202, 208], ["HMPV", "OBSERVATION", 70, 74], ["respiratory tract", "ANATOMY", 97, 114]]], ["In general, acute HMPV infection appears to be less severe than that caused by RSV; however, HMPV infection has been associated with several cases of severe pneumonitis leading to death ( [16] [17] [18] Nissen, unpublished data).Clinical featuresSome of the clinical features of HMPV disease in young hospitalized children are compared with the clinical features of young children hospitalized with RSV disease (Table 1) .", [["HMPV infection", "DISEASE", 18, 32], ["RSV", "DISEASE", 79, 82], ["HMPV infection", "DISEASE", 93, 107], ["pneumonitis", "DISEASE", 157, 168], ["death", "DISEASE", 180, 185], ["HMPV disease", "DISEASE", 279, 291], ["RSV disease", "DISEASE", 399, 410], ["HMPV", "ORGANISM", 18, 22], ["RSV", "ORGANISM", 79, 82], ["HMPV", "ORGANISM", 93, 97], ["HMPV", "ORGANISM", 279, 283], ["children", "ORGANISM", 314, 322], ["children", "ORGANISM", 372, 380], ["RSV", "ORGANISM", 399, 402], ["children", "SPECIES", 314, 322], ["children", "SPECIES", 372, 380], ["HMPV", "SPECIES", 18, 22], ["RSV", "SPECIES", 79, 82], ["HMPV", "SPECIES", 93, 97], ["HMPV", "SPECIES", 279, 283], ["RSV", "SPECIES", 399, 402], ["acute HMPV infection", "PROBLEM", 12, 32], ["RSV", "PROBLEM", 79, 82], ["HMPV infection", "PROBLEM", 93, 107], ["severe pneumonitis", "PROBLEM", 150, 168], ["death", "PROBLEM", 180, 185], ["Nissen", "TREATMENT", 203, 209], ["HMPV disease", "PROBLEM", 279, 291], ["RSV disease", "PROBLEM", 399, 410], ["acute", "OBSERVATION_MODIFIER", 12, 17], ["HMPV", "OBSERVATION", 18, 22], ["infection", "OBSERVATION", 23, 32], ["less severe", "OBSERVATION_MODIFIER", 47, 58], ["RSV", "OBSERVATION", 79, 82], ["infection", "OBSERVATION", 98, 107], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["pneumonitis", "OBSERVATION", 157, 168], ["HMPV disease", "OBSERVATION", 279, 291]]], ["Common clinical features for HMPV infection may include bronchiolitis (27-59%), pneumonia (8-27%), virus associated asthma exacerbation (5-27%), laryngotracheobronchitis (croup) (3-18%), apnoea (12%), and otitis media (12%) ( [8, 22] Nissen, unpublished data).", [["HMPV infection", "DISEASE", 29, 43], ["bronchiolitis", "DISEASE", 56, 69], ["pneumonia", "DISEASE", 80, 89], ["asthma", "DISEASE", 116, 122], ["laryngotracheobronchitis", "DISEASE", 145, 169], ["croup", "DISEASE", 171, 176], ["apnoea", "DISEASE", 187, 193], ["otitis", "DISEASE", 205, 211], ["HMPV", "ORGANISM", 29, 33], ["HMPV", "SPECIES", 29, 33], ["HMPV infection", "PROBLEM", 29, 43], ["bronchiolitis", "PROBLEM", 56, 69], ["pneumonia", "PROBLEM", 80, 89], ["virus associated asthma exacerbation", "PROBLEM", 99, 135], ["laryngotracheobronchitis (croup)", "PROBLEM", 145, 177], ["apnoea", "PROBLEM", 187, 193], ["otitis media", "PROBLEM", 205, 217], ["Nissen", "TREATMENT", 234, 240], ["HMPV", "OBSERVATION", 29, 33], ["bronchiolitis", "OBSERVATION", 56, 69], ["pneumonia", "OBSERVATION", 80, 89], ["asthma", "OBSERVATION", 116, 122], ["otitis", "OBSERVATION", 205, 211]]], ["When a chest radiograph was performed, abnormalities were noted in 39-84% of HMPV cases, with bilateral pneumonic infiltrates and hyperinflation the most frequent ( [8, 31] Nissen, unpublished data).", [["chest", "ANATOMY", 7, 12], ["HMPV", "DISEASE", 77, 81], ["HMPV", "ORGANISM", 77, 81], ["HMPV", "SPECIES", 77, 81], ["a chest radiograph", "TEST", 5, 23], ["abnormalities", "PROBLEM", 39, 52], ["HMPV cases", "TEST", 77, 87], ["bilateral pneumonic infiltrates", "PROBLEM", 94, 125], ["hyperinflation", "PROBLEM", 130, 144], ["Nissen", "TREATMENT", 173, 179], ["chest", "ANATOMY", 7, 12], ["bilateral", "ANATOMY_MODIFIER", 94, 103], ["pneumonic", "OBSERVATION_MODIFIER", 104, 113], ["infiltrates", "OBSERVATION", 114, 125], ["hyperinflation", "OBSERVATION", 130, 144]]], ["Acute complications associated with HMPV infection led to oxygen therapy (32-54%), intensive care admission (8-15%), or mechanical ventilation (5-8%) ([8] Nissen, unpublished data).", [["HMPV infection", "DISEASE", 36, 50], ["oxygen", "CHEMICAL", 58, 64], ["oxygen", "CHEMICAL", 58, 64], ["HMPV", "ORGANISM", 36, 40], ["oxygen", "SIMPLE_CHEMICAL", 58, 64], ["HMPV", "SPECIES", 36, 40], ["Acute complications", "PROBLEM", 0, 19], ["HMPV infection", "PROBLEM", 36, 50], ["oxygen therapy", "TREATMENT", 58, 72], ["mechanical ventilation", "TREATMENT", 120, 142], ["Nissen", "TREATMENT", 155, 161], ["complications", "OBSERVATION", 6, 19], ["HMPV infection", "OBSERVATION", 36, 50], ["oxygen therapy", "OBSERVATION", 58, 72], ["mechanical ventilation", "OBSERVATION", 120, 142]]], ["HMPV re-infection has been observed [17, 32] ; however little is known regarding the outcome of re-infection.", [["HMPV re-infection", "DISEASE", 0, 17], ["HMPV", "ORGANISM", 0, 4], ["HMPV", "SPECIES", 0, 4], ["HMPV re-infection", "PROBLEM", 0, 17], ["re-infection", "PROBLEM", 96, 108], ["re-infection", "OBSERVATION", 5, 17], ["re-infection", "OBSERVATION", 96, 108]]], ["Similar to RSV infection, a wide spectrum of potential risk factors for HMPV infection has been examined, but none have been conclusively linked with disease [8] .", [["RSV infection", "DISEASE", 11, 24], ["HMPV infection", "DISEASE", 72, 86], ["RSV", "ORGANISM", 11, 14], ["HMPV", "ORGANISM", 72, 76], ["RSV", "SPECIES", 11, 14], ["HMPV", "SPECIES", 72, 76], ["RSV infection", "PROBLEM", 11, 24], ["potential risk factors", "PROBLEM", 45, 67], ["HMPV infection", "PROBLEM", 72, 86], ["RSV", "OBSERVATION_MODIFIER", 11, 14], ["infection", "OBSERVATION", 15, 24], ["wide", "OBSERVATION_MODIFIER", 28, 32], ["infection", "OBSERVATION", 77, 86]]], ["There is mounting evidence that HMPV infection may lead to asthma or chronic lung disease [12, [32] [33] [34] , and it has been suggested that there may be an increased risk of post-infectious bronchial hyperreactivity following HMPV infection (Nissen, unpublished data) .", [["lung", "ANATOMY", 77, 81], ["bronchial", "ANATOMY", 193, 202], ["HMPV infection", "DISEASE", 32, 46], ["asthma", "DISEASE", 59, 65], ["chronic lung disease", "DISEASE", 69, 89], ["bronchial hyperreactivity", "DISEASE", 193, 218], ["HMPV infection", "DISEASE", 229, 243], ["HMPV", "ORGANISM", 32, 36], ["lung", "ORGAN", 77, 81], ["HMPV", "ORGANISM", 229, 233], ["HMPV", "SPECIES", 32, 36], ["HMPV", "SPECIES", 229, 233], ["HMPV infection", "PROBLEM", 32, 46], ["asthma", "PROBLEM", 59, 65], ["chronic lung disease", "PROBLEM", 69, 89], ["post-infectious bronchial hyperreactivity", "PROBLEM", 177, 218], ["HMPV infection", "PROBLEM", 229, 243], ["Nissen", "TREATMENT", 245, 251], ["HMPV", "OBSERVATION_MODIFIER", 32, 36], ["infection", "OBSERVATION", 37, 46], ["may lead to", "UNCERTAINTY", 47, 58], ["asthma", "OBSERVATION", 59, 65], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["lung", "ANATOMY", 77, 81], ["disease", "OBSERVATION", 82, 89], ["may be", "UNCERTAINTY", 149, 155], ["increased", "OBSERVATION_MODIFIER", 159, 168], ["post-infectious", "OBSERVATION_MODIFIER", 177, 192], ["bronchial", "ANATOMY", 193, 202], ["hyperreactivity", "OBSERVATION", 203, 218], ["HMPV infection", "OBSERVATION", 229, 243]]], ["However, there are conflicting reports to the contrary [31, 35] , thus it remains unclear if HMPV may cause or precipitate conditions related to asthma pathogenesis.Clinical featuresRSV infection is the most common cause of viral nosocomial infection in pediatric wards, and represents a significant additional burden on health care resources [36, 37] .", [["HMPV", "DISEASE", 93, 97], ["asthma", "DISEASE", 145, 151], ["featuresRSV infection", "DISEASE", 174, 195], ["viral nosocomial infection", "DISEASE", 224, 250], ["HMPV", "ORGANISM", 93, 97], ["HMPV", "SPECIES", 93, 97], ["HMPV", "PROBLEM", 93, 97], ["precipitate conditions", "PROBLEM", 111, 133], ["asthma pathogenesis", "PROBLEM", 145, 164], ["Clinical featuresRSV infection", "PROBLEM", 165, 195], ["viral nosocomial infection", "PROBLEM", 224, 250], ["asthma", "OBSERVATION", 145, 151], ["infection", "OBSERVATION", 186, 195], ["most common", "OBSERVATION_MODIFIER", 203, 214], ["viral", "OBSERVATION_MODIFIER", 224, 229], ["nosocomial", "OBSERVATION_MODIFIER", 230, 240], ["infection", "OBSERVATION", 241, 250], ["significant", "OBSERVATION_MODIFIER", 288, 299]]], ["Although the disease burden of HMPV is unclear, recent evidence suggests that nosocomial infections with HMPV may be similar to those caused by RSV (Nissen, unpublished data) .", [["HMPV", "DISEASE", 31, 35], ["nosocomial infections", "DISEASE", 78, 99], ["HMPV", "DISEASE", 105, 109], ["HMPV", "ORGANISM", 31, 35], ["HMPV", "ORGANISM", 105, 109], ["RSV", "ORGANISM", 144, 147], ["HMPV", "SPECIES", 31, 35], ["HMPV", "SPECIES", 105, 109], ["RSV", "SPECIES", 144, 147], ["the disease burden", "PROBLEM", 9, 27], ["HMPV", "PROBLEM", 31, 35], ["nosocomial infections", "PROBLEM", 78, 99], ["HMPV", "PROBLEM", 105, 109], ["RSV", "PROBLEM", 144, 147], ["Nissen", "TREATMENT", 149, 155], ["disease", "OBSERVATION", 13, 20], ["HMPV", "OBSERVATION", 31, 35], ["nosocomial", "OBSERVATION_MODIFIER", 78, 88], ["infections", "OBSERVATION", 89, 99]]], ["Given similar mode of transmission, it is likely that similar infection control practices should be applied for HMPV as for RSV, particularly in neonatal health care settings.", [["infection", "DISEASE", 62, 71], ["RSV", "DISEASE", 124, 127], ["HMPV", "ORGANISM", 112, 116], ["RSV", "ORGANISM", 124, 127], ["HMPV", "SPECIES", 112, 116], ["RSV", "SPECIES", 124, 127], ["similar infection control practices", "PROBLEM", 54, 89], ["HMPV", "PROBLEM", 112, 116], ["RSV", "PROBLEM", 124, 127], ["is likely", "UNCERTAINTY", 39, 48], ["similar", "OBSERVATION_MODIFIER", 54, 61], ["infection", "OBSERVATION", 62, 71]]], ["The incidence of co-infections with HMPV has not been adequately defined, but co-infections with other viral respiratory pathogens may occur, e.g. RSV, influenza virus and SARS-coronavirus [5, 16, 38, 39] .", [["co-infections", "DISEASE", 17, 30], ["HMPV", "DISEASE", 36, 40], ["viral respiratory pathogens", "DISEASE", 103, 130], ["influenza virus", "DISEASE", 152, 167], ["SARS-coronavirus", "DISEASE", 172, 188], ["HMPV", "ORGANISM", 36, 40], ["RSV", "ORGANISM", 147, 150], ["influenza virus", "ORGANISM", 152, 167], ["SARS-coronavirus", "ORGANISM", 172, 188], ["influenza virus", "SPECIES", 152, 167], ["SARS-coronavirus", "SPECIES", 172, 188], ["HMPV", "SPECIES", 36, 40], ["RSV", "SPECIES", 147, 150], ["SARS-coronavirus", "SPECIES", 172, 188], ["co-infections", "PROBLEM", 17, 30], ["HMPV", "PROBLEM", 36, 40], ["co-infections", "PROBLEM", 78, 91], ["other viral respiratory pathogens", "PROBLEM", 97, 130], ["RSV", "PROBLEM", 147, 150], ["influenza virus", "PROBLEM", 152, 167], ["SARS", "PROBLEM", 172, 176], ["coronavirus", "PROBLEM", 177, 188], ["co-infections", "OBSERVATION", 17, 30], ["HMPV", "OBSERVATION", 36, 40]]], ["Boivin et al. [16] reported that in Canada, 24% (nine of 38) of HMPV-positive isolates were co-infected with other viruses; however, it is not known if viral co-infections affect the severity of HMPV disease [38] .", [["viral co-infections", "DISEASE", 152, 171], ["HMPV disease", "DISEASE", 195, 207], ["HMPV", "ORGANISM", 64, 68], ["HMPV", "ORGANISM", 195, 199], ["HMPV", "SPECIES", 195, 199], ["HMPV", "PROBLEM", 64, 68], ["positive isolates", "PROBLEM", 69, 86], ["other viruses", "PROBLEM", 109, 122], ["viral co-infections", "PROBLEM", 152, 171], ["HMPV disease", "PROBLEM", 195, 207], ["HMPV disease", "OBSERVATION", 195, 207]]], ["Similarly, in a study examining the overall impact of HMPV infection in 1505 children, of 42 HMPV-positive samples tested, there was RSV or influenza virus co-infection rate of 16.7% (39) .", [["samples", "ANATOMY", 107, 114], ["HMPV infection", "DISEASE", 54, 68], ["influenza virus co-infection", "DISEASE", 140, 168], ["HMPV", "ORGANISM", 54, 58], ["children", "ORGANISM", 77, 85], ["HMPV", "ORGANISM", 93, 97], ["samples", "CANCER", 107, 114], ["RSV", "ORGANISM", 133, 136], ["influenza virus", "ORGANISM", 140, 155], ["children", "SPECIES", 77, 85], ["influenza virus", "SPECIES", 140, 155], ["HMPV", "SPECIES", 54, 58], ["HMPV", "SPECIES", 93, 97], ["RSV", "SPECIES", 133, 136], ["a study", "TEST", 14, 21], ["HMPV infection", "PROBLEM", 54, 68], ["HMPV", "TEST", 93, 97], ["positive samples", "TEST", 98, 114], ["RSV", "PROBLEM", 133, 136], ["influenza virus co-infection rate", "PROBLEM", 140, 173], ["HMPV infection", "OBSERVATION", 54, 68], ["influenza virus", "OBSERVATION", 140, 155]]], ["The symptoms associated with HMPV coinfection were presentation of fever that was more frequent in the HMPV-and influenza-positive children and wheezing with bronchiolitis or asthma exacerbation that was more frequent among HMPV-and RSV-positive cases.", [["HMPV coinfection", "DISEASE", 29, 45], ["fever", "DISEASE", 67, 72], ["influenza-positive", "DISEASE", 112, 130], ["wheezing", "DISEASE", 144, 152], ["bronchiolitis", "DISEASE", 158, 171], ["asthma", "DISEASE", 175, 181], ["HMPV", "ORGANISM", 29, 33], ["HMPV", "ORGANISM", 103, 107], ["influenza", "ORGANISM", 112, 121], ["children", "ORGANISM", 131, 139], ["HMPV", "ORGANISM", 224, 228], ["RSV", "ORGANISM", 233, 236], ["children", "SPECIES", 131, 139], ["HMPV", "SPECIES", 29, 33], ["HMPV", "SPECIES", 103, 107], ["HMPV", "SPECIES", 224, 228], ["RSV", "SPECIES", 233, 236], ["The symptoms", "PROBLEM", 0, 12], ["HMPV coinfection", "PROBLEM", 29, 45], ["fever", "PROBLEM", 67, 72], ["the HMPV", "PROBLEM", 99, 107], ["influenza", "PROBLEM", 112, 121], ["wheezing", "PROBLEM", 144, 152], ["bronchiolitis", "PROBLEM", 158, 171], ["asthma exacerbation", "PROBLEM", 175, 194], ["HMPV", "TEST", 224, 228], ["RSV", "TEST", 233, 236], ["HMPV coinfection", "OBSERVATION", 29, 45], ["bronchiolitis", "OBSERVATION", 158, 171], ["asthma", "OBSERVATION", 175, 181]]], ["Significant clinical respiratory bacterial infections associated with HMPV detection have also been reported, though less frequently than viruses, e.g. Staphylococcus aureus, Streptococcus pneumoniae, and Stenotrophomonas maltophilia ([16] Nissen, unpublished data).", [["respiratory bacterial infections", "DISEASE", 21, 53], ["Staphylococcus aureus", "DISEASE", 152, 173], ["Streptococcus pneumoniae", "DISEASE", 175, 199], ["Stenotrophomonas maltophilia", "DISEASE", 205, 233], ["HMPV", "ORGANISM", 70, 74], ["Staphylococcus aureus", "ORGANISM", 152, 173], ["Streptococcus pneumoniae", "ORGANISM", 175, 199], ["Stenotrophomonas maltophilia", "ORGANISM", 205, 233], ["Staphylococcus aureus", "SPECIES", 152, 173], ["Streptococcus pneumoniae", "SPECIES", 175, 199], ["Stenotrophomonas maltophilia", "SPECIES", 205, 233], ["HMPV", "SPECIES", 70, 74], ["Staphylococcus aureus", "SPECIES", 152, 173], ["Streptococcus pneumoniae", "SPECIES", 175, 199], ["Stenotrophomonas maltophilia", "SPECIES", 205, 233], ["Significant clinical respiratory bacterial infections", "PROBLEM", 0, 53], ["HMPV detection", "PROBLEM", 70, 84], ["Staphylococcus aureus", "PROBLEM", 152, 173], ["Streptococcus pneumoniae", "PROBLEM", 175, 199], ["Stenotrophomonas maltophilia", "PROBLEM", 205, 233], ["Nissen", "TREATMENT", 240, 246], ["respiratory bacterial infections", "OBSERVATION", 21, 53], ["HMPV", "OBSERVATION", 70, 74], ["Staphylococcus aureus", "OBSERVATION", 152, 173], ["Streptococcus pneumoniae", "OBSERVATION", 175, 199]]], ["It may be important to note that HMPV does not appear to be associated with asymptomatic carriage in the nasopharynx. van den Hoogen et al.Clinical features[1] noted that the virus was not detected in respiratory samples taken from 400 asymptomatic children younger than 2 years of age.Immune response to HMPV infectionThe agents of immunity provide host resistance to infection, and deficiencies or absence of aspects of the immune response may lead to a prolonged period of recovery, subsequent re-infection, or potentially persistence [30] .", [["nasopharynx", "ANATOMY", 105, 116], ["respiratory samples", "ANATOMY", 201, 220], ["HMPV infection", "DISEASE", 305, 319], ["infection", "DISEASE", 369, 378], ["HMPV", "ORGANISM", 33, 37], ["nasopharynx", "ORGAN", 105, 116], ["respiratory samples", "CANCER", 201, 220], ["children", "ORGANISM", 249, 257], ["HMPV", "ORGANISM", 305, 309], ["children", "SPECIES", 249, 257], ["HMPV", "SPECIES", 33, 37], ["HMPV", "SPECIES", 305, 309], ["HMPV", "PROBLEM", 33, 37], ["asymptomatic carriage in the nasopharynx", "PROBLEM", 76, 116], ["the virus", "PROBLEM", 171, 180], ["Immune response", "PROBLEM", 286, 301], ["HMPV infection", "PROBLEM", 305, 319], ["infection", "PROBLEM", 369, 378], ["subsequent re-infection", "PROBLEM", 486, 509], ["HMPV", "OBSERVATION", 33, 37], ["asymptomatic", "OBSERVATION_MODIFIER", 76, 88], ["carriage", "OBSERVATION", 89, 97], ["nasopharynx", "ANATOMY", 105, 116], ["virus", "OBSERVATION", 175, 180], ["HMPV infection", "OBSERVATION", 305, 319], ["infection", "OBSERVATION", 369, 378], ["re-infection", "OBSERVATION", 497, 509]]], ["To date, the majority of studies examining the immune response to HMPV infection have been restricted to animal models, and only limited data are available regarding the immune response to HMPV infection in the human host.", [["HMPV infection", "DISEASE", 66, 80], ["HMPV infection", "DISEASE", 189, 203], ["HMPV", "ORGANISM", 66, 70], ["HMPV", "ORGANISM", 189, 193], ["human", "ORGANISM", 211, 216], ["human", "SPECIES", 211, 216], ["HMPV", "SPECIES", 66, 70], ["HMPV", "SPECIES", 189, 193], ["human", "SPECIES", 211, 216], ["studies", "TEST", 25, 32], ["HMPV infection", "PROBLEM", 66, 80], ["HMPV infection", "PROBLEM", 189, 203], ["HMPV infection", "OBSERVATION", 66, 80], ["HMPV infection", "OBSERVATION", 189, 203]]], ["Preliminary human studies from our laboratory indicate that both serum and secretory antibodies are produced in response to infection with HMPV; however, the role of these immune components in long-term protection against re-infection with HMPV is unknown but the subject of ongoing studies.Immune response to HMPV infectionStudies in animal models have provided the foundation for understanding aspects of immunity and disease pathogenesis associated with human viral pathogens.", [["serum", "ANATOMY", 65, 70], ["infection", "DISEASE", 124, 133], ["HMPV", "DISEASE", 139, 143], ["HMPV", "DISEASE", 240, 244], ["HMPV infectionStudies", "DISEASE", 310, 331], ["human", "ORGANISM", 12, 17], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["secretory antibodies", "GENE_OR_GENE_PRODUCT", 75, 95], ["HMPV", "ORGANISM", 139, 143], ["HMPV", "ORGANISM", 240, 244], ["HMPV", "ORGANISM", 310, 314], ["human", "ORGANISM", 457, 462], ["serum and secretory antibodies", "PROTEIN", 65, 95], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 457, 462], ["human", "SPECIES", 12, 17], ["HMPV", "SPECIES", 139, 143], ["HMPV", "SPECIES", 240, 244], ["HMPV", "SPECIES", 310, 314], ["human", "SPECIES", 457, 462], ["Preliminary human studies", "TEST", 0, 25], ["our laboratory", "TEST", 31, 45], ["both serum", "TEST", 60, 70], ["secretory antibodies", "TEST", 75, 95], ["infection", "PROBLEM", 124, 133], ["HMPV", "PROBLEM", 139, 143], ["these immune components", "TREATMENT", 166, 189], ["long-term protection", "TREATMENT", 193, 213], ["re-infection", "PROBLEM", 222, 234], ["HMPV", "PROBLEM", 240, 244], ["ongoing studies", "TEST", 275, 290], ["Immune response", "PROBLEM", 291, 306], ["HMPV infectionStudies", "PROBLEM", 310, 331], ["disease pathogenesis", "PROBLEM", 420, 440], ["human viral pathogens", "PROBLEM", 457, 478], ["infection", "OBSERVATION", 124, 133], ["HMPV infectionStudies", "OBSERVATION", 310, 331]]], ["Given the clinical and genomic similarities between RSV and HMPV (Table 1 and Fig. 1) , it is important to consider what has been learned from RSV studies in animal models to guide prospective HMPV studies, and important to note that none of the HMPV proteins have yet been fully biochemically characterized.", [["RSV", "ORGANISM", 52, 55], ["RSV", "ORGANISM", 143, 146], ["HMPV", "ORGANISM", 246, 250], ["HMPV proteins", "PROTEIN", 246, 259], ["RSV", "SPECIES", 52, 55], ["HMPV", "SPECIES", 60, 64], ["RSV", "SPECIES", 143, 146], ["HMPV", "SPECIES", 193, 197], ["HMPV", "SPECIES", 246, 250], ["RSV", "PROBLEM", 52, 55], ["HMPV", "TEST", 60, 64], ["RSV studies", "TEST", 143, 154], ["prospective HMPV studies", "TEST", 181, 205], ["the HMPV proteins", "TEST", 242, 259]]], ["RSV has two major surface proteins important for infection, i.e. the attachment (G) and fusion (F) proteins.", [["surface", "ANATOMY", 18, 25], ["infection", "DISEASE", 49, 58], ["RSV", "ORGANISM", 0, 3], ["fusion (F) proteins", "GENE_OR_GENE_PRODUCT", 88, 107], ["major surface proteins", "PROTEIN", 12, 34], ["attachment (G) and fusion (F) proteins", "PROTEIN", 69, 107], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["infection", "PROBLEM", 49, 58], ["the attachment (G) and fusion (F) proteins", "TREATMENT", 65, 107], ["important for", "UNCERTAINTY", 35, 48], ["infection", "OBSERVATION", 49, 58]]], ["RSV infects respiratory epithelium by interaction of heparinbinding domains on these surface proteins with glycosaminoglycans (GAGs) on the cell surface [40, 41] ; however, G protein contributes to the majority of virus binding [42, 43] .", [["respiratory epithelium", "ANATOMY", 12, 34], ["surface", "ANATOMY", 85, 92], ["cell surface", "ANATOMY", 140, 152], ["RSV", "ORGANISM", 0, 3], ["respiratory epithelium", "TISSUE", 12, 34], ["glycosaminoglycans", "GENE_OR_GENE_PRODUCT", 107, 125], ["GAGs", "GENE_OR_GENE_PRODUCT", 127, 131], ["cell surface", "CELLULAR_COMPONENT", 140, 152], ["G protein", "GENE_OR_GENE_PRODUCT", 173, 182], ["heparinbinding domains", "PROTEIN", 53, 75], ["surface proteins", "PROTEIN", 85, 101], ["G protein", "PROTEIN", 173, 182], ["RSV", "SPECIES", 0, 3], ["RSV infects respiratory epithelium", "PROBLEM", 0, 34], ["heparinbinding domains", "PROBLEM", 53, 75], ["these surface proteins", "TEST", 79, 101], ["glycosaminoglycans (GAGs", "TEST", 107, 131], ["the cell surface", "TEST", 136, 152], ["G protein", "TEST", 173, 182], ["virus binding", "PROBLEM", 214, 227], ["respiratory epithelium", "OBSERVATION", 12, 34]]], ["In addition, the non-glycosylated, central conserved region of the G protein contains a CX3C chemokine motif at amino acid positions 182-186 that is capable of interacting with the CX3C chemokine receptor, CX3CR1, and facilitating infection [44] .", [["amino acid positions 182-186", "CHEMICAL", 112, 140], ["infection", "DISEASE", 231, 240], ["amino acid", "CHEMICAL", 112, 122], ["G protein", "GENE_OR_GENE_PRODUCT", 67, 76], ["CX3C", "GENE_OR_GENE_PRODUCT", 88, 92], ["amino acid", "AMINO_ACID", 112, 122], ["182-186", "AMINO_ACID", 133, 140], ["CX3C chemokine receptor", "GENE_OR_GENE_PRODUCT", 181, 204], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 206, 212], ["non-glycosylated, central conserved region", "PROTEIN", 17, 59], ["G protein", "PROTEIN", 67, 76], ["CX3C chemokine motif", "PROTEIN", 88, 108], ["CX3C chemokine receptor", "PROTEIN", 181, 204], ["CX3CR1", "PROTEIN", 206, 212], ["the G protein", "TREATMENT", 63, 76], ["a CX3C chemokine motif", "TREATMENT", 86, 108], ["amino acid positions", "TEST", 112, 132], ["the CX3C chemokine receptor", "TREATMENT", 177, 204], ["CX3CR1", "TEST", 206, 212], ["facilitating infection", "PROBLEM", 218, 240], ["infection", "OBSERVATION", 231, 240]]], ["The putative HMPV G protein does not appear to have a CX3C chemokine motif; however similar to RSV, appears to consist of a type II mucin-like glycoprotein based on the distribution of hydrophobic and hydrophilic regions along the predicted amino acid sequence [21] .", [["amino acid", "CHEMICAL", 241, 251], ["amino acid", "CHEMICAL", 241, 251], ["HMPV G", "GENE_OR_GENE_PRODUCT", 13, 19], ["RSV", "ORGANISM", 95, 98], ["mucin", "GENE_OR_GENE_PRODUCT", 132, 137], ["amino acid", "AMINO_ACID", 241, 251], ["HMPV G protein", "PROTEIN", 13, 27], ["CX3C chemokine motif", "PROTEIN", 54, 74], ["type II mucin-like glycoprotein", "PROTEIN", 124, 155], ["hydrophobic and hydrophilic regions", "PROTEIN", 185, 220], ["RSV", "SPECIES", 95, 98], ["The putative HMPV G protein", "TEST", 0, 27], ["a CX3C chemokine motif", "TEST", 52, 74], ["RSV", "PROBLEM", 95, 98], ["a type II mucin-like glycoprotein", "PROBLEM", 122, 155], ["hydrophobic and hydrophilic regions", "PROBLEM", 185, 220], ["the predicted amino acid sequence", "TEST", 227, 260], ["HMPV", "OBSERVATION", 13, 17], ["RSV", "OBSERVATION", 95, 98], ["hydrophobic", "OBSERVATION_MODIFIER", 185, 196], ["hydrophilic", "ANATOMY_MODIFIER", 201, 212]]], ["The putative HMPV F protein, like RSV, has two heptad repeats that for RSV are required for viral fusion [45, 46] , thus the RSV and HMPV G and F proteins appear to have similar features necessary for infection.", [["infection", "DISEASE", 201, 210], ["HMPV F", "GENE_OR_GENE_PRODUCT", 13, 19], ["RSV", "ORGANISM", 34, 37], ["RSV", "ORGANISM", 71, 74], ["RSV", "ORGANISM", 125, 128], ["HMPV G", "GENE_OR_GENE_PRODUCT", 133, 139], ["F proteins", "GENE_OR_GENE_PRODUCT", 144, 154], ["HMPV F protein", "PROTEIN", 13, 27], ["RSV", "PROTEIN", 34, 37], ["heptad repeats", "PROTEIN", 47, 61], ["RSV and HMPV G and F proteins", "PROTEIN", 125, 154], ["RSV", "SPECIES", 34, 37], ["RSV", "SPECIES", 71, 74], ["RSV", "SPECIES", 125, 128], ["HMPV", "SPECIES", 133, 137], ["The putative HMPV F protein", "TEST", 0, 27], ["RSV", "PROBLEM", 34, 37], ["two heptad repeats", "TREATMENT", 43, 61], ["RSV", "PROBLEM", 71, 74], ["viral fusion", "TEST", 92, 104], ["the RSV", "TEST", 121, 128], ["HMPV G and F proteins", "TEST", 133, 154], ["infection", "PROBLEM", 201, 210], ["RSV", "OBSERVATION", 34, 37], ["infection", "OBSERVATION", 201, 210]]], ["The cell types in the lung targeted by HMPV are not known.", [["cell", "ANATOMY", 4, 8], ["lung", "ANATOMY", 22, 26], ["cell", "CELL", 4, 8], ["lung", "ORGAN", 22, 26], ["HMPV", "ORGANISM", 39, 43], ["HMPV", "SPECIES", 39, 43], ["HMPV", "PROBLEM", 39, 43], ["cell types", "OBSERVATION", 4, 14], ["lung", "ANATOMY", 22, 26], ["HMPV", "OBSERVATION", 39, 43]]], ["RSV primarily infects type II respiratory epithelial cells, and in human primary airway epithelial cell cultures, specifically targets ciliated columnar cells [47] .", [["type II respiratory epithelial cells", "ANATOMY", 22, 58], ["primary airway epithelial cell cultures", "ANATOMY", 73, 112], ["ciliated columnar cells", "ANATOMY", 135, 158], ["RSV", "ORGANISM", 0, 3], ["type II respiratory epithelial cells", "CELL", 22, 58], ["human", "ORGANISM", 67, 72], ["airway epithelial cell cultures", "CELL", 81, 112], ["ciliated columnar cells", "CELL", 135, 158], ["type II respiratory epithelial cells", "CELL_TYPE", 22, 58], ["human primary airway epithelial cell cultures", "CELL_LINE", 67, 112], ["ciliated columnar cells", "CELL_TYPE", 135, 158], ["human", "SPECIES", 67, 72], ["RSV", "SPECIES", 0, 3], ["human", "SPECIES", 67, 72], ["RSV", "PROBLEM", 0, 3], ["type II respiratory epithelial cells", "PROBLEM", 22, 58], ["human primary airway epithelial cell cultures", "TEST", 67, 112], ["targets ciliated columnar cells", "PROBLEM", 127, 158], ["respiratory epithelial cells", "OBSERVATION", 30, 58], ["airway", "ANATOMY", 81, 87], ["epithelial cell cultures", "OBSERVATION", 88, 112], ["columnar cells", "OBSERVATION", 144, 158]]], ["There is mounting evidence that RSV may cause persistent or latent infection, as RSV protein and genomic RNA have been detected in mouse lungs for at least 180 days postinfection, as well as in lung alveolar macrophages in guinea pigs, in murine macrophage-like cells and macrophage cultures, and in B cells following infection with bovine RSV [30, 48] .", [["lungs", "ANATOMY", 137, 142], ["lung alveolar macrophages", "ANATOMY", 194, 219], ["macrophage-like cells", "ANATOMY", 246, 267], ["macrophage cultures", "ANATOMY", 272, 291], ["B cells", "ANATOMY", 300, 307], ["RSV", "DISEASE", 32, 35], ["infection", "DISEASE", 67, 76], ["infection", "DISEASE", 318, 327], ["RSV", "ORGANISM", 32, 35], ["RSV", "ORGANISM", 81, 84], ["mouse", "ORGANISM", 131, 136], ["lungs", "ORGAN", 137, 142], ["lung alveolar macrophages", "CELL", 194, 219], ["guinea pigs", "ORGANISM", 223, 234], ["murine", "ORGANISM", 239, 245], ["macrophage-like cells", "CELL", 246, 267], ["macrophage cultures", "CELL", 272, 291], ["B cells", "CELL", 300, 307], ["bovine", "ORGANISM", 333, 339], ["RSV", "ORGANISM", 340, 343], ["RSV protein", "PROTEIN", 81, 92], ["genomic RNA", "RNA", 97, 108], ["lung alveolar macrophages", "CELL_TYPE", 194, 219], ["murine macrophage-like cells", "CELL_TYPE", 239, 267], ["macrophage cultures", "CELL_LINE", 272, 291], ["B cells", "CELL_TYPE", 300, 307], ["mouse", "SPECIES", 131, 136], ["guinea pigs", "SPECIES", 223, 234], ["murine", "SPECIES", 239, 245], ["bovine", "SPECIES", 333, 339], ["RSV", "SPECIES", 32, 35], ["RSV", "SPECIES", 81, 84], ["mouse", "SPECIES", 131, 136], ["guinea pigs", "SPECIES", 223, 234], ["RSV", "SPECIES", 340, 343], ["RSV", "PROBLEM", 32, 35], ["persistent or latent infection", "PROBLEM", 46, 76], ["RSV protein and genomic RNA", "PROBLEM", 81, 108], ["lung alveolar macrophages", "PROBLEM", 194, 219], ["guinea pigs", "TREATMENT", 223, 234], ["like cells", "PROBLEM", 257, 267], ["macrophage cultures", "TEST", 272, 291], ["infection", "PROBLEM", 318, 327], ["bovine RSV", "PROBLEM", 333, 343], ["RSV", "OBSERVATION", 32, 35], ["may cause", "UNCERTAINTY", 36, 45], ["persistent", "OBSERVATION_MODIFIER", 46, 56], ["latent", "OBSERVATION_MODIFIER", 60, 66], ["infection", "OBSERVATION", 67, 76], ["genomic RNA", "OBSERVATION", 97, 108], ["lungs", "ANATOMY", 137, 142], ["lung", "ANATOMY", 194, 198], ["alveolar macrophages", "OBSERVATION", 199, 219], ["guinea pigs", "OBSERVATION", 223, 234]]], ["These features allude to the possibility that RSV persistence may serve as a reservoir for transmission, reinfection, or contribute to the pathogenesis of chronic wheezing and asthma in children who have experienced bronchiolitis.", [["wheezing", "DISEASE", 163, 171], ["asthma", "DISEASE", 176, 182], ["bronchiolitis", "DISEASE", 216, 229], ["RSV", "ORGANISM", 46, 49], ["children", "ORGANISM", 186, 194], ["children", "SPECIES", 186, 194], ["RSV", "SPECIES", 46, 49], ["RSV persistence", "PROBLEM", 46, 61], ["reinfection", "PROBLEM", 105, 116], ["chronic wheezing", "PROBLEM", 155, 171], ["asthma", "PROBLEM", 176, 182], ["bronchiolitis", "PROBLEM", 216, 229], ["RSV", "OBSERVATION", 46, 49], ["chronic", "OBSERVATION_MODIFIER", 155, 162], ["wheezing", "OBSERVATION", 163, 171], ["asthma", "OBSERVATION", 176, 182], ["bronchiolitis", "OBSERVATION", 216, 229]]], ["It is not known if HMPV persists in humans; however, studies from our laboratories have shown that infectious HMPV persists in the lungs of BALB/c mice up to day 60 postinfection (p.i.) despite the presence of neutralizing antibodies, and genomic RNA can be detected in the lungs for \u2265180 days pi by RT-PCR [27] .", [["lungs", "ANATOMY", 131, 136], ["lungs", "ANATOMY", 274, 279], ["HMPV", "ORGANISM", 19, 23], ["humans", "ORGANISM", 36, 42], ["HMPV", "ORGANISM", 110, 114], ["lungs", "ORGAN", 131, 136], ["BALB/c mice", "ORGANISM", 140, 151], ["lungs", "ORGAN", 274, 279], ["neutralizing antibodies", "PROTEIN", 210, 233], ["genomic RNA", "RNA", 239, 250], ["humans", "SPECIES", 36, 42], ["mice", "SPECIES", 147, 151], ["HMPV", "SPECIES", 19, 23], ["humans", "SPECIES", 36, 42], ["HMPV", "SPECIES", 110, 114], ["mice", "SPECIES", 147, 151], ["HMPV", "PROBLEM", 19, 23], ["our laboratories", "TEST", 66, 82], ["infectious HMPV", "PROBLEM", 99, 114], ["neutralizing antibodies", "PROBLEM", 210, 233], ["genomic RNA", "PROBLEM", 239, 250], ["PCR", "TEST", 303, 306], ["not known", "UNCERTAINTY", 6, 15], ["HMPV", "OBSERVATION", 19, 23], ["infectious", "OBSERVATION_MODIFIER", 99, 109], ["HMPV", "OBSERVATION", 110, 114], ["lungs", "ANATOMY", 131, 136], ["lungs", "ANATOMY", 274, 279]]], ["Consistent with attenuated responses and virus persistence [49] , HMPV infection in young children appears to induce a restricted chemokinemediated inflammatory response, particularly compared to RSV infection [10] .", [["HMPV infection", "DISEASE", 66, 80], ["RSV infection", "DISEASE", 196, 209], ["HMPV", "ORGANISM", 66, 70], ["children", "ORGANISM", 90, 98], ["RSV", "ORGANISM", 196, 199], ["children", "SPECIES", 90, 98], ["HMPV", "SPECIES", 66, 70], ["RSV", "SPECIES", 196, 199], ["attenuated responses", "PROBLEM", 16, 36], ["virus persistence", "PROBLEM", 41, 58], ["HMPV infection", "PROBLEM", 66, 80], ["a restricted chemokinemediated inflammatory response", "PROBLEM", 117, 169], ["RSV infection", "PROBLEM", 196, 209], ["attenuated", "OBSERVATION_MODIFIER", 16, 26], ["infection", "OBSERVATION", 71, 80], ["inflammatory", "OBSERVATION_MODIFIER", 148, 160]]], ["Our recent studies from examining features of the innate and adaptive immune response to HMPV infection in a BALB/c mouse model have shown that primary HMPV infection elicits weak innate and aberrant adaptive immune response (Alvarez et al., in press).", [["HMPV infection", "DISEASE", 89, 103], ["HMPV infection", "DISEASE", 152, 166], ["HMPV", "ORGANISM", 89, 93], ["BALB/c mouse", "ORGANISM", 109, 121], ["HMPV", "ORGANISM", 152, 156], ["mouse", "SPECIES", 116, 121], ["HMPV", "SPECIES", 89, 93], ["mouse", "SPECIES", 116, 121], ["HMPV", "SPECIES", 152, 156], ["Our recent studies", "TEST", 0, 18], ["HMPV infection", "PROBLEM", 89, 103], ["a BALB/c mouse model", "TREATMENT", 107, 127], ["primary HMPV infection", "PROBLEM", 144, 166], ["weak innate", "PROBLEM", 175, 186], ["aberrant adaptive immune response", "PROBLEM", 191, 224], ["HMPV infection", "OBSERVATION", 89, 103], ["primary", "OBSERVATION_MODIFIER", 144, 151], ["HMPV infection", "OBSERVATION", 152, 166]]], ["These responses are characterized by induction of a Th2-type cytokine response at later stages of infection that coincides with increased IL-10 expression and persistent virus replication in the lung.", [["lung", "ANATOMY", 195, 199], ["infection", "DISEASE", 98, 107], ["IL-10", "GENE_OR_GENE_PRODUCT", 138, 143], ["lung", "ORGAN", 195, 199], ["cytokine", "PROTEIN", 61, 69], ["IL", "PROTEIN", 138, 140], ["a Th2-type cytokine response", "PROBLEM", 50, 78], ["infection", "PROBLEM", 98, 107], ["increased IL", "PROBLEM", 128, 140], ["persistent virus replication in the lung", "PROBLEM", 159, 199], ["infection", "OBSERVATION", 98, 107], ["increased", "OBSERVATION_MODIFIER", 128, 137], ["IL", "OBSERVATION_MODIFIER", 138, 140], ["persistent", "OBSERVATION_MODIFIER", 159, 169], ["virus replication", "OBSERVATION", 170, 187], ["lung", "ANATOMY", 195, 199]]], ["Examination of the CTL and antibody response to HMPV infection revealed a delayed response, but passive transfer of HMPV-specific antibodies provided considerable protection (Alvarez et al., in press).", [["HMPV infection", "DISEASE", 48, 62], ["CTL", "CELL", 19, 22], ["HMPV", "ORGANISM", 48, 52], ["HMPV", "ORGANISM", 116, 120], ["HMPV-specific antibodies", "PROTEIN", 116, 140], ["HMPV", "SPECIES", 48, 52], ["HMPV", "SPECIES", 116, 120], ["Examination", "TEST", 0, 11], ["the CTL", "TEST", 15, 22], ["HMPV infection", "PROBLEM", 48, 62], ["a delayed response", "PROBLEM", 72, 90], ["HMPV", "TREATMENT", 116, 120], ["specific antibodies", "TREATMENT", 121, 140]]], ["These features are consistent with virus persistence, the existence of complex immune interactions in response to HMPV infection, and that the immune response to HMPV is unique compared to RSV infection in BALB/c mice.Immune response to HMPV infectionInnate immune responses provide the first line of defense against infection, and affect the magnitude and quality of the acquired immune response.", [["HMPV infection", "DISEASE", 114, 128], ["RSV infection", "DISEASE", 189, 202], ["HMPV infection", "DISEASE", 237, 251], ["infection", "DISEASE", 317, 326], ["HMPV", "ORGANISM", 114, 118], ["HMPV", "ORGANISM", 162, 166], ["RSV", "ORGANISM", 189, 192], ["BALB/c mice", "ORGANISM", 206, 217], ["HMPV", "ORGANISM", 237, 241], ["mice", "SPECIES", 213, 217], ["HMPV", "SPECIES", 114, 118], ["HMPV", "SPECIES", 162, 166], ["RSV", "SPECIES", 189, 192], ["mice", "SPECIES", 213, 217], ["HMPV", "SPECIES", 237, 241], ["virus persistence", "PROBLEM", 35, 52], ["complex immune interactions", "PROBLEM", 71, 98], ["HMPV infection", "PROBLEM", 114, 128], ["the immune response", "PROBLEM", 139, 158], ["HMPV", "PROBLEM", 162, 166], ["RSV infection", "PROBLEM", 189, 202], ["Immune response", "PROBLEM", 218, 233], ["HMPV infection", "PROBLEM", 237, 251], ["infection", "PROBLEM", 317, 326], ["consistent with", "UNCERTAINTY", 19, 34], ["virus", "OBSERVATION", 35, 40], ["complex", "OBSERVATION_MODIFIER", 71, 78], ["immune interactions", "OBSERVATION", 79, 98], ["HMPV infection", "OBSERVATION", 114, 128], ["infection", "OBSERVATION", 193, 202], ["infection", "OBSERVATION", 317, 326]]], ["Conserved structural motifs on pathogens trigger pattern recognition receptors, e.g. Toll-like receptors (TLRs), which initiate signaling cascades, activation of the transcription factor NF-jB, and expression of proinflammatory and effector cytokines required to direct the acquired immune response [50, 51] .", [["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 49, 78], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 85, 104], ["TLRs", "GENE_OR_GENE_PRODUCT", 106, 110], ["NF-jB", "GENE_OR_GENE_PRODUCT", 187, 192], ["pattern recognition receptors", "PROTEIN", 49, 78], ["Toll-like receptors", "PROTEIN", 85, 104], ["TLRs", "PROTEIN", 106, 110], ["transcription factor", "PROTEIN", 166, 186], ["NF", "PROTEIN", 187, 189], ["jB", "PROTEIN", 190, 192], ["proinflammatory and effector cytokines", "PROTEIN", 212, 250], ["signaling cascades", "PROBLEM", 128, 146], ["proinflammatory and effector cytokines", "PROBLEM", 212, 250], ["jB", "ANATOMY", 190, 192]]], ["It is not known if HMPV proteins interact with TLRs; however, the RSV F protein has been shown to stimulate innate immunity through activation of CD14 and TLR4 [52] , and TLR4-deficient mice challenged with RSV exhibit impaired pulmonary NK and CD14 + cell trafficking, deficient NK cell function, impaired interleukin IL-12 expression, and impaired virus clearance [53] .", [["pulmonary NK", "ANATOMY", 228, 240], ["CD14 + cell", "ANATOMY", 245, 256], ["NK cell", "ANATOMY", 280, 287], ["impaired virus clearance", "DISEASE", 341, 365], ["HMPV", "ORGANISM", 19, 23], ["TLRs", "GENE_OR_GENE_PRODUCT", 47, 51], ["RSV F", "GENE_OR_GENE_PRODUCT", 66, 71], ["CD14", "GENE_OR_GENE_PRODUCT", 146, 150], ["TLR4 [52]", "GENE_OR_GENE_PRODUCT", 155, 164], ["TLR4", "GENE_OR_GENE_PRODUCT", 171, 175], ["mice", "ORGANISM", 186, 190], ["RSV", "ORGANISM", 207, 210], ["pulmonary NK", "CELL", 228, 240], ["CD14", "GENE_OR_GENE_PRODUCT", 245, 249], ["cell", "CELL", 252, 256], ["NK cell", "CELL", 280, 287], ["interleukin", "GENE_OR_GENE_PRODUCT", 307, 318], ["IL-12", "GENE_OR_GENE_PRODUCT", 319, 324], ["HMPV proteins", "PROTEIN", 19, 32], ["TLRs", "PROTEIN", 47, 51], ["RSV F protein", "PROTEIN", 66, 79], ["CD14", "PROTEIN", 146, 150], ["TLR4", "PROTEIN", 155, 159], ["TLR4", "PROTEIN", 171, 175], ["CD14", "PROTEIN", 245, 249], ["interleukin IL-12", "PROTEIN", 307, 324], ["mice", "SPECIES", 186, 190], ["HMPV", "SPECIES", 19, 23], ["RSV", "SPECIES", 66, 69], ["mice", "SPECIES", 186, 190], ["RSV", "SPECIES", 207, 210], ["HMPV proteins", "PROBLEM", 19, 32], ["the RSV F protein", "TEST", 62, 79], ["CD14", "TEST", 146, 150], ["TLR4", "TEST", 155, 159], ["TLR4", "TEST", 171, 175], ["RSV", "PROBLEM", 207, 210], ["impaired pulmonary NK", "PROBLEM", 219, 240], ["CD14", "TEST", 245, 249], ["cell trafficking", "TEST", 252, 268], ["deficient NK cell function", "PROBLEM", 270, 296], ["impaired interleukin IL", "PROBLEM", 298, 321], ["impaired virus clearance", "PROBLEM", 341, 365], ["not known", "UNCERTAINTY", 6, 15], ["pulmonary NK", "ANATOMY", 228, 240], ["cell trafficking", "OBSERVATION", 252, 268], ["deficient NK cell function", "OBSERVATION", 270, 296], ["impaired", "OBSERVATION_MODIFIER", 298, 306], ["interleukin", "OBSERVATION_MODIFIER", 307, 318]]], ["Airway epithelial cells express a variety of functionally active TLRs including TLR4 [54] , and RSV infection of respiratory epithelial cells has been shown to induce increased TLR4 mRNA expression and TLR4 membrane localization [55] .", [["Airway epithelial cells", "ANATOMY", 0, 23], ["respiratory epithelial cells", "ANATOMY", 113, 141], ["membrane", "ANATOMY", 207, 215], ["RSV infection", "DISEASE", 96, 109], ["Airway epithelial cells", "CELL", 0, 23], ["TLRs", "GENE_OR_GENE_PRODUCT", 65, 69], ["TLR4", "GENE_OR_GENE_PRODUCT", 80, 84], ["RSV", "ORGANISM", 96, 99], ["respiratory epithelial cells", "CELL", 113, 141], ["TLR4", "GENE_OR_GENE_PRODUCT", 177, 181], ["TLR4", "GENE_OR_GENE_PRODUCT", 202, 206], ["membrane", "CELLULAR_COMPONENT", 207, 215], ["Airway epithelial cells", "CELL_TYPE", 0, 23], ["TLRs", "PROTEIN", 65, 69], ["TLR4", "PROTEIN", 80, 84], ["respiratory epithelial cells", "CELL_TYPE", 113, 141], ["TLR4 mRNA", "RNA", 177, 186], ["TLR4", "PROTEIN", 202, 206], ["RSV", "SPECIES", 96, 99], ["Airway epithelial cells", "PROBLEM", 0, 23], ["RSV infection of respiratory epithelial cells", "PROBLEM", 96, 141], ["increased TLR4 mRNA expression", "PROBLEM", 167, 197], ["TLR4 membrane localization", "TEST", 202, 228], ["epithelial cells", "OBSERVATION", 7, 23], ["RSV", "ANATOMY", 96, 99], ["infection", "OBSERVATION", 100, 109], ["respiratory epithelial cells", "OBSERVATION", 113, 141], ["increased", "OBSERVATION_MODIFIER", 167, 176], ["TLR4 mRNA", "OBSERVATION", 177, 186], ["TLR4 membrane", "OBSERVATION", 202, 215]]], ["In addition, children experiencing RSV bronchiolitis have significantly higher TLR4 expression on peripheral blood monocytes compared to controls which remains elevated for 4-6 weeks as the children enter the convalescent phase of RSV bronchiolitis [56] .", [["peripheral blood monocytes", "ANATOMY", 98, 124], ["bronchiolitis", "DISEASE", 39, 52], ["bronchiolitis", "DISEASE", 235, 248], ["children", "ORGANISM", 13, 21], ["RSV", "ORGANISM", 35, 38], ["TLR4", "GENE_OR_GENE_PRODUCT", 79, 83], ["peripheral blood monocytes", "ORGANISM_SUBSTANCE", 98, 124], ["children", "ORGANISM", 190, 198], ["RSV", "ORGANISM", 231, 234], ["TLR4", "PROTEIN", 79, 83], ["peripheral blood monocytes", "CELL_TYPE", 98, 124], ["children", "SPECIES", 13, 21], ["RSV", "SPECIES", 35, 38], ["children", "SPECIES", 190, 198], ["RSV", "SPECIES", 35, 38], ["RSV", "SPECIES", 231, 234], ["RSV bronchiolitis", "PROBLEM", 35, 52], ["peripheral blood monocytes", "TEST", 98, 124], ["RSV bronchiolitis", "PROBLEM", 231, 248], ["RSV", "OBSERVATION_MODIFIER", 35, 38], ["bronchiolitis", "OBSERVATION", 39, 52], ["significantly", "OBSERVATION_MODIFIER", 58, 71], ["higher", "OBSERVATION_MODIFIER", 72, 78], ["TLR4 expression", "OBSERVATION", 79, 94], ["peripheral", "ANATOMY_MODIFIER", 98, 108], ["blood", "ANATOMY", 109, 114], ["convalescent phase", "OBSERVATION_MODIFIER", 209, 227], ["RSV bronchiolitis", "OBSERVATION", 231, 248]]], ["These results suggest an important role for TLR4 in the immune response to RSV infection and associated disease pathogenesis.", [["RSV infection", "DISEASE", 75, 88], ["TLR4", "GENE_OR_GENE_PRODUCT", 44, 48], ["RSV", "ORGANISM", 75, 78], ["TLR4", "PROTEIN", 44, 48], ["RSV", "SPECIES", 75, 78], ["TLR4", "TREATMENT", 44, 48], ["RSV infection", "PROBLEM", 75, 88], ["associated disease pathogenesis", "PROBLEM", 93, 124], ["RSV infection", "OBSERVATION", 75, 88]]], ["The motif on the RSV F protein that triggers TLR4 activation is unknown, but there is 30-43% amino acid identity between RSV and HMPV F protein [45] , thus there is a possibility that HMPV F protein may have similar features.", [["amino acid", "CHEMICAL", 93, 103], ["amino acid", "CHEMICAL", 93, 103], ["RSV F", "GENE_OR_GENE_PRODUCT", 17, 22], ["TLR4", "GENE_OR_GENE_PRODUCT", 45, 49], ["amino acid", "AMINO_ACID", 93, 103], ["RSV", "ORGANISM", 121, 124], ["HMPV F", "GENE_OR_GENE_PRODUCT", 129, 135], ["HMPV F", "GENE_OR_GENE_PRODUCT", 184, 190], ["RSV F protein", "PROTEIN", 17, 30], ["TLR4", "PROTEIN", 45, 49], ["HMPV F protein", "PROTEIN", 184, 198], ["RSV", "SPECIES", 17, 20], ["RSV", "SPECIES", 121, 124], ["HMPV", "SPECIES", 184, 188], ["the RSV F protein", "TEST", 13, 30], ["TLR4 activation", "TEST", 45, 60], ["amino acid identity", "TEST", 93, 112], ["RSV", "TEST", 121, 124], ["HMPV F protein", "TEST", 129, 143], ["HMPV F protein", "PROBLEM", 184, 198], ["TLR4 activation", "OBSERVATION", 45, 60]]], ["Since TLRs are important initiators of inflammation and immunity, one consequence of RSV-mediated TLR4 activation may be initiation of pathophysiologic processes that exacerbate obstructive airways.", [["airways", "ANATOMY", 190, 197], ["inflammation", "DISEASE", 39, 51], ["TLRs", "GENE_OR_GENE_PRODUCT", 6, 10], ["RSV", "ORGANISM", 85, 88], ["TLR4", "GENE_OR_GENE_PRODUCT", 98, 102], ["airways", "MULTI-TISSUE_STRUCTURE", 190, 197], ["TLRs", "PROTEIN", 6, 10], ["TLR4", "PROTEIN", 98, 102], ["RSV", "SPECIES", 85, 88], ["inflammation", "PROBLEM", 39, 51], ["RSV-mediated TLR4 activation", "TREATMENT", 85, 113], ["pathophysiologic processes", "PROBLEM", 135, 161], ["obstructive airways", "PROBLEM", 178, 197], ["inflammation", "OBSERVATION", 39, 51], ["obstructive", "OBSERVATION", 178, 189], ["airways", "ANATOMY", 190, 197]]], ["The innate immune response to RSV infection is also modified by G protein expression.", [["RSV infection", "DISEASE", 30, 43], ["RSV", "ORGANISM", 30, 33], ["G protein", "GENE_OR_GENE_PRODUCT", 64, 73], ["G protein", "PROTEIN", 64, 73], ["RSV", "SPECIES", 30, 33], ["RSV infection", "PROBLEM", 30, 43], ["RSV infection", "OBSERVATION", 30, 43]]], ["Studies in mice have shown that RSV G protein Fig. 1.", [["mice", "ORGANISM", 11, 15], ["RSV G protein", "GENE_OR_GENE_PRODUCT", 32, 45], ["RSV G protein", "PROTEIN", 32, 45], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["RSV", "SPECIES", 32, 35], ["Studies", "TEST", 0, 7], ["RSV G protein Fig", "PROBLEM", 32, 49], ["RSV", "OBSERVATION", 32, 35], ["protein Fig", "OBSERVATION", 38, 49]]], ["Th 1 -driven response in non-atopic individuals.", [["Th 1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Th 1", "PROTEIN", 0, 4], ["non-atopic individuals", "PROBLEM", 25, 47], ["non-atopic individuals", "OBSERVATION", 25, 47]]], ["Following RSV infection, a predominant Th1 response is elicited, leading to the secretion of IFN-c and IL-2, which contribute to macrophage activation and promote IgG 2a antibody synthesis in the lower respiratory tract.", [["macrophage", "ANATOMY", 129, 139], ["lower respiratory tract", "ANATOMY", 196, 219], ["RSV infection", "DISEASE", 10, 23], ["RSV", "ORGANISM", 10, 13], ["IFN-c", "GENE_OR_GENE_PRODUCT", 93, 98], ["IL-2", "GENE_OR_GENE_PRODUCT", 103, 107], ["macrophage", "CELL", 129, 139], ["IgG 2a antibody", "GENE_OR_GENE_PRODUCT", 163, 178], ["lower", "ORGANISM_SUBDIVISION", 196, 201], ["respiratory tract", "ORGANISM_SUBDIVISION", 202, 219], ["IFN-c and IL-2", "PROTEIN", 93, 107], ["IgG 2a antibody", "PROTEIN", 163, 178], ["RSV", "SPECIES", 10, 13], ["RSV infection", "PROBLEM", 10, 23], ["the secretion of IFN", "PROBLEM", 76, 96], ["macrophage activation", "PROBLEM", 129, 150], ["IgG 2a antibody synthesis", "TREATMENT", 163, 188], ["RSV", "ANATOMY", 10, 13], ["infection", "OBSERVATION", 14, 23], ["predominant", "OBSERVATION_MODIFIER", 27, 38], ["Th1 response", "OBSERVATION", 39, 51], ["macrophage activation", "OBSERVATION", 129, 150], ["IgG 2a", "OBSERVATION", 163, 169], ["antibody synthesis", "OBSERVATION", 170, 188], ["lower", "ANATOMY_MODIFIER", 196, 201], ["respiratory tract", "ANATOMY", 202, 219]]], ["The subsequent CTL response is observed in conjunction with an IL-12-induced NK cell response, resulting in viral clearance and resolution of the infection in the airways.", [["NK cell", "ANATOMY", 77, 84], ["airways", "ANATOMY", 163, 170], ["infection", "DISEASE", 146, 155], ["IL-12", "GENE_OR_GENE_PRODUCT", 63, 68], ["NK cell", "CELL", 77, 84], ["airways", "MULTI-TISSUE_STRUCTURE", 163, 170], ["an IL", "TEST", 60, 65], ["viral clearance", "PROBLEM", 108, 123], ["the infection in the airways", "PROBLEM", 142, 170], ["NK cell response", "OBSERVATION", 77, 93], ["viral clearance", "OBSERVATION", 108, 123], ["infection", "OBSERVATION", 146, 155], ["airways", "ANATOMY", 163, 170]]], ["Secretion of IL-12 by antigen-presenting cells (APC) further contributes to NK cell activation and to a positive feedback on the Th 1 response.", [["antigen-presenting cells", "ANATOMY", 22, 46], ["NK cell", "ANATOMY", 76, 83], ["IL-12", "GENE_OR_GENE_PRODUCT", 13, 18], ["antigen-presenting cells", "CELL", 22, 46], ["APC", "GENE_OR_GENE_PRODUCT", 48, 51], ["NK cell", "CELL", 76, 83], ["Th 1", "GENE_OR_GENE_PRODUCT", 129, 133], ["IL-12", "PROTEIN", 13, 18], ["antigen-presenting cells", "CELL_TYPE", 22, 46], ["APC", "CELL_TYPE", 48, 51], ["Th 1", "PROTEIN", 129, 133], ["Secretion of IL", "TEST", 0, 15], ["NK cell activation", "PROBLEM", 76, 94], ["NK cell activation", "OBSERVATION", 76, 94]]], ["Upon re-infection with RSV, a memory Th 1 response is activated in the airways, thus re-initiating the IFN-c/IL-12 stimuli towards viral clearance and resolution.", [["airways", "ANATOMY", 71, 78], ["RSV", "ORGANISM", 23, 26], ["Th 1", "GENE_OR_GENE_PRODUCT", 37, 41], ["airways", "MULTI-TISSUE_STRUCTURE", 71, 78], ["IFN-c", "GENE_OR_GENE_PRODUCT", 103, 108], ["IL-12", "GENE_OR_GENE_PRODUCT", 109, 114], ["IFN", "PROTEIN", 103, 106], ["RSV", "SPECIES", 23, 26], ["re-infection", "PROBLEM", 5, 17], ["RSV", "PROBLEM", 23, 26], ["the IFN-c/IL", "TREATMENT", 99, 111], ["viral clearance", "TEST", 131, 146], ["re-infection", "OBSERVATION", 5, 17], ["RSV", "OBSERVATION", 23, 26], ["airways", "ANATOMY", 71, 78]]], ["Th 2 -driven response in atopic individuals (age-related or genetic predisposition): In a Th1-deficient system (common in neonates), RSV infection or allergen exposure elicits a predominantly Th 2 -driven response.", [["infection", "DISEASE", 137, 146], ["Th 2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Th1", "GENE_OR_GENE_PRODUCT", 90, 93], ["neonates", "ORGANISM", 122, 130], ["RSV", "ORGANISM", 133, 136], ["Th 2", "GENE_OR_GENE_PRODUCT", 192, 196], ["RSV", "SPECIES", 133, 136], ["RSV infection", "PROBLEM", 133, 146], ["allergen exposure", "PROBLEM", 150, 167], ["RSV", "ANATOMY", 133, 136], ["infection", "OBSERVATION", 137, 146]]], ["This results in the production of prominent Th 2 cytokines, IL-4 and IL-13, which contribute to mast cell activation and drive IgE synthesis. cd T-cells, a specialized T cell subset, were found to promote IgE antibodies, which have been associated with airway hyperreactivity observed in the lungs of asthmatic patients.", [["mast cell", "ANATOMY", 96, 105], ["cd T-cells", "ANATOMY", 142, 152], ["T cell", "ANATOMY", 168, 174], ["airway", "ANATOMY", 253, 259], ["lungs", "ANATOMY", 292, 297], ["airway hyperreactivity", "DISEASE", 253, 275], ["asthmatic", "DISEASE", 301, 310], ["Th 2", "GENE_OR_GENE_PRODUCT", 44, 48], ["IL-4", "GENE_OR_GENE_PRODUCT", 60, 64], ["IL-13", "GENE_OR_GENE_PRODUCT", 69, 74], ["mast cell", "CELL", 96, 105], ["IgE", "GENE_OR_GENE_PRODUCT", 127, 130], ["T cell", "CELL", 168, 174], ["IgE antibodies", "GENE_OR_GENE_PRODUCT", 205, 219], ["airway", "MULTI-TISSUE_STRUCTURE", 253, 259], ["lungs", "ORGAN", 292, 297], ["patients", "ORGANISM", 311, 319], ["Th 2 cytokines", "PROTEIN", 44, 58], ["IL-4", "PROTEIN", 60, 64], ["IL-13", "PROTEIN", 69, 74], ["IgE", "PROTEIN", 127, 130], ["cd T-cells", "CELL_TYPE", 142, 152], ["T cell subset", "CELL_TYPE", 168, 181], ["IgE antibodies", "PROTEIN", 205, 219], ["patients", "SPECIES", 311, 319], ["prominent Th 2 cytokines", "PROBLEM", 34, 58], ["IL", "TEST", 60, 62], ["mast cell activation", "PROBLEM", 96, 116], ["drive IgE synthesis", "PROBLEM", 121, 140], ["a specialized T cell subset", "PROBLEM", 154, 181], ["IgE antibodies", "TEST", 205, 219], ["airway hyperreactivity", "PROBLEM", 253, 275], ["asthmatic patients", "PROBLEM", 301, 319], ["prominent", "OBSERVATION_MODIFIER", 34, 43], ["mast cell activation", "OBSERVATION", 96, 116], ["IgE antibodies", "OBSERVATION", 205, 219], ["associated with", "UNCERTAINTY", 237, 252], ["airway", "ANATOMY", 253, 259], ["hyperreactivity", "OBSERVATION", 260, 275], ["lungs", "ANATOMY", 292, 297], ["asthmatic patients", "OBSERVATION", 301, 319]]], ["IL-5, a cytokine implicated in eosinophilia, is also known to stimulate mast-cells, resulting in degranulation and release of histamines.", [["mast-cells", "ANATOMY", 72, 82], ["eosinophilia", "DISEASE", 31, 43], ["histamines", "CHEMICAL", 126, 136], ["IL-5", "GENE_OR_GENE_PRODUCT", 0, 4], ["mast-cells", "CELL", 72, 82], ["histamines", "GENE_OR_GENE_PRODUCT", 126, 136], ["IL-5", "PROTEIN", 0, 4], ["cytokine", "PROTEIN", 8, 16], ["mast-cells", "CELL_TYPE", 72, 82], ["eosinophilia", "PROBLEM", 31, 43], ["degranulation", "PROBLEM", 97, 110], ["histamines", "TEST", 126, 136], ["eosinophilia", "OBSERVATION", 31, 43], ["degranulation", "OBSERVATION", 97, 110]]], ["Another potent Th 2 cytokine, IL-10, stimulates lung epithelial cells resulting in mucus excretion, and is known to inhibit APCs, therefore preventing IL-12 from initiating a Th 1 response.", [["lung epithelial cells", "ANATOMY", 48, 69], ["mucus", "ANATOMY", 83, 88], ["APCs", "ANATOMY", 124, 128], ["Th 2", "GENE_OR_GENE_PRODUCT", 15, 19], ["IL-10", "GENE_OR_GENE_PRODUCT", 30, 35], ["lung epithelial cells", "CELL", 48, 69], ["mucus", "ORGANISM_SUBSTANCE", 83, 88], ["APCs", "CELL", 124, 128], ["IL-12", "GENE_OR_GENE_PRODUCT", 151, 156], ["Th 1", "GENE_OR_GENE_PRODUCT", 175, 179], ["Th 2 cytokine", "PROTEIN", 15, 28], ["IL-10", "PROTEIN", 30, 35], ["lung epithelial cells", "CELL_TYPE", 48, 69], ["APCs", "CELL_TYPE", 124, 128], ["IL-12", "PROTEIN", 151, 156], ["Another potent Th 2 cytokine, IL", "TREATMENT", 0, 32], ["stimulates lung epithelial cells", "PROBLEM", 37, 69], ["mucus excretion", "PROBLEM", 83, 98], ["IL", "TREATMENT", 151, 153], ["lung", "ANATOMY", 48, 52], ["epithelial cells", "OBSERVATION", 53, 69], ["mucus excretion", "OBSERVATION", 83, 98]]], ["The presence of a potent chemokine, CCL5 (RANTES) further contributes to an exacerbated lower respiratory tract inflammation.", [["lower respiratory tract", "ANATOMY", 88, 111], ["respiratory tract inflammation", "DISEASE", 94, 124], ["CCL5", "GENE_OR_GENE_PRODUCT", 36, 40], ["RANTES", "GENE_OR_GENE_PRODUCT", 42, 48], ["tract", "ORGANISM_SUBDIVISION", 106, 111], ["chemokine", "PROTEIN", 25, 34], ["CCL5", "PROTEIN", 36, 40], ["RANTES", "PROTEIN", 42, 48], ["a potent chemokine, CCL5 (RANTES)", "TREATMENT", 16, 49], ["an exacerbated lower respiratory tract inflammation", "PROBLEM", 73, 124], ["potent", "OBSERVATION_MODIFIER", 18, 24], ["exacerbated", "OBSERVATION_MODIFIER", 76, 87], ["lower", "ANATOMY_MODIFIER", 88, 93], ["respiratory tract", "ANATOMY", 94, 111], ["inflammation", "OBSERVATION", 112, 124]]], ["Re-infection with RSV or re-exposure to an allergen in early childhood re-activates a memory Th 2 response, resulting in the initiation of inflammatory processes in the airways.", [["airways", "ANATOMY", 169, 176], ["Re-infection", "DISEASE", 0, 12], ["RSV", "DISEASE", 18, 21], ["RSV", "ORGANISM", 18, 21], ["Th 2", "GENE_OR_GENE_PRODUCT", 93, 97], ["airways", "MULTI-TISSUE_STRUCTURE", 169, 176], ["RSV", "SPECIES", 18, 21], ["Re-infection", "PROBLEM", 0, 12], ["RSV", "PROBLEM", 18, 21], ["inflammatory processes in the airways", "PROBLEM", 139, 176], ["RSV", "OBSERVATION", 18, 21], ["inflammatory", "OBSERVATION", 139, 151], ["airways", "ANATOMY", 169, 176]]], ["Synergistic action of RSV re-infection and allergen re-exposure in atopic individuals (young child or elderly) result in exacerbated airway pathology with persistent wheezing and asthma symptoms. expression is associated with aberrant T cell responses [57] , altered pulmonary NK cell and PMN trafficking [58] , modified CC and CXC chemokine mRNA expression by bronchoalveolar leukocytes [59] , and CX3C chemokine mimicry that affects leukocyte chemotaxis and fractalkine-mediated responses [44] .", [["airway", "ANATOMY", 133, 139], ["T cell", "ANATOMY", 235, 241], ["pulmonary NK cell", "ANATOMY", 267, 284], ["PMN", "ANATOMY", 289, 292], ["bronchoalveolar leukocytes", "ANATOMY", 361, 387], ["leukocyte", "ANATOMY", 435, 444], ["RSV re-infection", "DISEASE", 22, 38], ["wheezing", "DISEASE", 166, 174], ["asthma", "DISEASE", 179, 185], ["RSV", "ORGANISM", 22, 25], ["airway", "MULTI-TISSUE_STRUCTURE", 133, 139], ["T cell", "CELL", 235, 241], ["pulmonary NK cell", "CELL", 267, 284], ["PMN", "CELL", 289, 292], ["CC", "CELL", 321, 323], ["CXC", "GENE_OR_GENE_PRODUCT", 328, 331], ["bronchoalveolar leukocytes", "CELL", 361, 387], ["CX3C chemokine", "GENE_OR_GENE_PRODUCT", 399, 413], ["leukocyte", "CELL", 435, 444], ["fractalkine", "GENE_OR_GENE_PRODUCT", 460, 471], ["pulmonary NK cell", "CELL_TYPE", 267, 284], ["PMN", "CELL_TYPE", 289, 292], ["CXC chemokine mRNA", "RNA", 328, 346], ["bronchoalveolar leukocytes", "CELL_TYPE", 361, 387], ["chemokine", "PROTEIN", 404, 413], ["fractalkine", "PROTEIN", 460, 471], ["RSV", "SPECIES", 22, 25], ["RSV re-infection", "PROBLEM", 22, 38], ["exacerbated airway pathology", "PROBLEM", 121, 149], ["persistent wheezing", "PROBLEM", 155, 174], ["asthma symptoms", "PROBLEM", 179, 194], ["aberrant T cell responses", "PROBLEM", 226, 251], ["altered pulmonary NK cell", "PROBLEM", 259, 284], ["PMN trafficking", "TEST", 289, 304], ["modified CC and CXC chemokine mRNA expression", "TEST", 312, 357], ["bronchoalveolar leukocytes", "TEST", 361, 387], ["CX3C chemokine mimicry", "TEST", 399, 421], ["leukocyte chemotaxis", "TEST", 435, 455], ["fractalkine", "TEST", 460, 471], ["RSV re-infection", "OBSERVATION", 22, 38], ["airway", "ANATOMY", 133, 139], ["pathology", "OBSERVATION", 140, 149], ["persistent", "OBSERVATION_MODIFIER", 155, 165], ["wheezing", "OBSERVATION", 166, 174], ["pulmonary", "ANATOMY", 267, 276], ["NK cell", "OBSERVATION", 277, 284], ["bronchoalveolar leukocytes", "OBSERVATION", 361, 387]]], ["It is possible that HMPV G protein may also mediate immune modulatory effects; however, the putative HMPV G protein does not appear to contain a CX3C chemokine motif, and its deduced amino acid sequence analysis suggests it is highly divergent from RSV G protein [6, 21, 60] .Immune response to HMPV infectionLittle is known about the acquired immune response to HMPV infection in either animal models or humans.", [["amino acid", "CHEMICAL", 183, 193], ["HMPV infectionLittle", "DISEASE", 295, 315], ["HMPV infection", "DISEASE", 363, 377], ["amino acid", "CHEMICAL", 183, 193], ["HMPV G", "GENE_OR_GENE_PRODUCT", 20, 26], ["HMPV G", "GENE_OR_GENE_PRODUCT", 101, 107], ["CX3C", "GENE_OR_GENE_PRODUCT", 145, 149], ["amino acid", "AMINO_ACID", 183, 193], ["RSV G protein", "GENE_OR_GENE_PRODUCT", 249, 262], ["HMPV", "ORGANISM", 295, 299], ["HMPV", "ORGANISM", 363, 367], ["humans", "ORGANISM", 405, 411], ["HMPV G protein", "PROTEIN", 20, 34], ["HMPV G protein", "PROTEIN", 101, 115], ["CX3C chemokine motif", "PROTEIN", 145, 165], ["RSV G protein", "PROTEIN", 249, 262], ["humans", "SPECIES", 405, 411], ["HMPV", "SPECIES", 20, 24], ["RSV", "SPECIES", 249, 252], ["HMPV", "SPECIES", 295, 299], ["HMPV", "SPECIES", 363, 367], ["humans", "SPECIES", 405, 411], ["HMPV G protein", "PROBLEM", 20, 34], ["the putative HMPV G protein", "TEST", 88, 115], ["a CX3C chemokine motif", "TEST", 143, 165], ["its deduced amino acid sequence analysis", "TEST", 171, 211], ["RSV G protein", "TEST", 249, 262], ["HMPV infectionLittle", "PROBLEM", 295, 315], ["HMPV infection", "PROBLEM", 363, 377], ["HMPV", "OBSERVATION", 20, 24], ["HMPV", "OBSERVATION", 295, 299], ["HMPV infection", "OBSERVATION", 363, 377]]], ["In contrast, the protective antibody response to RSV infection is directed against the two major viral proteins, i.e. F and G, and serum neutralizing antibody responses are primarily directed against the F protein [61] .", [["serum", "ANATOMY", 131, 136], ["RSV infection", "DISEASE", 49, 62], ["RSV", "ORGANISM", 49, 52], ["G", "GENE_OR_GENE_PRODUCT", 124, 125], ["serum", "ORGANISM_SUBSTANCE", 131, 136], ["viral proteins", "PROTEIN", 97, 111], ["F and G", "PROTEIN", 118, 125], ["serum neutralizing antibody", "PROTEIN", 131, 158], ["F protein", "PROTEIN", 204, 213], ["RSV", "SPECIES", 49, 52], ["the protective antibody response", "TEST", 13, 45], ["RSV infection", "PROBLEM", 49, 62], ["the two major viral proteins", "PROBLEM", 83, 111], ["G", "TEST", 124, 125], ["serum neutralizing antibody responses", "TEST", 131, 168], ["the F protein", "TEST", 200, 213], ["RSV infection", "OBSERVATION", 49, 62]]], ["Although the neutralization and protective antigens of HMPV remain to be determined, it is likely that the high degree of divergence of the G protein between and within HMPV subgroups [21, 60] will contribute to limited cross-neutralizing and cross-protective antibody responses as has been observed for RSV [61] .", [["HMPV", "ORGANISM", 55, 59], ["G protein", "GENE_OR_GENE_PRODUCT", 140, 149], ["HMPV", "ORGANISM", 169, 173], ["RSV", "ORGANISM", 304, 307], ["G protein", "PROTEIN", 140, 149], ["HMPV", "SPECIES", 55, 59], ["RSV", "SPECIES", 304, 307], ["the neutralization", "TREATMENT", 9, 27], ["HMPV", "PROBLEM", 55, 59], ["the G protein", "TREATMENT", 136, 149], ["limited cross-neutralizing", "PROBLEM", 212, 238], ["RSV", "PROBLEM", 304, 307]]], ["The T cell response to HMPV infection in humans has not been characterized; however recent studies from our laboratories have shown that antibody-mediated depletion of T-cells or DX5 + cells in BALB/c mice results in increased HMPV titers in the lungs of infected mice suggesting that cytotoxic cells control aspects of replication and may control HMPV persistence [27] .Links between respiratory viral infections and asthma exacerbationsAsthma is a chronic, episodic inflammatory disease of the airways where inflammation is the cause of airway hyperreactivity with associated narrowing of the small airways and variable airflow in response to triggering events that include allergens, viral infections, and exposure to airway irritants [62] [63] [64] [65] [66] .", [["T cell", "ANATOMY", 4, 10], ["T-cells", "ANATOMY", 168, 175], ["DX5 + cells", "ANATOMY", 179, 190], ["lungs", "ANATOMY", 246, 251], ["cells", "ANATOMY", 295, 300], ["airways", "ANATOMY", 496, 503], ["airway", "ANATOMY", 539, 545], ["small airways", "ANATOMY", 595, 608], ["airway", "ANATOMY", 721, 727], ["HMPV infection", "DISEASE", 23, 37], ["respiratory viral infections", "DISEASE", 385, 413], ["asthma", "DISEASE", 418, 424], ["Asthma", "DISEASE", 438, 444], ["inflammation", "DISEASE", 510, 522], ["airway hyperreactivity", "DISEASE", 539, 561], ["viral infections", "DISEASE", 687, 703], ["[62] [63] [64] [65]", "CHEMICAL", 738, 757], ["T cell", "CELL", 4, 10], ["HMPV", "ORGANISM", 23, 27], ["humans", "ORGANISM", 41, 47], ["T-cells", "CELL", 168, 175], ["DX5 + cells", "CELL", 179, 190], ["BALB/c mice", "ORGANISM", 194, 205], ["HMPV", "ORGANISM", 227, 231], ["lungs", "ORGAN", 246, 251], ["mice", "ORGANISM", 264, 268], ["cytotoxic cells", "CELL", 285, 300], ["HMPV", "ORGANISM", 348, 352], ["airways", "MULTI-TISSUE_STRUCTURE", 496, 503], ["airway", "MULTI-TISSUE_STRUCTURE", 539, 545], ["airways", "MULTI-TISSUE_STRUCTURE", 601, 608], ["[62] [63] [64] [65] [66]", "SIMPLE_CHEMICAL", 738, 762], ["T-cells", "CELL_TYPE", 168, 175], ["DX5 + cells", "CELL_TYPE", 179, 190], ["cytotoxic cells", "CELL_TYPE", 285, 300], ["humans", "SPECIES", 41, 47], ["mice", "SPECIES", 201, 205], ["mice", "SPECIES", 264, 268], ["HMPV", "SPECIES", 23, 27], ["humans", "SPECIES", 41, 47], ["mice", "SPECIES", 201, 205], ["HMPV", "SPECIES", 227, 231], ["mice", "SPECIES", 264, 268], ["HMPV", "SPECIES", 348, 352], ["HMPV infection", "PROBLEM", 23, 37], ["recent studies", "TEST", 84, 98], ["our laboratories", "TEST", 104, 120], ["antibody", "TEST", 137, 145], ["T-cells", "PROBLEM", 168, 175], ["DX5 + cells", "PROBLEM", 179, 190], ["BALB", "TEST", 194, 198], ["increased HMPV titers", "PROBLEM", 217, 238], ["cytotoxic cells", "TREATMENT", 285, 300], ["HMPV persistence", "PROBLEM", 348, 364], ["respiratory viral infections", "PROBLEM", 385, 413], ["asthma exacerbations", "PROBLEM", 418, 438], ["Asthma", "PROBLEM", 438, 444], ["a chronic, episodic inflammatory disease of the airways", "PROBLEM", 448, 503], ["inflammation", "PROBLEM", 510, 522], ["airway hyperreactivity", "PROBLEM", 539, 561], ["associated narrowing of the small airways", "PROBLEM", 567, 608], ["variable airflow", "PROBLEM", 613, 629], ["triggering events", "PROBLEM", 645, 662], ["allergens", "PROBLEM", 676, 685], ["viral infections", "PROBLEM", 687, 703], ["airway irritants", "TEST", 721, 737], ["HMPV", "OBSERVATION_MODIFIER", 23, 27], ["infection", "OBSERVATION", 28, 37], ["increased", "OBSERVATION_MODIFIER", 217, 226], ["HMPV titers", "OBSERVATION", 227, 238], ["lungs", "ANATOMY", 246, 251], ["cytotoxic cells", "OBSERVATION", 285, 300], ["respiratory", "ANATOMY", 385, 396], ["viral infections", "OBSERVATION", 397, 413], ["asthma", "OBSERVATION", 418, 424], ["chronic", "OBSERVATION_MODIFIER", 450, 457], ["episodic", "OBSERVATION_MODIFIER", 459, 467], ["inflammatory", "OBSERVATION_MODIFIER", 468, 480], ["airways", "ANATOMY", 496, 503], ["inflammation", "OBSERVATION", 510, 522], ["airway", "ANATOMY", 539, 545], ["hyperreactivity", "OBSERVATION", 546, 561], ["narrowing", "OBSERVATION", 578, 587], ["small airways", "ANATOMY", 595, 608], ["variable", "OBSERVATION_MODIFIER", 613, 621], ["airflow", "OBSERVATION", 622, 629], ["viral infections", "OBSERVATION", 687, 703], ["airway", "ANATOMY", 721, 727]]], ["Asthma is a major cause of morbidity and mortality affecting > 14 million people in the United States, and is the most common chronic disease of childhood, affecting > 4.8 million children [67] [68] [69] .", [["Asthma", "DISEASE", 0, 6], ["people", "ORGANISM", 74, 80], ["children", "ORGANISM", 180, 188], ["people", "SPECIES", 74, 80], ["children", "SPECIES", 180, 188], ["Asthma", "PROBLEM", 0, 6], ["morbidity", "PROBLEM", 27, 36], ["morbidity", "OBSERVATION", 27, 36], ["most common", "OBSERVATION_MODIFIER", 114, 125], ["chronic", "OBSERVATION_MODIFIER", 126, 133], ["disease", "OBSERVATION", 134, 141]]], ["Our understanding of the multifactorial nature of asthma is incomplete, and little is known regarding viral mechanisms that may contribute to asthma disease pathogenesis.", [["asthma", "DISEASE", 50, 56], ["asthma disease", "DISEASE", 142, 156], ["asthma", "PROBLEM", 50, 56], ["viral mechanisms", "PROBLEM", 102, 118], ["asthma disease pathogenesis", "PROBLEM", 142, 169], ["asthma", "OBSERVATION", 50, 56], ["may contribute to", "UNCERTAINTY", 124, 141], ["asthma", "OBSERVATION", 142, 148]]], ["Consistent with asthma being the most common chronic disease of childhood [68] , RSV is recognized as the primary cause of morbidity and life-threatening lower respiratory tract disease in infants and young children worldwide, and numerous studies suggest linkages between RSV infection in early childhood, respiratory sequelae, and subsequent manifestations of asthma [64, [69] [70] [71] .", [["lower respiratory tract", "ANATOMY", 154, 177], ["respiratory", "ANATOMY", 307, 318], ["asthma", "DISEASE", 16, 22], ["RSV", "DISEASE", 81, 84], ["lower respiratory tract disease", "DISEASE", 154, 185], ["RSV infection", "DISEASE", 273, 286], ["respiratory sequelae", "DISEASE", 307, 327], ["asthma", "DISEASE", 362, 368], ["RSV", "ORGANISM", 81, 84], ["lower", "ORGANISM_SUBDIVISION", 154, 159], ["respiratory tract", "ORGANISM_SUBDIVISION", 160, 177], ["infants", "ORGANISM", 189, 196], ["children", "ORGANISM", 207, 215], ["RSV", "ORGANISM", 273, 276], ["infants", "SPECIES", 189, 196], ["children", "SPECIES", 207, 215], ["RSV", "SPECIES", 81, 84], ["RSV", "SPECIES", 273, 276], ["asthma", "PROBLEM", 16, 22], ["RSV", "PROBLEM", 81, 84], ["morbidity", "PROBLEM", 123, 132], ["life-threatening lower respiratory tract disease", "PROBLEM", 137, 185], ["numerous studies", "TEST", 231, 247], ["RSV infection", "PROBLEM", 273, 286], ["respiratory sequelae", "PROBLEM", 307, 327], ["asthma", "PROBLEM", 362, 368], ["asthma", "OBSERVATION", 16, 22], ["most common", "OBSERVATION_MODIFIER", 33, 44], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["disease", "OBSERVATION", 53, 60], ["morbidity", "OBSERVATION", 123, 132], ["lower", "ANATOMY_MODIFIER", 154, 159], ["respiratory tract", "ANATOMY", 160, 177], ["RSV infection", "OBSERVATION", 273, 286], ["respiratory sequelae", "OBSERVATION", 307, 327]]], ["Several studies now indicate that HMPV infection may contribute to aspects of asthma pathogenesis [12, [32] [33] [34] .", [["HMPV infection", "DISEASE", 34, 48], ["asthma", "DISEASE", 78, 84], ["HMPV", "ORGANISM", 34, 38], ["HMPV", "SPECIES", 34, 38], ["Several studies", "TEST", 0, 15], ["HMPV infection", "PROBLEM", 34, 48], ["asthma pathogenesis", "PROBLEM", 78, 97], ["HMPV", "OBSERVATION", 34, 38]]], ["Similar to RSV infection in infants and young children, it is likely that HMPV does not engender a fully protective immune response [72] , as studies in mice have shown HMPV may cause persistent infection [27] .RSV and asthma pathogenesisSeveral cross-sectional and prospective studies indicate that RSV infection in early childhood is linked to subsequent manifestations of asthma.", [["RSV infection", "DISEASE", 11, 24], ["HMPV", "DISEASE", 169, 173], ["infection", "DISEASE", 195, 204], ["RSV", "DISEASE", 211, 214], ["asthma", "DISEASE", 219, 225], ["RSV infection", "DISEASE", 300, 313], ["asthma", "DISEASE", 375, 381], ["RSV", "ORGANISM", 11, 14], ["infants", "ORGANISM", 28, 35], ["children", "ORGANISM", 46, 54], ["HMPV", "ORGANISM", 74, 78], ["mice", "ORGANISM", 153, 157], ["HMPV", "ORGANISM", 169, 173], ["RSV", "ORGANISM", 211, 214], ["RSV", "ORGANISM", 300, 303], ["infants", "SPECIES", 28, 35], ["children", "SPECIES", 46, 54], ["mice", "SPECIES", 153, 157], ["RSV", "SPECIES", 211, 214], ["RSV", "SPECIES", 11, 14], ["HMPV", "SPECIES", 74, 78], ["mice", "SPECIES", 153, 157], ["HMPV", "SPECIES", 169, 173], ["RSV", "SPECIES", 211, 214], ["RSV", "SPECIES", 300, 303], ["RSV infection", "PROBLEM", 11, 24], ["HMPV", "PROBLEM", 74, 78], ["HMPV", "PROBLEM", 169, 173], ["persistent infection", "PROBLEM", 184, 204], ["RSV", "PROBLEM", 211, 214], ["asthma pathogenesis", "PROBLEM", 219, 238], ["prospective studies", "TEST", 266, 285], ["RSV infection", "PROBLEM", 300, 313], ["asthma", "PROBLEM", 375, 381], ["RSV", "OBSERVATION_MODIFIER", 11, 14], ["infection", "OBSERVATION", 15, 24], ["persistent", "OBSERVATION_MODIFIER", 184, 194], ["infection", "OBSERVATION", 195, 204], ["asthma", "OBSERVATION", 219, 225], ["RSV", "OBSERVATION_MODIFIER", 300, 303], ["infection", "OBSERVATION", 304, 313], ["asthma", "OBSERVATION", 375, 381]]], ["For example, in school children, 80% of wheezing episodes have been associated with viral respiratory tract infections [73] .", [["respiratory tract", "ANATOMY", 90, 107], ["wheezing", "DISEASE", 40, 48], ["viral respiratory tract infections", "DISEASE", 84, 118], ["children", "ORGANISM", 23, 31], ["tract", "ORGANISM_SUBDIVISION", 102, 107], ["children", "SPECIES", 23, 31], ["wheezing episodes", "PROBLEM", 40, 57], ["viral respiratory tract infections", "PROBLEM", 84, 118], ["respiratory tract", "ANATOMY", 90, 107]]], ["In infants and toddlers under the age of 2 years, RSV is the virus most frequently isolated during wheezing episodes [74] .", [["wheezing", "DISEASE", 99, 107], ["infants", "ORGANISM", 3, 10], ["RSV", "ORGANISM", 50, 53], ["infants", "SPECIES", 3, 10], ["RSV", "SPECIES", 50, 53], ["RSV", "PROBLEM", 50, 53], ["the virus", "PROBLEM", 57, 66], ["wheezing episodes", "PROBLEM", 99, 116]]], ["In addition, epidemiological evidence suggests that RSV may also contribute to early allergic sensitization and subsequent development of childhood asthma.", [["allergic sensitization", "DISEASE", 85, 107], ["asthma", "DISEASE", 148, 154], ["RSV", "ORGANISM", 52, 55], ["RSV", "SPECIES", 52, 55], ["RSV", "PROBLEM", 52, 55], ["early allergic sensitization", "PROBLEM", 79, 107], ["childhood asthma", "PROBLEM", 138, 154], ["RSV", "OBSERVATION", 52, 55], ["may also contribute to", "UNCERTAINTY", 56, 78], ["early", "OBSERVATION_MODIFIER", 79, 84], ["allergic", "OBSERVATION", 85, 93], ["childhood", "OBSERVATION_MODIFIER", 138, 147], ["asthma", "OBSERVATION", 148, 154]]], ["For example, Frick and colleagues observed a coincidence of respiratory infections and the onset of allergic sensitization to aeroallergens in infants with a positive family history of allergy [75] .", [["respiratory", "ANATOMY", 60, 71], ["respiratory infections", "DISEASE", 60, 82], ["allergic sensitization", "DISEASE", 100, 122], ["allergy", "DISEASE", 185, 192], ["infants", "ORGANISM", 143, 150], ["infants", "SPECIES", 143, 150], ["respiratory infections", "PROBLEM", 60, 82], ["allergic sensitization", "PROBLEM", 100, 122], ["aeroallergens", "PROBLEM", 126, 139], ["allergy", "PROBLEM", 185, 192], ["respiratory", "ANATOMY", 60, 71], ["infections", "OBSERVATION", 72, 82], ["allergic sensitization", "OBSERVATION", 100, 122]]], ["In a prospective cohort study with matched controls, Sigurs and colleagues identified RSV bronchiolitis in infancy as the most important risk factor for the subsequent development of asthma and sensitization to common allergens by the age of 3 years [76] .", [["RSV bronchiolitis", "DISEASE", 86, 103], ["asthma", "DISEASE", 183, 189], ["RSV", "ORGANISM", 86, 89], ["RSV", "SPECIES", 86, 89], ["a prospective cohort study", "TEST", 3, 29], ["RSV bronchiolitis", "PROBLEM", 86, 103], ["asthma", "PROBLEM", 183, 189], ["RSV bronchiolitis", "OBSERVATION", 86, 103], ["asthma", "OBSERVATION", 183, 189]]], ["This risk further increased if there was a family history of asthma or atopy.", [["asthma", "DISEASE", 61, 67], ["atopy", "DISEASE", 71, 76], ["asthma", "PROBLEM", 61, 67], ["atopy", "PROBLEM", 71, 76], ["asthma", "OBSERVATION", 61, 67]]], ["A follow-up report by the same group showed that by the age of 7 years, allergic sensitization and asthma were still more prevalent in the group of children who had had RSV bronchiolitis in the first year of life than in the controls [77] .", [["allergic sensitization", "DISEASE", 72, 94], ["asthma", "DISEASE", 99, 105], ["bronchiolitis", "DISEASE", 173, 186], ["children", "ORGANISM", 148, 156], ["RSV", "ORGANISM", 169, 172], ["children", "SPECIES", 148, 156], ["RSV", "SPECIES", 169, 172], ["allergic sensitization", "PROBLEM", 72, 94], ["asthma", "PROBLEM", 99, 105], ["RSV bronchiolitis", "PROBLEM", 169, 186], ["RSV bronchiolitis", "OBSERVATION", 169, 186]]], ["Recently, Schauer et al. confirmed the increased risk for allergen sensitization and asthma symptoms in 12-month-old infants following RSV bronchiolitis [78] .", [["allergen sensitization", "DISEASE", 58, 80], ["asthma symptoms", "DISEASE", 85, 100], ["bronchiolitis", "DISEASE", 139, 152], ["infants", "ORGANISM", 117, 124], ["RSV", "ORGANISM", 135, 138], ["infants", "SPECIES", 117, 124], ["RSV", "SPECIES", 135, 138], ["allergen sensitization", "PROBLEM", 58, 80], ["asthma symptoms", "PROBLEM", 85, 100], ["RSV bronchiolitis", "PROBLEM", 135, 152], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["risk for", "UNCERTAINTY", 49, 57], ["allergen sensitization", "OBSERVATION", 58, 80], ["RSV", "ANATOMY", 135, 138], ["bronchiolitis", "OBSERVATION", 139, 152]]], ["Interestingly, sensitization was almost exclusively linked to food allergens, suggesting that pulmonary infection with RSV has a systemic impact on sensitization.", [["pulmonary", "ANATOMY", 94, 103], ["pulmonary infection", "DISEASE", 94, 113], ["RSV", "DISEASE", 119, 122], ["pulmonary", "ORGAN", 94, 103], ["RSV", "ORGANISM", 119, 122], ["RSV", "SPECIES", 119, 122], ["pulmonary infection", "PROBLEM", 94, 113], ["RSV", "PROBLEM", 119, 122], ["pulmonary", "ANATOMY", 94, 103], ["infection", "OBSERVATION", 104, 113], ["RSV", "OBSERVATION", 119, 122]]], ["However, several studies which have shown a link between RSV bronchiolitis and asthma do not find an association with allergen sensitization [79] [80] [81] .", [["bronchiolitis", "DISEASE", 61, 74], ["asthma", "DISEASE", 79, 85], ["RSV", "ORGANISM", 57, 60], ["RSV", "SPECIES", 57, 60], ["several studies", "TEST", 9, 24], ["RSV bronchiolitis", "PROBLEM", 57, 74], ["asthma", "PROBLEM", 79, 85], ["allergen sensitization", "TEST", 118, 140], ["RSV bronchiolitis", "OBSERVATION", 57, 74], ["asthma", "OBSERVATION", 79, 85]]], ["It is likely that the studies showing RSV infection with allergen sensitization reflect the relatively small minority of RSV-infected children who require hospitalization, thus selecting for those with a predisposition to severe RSV disease.", [["RSV infection", "DISEASE", 38, 51], ["allergen sensitization", "DISEASE", 57, 79], ["RSV-infected", "DISEASE", 121, 133], ["RSV disease", "DISEASE", 229, 240], ["RSV", "ORGANISM", 38, 41], ["RSV", "ORGANISM", 121, 124], ["children", "ORGANISM", 134, 142], ["RSV", "ORGANISM", 229, 232], ["children", "SPECIES", 134, 142], ["RSV", "SPECIES", 38, 41], ["RSV", "SPECIES", 121, 124], ["RSV", "SPECIES", 229, 232], ["the studies", "TEST", 18, 29], ["RSV infection", "PROBLEM", 38, 51], ["allergen sensitization", "TREATMENT", 57, 79], ["severe RSV disease", "PROBLEM", 222, 240], ["RSV", "OBSERVATION_MODIFIER", 38, 41], ["infection", "OBSERVATION", 42, 51], ["small", "OBSERVATION_MODIFIER", 103, 108], ["minority", "OBSERVATION_MODIFIER", 109, 117], ["RSV", "OBSERVATION", 121, 124], ["severe", "OBSERVATION_MODIFIER", 222, 228], ["RSV", "OBSERVATION", 229, 232]]], ["Perhaps the most compelling study because of large birth cohort examined is from the Tucson children's respiratory study group [76] .", [["children", "SPECIES", 92, 100], ["large", "OBSERVATION_MODIFIER", 45, 50]]], ["In this study all children with RSV infection during the first 3 years of life were followed, and the results showed that these children had an increased risk to wheeze at age 6, but this risk did not persist beyond age 13 years.", [["RSV infection", "DISEASE", 32, 45], ["wheeze", "DISEASE", 162, 168], ["children", "ORGANISM", 18, 26], ["RSV", "ORGANISM", 32, 35], ["children", "ORGANISM", 128, 136], ["children", "SPECIES", 18, 26], ["RSV", "SPECIES", 32, 35], ["children", "SPECIES", 128, 136], ["RSV", "SPECIES", 32, 35], ["this study", "TEST", 3, 13], ["RSV infection", "PROBLEM", 32, 45], ["wheeze", "PROBLEM", 162, 168], ["infection", "OBSERVATION", 36, 45], ["increased", "OBSERVATION_MODIFIER", 144, 153]]], ["In this study, RSV infection was not a risk factor for allergen sensitization indicating that only severe RSV bronchiolitis may be associated with early allergen sensitization.RSV and asthma pathogenesisIt is also important to note that the majority of infants infected with RSV do not develop severe disease or asthma.", [["RSV infection", "DISEASE", 15, 28], ["allergen sensitization", "DISEASE", 55, 77], ["bronchiolitis", "DISEASE", 110, 123], ["allergen sensitization", "DISEASE", 153, 175], ["RSV", "DISEASE", 176, 179], ["asthma", "DISEASE", 184, 190], ["asthma", "DISEASE", 312, 318], ["RSV", "ORGANISM", 15, 18], ["RSV", "ORGANISM", 106, 109], ["RSV", "ORGANISM", 176, 179], ["infants", "ORGANISM", 253, 260], ["RSV", "ORGANISM", 275, 278], ["RSV", "SPECIES", 176, 179], ["infants", "SPECIES", 253, 260], ["RSV", "SPECIES", 15, 18], ["RSV", "SPECIES", 106, 109], ["RSV", "SPECIES", 176, 179], ["RSV", "SPECIES", 275, 278], ["this study", "TEST", 3, 13], ["RSV infection", "PROBLEM", 15, 28], ["allergen sensitization", "TREATMENT", 55, 77], ["severe RSV bronchiolitis", "PROBLEM", 99, 123], ["early allergen sensitization", "PROBLEM", 147, 175], ["RSV", "PROBLEM", 176, 179], ["asthma pathogenesis", "PROBLEM", 184, 203], ["RSV", "PROBLEM", 275, 278], ["severe disease", "PROBLEM", 294, 308], ["asthma", "PROBLEM", 312, 318], ["infection", "OBSERVATION", 19, 28], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["RSV bronchiolitis", "OBSERVATION", 106, 123], ["may be associated with", "UNCERTAINTY", 124, 146], ["early", "OBSERVATION_MODIFIER", 147, 152], ["allergen sensitization", "OBSERVATION", 153, 175], ["asthma", "OBSERVATION", 184, 190], ["severe", "OBSERVATION_MODIFIER", 294, 300], ["disease", "OBSERVATION", 301, 308], ["asthma", "OBSERVATION", 312, 318]]], ["Consistent with this hypothesis, several studies have shown that the Th2-type cytokine, IL-4, may be linked to the development of severe RSV disease in humans.", [["RSV disease", "DISEASE", 137, 148], ["IL-4", "GENE_OR_GENE_PRODUCT", 88, 92], ["RSV", "ORGANISM", 137, 140], ["humans", "ORGANISM", 152, 158], ["Th2-type cytokine", "PROTEIN", 69, 86], ["IL-4", "PROTEIN", 88, 92], ["humans", "SPECIES", 152, 158], ["RSV", "SPECIES", 137, 140], ["humans", "SPECIES", 152, 158], ["this hypothesis", "PROBLEM", 16, 31], ["several studies", "TEST", 33, 48], ["severe RSV disease in humans", "PROBLEM", 130, 158], ["severe", "OBSERVATION_MODIFIER", 130, 136], ["RSV disease", "OBSERVATION", 137, 148]]], ["Infants hospitalized with RSV bronchiolitis and having IL-4 and IL-4Ra gene variants, i.e. IL-4 590T allele and IL-4Ra chain R551 allele, developed more severe disease compared to case-control patients [82] , and patients with a common IL-4 haplotype variant, i.e. -589T promoter variant, were shown to be over-represented among all patients examined with severe RSV disease [83] .", [["bronchiolitis", "DISEASE", 30, 43], ["RSV disease", "DISEASE", 363, 374], ["Infants", "ORGANISM", 0, 7], ["RSV", "ORGANISM", 26, 29], ["IL-4", "GENE_OR_GENE_PRODUCT", 55, 59], ["IL-4Ra", "GENE_OR_GENE_PRODUCT", 64, 70], ["IL-4", "GENE_OR_GENE_PRODUCT", 91, 95], ["IL-4Ra chain R551", "GENE_OR_GENE_PRODUCT", 112, 129], ["patients", "ORGANISM", 193, 201], ["patients", "ORGANISM", 213, 221], ["IL-4", "GENE_OR_GENE_PRODUCT", 236, 240], ["patients", "ORGANISM", 333, 341], ["RSV", "ORGANISM", 363, 366], ["IL-4 590T allele", "DNA", 91, 107], ["R551 allele", "DNA", 125, 136], ["Infants", "SPECIES", 0, 7], ["RSV", "SPECIES", 26, 29], ["patients", "SPECIES", 193, 201], ["patients", "SPECIES", 213, 221], ["patients", "SPECIES", 333, 341], ["RSV", "SPECIES", 26, 29], ["RSV", "SPECIES", 363, 366], ["RSV bronchiolitis", "PROBLEM", 26, 43], ["IL", "TEST", 55, 57], ["IL", "TREATMENT", 64, 66], ["more severe disease", "PROBLEM", 148, 167], ["severe RSV disease", "PROBLEM", 356, 374], ["RSV bronchiolitis", "OBSERVATION", 26, 43], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["disease", "OBSERVATION", 160, 167], ["severe", "OBSERVATION_MODIFIER", 356, 362], ["RSV", "OBSERVATION", 363, 366]]], ["These studies suggest that these IL-4 and IL-4Ra gene variants may be risk factors for severe RSV disease.", [["RSV disease", "DISEASE", 94, 105], ["IL-4", "GENE_OR_GENE_PRODUCT", 33, 37], ["IL-4Ra", "GENE_OR_GENE_PRODUCT", 42, 48], ["RSV", "ORGANISM", 94, 97], ["IL-4 and IL-4Ra gene variants", "DNA", 33, 62], ["RSV", "SPECIES", 94, 97], ["These studies", "TEST", 0, 13], ["these IL", "TEST", 27, 35], ["IL-4Ra gene variants", "TREATMENT", 42, 62], ["severe RSV disease", "PROBLEM", 87, 105], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["RSV", "OBSERVATION", 94, 97]]], ["Since HMPV infection is a leading cause of respiratory tract infection in the first years of life, and induces a spectrum of disease similar to that of RSV including bronchiolitis and exacerbation of asthma [84] , it is possible that patients with IL-4 or other Th2-type cytokine gene variants may have similar risk following HMPV infection.Immune mechanisms associated with RSV-induced asthmaThe immune mechanisms associated with virus-induced asthma exacerbation have been the subject of intense research in recent years.", [["respiratory tract", "ANATOMY", 43, 60], ["HMPV infection", "DISEASE", 6, 20], ["respiratory tract infection", "DISEASE", 43, 70], ["RSV", "DISEASE", 152, 155], ["bronchiolitis", "DISEASE", 166, 179], ["asthma", "DISEASE", 200, 206], ["HMPV infection", "DISEASE", 326, 340], ["asthma", "DISEASE", 387, 393], ["asthma", "DISEASE", 445, 451], ["HMPV", "ORGANISM", 6, 10], ["respiratory tract", "ORGANISM_SUBDIVISION", 43, 60], ["RSV", "ORGANISM", 152, 155], ["patients", "ORGANISM", 234, 242], ["IL-4", "GENE_OR_GENE_PRODUCT", 248, 252], ["Th2", "GENE_OR_GENE_PRODUCT", 262, 265], ["HMPV", "ORGANISM", 326, 330], ["RSV", "ORGANISM", 375, 378], ["Th2-type cytokine gene variants", "DNA", 262, 293], ["patients", "SPECIES", 234, 242], ["HMPV", "SPECIES", 6, 10], ["RSV", "SPECIES", 152, 155], ["HMPV", "SPECIES", 326, 330], ["RSV", "SPECIES", 375, 378], ["HMPV infection", "PROBLEM", 6, 20], ["respiratory tract infection", "PROBLEM", 43, 70], ["disease", "PROBLEM", 125, 132], ["RSV", "PROBLEM", 152, 155], ["bronchiolitis", "PROBLEM", 166, 179], ["exacerbation", "PROBLEM", 184, 196], ["asthma", "PROBLEM", 200, 206], ["IL", "TEST", 248, 250], ["Th2-type cytokine gene variants", "TREATMENT", 262, 293], ["HMPV infection", "PROBLEM", 326, 340], ["Immune mechanisms", "PROBLEM", 341, 358], ["RSV", "PROBLEM", 375, 378], ["asthma", "PROBLEM", 387, 393], ["The immune mechanisms", "PROBLEM", 393, 414], ["virus", "PROBLEM", 431, 436], ["asthma exacerbation", "PROBLEM", 445, 464], ["infection", "OBSERVATION", 11, 20], ["respiratory tract", "ANATOMY", 43, 60], ["infection", "OBSERVATION", 61, 70], ["disease", "OBSERVATION", 125, 132], ["RSV", "OBSERVATION", 152, 155], ["bronchiolitis", "OBSERVATION", 166, 179], ["asthma", "OBSERVATION", 200, 206], ["HMPV infection", "OBSERVATION", 326, 340], ["RSV", "OBSERVATION", 375, 378], ["asthma", "OBSERVATION", 387, 393], ["virus", "OBSERVATION", 431, 436], ["asthma", "OBSERVATION", 445, 451], ["intense", "OBSERVATION_MODIFIER", 490, 497]]], ["Primary RSV infection has been studied in a variety of animal models.", [["RSV infection", "DISEASE", 8, 21], ["RSV", "ORGANISM", 8, 11], ["RSV", "SPECIES", 8, 11], ["Primary RSV infection", "PROBLEM", 0, 21], ["RSV", "OBSERVATION_MODIFIER", 8, 11], ["infection", "OBSERVATION", 12, 21]]], ["In general, animal studies have shown that RSV infection is associated with an influx of inflammatory cells to the airways, including eosinophils and neutrophils, resulting in the development of airway hyperresponsiveness (AHR) [85, 86] .", [["inflammatory cells", "ANATOMY", 89, 107], ["airways", "ANATOMY", 115, 122], ["eosinophils", "ANATOMY", 134, 145], ["neutrophils", "ANATOMY", 150, 161], ["airway", "ANATOMY", 195, 201], ["RSV infection", "DISEASE", 43, 56], ["airway hyperresponsiveness", "DISEASE", 195, 221], ["RSV", "ORGANISM", 43, 46], ["inflammatory cells", "CELL", 89, 107], ["airways", "MULTI-TISSUE_STRUCTURE", 115, 122], ["eosinophils", "CELL", 134, 145], ["neutrophils", "CELL", 150, 161], ["airway", "MULTI-TISSUE_STRUCTURE", 195, 201], ["inflammatory cells", "CELL_TYPE", 89, 107], ["eosinophils", "CELL_TYPE", 134, 145], ["neutrophils", "CELL_TYPE", 150, 161], ["RSV", "SPECIES", 43, 46], ["animal studies", "TEST", 12, 26], ["RSV infection", "PROBLEM", 43, 56], ["inflammatory cells", "PROBLEM", 89, 107], ["eosinophils", "TEST", 134, 145], ["neutrophils", "TEST", 150, 161], ["airway hyperresponsiveness", "PROBLEM", 195, 221], ["RSV", "OBSERVATION_MODIFIER", 43, 46], ["infection", "OBSERVATION", 47, 56], ["inflammatory cells", "OBSERVATION", 89, 107], ["airways", "ANATOMY", 115, 122], ["airway", "ANATOMY", 195, 201], ["hyperresponsiveness", "OBSERVATION", 202, 221]]], ["AHR and pulmonary granular cell infiltration are hallmark features of bronchial asthma.", [["pulmonary granular cell", "ANATOMY", 8, 31], ["bronchial", "ANATOMY", 70, 79], ["bronchial asthma", "DISEASE", 70, 86], ["pulmonary granular cell", "CELL", 8, 31], ["AHR", "TEST", 0, 3], ["pulmonary granular cell infiltration", "PROBLEM", 8, 44], ["bronchial asthma", "PROBLEM", 70, 86], ["pulmonary", "ANATOMY", 8, 17], ["granular cell infiltration", "OBSERVATION", 18, 44], ["bronchial", "ANATOMY", 70, 79], ["asthma", "OBSERVATION", 80, 86]]], ["The pattern of cytokine expression associated with RSV has also been shown to be an important feature that may contribute to disease pathogenesis.", [["RSV", "ORGANISM", 51, 54], ["cytokine", "PROTEIN", 15, 23], ["RSV", "SPECIES", 51, 54], ["cytokine expression", "PROBLEM", 15, 34], ["RSV", "PROBLEM", 51, 54], ["disease pathogenesis", "PROBLEM", 125, 145], ["cytokine expression", "OBSERVATION", 15, 34], ["RSV", "OBSERVATION", 51, 54], ["may contribute to", "UNCERTAINTY", 107, 124], ["disease", "OBSERVATION", 125, 132]]], ["In the murine model, primary RSV infection leads to mixed Th1/Th2-type immune responses [30] ; however, RSV G protein appears to sensitize for Th2type responses characterized by IL-4, IL-5, IL-13 and IL-10 expression [30, [57] [58] [59] 87 ].", [["RSV infection", "DISEASE", 29, 42], ["murine", "ORGANISM", 7, 13], ["RSV", "ORGANISM", 29, 32], ["Th1", "GENE_OR_GENE_PRODUCT", 58, 61], ["Th2", "GENE_OR_GENE_PRODUCT", 62, 65], ["RSV", "ORGANISM", 104, 107], ["G", "GENE_OR_GENE_PRODUCT", 108, 109], ["Th2type", "GENE_OR_GENE_PRODUCT", 143, 150], ["IL-4", "GENE_OR_GENE_PRODUCT", 178, 182], ["IL-5", "GENE_OR_GENE_PRODUCT", 184, 188], ["IL-13", "GENE_OR_GENE_PRODUCT", 190, 195], ["IL-10", "GENE_OR_GENE_PRODUCT", 200, 205], ["RSV G protein", "PROTEIN", 104, 117], ["murine", "SPECIES", 7, 13], ["RSV", "SPECIES", 29, 32], ["RSV", "SPECIES", 104, 107], ["primary RSV infection", "PROBLEM", 21, 42], ["RSV G protein", "TEST", 104, 117], ["Th2type responses", "TEST", 143, 160], ["IL", "TEST", 178, 180], ["IL", "TEST", 184, 186], ["IL", "TEST", 190, 192], ["IL", "TEST", 200, 202], ["RSV infection", "OBSERVATION", 29, 42]]], ["In addition, by using depleting antibodies and knock-out mice, Schwarze et al. defined critical roles for IL-5 and for CD8+ T-cells, but not IFN-c, in the development of AHR in acute RSV infection [88, 89] .", [["CD8+ T-cells", "ANATOMY", 119, 131], ["RSV infection", "DISEASE", 183, 196], ["mice", "ORGANISM", 57, 61], ["IL-5", "GENE_OR_GENE_PRODUCT", 106, 110], ["CD8", "GENE_OR_GENE_PRODUCT", 119, 122], ["IFN-c", "GENE_OR_GENE_PRODUCT", 141, 146], ["RSV", "ORGANISM", 183, 186], ["IL-5", "PROTEIN", 106, 110], ["CD8", "PROTEIN", 119, 122], ["IFN-c", "PROTEIN", 141, 146], ["mice", "SPECIES", 57, 61], ["RSV", "SPECIES", 183, 186], ["depleting antibodies", "TREATMENT", 22, 42], ["IL", "TEST", 106, 108], ["CD8+ T-cells", "PROBLEM", 119, 131], ["IFN", "PROBLEM", 141, 144], ["AHR", "PROBLEM", 170, 173], ["acute RSV infection", "PROBLEM", 177, 196], ["acute", "OBSERVATION_MODIFIER", 177, 182], ["RSV infection", "OBSERVATION", 183, 196]]], ["In addition, IL-13-induced Stat-6 signaling also seems to be important for RSV-induced AHR [90] .", [["IL-13", "GENE_OR_GENE_PRODUCT", 13, 18], ["Stat-6", "GENE_OR_GENE_PRODUCT", 27, 33], ["RSV", "ORGANISM", 75, 78], ["IL-13", "PROTEIN", 13, 18], ["Stat-6", "PROTEIN", 27, 33], ["RSV", "SPECIES", 75, 78], ["IL", "TEST", 13, 15], ["RSV", "PROBLEM", 75, 78]]], ["To test the hypothesis that RSV infection may trigger and enhance allergic sensitization to inhaled antigens, numerous animal models of infection and concomitant allergen sensitization have been examined.", [["RSV infection", "DISEASE", 28, 41], ["allergic sensitization", "DISEASE", 66, 88], ["infection", "DISEASE", 136, 145], ["allergen sensitization", "DISEASE", 162, 184], ["RSV", "ORGANISM", 28, 31], ["RSV", "SPECIES", 28, 31], ["RSV infection", "PROBLEM", 28, 41], ["allergic sensitization", "PROBLEM", 66, 88], ["inhaled antigens", "TREATMENT", 92, 108], ["infection", "PROBLEM", 136, 145], ["concomitant allergen sensitization", "TREATMENT", 150, 184], ["RSV", "OBSERVATION_MODIFIER", 28, 31], ["infection", "OBSERVATION", 32, 41], ["infection", "OBSERVATION", 136, 145]]], ["For example, Leibovitz et al. [91] and Freihorst et al. [92] showed increased levels of allergen-specific antibodies to ovalbumin (OVA) and ragweed in serum (IgE, IgG) and in bronchoalveolar lavage (BAL) fluid (IgA, IgG) of mice exposed to these allergens during RSV infection.", [["serum", "ANATOMY", 151, 156], ["bronchoalveolar lavage (BAL) fluid", "ANATOMY", 175, 209], ["RSV infection", "DISEASE", 263, 276], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 120, 129], ["OVA", "SIMPLE_CHEMICAL", 131, 134], ["serum", "ORGANISM_SUBSTANCE", 151, 156], ["IgE", "GENE_OR_GENE_PRODUCT", 158, 161], ["IgG", "GENE_OR_GENE_PRODUCT", 163, 166], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 175, 197], ["BAL", "MULTI-TISSUE_STRUCTURE", 199, 202], ["fluid", "ORGANISM_SUBSTANCE", 204, 209], ["IgA", "GENE_OR_GENE_PRODUCT", 211, 214], ["IgG", "GENE_OR_GENE_PRODUCT", 216, 219], ["mice", "ORGANISM", 224, 228], ["RSV", "ORGANISM", 263, 266], ["allergen-specific antibodies", "PROTEIN", 88, 116], ["ovalbumin", "PROTEIN", 120, 129], ["IgE", "PROTEIN", 158, 161], ["IgG", "PROTEIN", 163, 166], ["IgA", "PROTEIN", 211, 214], ["IgG", "PROTEIN", 216, 219], ["mice", "SPECIES", 224, 228], ["mice", "SPECIES", 224, 228], ["RSV", "SPECIES", 263, 266], ["Leibovitz et al.", "TEST", 13, 29], ["Freihorst et al.", "TEST", 39, 55], ["increased levels of allergen", "PROBLEM", 68, 96], ["OVA", "PROBLEM", 131, 134], ["ragweed in serum (IgE", "TEST", 140, 161], ["IgG", "TEST", 163, 166], ["bronchoalveolar lavage", "TEST", 175, 197], ["BAL) fluid", "TEST", 199, 209], ["IgA", "TEST", 211, 214], ["these allergens", "PROBLEM", 240, 255], ["RSV infection", "PROBLEM", 263, 276], ["bronchoalveolar lavage", "OBSERVATION", 175, 197], ["RSV infection", "OBSERVATION", 263, 276]]], ["More recently, O'Donnell et al. [93] reported the induction of anaphylactic antibodies following infection with RSV and concomitant sensitization to OVA-aerosol, but not after sensitization without infection.", [["anaphylactic antibodies", "DISEASE", 63, 86], ["infection", "DISEASE", 97, 106], ["OVA-aerosol", "CHEMICAL", 149, 160], ["infection", "DISEASE", 198, 207], ["RSV", "ORGANISM", 112, 115], ["anaphylactic antibodies", "PROTEIN", 63, 86], ["RSV", "SPECIES", 112, 115], ["anaphylactic antibodies", "PROBLEM", 63, 86], ["infection", "PROBLEM", 97, 106], ["RSV", "PROBLEM", 112, 115], ["concomitant sensitization to OVA", "TREATMENT", 120, 152], ["aerosol", "TREATMENT", 153, 160], ["infection", "PROBLEM", 198, 207], ["infection", "OBSERVATION", 198, 207]]], ["The ability of RSV and other respiratory viruses to increase production of allergenspecific antibodies has also been shown in guinea pig models of RSV infection where virus infection leads to increased permeability of the respiratory mucosa [94, 95] .", [["respiratory mucosa", "ANATOMY", 222, 240], ["RSV infection", "DISEASE", 147, 160], ["infection", "DISEASE", 173, 182], ["RSV", "ORGANISM", 15, 18], ["guinea pig", "ORGANISM", 126, 136], ["RSV", "ORGANISM", 147, 150], ["respiratory mucosa", "MULTI-TISSUE_STRUCTURE", 222, 240], ["allergenspecific antibodies", "PROTEIN", 75, 102], ["guinea pig", "SPECIES", 126, 136], ["RSV", "SPECIES", 15, 18], ["guinea pig", "SPECIES", 126, 136], ["RSV", "SPECIES", 147, 150], ["RSV", "PROBLEM", 15, 18], ["other respiratory viruses", "PROBLEM", 23, 48], ["allergenspecific antibodies", "PROBLEM", 75, 102], ["RSV infection", "PROBLEM", 147, 160], ["virus infection", "PROBLEM", 167, 182], ["increased permeability of the respiratory mucosa", "PROBLEM", 192, 240], ["RSV", "OBSERVATION", 15, 18], ["respiratory viruses", "OBSERVATION", 29, 48], ["RSV infection", "OBSERVATION", 147, 160], ["increased", "OBSERVATION_MODIFIER", 192, 201], ["permeability", "OBSERVATION_MODIFIER", 202, 214], ["respiratory mucosa", "ANATOMY", 222, 240]]], ["This may be an important factor for virus-induced enhancement of airway sensitization.Immune mechanisms associated with RSV-induced asthmaRSV studies in animal models have shown that G protein expression is also associated with the induction of pulmonary substance P (SP) expression [57] [58] [59] 96] .", [["airway", "ANATOMY", 65, 71], ["pulmonary", "ANATOMY", 245, 254], ["airway", "MULTI-TISSUE_STRUCTURE", 65, 71], ["RSV", "ORGANISM", 120, 123], ["G protein", "GENE_OR_GENE_PRODUCT", 183, 192], ["pulmonary", "ORGAN", 245, 254], ["G protein", "PROTEIN", 183, 192], ["RSV", "SPECIES", 120, 123], ["virus", "PROBLEM", 36, 41], ["airway sensitization", "PROBLEM", 65, 85], ["Immune mechanisms", "PROBLEM", 86, 103], ["RSV", "PROBLEM", 120, 123], ["G protein expression", "PROBLEM", 183, 203], ["may be", "UNCERTAINTY", 5, 11], ["airway", "ANATOMY", 65, 71], ["pulmonary", "ANATOMY", 245, 254]]], ["SP may exacerbate expression of regulatory mediators, up-regulate cell surface receptors important in leukocyte activation and migration, and mediate pathophysiology associated with mucus production, vascular leakage, and induction of smooth muscle contraction [97] [98] [99] [100] [101] [102] [103] [104] .", [["cell surface", "ANATOMY", 66, 78], ["leukocyte", "ANATOMY", 102, 111], ["mucus", "ANATOMY", 182, 187], ["vascular", "ANATOMY", 200, 208], ["smooth muscle", "ANATOMY", 235, 248], ["SP", "CHEMICAL", 0, 2], ["cell", "CELL", 66, 70], ["leukocyte", "CELL", 102, 111], ["mucus", "MULTI-TISSUE_STRUCTURE", 182, 187], ["vascular", "MULTI-TISSUE_STRUCTURE", 200, 208], ["smooth muscle", "TISSUE", 235, 248], ["[99] [100] [101] [102] [103] [104]", "SIMPLE_CHEMICAL", 271, 305], ["SP", "PROTEIN", 0, 2], ["regulatory mediators", "PROTEIN", 32, 52], ["cell surface receptors", "PROTEIN", 66, 88], ["regulatory mediators", "PROBLEM", 32, 52], ["regulate cell surface receptors", "TREATMENT", 57, 88], ["leukocyte activation", "TEST", 102, 122], ["mucus production", "PROBLEM", 182, 198], ["vascular leakage", "PROBLEM", 200, 216], ["smooth muscle contraction", "TEST", 235, 260], ["vascular", "ANATOMY", 200, 208], ["leakage", "OBSERVATION", 209, 216]]], ["In addition, pulmonary SP expression affects respiratory rates in RSV-infected mice [103] .", [["pulmonary", "ANATOMY", 13, 22], ["respiratory", "ANATOMY", 45, 56], ["RSV-infected", "DISEASE", 66, 78], ["pulmonary", "ORGAN", 13, 22], ["SP", "GENE_OR_GENE_PRODUCT", 23, 25], ["RSV", "ORGANISM", 66, 69], ["mice", "ORGANISM", 79, 83], ["SP", "PROTEIN", 23, 25], ["mice", "SPECIES", 79, 83], ["RSV", "SPECIES", 66, 69], ["mice", "SPECIES", 79, 83], ["respiratory rates", "TEST", 45, 62], ["RSV", "PROBLEM", 66, 69], ["pulmonary", "ANATOMY", 13, 22]]], ["The cytokine program associated with HMPV infection in humans is not known, but given the clinical similarities between RSV and HMPV infection [6, 7, 105] and our recent studies in mice (Alvarez et al., in press) it is likely that HMPV infection may induce similarly aberrant cytokine responses.Immune mechanisms associated with RSV-induced asthmaHMPV infection is associated with clinical diagnoses of pneumonia, asthma exacerbation, or acute bronchiolitis [12, 33] .", [["HMPV infection", "DISEASE", 37, 51], ["HMPV infection", "DISEASE", 128, 142], ["HMPV infection", "DISEASE", 231, 245], ["asthmaHMPV infection", "DISEASE", 341, 361], ["pneumonia", "DISEASE", 403, 412], ["asthma", "DISEASE", 414, 420], ["bronchiolitis", "DISEASE", 444, 457], ["HMPV", "ORGANISM", 37, 41], ["humans", "ORGANISM", 55, 61], ["RSV", "ORGANISM", 120, 123], ["HMPV", "ORGANISM", 128, 132], ["mice", "ORGANISM", 181, 185], ["HMPV", "ORGANISM", 231, 235], ["RSV", "ORGANISM", 329, 332], ["asthmaHMPV", "ORGANISM", 341, 351], ["cytokine", "PROTEIN", 4, 12], ["cytokine", "PROTEIN", 276, 284], ["humans", "SPECIES", 55, 61], ["mice", "SPECIES", 181, 185], ["HMPV", "SPECIES", 37, 41], ["humans", "SPECIES", 55, 61], ["RSV", "SPECIES", 120, 123], ["HMPV", "SPECIES", 128, 132], ["mice", "SPECIES", 181, 185], ["HMPV", "SPECIES", 231, 235], ["RSV", "SPECIES", 329, 332], ["asthmaHMPV", "SPECIES", 341, 351], ["The cytokine program", "TREATMENT", 0, 20], ["HMPV infection", "PROBLEM", 37, 51], ["RSV", "PROBLEM", 120, 123], ["HMPV infection", "PROBLEM", 128, 142], ["our recent studies", "TEST", 159, 177], ["HMPV infection", "PROBLEM", 231, 245], ["Immune mechanisms", "PROBLEM", 295, 312], ["RSV", "PROBLEM", 329, 332], ["asthmaHMPV infection", "PROBLEM", 341, 361], ["pneumonia", "PROBLEM", 403, 412], ["asthma exacerbation", "PROBLEM", 414, 433], ["acute bronchiolitis", "PROBLEM", 438, 457], ["HMPV", "OBSERVATION_MODIFIER", 37, 41], ["infection", "OBSERVATION", 42, 51], ["HMPV infection", "OBSERVATION", 128, 142], ["likely that", "UNCERTAINTY", 219, 230], ["HMPV", "OBSERVATION", 231, 235], ["RSV", "OBSERVATION", 329, 332], ["infection", "OBSERVATION", 352, 361], ["pneumonia", "OBSERVATION", 403, 412], ["asthma", "OBSERVATION", 414, 420], ["acute", "OBSERVATION_MODIFIER", 438, 443], ["bronchiolitis", "OBSERVATION", 444, 457]]], ["Emerging evidence suggests that following HMPV infection, wheezing is more likely to represent asthma exacerbation rather than acute bronchiolitis [12] .", [["HMPV infection", "DISEASE", 42, 56], ["wheezing", "DISEASE", 58, 66], ["asthma", "DISEASE", 95, 101], ["bronchiolitis", "DISEASE", 133, 146], ["HMPV", "ORGANISM", 42, 46], ["HMPV", "SPECIES", 42, 46], ["HMPV infection", "PROBLEM", 42, 56], ["wheezing", "PROBLEM", 58, 66], ["asthma exacerbation", "PROBLEM", 95, 114], ["acute bronchiolitis", "PROBLEM", 127, 146], ["HMPV", "OBSERVATION_MODIFIER", 42, 46], ["infection", "OBSERVATION", 47, 56], ["more likely to represent", "UNCERTAINTY", 70, 94], ["asthma", "OBSERVATION", 95, 101], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["bronchiolitis", "OBSERVATION", 133, 146]]], ["The disease burden associated with HMPV infection has not been fully defined; however, it is likely that HMPV may contribute to asthma pathogenesis in a fashion similar to RSV and be similarly linked with a similar level of asthma pathogenesis.", [["HMPV infection", "DISEASE", 35, 49], ["asthma", "DISEASE", 128, 134], ["RSV", "DISEASE", 172, 175], ["asthma", "DISEASE", 224, 230], ["HMPV", "ORGANISM", 35, 39], ["HMPV", "ORGANISM", 105, 109], ["RSV", "ORGANISM", 172, 175], ["HMPV", "SPECIES", 35, 39], ["HMPV", "SPECIES", 105, 109], ["RSV", "SPECIES", 172, 175], ["The disease burden", "PROBLEM", 0, 18], ["HMPV infection", "PROBLEM", 35, 49], ["HMPV", "PROBLEM", 105, 109], ["asthma pathogenesis", "PROBLEM", 128, 147], ["RSV", "PROBLEM", 172, 175], ["asthma pathogenesis", "PROBLEM", 224, 243], ["disease", "OBSERVATION", 4, 11], ["HMPV", "OBSERVATION_MODIFIER", 35, 39], ["infection", "OBSERVATION", 40, 49], ["fully defined", "OBSERVATION_MODIFIER", 63, 76], ["is likely", "UNCERTAINTY", 90, 99], ["HMPV", "OBSERVATION", 105, 109], ["may contribute to", "UNCERTAINTY", 110, 127], ["asthma", "OBSERVATION", 128, 134], ["asthma", "OBSERVATION", 224, 230]]], ["Thus, there is a critical need to better understand the mechanisms of host-virus interaction and disease pathogenesis that may lead to or exacerbate asthma in order to provide the foundation for intervention strategies.Concluding remarksA better understanding of the protective and disease causing mechanisms associated with HMPV infection is needed for disease intervention strategies given the substantial disease burden associated with HMPV infection.", [["asthma", "DISEASE", 149, 155], ["HMPV infection", "DISEASE", 325, 339], ["HMPV infection", "DISEASE", 439, 453], ["HMPV", "ORGANISM", 325, 329], ["HMPV", "ORGANISM", 439, 443], ["HMPV", "SPECIES", 325, 329], ["HMPV", "SPECIES", 439, 443], ["host-virus interaction", "PROBLEM", 70, 92], ["disease pathogenesis", "PROBLEM", 97, 117], ["asthma", "PROBLEM", 149, 155], ["intervention strategies", "TREATMENT", 195, 218], ["disease", "PROBLEM", 282, 289], ["HMPV infection", "PROBLEM", 325, 339], ["disease intervention strategies", "TREATMENT", 354, 385], ["the substantial disease burden", "PROBLEM", 392, 422], ["HMPV infection", "PROBLEM", 439, 453], ["substantial", "OBSERVATION_MODIFIER", 396, 407], ["disease", "OBSERVATION", 408, 415], ["HMPV infection", "OBSERVATION", 439, 453]]], ["HMPV predominantly causes respiratory tract infections in patients at the extremes of ages, thus unique HMPV disease intervention strategies may be required for young infants with maternal antibodies and the elderly with waning immunity.", [["respiratory tract", "ANATOMY", 26, 43], ["HMPV", "DISEASE", 0, 4], ["respiratory tract infections", "DISEASE", 26, 54], ["HMPV disease", "DISEASE", 104, 116], ["HMPV", "ORGANISM", 0, 4], ["respiratory tract", "ORGANISM_SUBDIVISION", 26, 43], ["patients", "ORGANISM", 58, 66], ["HMPV", "ORGANISM", 104, 108], ["infants", "ORGANISM", 167, 174], ["maternal antibodies", "PROTEIN", 180, 199], ["patients", "SPECIES", 58, 66], ["infants", "SPECIES", 167, 174], ["HMPV", "SPECIES", 0, 4], ["HMPV", "SPECIES", 104, 108], ["HMPV", "PROBLEM", 0, 4], ["respiratory tract infections", "PROBLEM", 26, 54], ["unique HMPV disease intervention strategies", "TREATMENT", 97, 140], ["maternal antibodies", "PROBLEM", 180, 199], ["respiratory tract infections", "OBSERVATION", 26, 54], ["HMPV", "OBSERVATION", 104, 108]]], ["The insights revealed from RSV studies should be considered in guiding HMPV studies since these viruses have similar clinical outcomes.", [["RSV", "ORGANISM", 27, 30], ["HMPV", "ORGANISM", 71, 75], ["RSV", "SPECIES", 27, 30], ["HMPV", "SPECIES", 71, 75], ["RSV studies", "TEST", 27, 38], ["HMPV studies", "TEST", 71, 83], ["these viruses", "PROBLEM", 90, 103], ["RSV", "OBSERVATION", 27, 30]]], ["With proper translation of RSV findings from animal and human studies, it may be possible to improve our understanding of the host response to HMPV infection, understand the relationship between RSV and HMPV infection, and avoid disease intervention setbacks.", [["HMPV infection", "DISEASE", 143, 157], ["HMPV infection", "DISEASE", 203, 217], ["RSV", "ORGANISM", 27, 30], ["human", "ORGANISM", 56, 61], ["HMPV", "ORGANISM", 143, 147], ["RSV", "ORGANISM", 195, 198], ["HMPV", "ORGANISM", 203, 207], ["human", "SPECIES", 56, 61], ["RSV", "SPECIES", 27, 30], ["human", "SPECIES", 56, 61], ["HMPV", "SPECIES", 143, 147], ["RSV", "SPECIES", 195, 198], ["HMPV", "SPECIES", 203, 207], ["RSV findings", "PROBLEM", 27, 39], ["animal and human studies", "TEST", 45, 69], ["HMPV infection", "PROBLEM", 143, 157], ["RSV", "PROBLEM", 195, 198], ["HMPV infection", "PROBLEM", 203, 217], ["disease intervention setbacks", "TREATMENT", 229, 258], ["RSV", "OBSERVATION", 27, 30], ["infection", "OBSERVATION", 148, 157], ["HMPV infection", "OBSERVATION", 203, 217]]]]}